<SEC-DOCUMENT>0001654954-21-009088.txt : 20210816 <SEC-HEADER>0001654954-21-009088.hdr.sgml : 20210816 <ACCEPTANCE-DATETIME>20210816163148 ACCESSION NUMBER: 0001654954-21-009088 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC. CENTRAL INDEX KEY: 0000034956 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262593535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34600 FILM NUMBER: 211178893 BUSINESS ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-806-4414 MAIL ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC. DATE OF NAME CHANGE: 20080703 FORMER COMPANY: FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SINEQUANON CORP DATE OF NAME CHANGE: 19901219 </SEC-HEADER> <DOCUMENT> <TYPE>10-Q <SEQUENCE>1 <FILENAME>tenx_10q.htm <DESCRIPTION>QUARTERLY REPORT <TEXT> <XBRL> <?xml version="1.0" encoding="UTF-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:tenx="http://tenaxthera.com/20210630"><head><title>tenx_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:left;font:10pt times new roman"><div style='display:none;text-align:left;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2021-01-01to2021-06-30">0000034956</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2021-01-01to2021-06-30">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2021-01-01to2021-06-30">Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2021-01-01to2021-06-30">2021</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" unitRef="Shares" decimals="0">9999790</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="0">5181346</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="0">210</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">12619369</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" unitRef="Shares" decimals="0">25210312</ix:nonFraction><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0" sign="-">2279868</ix:nonFraction><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">2000</ix:nonFraction><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">1000</ix:nonFraction><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="From2021-01-01to2021-06-30">P2Y</ix:nonNumeric><ix:nonFraction name="tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" contextRef="From2021-01-01to2021-06-30" unitRef="Shares" decimals="0" sign="-">801576</ix:nonFraction><ix:nonFraction name="tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" contextRef="AsOf2021-06-30" unitRef="Shares" decimals="0">15797503</ix:nonFraction><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">1.27</ix:nonFraction><ix:nonFraction name="tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" unitRef="Shares" decimals="0" sign="-">13</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2018-12-11_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2020-04-01to2020-06-30_tenx_Amended1999StockPlanMember" unitRef="Shares" decimals="0">15000</ix:nonFraction><ix:nonNumeric name="tenx:StockOptionsGrantedVestingPeriod" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member">Stock options granted generally vest over three to four years.</ix:nonNumeric><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member">P10Y</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="tenx:WarrantToPurchaseOfCommonStockExercisePrice" contextRef="AsOf2018-12-11" unitRef="USDPShares" decimals="INF">11.93</ix:nonFraction><ix:nonFraction name="tenx:WarrantToPurchaseOfCommonStockExercisePrice" contextRef="AsOf2018-12-11_tenx_InvestorsMember" unitRef="USDPShares" decimals="INF">1.04</ix:nonFraction><ix:nonFraction name="tenx:FairValueAllocatedPrefundedWarrants" contextRef="AsOf2018-12-11_tenx_InvestorsMember" unitRef="USD" decimals="0">1100000.0</ix:nonFraction><ix:nonFraction name="tenx:FairValueAllocatedWarrants" contextRef="From2018-12-01to2018-12-11_tenx_InvestorsMember" unitRef="USD" decimals="0">1100000.0</ix:nonFraction><ix:nonFraction name="tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStock" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="Shares" decimals="0">2360313</ix:nonFraction><ix:nonFraction name="tenx:UnregisteredWarrantsExercisePrice" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="USDPShares" decimals="INF">1.04</ix:nonFraction><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="USD" decimals="0">1100000.0</ix:nonFraction><ix:nonFraction name="tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="Shares" decimals="0">7783616</ix:nonFraction><ix:nonFraction name="tenx:UnregisteredWarrantsExercisePrice" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="USDPShares" decimals="INF">0.903</ix:nonFraction><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="USD" decimals="0">3500000.0</ix:nonFraction><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="Shares" decimals="0">177023</ix:nonFraction><ix:nonFraction name="tenx:WarrantToPurchaseOfCommonStockExercisePrice" contextRef="AsOf2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="USDPShares" decimals="INF">1.4564</ix:nonFraction><ix:nonNumeric name="tenx:WarrantToPurchaseOfCommonStockTerm" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember">P5Y</ix:nonNumeric><ix:nonFraction name="tenx:EstimatedFairValueofWarrantIssuedForServices" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="USD" decimals="0">66201</ix:nonFraction><ix:nonFraction name="tenx:IssuedUnderwriterWarrantTopurchaseCommonStock" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="Shares" decimals="0">94413</ix:nonFraction><ix:nonFraction name="tenx:UnderwriterWarrantToPurchaseCommonStockExercisePrice" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="USDPShares" decimals="INF">1.4564</ix:nonFraction><ix:nonFraction name="tenx:UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" unitRef="USD" decimals="0">35308</ix:nonFraction><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-31_tenx_July2020WarrantsMember" unitRef="Shares" decimals="0">583771</ix:nonFraction><ix:nonFraction name="tenx:WarrantToPurchaseOfCommonStockExercisePrice" contextRef="AsOf2020-07-31_tenx_July2020WarrantsMember" unitRef="USDPShares" decimals="INF">1.2848</ix:nonFraction><ix:nonNumeric name="tenx:WarrantToPurchaseOfCommonStockTerm" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember">P5Y</ix:nonNumeric><ix:nonFraction name="tenx:EstimatedFairValueofWarrantIssuedForServicese" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="USD" decimals="0">399445</ix:nonFraction><ix:nonFraction name="tenx:IssuedUnderwriterWarrantTopurchaseCommonStock" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="Shares" decimals="0">311345</ix:nonFraction><ix:nonFraction name="tenx:UnderwriterWarrantToPurchaseCommonStockExercisePrice" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="USDPShares" decimals="INF">1.2848</ix:nonFraction><ix:nonFraction name="tenx:UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" unitRef="USD" decimals="0">213038</ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-01to2021-06-30" unitRef="USD" decimals="0">545000</ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-01to2021-06-30" unitRef="Shares" decimals="0">282202</ix:nonFraction><ix:nonFraction name="tenx:CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" contextRef="From2021-01-01to2021-06-30_tenx_MarchTwentyTwentyWarrantsMember" unitRef="Shares" decimals="0">119491</ix:nonFraction><ix:nonFraction name="tenx:CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" contextRef="From2021-01-01to2021-06-30_tenx_July2020WarrantsMember" unitRef="Shares" decimals="0">399883</ix:nonFraction><ix:nonFraction name="tenx:PrefundedWarrantsOutstanding" contextRef="AsOf2021-06-30" unitRef="Shares" decimals="0">5260005</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">10232</ix:nonFraction><ix:nonFraction name="tenx:RightsPreferencesAndPrivilegesConversionIntoShare" contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">882</ix:nonFraction><ix:nonFraction name="tenx:RightsPreferencesAndPrivilegesConversionIntoShare1" contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">119</ix:nonFraction><ix:nonFraction name="tenx:StockConvertibleIntoAggregateSharesOfCommonStock" contextRef="AsOf2021-06-10_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">10232000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="tenx:CommonStockParOrStatedValuePerShares" contextRef="AsOf2020-03-13" unitRef="USDPShares" decimals="INF">1.1651</ix:nonFraction><ix:nonFraction name="tenx:CommonStockParOrStatedValuePerShares" contextRef="AsOf2021-06-30" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction><ix:nonFraction name="tenx:CommonStockSharesIssue" contextRef="AsOf2020-03-13" unitRef="Shares" decimals="0">750000</ix:nonFraction><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-01to2021-06-30_tenx_Amended1999StockPlanMember" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_tenx_Amended1999StockPlanMember" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" unitRef="Shares" decimals="0">200000</ix:nonFraction><ix:nonFraction name="tenx:StockOptionsGrantedFairMarketValuePercentage" contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" unitRef="Pure" decimals="INF">0.85</ix:nonFraction><ix:nonNumeric name="tenx:MaturityPeriod" contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember">P5Y6M</ix:nonNumeric><ix:nonNumeric name="tenx:MaturityPeriod" contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='tenx-20210630.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2021-01-01to2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SeparationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tenx:MrDitonnoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SeparationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tenx:MrDitonnoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:RegistrationRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:RegistrationRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-01-15_tenx_InducementStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_tenx_InducementStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-10_us-gaap_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_us-gaap_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_July2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">tenx:July2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_MarchTwentyTwentyWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:MarchTwentyTwentyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-07-31_tenx_July2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">tenx:July2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_tenx_MarchTwentyTwentyWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:MarchTwentyTwentyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">tenx:July2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:MarchTwentyTwentyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-07-08_tenx_InvestorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-07-08_tenx_InvestorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2018-12-01to2018-12-11_tenx_InvestorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-11_tenx_InvestorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-07-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-07-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-05-20to2021-06-09_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-20</xbrli:startDate><xbrli:endDate>2021-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-05-20to2019-06-12_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-20</xbrli:startDate><xbrli:endDate>2019-06-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2015-08-20to2015-09-15_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-20</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2015-09-01to2015-09-15_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-06-01to2021-06-10_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2016-06-01to2016-06-16_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-11_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_tenx_Amended1999StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_tenx_StockIncentivePlan2016Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2013-11-01to2013-11-13_tenx_SimdaxLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-11-01</xbrli:startDate><xbrli:endDate>2013-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_SeriesBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2015-08-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_tenx_ConvertiblePreferredSharesOutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:ConvertiblePreferredSharesOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_PrefundedWarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:PrefundedWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_ConvertiblePreferredSharesOutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:ConvertiblePreferredSharesOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_tenx_SimdaxLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_tenx_WarranttoPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:WarranttoPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-06-30_tenx_WarranttoPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:WarranttoPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_tenx_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-08-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000034956</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:24pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2021-01-01to2021-06-30">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:boolballotbox">☒</ix:nonNumeric></strong><strong> </strong></p></td><td style="width:76%;vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2021-01-01to2021-06-30" format="ixt:datemonthdayyearen">June 30, 2021</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>OR</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></strong><strong> </strong></p></td><td style="width:76%;vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>FOR THE TRANSITION PERIOD FROM TO </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Commission File Number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2021-01-01to2021-06-30">001-34600</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="MARGIN: 0px; text-align:center;"><strong><span style="font-size:24pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2021-01-01to2021-06-30">TENAX THERAPEUTICS, INC</ix:nonNumeric>.</span></strong></p></td></tr><tr style="height:15px"><td><p style="MARGIN: 0px; text-align:center;"><strong>(Exact name of registrant as specified in its charter)</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"> </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="MARGIN: 0px; text-align:center;"> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2021-01-01to2021-06-30">26-2593535</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(State of incorporation)</strong></p></td><td><p style="MARGIN: 0px; text-align:center;"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(I.R.S. Employer Identification No.)</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2021-01-01to2021-06-30">ONE Copley Parkway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2021-01-01to2021-06-30">Suite 490</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2021-01-01to2021-06-30">Morrisville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen">North Carolina</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2021-01-01to2021-06-30">27560</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(Address of principal executive offices)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2021-01-01to2021-06-30">919</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2021-01-01to2021-06-30">855-2100</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(Registrant’s telephone number, including area code)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:33%;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Title of each class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:33%;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Trading Symbol(s)</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:34%;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Name of each exchange on which registered</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2021-01-01to2021-06-30">Common Stock, $0.0001 par value per share</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2021-01-01to2021-06-30">TENX</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">The <ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2021-01-01to2021-06-30">Yes</ix:nonNumeric> ☒   No ☐</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2021-01-01to2021-06-30">Yes</ix:nonNumeric> ☒   No ☐</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:40%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Large Accelerated filer</p></td><td style="width:10%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">☐</p></td><td style="width:40%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Accelerated filer</p></td><td style="width:10%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">☐</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:entityfilercategoryen">Non-Accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">☒</p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Smaller reporting company</p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:boolballotbox">☒</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">☐</p></td><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td><p style="MARGIN: 0px; text-align:left;"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:boolballotbox">☐</ix:nonNumeric>   No ☒</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">As of August 12, 2021, the registrant had outstanding <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-08-12" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF">25,201,312</ix:nonFraction> shares of Common Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 23pt; text-align:left;"> </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td> </td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">TABLE OF CONTENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"></td><td></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PAGE</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong><a href="#p1">PART I. FINANCIAL INFORMATION</a></strong></p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i1">Item 1.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i1">Condensed Consolidated Financial Statements</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">3</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#bs">Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">3</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#so">Condensed Consolidated Statements of Comprehensive Loss (Unaudited) for the Three and Six Months Ended June 30, 2021 and 2020</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">4</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#se">Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) for the Three and Six Months Ended June 30, 2021 and 2020</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">5</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#cf">Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2021 and 2020</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">6</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#note">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">7</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i2">Item 2.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i2">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">21</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i3">Item 3.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i3">Quantitative and Qualitative Disclosures About Market Risk</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">31</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i4">Item 4.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#i4">Controls and Procedures</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">31</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td></td><td><p style="margin:0px"> </p></td><td></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong><a href="#p2">PART II. OTHER INFORMATION</a></strong></p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii1">Item 1.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii1">Legal Proceedings</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">32</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii1a">Item 1A.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii1a">Risk Factors</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">32</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii5">Item 5.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii5">Other Information</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">32</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii6">Item 6.</a></p></td><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><a href="#ii6">Exhibits</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">32</p></td><td><p style="margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="p1">PART I - FINANCIAL INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="i1">ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="bs">TENAX THERAPEUTICS, INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>ASSETS</strong><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_354" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,671,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_355" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,250,241</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_356" name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">510,943</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_357" name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">462,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_358" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">349,862</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_359" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">82,578</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_360" name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,532,227</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_361" name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,795,506</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Right of use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_362" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">338,698</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_363" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">58,778</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_364" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,821</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_365" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_366" name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,435</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_367" name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,435</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_368" name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,885,181</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_369" name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,868,691</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>LIABILITIES AND STOCKHOLDERS EQUITY</strong></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_372" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">791,947</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_373" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">757,856</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_374" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">383,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_375" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,240,616</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Note payable</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_376" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_377" name="us-gaap:NotesPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">120,491</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px 0px 0px 15px">Total current liabilities</p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td class="ffcell"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_378" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,175,010</ix:nonFraction></p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td class="ffcell"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_379" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,118,963</ix:nonFraction></p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Long term liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_381" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">239,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_382" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Note payable</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_757" name="us-gaap:NotesPayable" contextRef="AsOf2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_756" name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">124,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Total long term liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_385" name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">239,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_386" name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">124,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_387" name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,414,049</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_388" name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,243,129</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Commitments and contingencies; see Note 8</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Preferred stock, undesignated, authorized <ix:nonFraction id="fid_640" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,999,790</ix:nonFraction> shares; See Note 9 Series A Preferred stock, par value $<ix:nonFraction id="fid_636" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">.0001</ix:nonFraction>, issued <ix:nonFraction id="fid_642" name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,181,346</ix:nonFraction> shares; outstanding <ix:nonFraction id="fid_646" name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction>, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_392" name="us-gaap:PreferredStockValue" contextRef="AsOf2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_393" name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Common stock, par value $<ix:nonFraction id="fid_650" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">.0001</ix:nonFraction> per share; authorized <ix:nonFraction id="fid_652" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">400,000,000</ix:nonFraction> shares; issued and outstanding <ix:nonFraction id="fid_655" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">25,201,312</ix:nonFraction> and <ix:nonFraction id="fid_654" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,619,369</ix:nonFraction> respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_394" name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,520</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_395" name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,262</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">272,953,869</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_397" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">250,644,197</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Accumulated other comprehensive loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_398" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">274</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_399" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">70</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Accumulated deficit </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_400" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">271,484,983</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_401" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">246,019,827</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Total stockholders equity </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_402" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,471,132</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_403" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,625,562</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Total liabilities and stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_404" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,885,181</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_405" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,868,691</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">  </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="so">TENAX THERAPEUTICS, INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Three months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_407" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,271,278</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">869,206</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_409" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,644,738</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_410" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,192,165</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_411" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">693,222</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_412" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,274,837</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_413" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,069,424</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_414" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,617,363</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_415" name="us-gaap:OperatingExpenses" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,964,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_416" name="us-gaap:OperatingExpenses" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,144,043</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_417" name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,714,162</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_418" name="us-gaap:OperatingExpenses" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,809,528</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Net operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_419" name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,964,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_420" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,144,043</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_421" name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,714,162</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_422" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,809,528</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_423" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">336</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_424" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">406</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_425" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_426" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">406</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other (income) expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_427" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">247,820</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_428" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,101</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_429" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">249,955</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_430" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,740</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_431" name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,717,016</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_432" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,146,550</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_433" name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,465,156</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_434" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,801,194</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Unrealized (gain) loss on marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_435" name="us-gaap:MarketableSecuritiesGainLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">128</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_436" name="us-gaap:MarketableSecuritiesGainLoss" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,238</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_437" name="us-gaap:MarketableSecuritiesGainLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">204</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_438" name="us-gaap:MarketableSecuritiesGainLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,616</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Total comprehensive loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_439" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,716,888</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_440" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,143,312</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,465,360</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_442" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,799,578</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net loss per share, basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_443" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-04-01to2021-06-30" unitRef="USDPShares" decimals="INF" sign="-">0.10</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_444" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-01to2020-06-30" unitRef="USDPShares" decimals="INF" sign="-">0.23</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_445" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-01-01to2021-06-30" unitRef="USDPShares" decimals="INF" sign="-">1.60</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_446" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-01to2020-06-30" unitRef="USDPShares" decimals="INF" sign="-">0.59</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_447" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,218,103</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_448" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,339,309</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_449" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,874,062</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_450" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,156,848</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">  </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="se">TENAX THERAPEUTICS, INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Accumulated </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Additional </strong></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>other  </strong></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Total </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>paid-in </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>capital</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="margin:0px"><strong>comprehensive</strong></p><p style="margin:0px"><strong>gain (loss) </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>Accumulated deficit </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="margin:0px"><strong>stockholders' equity </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Balance at December 31, 2019</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_451" name="us-gaap:SharesIssued" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">38,606</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_453" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_452" name="us-gaap:SharesIssued" contextRef="AsOf2019-12-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,741,860</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_454" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">674</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_455" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">239,939,797</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_456" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">458</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_457" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">236,168,436</ix:nonFraction></strong></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_458" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,772,497</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Common stock and pre-funded warrants sold, net of offering costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_460" name="tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">750,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_462" name="tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_463" name="tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,129,930</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_466" name="tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,130,005</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Compensation on options issued</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_468" name="tenx:CompensationOnOptionsIssued" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_469" name="tenx:CompensationOnOptionsIssued" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">72,376</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_472" name="tenx:CompensationOnOptionsIssued" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">72,376</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Common stock issued for services rendered</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_474" name="tenx:CommonStockIssuedForServicesRenderedShares" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">77,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_476" name="tenx:CommonStockIssuedForServicesRenderedAmount" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_477" name="tenx:CommonStockIssuedForServicesRenderedAmount" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,992</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_480" name="tenx:CommonStockIssuedForServicesRenderedAmount" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Common stock issued for convertible preferred stock</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_481" name="tenx:CommonStockIssuedForConvertiblePreferredStockShares" contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">38,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_483" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_482" name="tenx:CommonStockIssuedForConvertiblePreferredStockShares" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">38,396</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_484" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_485" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_488" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2020-01-01to2020-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Exercise of pre-funded warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_490" name="tenx:ExerciseOfPreFundedWarrantsShares" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">400,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_492" name="tenx:ExerciseOfPreFundedWarrantsAmount" contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_493" name="tenx:ExerciseOfPreFundedWarrantsAmount" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_496" name="tenx:ExerciseOfPreFundedWarrantsAmount" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Unrealized loss on marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_500" name="tenx:UnrealizedLossOnMarketableSecurities" contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,622</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_502" name="tenx:UnrealizedLossOnMarketableSecurities" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,622</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_507" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,654,644</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_508" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,654,644</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Balance at March 31, 2020</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_509" name="us-gaap:SharesIssued" contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_511" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_510" name="us-gaap:SharesIssued" contextRef="AsOf2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,008,243</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_512" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">801</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_513" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">242,242,095</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_514" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,164</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_515" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">238,823,080</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_516" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,418,652</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Compensation on options issued</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_518" name="tenx:CompensationOnOptionsIssued" contextRef="From2020-04-01to2020-06-30_tenx_CommonStocksMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_519" name="tenx:CompensationOnOptionsIssued" contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">63,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_522" name="tenx:CompensationOnOptionsIssued" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">63,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_524" name="tenx:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2020-04-01to2020-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,087,515</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_526" name="tenx:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2020-04-01to2020-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">209</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_527" name="tenx:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,690,455</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_530" name="tenx:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,690,664</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Unrealized gain on marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_534" name="tenx:UnrealizedGainOnMarketableSecurities" contextRef="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,238</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_536" name="tenx:UnrealizedGainOnMarketableSecurities" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,238</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_541" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,146,550</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(2,146,550</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Balance at June 30, 2020</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_543" name="us-gaap:SharesIssued" contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_545" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_544" name="us-gaap:SharesIssued" contextRef="AsOf2020-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,095,758</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_546" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,010</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_547" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">243,995,716</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_548" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,074</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_549" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">240,969,630</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_550" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,029,170</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Balance at December 31, 2020</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_551" name="us-gaap:SharesIssued" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_553" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_552" name="us-gaap:SharesIssued" contextRef="AsOf2020-12-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,619,369</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_554" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,262</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_555" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">250,644,197</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_556" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">70</ix:nonFraction></strong></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_557" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">246,019,827</ix:nonFraction></strong></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_558" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,625,562</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Common stock and preferred stock issued for asset acquisition</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_559" name="tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,232</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_561" name="tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_560" name="tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,892,905</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_562" name="tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">189</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_563" name="tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,582,141</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_566" name="tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" contextRef="From2021-01-01to2021-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,582,331</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Compensation on options issued</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_569" name="tenx:CompensationOnOptionsIssued" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,609</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_572" name="tenx:CompensationOnOptionsIssued" contextRef="From2021-01-01to2021-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,609</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_574" name="tenx:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">457,038</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_576" name="tenx:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">46</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_577" name="tenx:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">544,605</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_580" name="tenx:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-01to2021-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">544,651</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Unrealized loss on marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_584" name="tenx:UnrealizedLossOnMarketableSecurities" contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">332</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_586" name="tenx:UnrealizedLossOnMarketableSecurities" contextRef="From2021-01-01to2021-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">332</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_591" name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">23,748,140</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_592" name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">23,748,140</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Balance at March 31, 2021</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_593" name="us-gaap:SharesIssued" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,442</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_595" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_594" name="us-gaap:SharesIssued" contextRef="AsOf2021-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">14,969,312</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_596" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,497</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_597" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">272,862,552</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_598" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">402</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_599" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">269,767,967</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_600" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,095,681</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Common stock issued for convertible preferred stock</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_601" name="tenx:CommonStockIssuedForConvertiblePreferredStockShares" contextRef="From2021-04-01to2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">10,232</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_603" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2021-04-01to2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_602" name="tenx:CommonStockIssuedForConvertiblePreferredStockShares" contextRef="From2021-04-01to2021-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,232,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_604" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2021-04-01to2021-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,023</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_605" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2021-04-01to2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,022</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_608" name="tenx:CommonStockIssuedForConvertiblePreferredStockAmount" contextRef="From2021-04-01to2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Compensation on options issued</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_611" name="tenx:CompensationOnOptionsIssued" contextRef="From2021-04-01to2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">92,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_614" name="tenx:CompensationOnOptionsIssued" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">92,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Unrealized gain on marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_618" name="tenx:UnrealizedGainOnMarketableSecurities" contextRef="From2021-04-01to2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">128</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_620" name="tenx:UnrealizedGainOnMarketableSecurities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">128</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(1,717,016</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(1,717,016</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Balance at June 30, 2021</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_627" name="us-gaap:SharesIssued" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_629" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_628" name="us-gaap:SharesIssued" contextRef="AsOf2021-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">25,201,312</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_630" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_tenx_CommonStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,520</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_631" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">272,953,869</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_632" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">274</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong>(<ix:nonFraction id="fid_633" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">271,484,983</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_634" name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,471,132</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>  </strong></p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="cf">TENAX THERAPEUTICS, INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">CASH FLOWS FROM OPERATING ACTIVITIES</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net Loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_659" name="us-gaap:ProfitLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">25,465,156</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_660" name="us-gaap:ProfitLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,801,194</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Adjustments to reconcile net loss to net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_662" name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,026</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_663" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Interest on debt instrument</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_664" name="us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_665" name="us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">406</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Amortization of right of use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_666" name="us-gaap:AmortizationOfLeasedAsset" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,859</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_667" name="us-gaap:AmortizationOfLeasedAsset" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Gain on debt settlement and extinguishment</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_668" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">247,233</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_669" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Issuance of common stock and preferred stock for asset acquisition</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_670" name="tenx:IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,582,331</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_671" name="tenx:IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Issuance and vesting of compensatory stock options and warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_672" name="tenx:IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">183,948</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_673" name="tenx:IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">135,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Issuance of common stock for services rendered</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_674" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-01to2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_675" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">50,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Amortization of premium on marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_676" name="tenx:AmortizationOfPremiumOnMarketableSecurities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,896</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_677" name="tenx:AmortizationOfPremiumOnMarketableSecurities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,647</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Changes in operating assets and liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Accounts receivable, prepaid expenses and other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_679" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">267,284</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_680" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">170,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Accounts payable and accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_681" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">923,295</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_682" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">453,406</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Long term portion of lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_683" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,720</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_684" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">60,379</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_685" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,066,239</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_686" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,899,965</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">CASH FLOWS FROM INVESTING ACTIVITIES</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Purchase of marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_688" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">345,540</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_689" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">351,138</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Sale of marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_690" name="tenx:SaleOfMarketableSecurities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">290,184</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_691" name="tenx:SaleOfMarketableSecurities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">365,049</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Purchase of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_692" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,875</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_693" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Net cash (used in) provided by investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: medium none;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: medium none;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_694" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">57,231</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: medium none;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: medium none;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_695" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">CASH FLOWS FROM FINANCING ACTIVITIES</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Proceeds from the exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_697" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">544,651</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_698" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,690,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_699" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-01to2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_700" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,130,005</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Proceeds from the issuance of notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_701" name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2021-01-01to2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_702" name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">244,657</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 30px; text-align:left;">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: medium none;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: medium none;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_703" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">544,651</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: medium none;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: medium none;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_704" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,065,366</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net change in cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_705" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,578,819</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_706" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">820,688</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Cash and cash equivalents, beginning of period</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_707" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,250,241</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_708" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,905,993</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Cash and cash equivalents, end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_709" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,671,422</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_710" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,085,305</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td class="ffcell"><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td class="ffcell"><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">Non-cash investing activity</p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td class="ffcell"><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td class="ffcell"><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">Addition to right of use asset obtained from new operating lease liability</p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px">$</p></td><td class="ffcell" style="vertical-align:bottom;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_761" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">333,779</ix:nonFraction></p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px">$</p></td><td class="ffcell" style="vertical-align:bottom;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_762" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></p></td><td><p style="margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">    </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="note">TENAX THERAPEUTICS, INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><ix:nonNumeric id="fid_711" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 1. DESCRIPTION OF BUSINESS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Tenax Therapeutics, Inc. (the “Company”) was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. On June 17, 2008, the stockholders of Synthetic Blood International approved the Agreement and Plan of Merger dated April 28, 2008, between Synthetic Blood International and Oxygen Biotherapeutics, Inc., a Delaware corporation. Oxygen Biotherapeutics was formed on April 17, 2008 by Synthetic Blood International to participate in the merger for the purpose of changing the state of domicile of Synthetic Blood International from New Jersey to Delaware. Certificates of Merger were filed with the states of New Jersey and Delaware and the merger was effective June 30, 2008. Under the Plan of Merger, Oxygen Biotherapeutics was the surviving corporation and each share of Synthetic Blood International common stock outstanding on June 30, 2008 was converted to one share of Oxygen Biotherapeutics common stock. On September 19, 2014, the Company changed its name to Tenax Therapeutics, Inc. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 18, 2013, the Company created a wholly owned subsidiary, Life Newco, Inc., a Delaware corporation (“Life Newco”), to acquire certain assets of Phyxius Pharma, Inc., a Delaware corporation (“Phyxius”) pursuant to an Asset Purchase Agreement, dated October 21, 2013 (the “Asset Purchase Agreement”), by and among the Company, Life Newco, Phyxius and the stockholders of Phyxius (the “Phyxius Stockholders”). As further discussed in Note 8 below, on November 13, 2013, under the terms and subject to the conditions of the Asset Purchase Agreement, Life Newco acquired certain assets, including a license granting Life Newco an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, the Company entered into an Amendment (the “Amendment”) to the License between the Company and Orion Corporation, a global healthcare company incorporated under the laws of Finland (“Orion”), to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan to the scope of the License, subject to specified limitations. The Amendment also amends the tiered royalty payments based on net sales of the Product in the Territory (each as defined in the License, as amended by the Amendment) made by the Company and its sublicensees. Pursuant to the Amendment, the term of the License has been extended until 10 years after the launch of the Product in the Territory, provided that the License will continue after the end of the term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. In the event that no regulatory approval for the Product has been granted in the United States on or before September 20, 2028, however, either party will have the right to terminate the License with immediate effect. The Company intends to conduct an upcoming Phase 3 study in pulmonary hypertension patients utilizing one of these oral formulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, the Company, Life Newco II, Inc., a Delaware corporation and a wholly-owned, direct subsidiary of the Company (“Life Newco II”), PHPrecisionMed Inc., a Delaware corporation (“PHPM,”) and Dr. Stuart Rich, solely in his capacity as holders’ representative (in such capacity, the “Representative”), entered into an Agreement and Plan of Merger, dated January 15, 2021 (the “Merger Agreement”), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company would acquire 100% of the equity of PHPM. Under the terms of the Merger Agreement, Life Newco II would merge with and into PHPM, with PHPM surviving as a wholly owned subsidiary of the Company (the “Merger”). On January 15, 2021, the Company completed the acquisition contemplated by the Merger Agreement (the “Acquisition”). As a result of the Acquisition the Company intends to develop pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States and the rest of the world.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_712" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true" continuedAt="cont_9bc6cd"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Basis of Presentation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_721" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet on December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the period ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) rules and regulations. Operating results for the three and six-month period ended June 30, 2021 are not necessarily indicative of results for the full year or any other future periods. As such, it is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. </p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_9bc6cd" continuedAt="cont_fdee4e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_722" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Management believes the accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $271 million on June 30, 2021 and $246 million on December 31, 2020 and used cash in operations of $5.1 million and $4.9 million during the six months ended June 30, 2021 and 2020, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 10 below, the Company sold <ix:nonFraction id="fid_766" name="us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,773,269</ix:nonFraction> units ("Units") in a private placement at a purchase price of $<ix:nonFraction id="fid_767" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" contextRef="From2021-01-01to2021-06-30" unitRef="USDPShares" decimals="INF">2.095</ix:nonFraction> per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of common stock and one unregistered warrant to purchase one share of common stock for gross proceeds of approximately $<ix:nonFraction id="fid_768" name="tenx:AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">10</ix:nonFraction> million. The Company requires substantial additional funds to complete its planned clinical trials and to pursue regulatory approvals. Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying June 30, 2021 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, to maintain present financing, and to generate cash from future operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Use of Estimates</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_723" name="us-gaap:UseOfEstimates" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In preparing the unaudited condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Principles of Consolidation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_724" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying condensed consolidated financial statements include the accounts and transactions of the Company, Life Newco and Life Newco II. All material intercompany transactions and balances have been eliminated in consolidation.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Liquidity and Management’s Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_725" name="tenx:LiquidityAndManagementsPlanPolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 30, 2021, the Company had cash and cash equivalents, including the fair value of its marketable securities, of approximately $<ix:nonFraction id="fid_138" name="us-gaap:MarketableSecurities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.2</ix:nonFraction> million. The Company used $5.1 million of cash for operating activities during the six months ended June 30, 2021 and had stockholders’ equity of $<ix:nonFraction id="fid_743" name="us-gaap:StockholdersEquityBeforeTreasuryStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.5</ix:nonFraction> million, versus $4.6 million on December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company expects to continue to incur expenses related to development of imatinib for pulmonary arterial hypertension and levosimendan for pulmonary hypertension and to continue with the development of other potential product candidates. Based on its resources on June 30, 2021 and including the net proceeds from its July 2021 offering (as discussed in Note 10 below), the Company believes that it has sufficient capital to fund its planned operations through the second quarter of calendar year 2022. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_fdee4e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>COVID-19 Impact and Related Risks</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_726" name="tenx:Covid19ImpactPolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The continued spread of COVID-19 globally could adversely affect the Company’s ability to retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some of these investigators and site staff may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede movement or interrupt healthcare services, or if they become infected with COVID-19 themselves, which would delay the Company’s ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The full extent to which the COVID-19 pandemic and the various responses to it might impact the Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond the Company’s control.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Loss per Share</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_727" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Basic net loss per share, which excludes antidilutive securities, is computed by dividing net loss by the weighted-average number of common shares outstanding for that particular period. In contrast, diluted net loss per share considers the potential dilution that could occur from other equity instruments that would increase the total number of outstanding shares of common stock. Such amounts include shares potentially issuable under outstanding options, convertible preferred shares and warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following outstanding options, convertible preferred shares and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_730" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_123" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-06-30_tenx_WarranttoPurchaseCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,797,503</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_124" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30_tenx_WarranttoPurchaseCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,274,492</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_764" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-06-30_tenx_PrefundedWarrantsToPurchaseCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,260,005</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_125" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">779,885</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_126" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30_tenx_SimdaxLicenseAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">450,203</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_127" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-06-30_tenx_ConvertiblePreferredSharesOutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_128" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30_tenx_ConvertiblePreferredSharesOutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">210</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Leases</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_728" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in the Company’s condensed consolidated balance sheets. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. The Company’s leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that the Company will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to account for leases with an initial term of 12 months or less similar to previous guidance for operating leases, under which the Company will recognize those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Recent Accounting Pronouncements </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_729" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In December 2019, the Financial Accounting Standards Board (“FASB”) issued an accounting standard intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740, Income Taxes and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the FASB issued an accounting standard that amends how credit losses are measured and reported for certain financial instruments that are not accounted for at fair value through net income. This standard requires that credit losses be presented as an allowance rather than as a write-down for available-for-sale debt securities and will be effective for interim and annual reporting periods beginning January 1, 2023, with early adoption permitted. A modified retrospective approach is to be used for certain parts of this guidance, while other parts of the guidance are to be applied using a prospective approach. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_713" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true" continuedAt="cont_38a823"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 3. FAIR VALUE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines the fair value of its financial assets and liabilities in accordance with the Accounting Standards Codification (“ASC”) 820 Fair Value Measurements. The Company’s balance sheet includes the following financial instruments: cash and cash equivalents, investments in marketable securities, and warrant liabilities. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to the short-term nature of these instruments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Accounting for fair value measurements involves a single definition of fair value, along with a conceptual framework to measure fair value, with a fair value defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” The fair value measurement hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level one</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Quoted market prices in active markets for identical assets or liabilities;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level two</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inputs other than level one inputs that are either directly or indirectly observable; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level three</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company applies valuation techniques that (1) place greater reliance on observable inputs and less reliance on unobservable inputs and (2) are consistent with the market approach, the income approach and/or the cost approach, and include enhanced disclosures of fair value measurements in the Company’s condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Investments in Marketable Securities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive income/(loss), unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in other income in the condensed consolidated statements of comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. As of June 30, 2021, the Company believes that the costs of its investments are recoverable in all material respects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments is classified as Level 2 in the fair value hierarchy as defined in GAAP. These fair values are obtained from independent pricing services which utilize Level 2 inputs:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_731" name="tenx:ScheduleOfInvestmentsInMarketableSecurities" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amortized </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accrued </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized Gains</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized losses</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Corporate debt securities </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_140" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">506,530</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_142" name="us-gaap:AccruedInvestmentIncomeReceivable" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,690</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_144" name="us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains" contextRef="From2021-01-01to2021-06-30_us-gaap_CorporateDebtSecuritiesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">46</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_146" name="tenx:GrossUnrealizedLosses" contextRef="From2021-01-01to2021-06-30_us-gaap_CorporateDebtSecuritiesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">323</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_148" name="tenx:AvailableForSaleSecuritiesEstimatedFairValue" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">510,943</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total investments </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_139" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">506,530</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_141" name="us-gaap:AccruedInvestmentIncomeReceivable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,690</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_143" name="us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">46</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_145" name="tenx:GrossUnrealizedLosses" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">323</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_147" name="tenx:AvailableForSaleSecuritiesEstimatedFairValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">510,943</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">All of the Company’s investments have scheduled maturities of less than one year as of June 30, 2021 and December 31, 2020.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_38a823"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following tables summarize information regarding assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_732" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of June 30, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_151" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,671,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_152" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,671,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_154" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_156" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_159" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">510,943</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_160" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_162" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">510,943</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_164" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of December 31, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_150" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,250,241</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_153" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,250,241</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_155" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_157" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_158" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">462,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_161" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_163" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">462,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_165" name="us-gaap:AvailableForSaleSecurities" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">There were no significant transfers between levels in the six months ended June 30, 2021.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><ix:nonNumeric id="fid_714" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 4. BALANCE SHEET COMPONENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Property and equipment, net </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Property and equipment consist of the following as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_733" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Office furniture and fixtures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_167" name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">43,033</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_166" name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">43,033</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Computer equipment and software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_169" name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,631</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_168" name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,307</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_171" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">66,664</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_170" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">66,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_173" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,843</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_172" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,368</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_175" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,821</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_174" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Depreciation expense was approximately $<ix:nonFraction id="fid_185" name="us-gaap:Depreciation" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,000</ix:nonFraction> for each of the three-month periods ended June 30, 2021 and 2020. Depreciation expense was approximately $<ix:nonFraction id="fid_184" name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,000</ix:nonFraction> for each of the six-month periods ended June 30, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Accrued liabilities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Accrued liabilities consist of the following as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_734" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Employee related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_177" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">127,551</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_176" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">860,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Operating costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_179" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">154,051</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_178" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">319,608</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_181" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">101,461</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_180" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,379</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_183" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">383,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_182" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,240,616</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_715" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true" continuedAt="cont_7a2324"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 5. LEASE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In January 2011, the Company entered into the Lease with Concourse Associates, LLC for office facilities located at the premises in Morrisville, North Carolina (the “Lease”). The Lease was amended in August 2015 to extend the term for the <ix:nonFraction id="fid_198" name="us-gaap:AreaOfLand" contextRef="AsOf2015-08-31" format="ixt:numdotdecimal" unitRef="sqft" decimals="INF">5,954</ix:nonFraction> square foot rental. The current term began on March 1, 2016 and continues for <ix:nonNumeric id="fid_199" name="tenx:LeaseTermPeriod" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear">64</ix:nonNumeric> months to June 30, 2021. Rent payments began on July 1, 2016, following the conclusion of a four-month rent abatement period. <ix:nonNumeric id="fid_200" name="us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases" contextRef="From2021-01-01to2021-06-30">The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease thirty-six months after the commencement of the initial term if no additional space (“Expansion Space”) became available. On April 2, 2021, the Company negotiated a 3-year extension to the existing lease term, commencing July 1, 2021</ix:nonNumeric>. Beginning on the commencement date, the annual base rent will be increased to $<ix:nonFraction id="fid_201" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,034</ix:nonFraction> and will increase <ix:nonFraction id="fid_202" name="tenx:PercentageOfAnnualIncreaseInRent" contextRef="From2021-01-01to2021-06-30" unitRef="Pure" decimals="INF" scale="-2">2.5</ix:nonFraction>% annually for lease years 2 and 3. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_7a2324"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and determined that, except for the Lease described above, none of the Company’s contracts contain a lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The balance sheet classification of our lease liabilities was as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_735" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_191" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">101,461</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_188" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,379</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_189" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">239,039</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_190" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_193" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">340,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_192" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,379</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the maturities of our operating lease liabilities were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_736" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Year ending December 31, </strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_748" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">62,517</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_749" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">126,612</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_750" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">129,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_751" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">65,702</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_752" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">384,628</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_753" name="tenx:LessImputedInterest" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">44,128</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Operating lease liability</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Operating lease liabilities are based on the net present value of the remaining Lease payments over the remaining Lease term. In determining the present value of lease payments, the Company used the incremental borrowing rate based on the information available at the Lease commencement date. As of June 30, 2021, the remaining Lease term is <ix:nonNumeric id="fid_351" name="tenx:RemainingLeaseTerm" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear">36</ix:nonNumeric> months and the discount rate used to determine the operating lease liability was <ix:nonFraction id="fid_195" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-06-30" unitRef="Pure" decimals="INF" scale="-2">8.0</ix:nonFraction>%. For the six months ending June 30, 2021, the Company paid $<ix:nonFraction id="fid_196" name="us-gaap:LeaseCost" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">67,765</ix:nonFraction> in total lease expenses, including $5,963 for common area maintenance charges. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_716" name="us-gaap:DebtDisclosureTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 6. NOTE PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Payroll Protection Program Loan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On April 30, 2020, the Company received a loan pursuant to the Paycheck Protection Program (the “PPP Loan”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), as administered by the U.S. Small Business Administration (“SBA”). The PPP Loan in the principal amount of $<ix:nonFraction id="fid_203" name="tenx:PppLoanAmount" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">244,657</ix:nonFraction> was disbursed by First Horizon Bank (the “Lender”) pursuant to a promissory note issued by us (the “Note”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The PPP Loan has a two-year term and bears interest at a rate of <ix:nonFraction id="fid_206" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-06-30" unitRef="Pure" decimals="INF" scale="-2">1.00</ix:nonFraction>% per annum. Monthly principal and interest payments are deferred for sixteen months. Beginning September 30, 2021, the Company is required to make monthly payments of principal and interest of approximately $<ix:nonFraction id="fid_204" name="tenx:PppLoanMonthlyPayment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">31,100</ix:nonFraction> to the Lender. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations, and material adverse effects. The Company may prepay the principal of the PPP Loan at any time, subject to certain notice requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the terms of the CARES Act, Paycheck Protection Program loan recipients can apply for and be granted forgiveness for all or a portion of a loan granted under the program. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The Company is using the proceeds from the PPP Loan to fund payroll costs in accordance with the relevant terms and conditions of the CARES Act. However, no assurance is provided that forgiveness for any portion of the PPP Loan will be obtained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On May 28, 2021, the Company received notice from the SBA that the SBA had remitted $<ix:nonFraction id="fid_208" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">244,657</ix:nonFraction> in principal and $<ix:nonFraction id="fid_207" name="tenx:DebtInstrumentDecreaseForgivenessAccruedInterest" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,576</ix:nonFraction> in interest to the Lender in full forgiveness of the Company’s PPP Loan pursuant to the Company’s application to the SBA for forgiveness of the PPP Loan. The total amount was recorded as other income in the Company's condensed consolidated statement of comprehensive loss.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_717" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>NOTE 7. MERGER</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, the Company, Life Newco II, PHPM, and Dr. Stuart Rich, solely in his capacity as Representative, entered into the Merger Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company would acquire 100% of the equity of PHPM. Under the terms of the Merger Agreement, Life Newco II would merge with and into PHPM, with PHPM surviving as a wholly owned subsidiary of the Company. On January 15, 2021, the Company completed the Acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As consideration for the Merger, the stockholders of PHPM received (i) <ix:nonFraction id="fid_217" name="tenx:CommonStockAcquired" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,892,905</ix:nonFraction> shares of the Company’s common stock (“Common Stock”), and (ii) <ix:nonFraction id="fid_219" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2021-06-30_us-gaap_SeriesBMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,232</ix:nonFraction> shares of the Company’s Series B convertible preferred stock, which are convertible into up to an aggregate of <ix:nonFraction id="fid_216" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,232,000</ix:nonFraction> shares of Common Stock (“Preferred Stock”) (collectively, the “Merger Consideration”). The issuance of <ix:nonFraction id="fid_218" name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,212,492</ix:nonFraction> shares of Common Stock issuable upon conversion of the Preferred Stock, representing approximately 10% of the Merger Consideration, will be delayed as security for closing adjustments and post-closing indemnification obligations of PHPM and the stockholders of PHPM. Following receipt of the approval of the stockholders of the Company for the Conversion (as defined herein), each share of Preferred Stock will automatically convert into (i) 881.5 shares of Common Stock, and (ii) 118.5 shares of Common Stock to be delivered 24 months after the date of issuance of the Preferred Stock, subject to reduction for indemnification claims. The number of shares of Common Stock into which the Preferred Stock converts is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The Preferred Stock does not carry dividends or a liquidation preference. The Preferred Stock carries voting rights aggregating <ix:nonFraction id="fid_220" name="tenx:PercentageOfPreferredStockCarriesVotingRights" contextRef="From2021-01-01to2021-06-30" unitRef="Pure" decimals="INF" scale="-2">4.99</ix:nonFraction>% of the Company’s Common Stock voting power immediately prior to the closing of the Merger. The rights, preferences and privileges of the Preferred Stock are set forth in the Certificate of Designation of Series B Convertible Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on January 15, 2021 (the “Certificate of Designation”). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pursuant to the Merger Agreement, the Board of Directors, at its Annual Meeting of Shareholders held on June 10, 2021, recommended to the Company’s shareholders, and the shareholders approved, the conversion of the Preferred Stock pursuant to the Certificate of Designation (the “Conversion”). In addition, (i) at the Company’s first regularly scheduled Board meeting following the closing of the Merger, the Board must appoint one director designated by the Representative to serve on the Board, and (ii) as promptly as practicable after the Company has obtained stockholder approval for the Conversion, the Board must appoint two additional directors designated by the Representative to serve on the Board. Dr. Stuart Rich, the co-founder and Chief Executive Officer, and a stockholder of PHPM, and Dr. Michael Davidson and Dr. Declan Doogan, the two other designees of the Representative, were appointed to the Board on February 25, 2021. In connection with the closing of the Merger, Dr. Stuart Rich was also appointed Chief Medical Officer of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company evaluated this acquisition in accordance with ASC 805, Business Combinations, to determine whether the assets and operations of PHPM met the definition of a business. Included in the in-process research and development project is the historical know-how, formula protocols, designs, and procedures expected to be needed to complete the related phase of testing. The Company concluded that the in-process research and development project is an identifiable intangible asset that would be accounted for as a single asset in a business combination. The Company also qualitatively concluded that there is no fair value associated with the clinical research organization contract and the clinical manufacturing organization contract because the services are being provided at market rates and could be provided by multiple vendors in the marketplace. Therefore, all of the consideration in the transaction will be allocated to the in-process research and development project. As such, the Company concluded that substantially all of the fair value of the gross assets acquired is concentrated in the single in-process research and development asset and the set is not a business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company is planning to use the acquired asset to further its clinical develop in an upcoming phase 3 clinical trial for the treatment of patients with PAH. Although the acquired asset may have utility in other patient populations, future development decisions for the acquired asset will be contingent upon the results of the contemplated phase 3 program for PAH. As such, the acquired asset does not have an alternative future use at the acquisition date. In accordance with ASC 730, Research and Development, the Company concluded the entire Purchase Price for the asset acquisition will be recorded as an expense on the acquisition date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The consideration transferred, assets acquired and liabilities assumed were recognized as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_737" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of shares of Common Stock issued</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_209" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,369,371</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair Value of Series B Convertible Preferred Stock issued at closing</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_210" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,212,960</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Total fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_211" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,582,331</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tangible assets acquired</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_212" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2021-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable assumed</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_213" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">150,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IPR&D expense recognized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_214" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,732,331</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total fair value of consideration</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_215" name="tenx:InProcessResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,582,331</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_718" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 8. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Simdax license agreement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On November 13, 2013, the Company acquired, through its wholly owned subsidiary, Life Newco, that certain License Agreement (the “License”), dated September 20, 2013 by and between Phyxius and Orion Corporation, a global healthcare company incorporated under the laws of Finland (“Orion”), and that certain Side Letter, dated October 15, 2013 by and between Phyxius and Orion. The License grants the Company an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan (the “Product”) in the United States and Canada (the “Territory”) from Orion. Pursuant to the License, the Company must use Orion’s “Simdax®” trademark to commercialize the Product. The License also grants to the Company a right of first refusal to commercialize new developments of the Product, including developments as to the formulation, presentation, means of delivery, route of administration, dosage or indication, i.e., line extension products. Orion’s ongoing role under the License includes sublicense approval, serving as the sole source of manufacture, holding a first right to enforce intellectual property rights in the Territory, and certain regulatory participation rights. Additionally, the Company must grant back to Orion a broad non-exclusive license to any patents or clinical trial data related to the Product developed by the Company under the License. The License has a fifteen (<ix:nonNumeric id="fid_227" name="us-gaap:LongtermPurchaseCommitmentPeriod" contextRef="From2013-11-01to2013-11-13_tenx_SimdaxLicenseAgreementMember" format="ixt-sec:duryear">15</ix:nonNumeric>) year term, provided, however, that the License will continue after the end of the fifteen-year term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, the Company entered into the Amendment to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan to the scope of the License, subject to specified limitations. The Amendment also amends the tiered royalty payments based on net sales of the Product in the Territory (each as defined in the License, as amended by the Amendment) made by the Company and its sublicensees. Pursuant to the Amendment, the term of the License has been extended until <ix:nonNumeric id="fid_221" name="us-gaap:LongtermPurchaseCommitmentPeriod" contextRef="From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember" format="ixt-sec:duryear">10</ix:nonNumeric> years after the launch of the Product in the Territory, provided that the License will continue after the end of the term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. In the event that no regulatory approval for the Product has been granted in the United States on or before <ix:nonNumeric id="fid_222" name="tenx:LicenseAgreementMaturityDate" contextRef="From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember" format="ixt:datemonthdayyearen">September 20, 2028</ix:nonNumeric>, however, either party will have the right to terminate the License with immediate effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pursuant to the terms of the License, the Company paid to Orion a non-refundable up-front payment in the amount of $<ix:nonFraction id="fid_223" name="tenx:NonRefundableUpFrontPayment" contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.0</ix:nonFraction> million. The License also includes the following development milestones for which the Company shall make non-refundable payments to Orion no later than twenty-eight (28) days after the occurrence of the applicable milestone event: (1) $<ix:nonFraction id="fid_224" name="tenx:GrantPaidToAuthority" contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.0</ix:nonFraction> million upon the grant of United States Food and Drug Administration approval, including all registrations, licenses, authorizations and necessary approvals, to develop and/or commercialize the Product in the United States; and (2) $<ix:nonFraction id="fid_225" name="tenx:GrantPaidToAuthorityOne" contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.0</ix:nonFraction> million upon the grant of regulatory approval for the Product in Canada. Once commercialized, the Company is obligated to make certain non-refundable commercialization milestone payments to Orion, aggregating up to $<ix:nonFraction id="fid_226" name="tenx:NonRefundableCommercializationMilestonePayment" contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">13.0</ix:nonFraction> million, contingent upon achievement of certain cumulative net sales amounts in the Territory. The Company must also pay Orion tiered royalties based on net sales of the Product in the Territory made by the Company and its sublicensees. After the end of the term of the License, the Company must pay Orion a royalty based on net sales of the Product in the Territory for as long as the Company sells the Product in the Territory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the Company has not met any of the developmental milestones and, accordingly, has not recorded any liability for the contingent payments due to Orion.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_719" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true" continuedAt="cont_285b40"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 9. STOCKHOLDERS’ EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Preferred Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the Company’s Certificate of Incorporation, the Board is authorized, without further stockholder action, to provide for the issuance of up to 10,000,000 shares of preferred stock, par value $0.0001 per share, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_285b40" continuedAt="cont_28533b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Series B Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 7 above, on January 15, 2021 the Company issued <ix:nonFraction id="fid_80" name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,232</ix:nonFraction> shares of its Series B Stock, which were convertible into an aggregate of 10,232,000 shares of common stock, to the stockholders of PHPM as partial consideration for the Merger with PHPM pursuant to the Merger Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The rights, preferences and privileges of the Series B Stock are set forth in the Certificate of Designation. Following receipt of the approval of the stockholders of the Company for the Conversion, each share of Series B Stock will automatically convert into <ix:nonNumeric id="fid_86" name="us-gaap:PreferredStockVotingRights" contextRef="From2021-01-01to2021-06-30_us-gaap_SeriesBPreferredStockMember">(i) 881.5 shares of Common Stock and (ii) 118.5 shares of Common Stock, to be delivered 24 months after the date of issuance of the Preferred Stock</ix:nonNumeric>, subject to reduction for indemnification claims. The number of shares of Common Stock into which the Preferred Stock converts is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The Preferred Stock does not carry dividends or a liquidation preference. The Preferred Stock carries voting rights aggregating <ix:nonFraction id="fid_83" name="tenx:PreferredStockVotingRightsPercentage" contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" unitRef="Pure" decimals="INF" scale="-2">4.99</ix:nonFraction>% of the Company’s Common Stock voting power immediately prior to the closing of the Merger.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s shareholders approved the conversion of our outstanding Series B Stock into shares of common stock. As a result of the approval, all outstanding shares of Series B Stock were automatically converted into an aggregate of <ix:nonFraction id="fid_79" name="tenx:StockConvertibleIntoAggregateSharesOfCommonStock" contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,232,000</ix:nonFraction> shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were no shares of Series B Stock outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 22.5pt; text-align:left;"><em>Series A Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On December 11, 2018, the Company closed its underwritten offering of <ix:nonFraction id="fid_91" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,181,346</ix:nonFraction> units for net proceeds of approximately $<ix:nonFraction id="fid_90" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">9</ix:nonFraction> million. Each unit consists of (1) one share of the Company’s Series A convertible preferred stock, par value $0.0001 per share (the “Series A Stock”), (<ix:nonNumeric id="fid_94" name="tenx:WarranToPurchaseOfCommonStockTerm" contextRef="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:duryear">2</ix:nonNumeric>) a two-year warrant to purchase one share of common stock at an exercise price of $1.93, and (3) a five-year warrant to purchase one share of common stock at an exercise price of $1.93. In accordance with ASC 480, the estimated fair value of $1,800,016 for the beneficial conversion feature was recognized as a deemed dividend on the Series A Stock during the year ended December 31, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The table below sets forth a summary of the designation, powers, preferences and rights of the Series A Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:15%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"> Conversion</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Subject to the ownership limitations described below, the Series A Stock is convertible at any time at the option of the holder into shares of the Company’s common stock at a conversion ratio determined by dividing the stated value of the Series A Stock by a conversion price of $1.93 per share. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company will not affect any conversion of the Series A Stock, nor shall a holder convert its shares of Series A Stock, to the extent that such conversion would cause the holder to have acquired, through conversion of the Series A Stock or otherwise, beneficial ownership of a number shares of common stock in excess of <ix:nonFraction id="fid_97" name="tenx:PreferredStockVotingRightsPercentage" contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="INF" scale="-2">4.99</ix:nonFraction>% (or, at the election of the holder prior to the issuance of any shares of Series A Stock, <ix:nonFraction id="fid_98" name="tenx:PreferredStockVotingRightsPercentage1" contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" unitRef="Pure" decimals="INF" scale="-2">9.99</ix:nonFraction>%) of the common stock outstanding after giving effect to such exercise.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividends </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In the event the Company pays dividends on its shares of common stock, the holders of the Series A Stock will be entitled to receive dividends on shares of Series A Stock equal, on an as-if-converted basis, to and in the same form as paid on the common stock. No other dividends will be paid on the shares of Series A Stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Liquidation</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Upon any liquidation, dissolution or winding up of the Company after payment or provision for payment of debts and other liabilities of the Company, the holders of Series A Stock shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount equal to the amount that a holder of common stock would receive if the Series A Stock were fully converted to common stock, which amounts will be paid pari passu with all holders of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Voting rights</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares of Series A Stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the then outstanding Series A Stock will be required to amend the terms of the Series A Stock or to take other action that adversely affects the rights of the holders of Series A Stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were 210 shares of Series A Stock outstanding. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_28533b" continuedAt="cont_04eae7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company’s Certificate of Incorporation authorizes it to issue <ix:nonFraction id="fid_60" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">400,000,000</ix:nonFraction> shares of $0.0001 par value common stock. As of June 30, 2021, and December 31, 2020, there were <ix:nonFraction id="fid_62" name="tenx:CommonStockSharesIssue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">25,201,312</ix:nonFraction> and 12,619,369 shares of common stock issued and outstanding, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On March 13, 2020, the Company completed a registered direct offering to a single healthcare-focused institutional investor (the “Investor”) for the issuance and sale of 750,000 shares of its common stock at a purchase price of $<ix:nonFraction id="fid_106" name="tenx:WarrantToPurchaseOfCommonStockExercisePrice" contextRef="AsOf2020-03-13" unitRef="USDPShares" decimals="INF">1.1651</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction id="fid_104" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-03-13" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,610,313</ix:nonFraction> shares of its common stock, at a purchase price of $1.1650 per pre-funded warrant (which represents the per share offering price for the common stock less $0.0001, the exercise price of each pre-funded warrant), for gross proceeds of approximately $2.75 million, priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company issued to the Investor unregistered warrants to purchase up to <ix:nonFraction id="fid_111" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2018-12-11_tenx_InvestorsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,360,313</ix:nonFraction> shares of its common stock. The unregistered warrants have an exercise price of $1.04 per share and exercise period commencing immediately upon the issuance date and a term of five and one-half years. The net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses were approximately $<ix:nonFraction id="fid_116" name="tenx:NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" contextRef="AsOf2018-12-11_tenx_InvestorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-3" scale="6">2.125</ix:nonFraction> million. The fair value allocated to the common stock, pre-funded warrants and warrants was $<ix:nonFraction id="fid_118" name="tenx:FairValueAllocatedCommonStock" contextRef="AsOf2018-12-11_tenx_InvestorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.5</ix:nonFraction> million, $1.1 million and $1.1 million, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On July 8, 2020, the Company completed a registered direct offering with the Investor for the issuance and sale of 2,523,611 shares of its common stock at a purchase price of $<ix:nonFraction id="fid_245" name="tenx:CommonStockParOrStatedValuePerShares" contextRef="AsOf2020-07-08" unitRef="USDPShares" decimals="INF">1.0278</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction id="fid_246" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-08" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">652,313</ix:nonFraction> shares of its common stock, at a purchase price of $<ix:nonFraction id="fid_247" name="tenx:WarrantToPurchaseOfCommonStockExercisePrice" contextRef="AsOf2020-07-08" unitRef="USDPShares" decimals="INF">1.0277</ix:nonFraction> per pre-funded warrant (which represents the per share offering price for the common stock less $0.0001, the exercise price of each pre-funded warrant). The Company issued in a concurrent private placement unregistered pre-funded warrants to purchase up to <ix:nonFraction id="fid_249" name="tenx:ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" contextRef="From2020-07-01to2020-07-08" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,607,692</ix:nonFraction> shares of common stock at the same purchase price as the registered pre-funded warrants, and unregistered common stock warrants to purchase up to <ix:nonFraction id="fid_250" name="tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStock" contextRef="From2020-07-01to2020-07-08" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,783,616</ix:nonFraction> shares of common stock for aggregate gross proceeds of approximately $<ix:nonFraction id="fid_251" name="tenx:UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" contextRef="From2020-07-01to2020-07-08" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">8.0</ix:nonFraction> million, priced at-the-market under Nasdaq rules. The unregistered warrants have an exercise price of $<ix:nonFraction id="fid_252" name="tenx:UnregisteredWarrantsExercisePrice" contextRef="From2020-07-01to2020-07-08" unitRef="USDPShares" decimals="INF">0.903</ix:nonFraction> per share and exercise period commencing immediately upon the issuance date and a term of five and one-half years. The net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses were approximately $<ix:nonFraction id="fid_254" name="tenx:NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" contextRef="AsOf2020-07-08" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">6.5</ix:nonFraction> million. The fair value allocated to the common stock, pre-funded warrants and warrants was $<ix:nonFraction id="fid_255" name="tenx:FairValueAllocatedCommonStock" contextRef="AsOf2020-07-08_tenx_InvestorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.5</ix:nonFraction> million, $<ix:nonFraction id="fid_256" name="tenx:FairValueAllocatedPrefundedWarrants" contextRef="AsOf2020-07-08_tenx_InvestorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">3.0</ix:nonFraction> million and $<ix:nonFraction id="fid_257" name="tenx:FairValueAllocatedWarrants" contextRef="From2020-07-01to2020-07-08_tenx_InvestorsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">3.5</ix:nonFraction> million, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were <ix:nonFraction id="fid_244" name="tenx:CommonStockSharesIssue" contextRef="AsOf2020-07-08" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,260,005</ix:nonFraction> pre-funded warrants outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Warrants</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>March 2020 Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As part of the March 2020 registered direct offering, the Company issued unregistered warrants to purchase 2,360,313 shares of its common stock at an exercise price of $1.04 per share and contractual term of five and one-half years. The unregistered warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. In accordance with ASC 480, these warrants are classified as equity and their relative fair value of approximately $1.1 million was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>July 2020 Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As part of the July 2020 offering, the Company issued unregistered warrants to purchase 7,783,616 shares of its common stock at an exercise price of $0.903 per share and contractual term of five and one-half years. The unregistered warrants were offered in a private placement under Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. In accordance with ASC 480, these warrants are classified as equity and their relative fair value of approximately $3.5 million was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Warrants Issued for Services</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In connection with the March 2020 offering described above, the Company issued designees of the placement agent warrants to purchase 177,023 shares of common stock at an exercise price of $1.4564 and a contractual term of five years. In accordance with ASC 815, these warrants are classified as equity and its estimated fair value of $66,201 was recognized as additional paid in capital. Additionally, the Company issued to its previous underwriter a warrant to purchase 94,413 shares of common stock at an exercise price of $1.4564 per share and contractual term of five years. In accordance with ASC 815, this warrant is classified as equity and its estimated fair value of $35,308 was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_04eae7" continuedAt="cont_bb291b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In connection with the July 2020 offering described above, the Company issued designees of the placement agent warrants to purchase 583,771 shares of common stock at an exercise price of $1.2848 and a contractual term of five years. In accordance with ASC 815, these warrants are classified as equity and its estimated fair value of $399,445 was recognized as additional paid in capital. Additionally, the Company issued to its previous underwriter a warrant to purchase 311,345 shares of common stock at an exercise price of $1.2848 per share and contractual term of five years. In accordance with ASC 815, this warrant is classified as equity and its estimated fair value of $213,038 was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company received approximately $545,000 and issued 282,202 shares of common stock upon the exercise of previously outstanding warrants issued in connection with the Company’s December 2018 offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company issued 119,491 shares of common stock upon the cashless exercise of previously outstanding placement agent warrants issued in connection with the Company’s March 2020 offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company issued 399,883 shares of common stock upon the cashless exercise of previously outstanding placement agent warrants issued in connection with the Company’s July 2020 offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the Company has <ix:nonFraction id="fid_258" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,797,503</ix:nonFraction> warrants outstanding. The following table summarizes the Company’s warrant activity for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_738" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_0" name="tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,599,079</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_5" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">1.29</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(801,576</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_7" name="tenx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-06-30" unitRef="USDPShares" decimals="INF">1.54</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at June 30, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>15,797,503</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-06-30" unitRef="USDPShares" decimals="INF">1.27</ix:nonFraction></strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em><strong>2016 Stock Incentive Plan</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the Company adopted the 2016 Stock Incentive Plan (the “2016 Plan”). Under the 2016 Plan, with the approval of the Compensation Committee of the Board of Directors, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, cash-based awards or other stock-based awards. On June 16, 2016, the Company’s stockholders approved the 2016 Plan and authorized for issuance under the 2016 Plan a total of 150,000 shares of common stock. On June 13, 2019, the Company’s stockholders approved an amendment to the 2016 Plan which increased the number of shares of common stock authorized for issuance under the 2016 Plan to a total of <ix:nonFraction id="fid_291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-05-20to2019-06-12_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">750,000</ix:nonFraction> shares, up from 150,000 previously authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s stockholders approved an amendment to the 2016 Plan which increased the number of shares of common stock authorized for issuance under the 2016 Plan to a total of <ix:nonFraction id="fid_293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-05-20to2021-06-09_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="-5" scale="6">1.5</ix:nonFraction> million shares, up from <ix:nonFraction id="fid_289" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-06-01to2021-06-10_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">750,000</ix:nonFraction> previously authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the shares available for grant under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_739" name="tenx:SharesAvailableForGrantTableTextblock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Available </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>for Grant</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2020-12-31_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">356,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_74" name="tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">750,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">328,750</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">777,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>2016 Plan Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stock options granted under the 2016 Plan may be either incentive stock options (“ISOs”), or nonqualified stock options (“NSOs”). ISOs may be granted only to employees. NSOs may be granted to employees, consultants and directors. Stock options under the 2016 Plan may be granted with a term of up to ten years and at prices no less than fair market value at the time of grant. Stock options granted generally vest over three to four years. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_bb291b" continuedAt="cont_2c175e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the outstanding stock options under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_740" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">393,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_tenx_StockIncentivePlan2016Member" unitRef="USDPShares" decimals="INF">1.81</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">328,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_22" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" unitRef="USDPShares" decimals="INF">1.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">722,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" unitRef="USDPShares" decimals="INF">1.83</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company chose the “straight-line” attribution method for allocating compensation costs of each stock option over the requisite service period using the Black-Scholes Option Pricing Model to calculate the grant date fair value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company recorded compensation expense for these stock option grants of $<ix:nonFraction id="fid_272" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-01to2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">92,339</ix:nonFraction> and $<ix:nonFraction id="fid_68" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-01to2020-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,672</ix:nonFraction> for the three months ended June 30, 2021 and 2020, and $<ix:nonFraction id="fid_66" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">182,658</ix:nonFraction> and $<ix:nonFraction id="fid_296" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">112,833</ix:nonFraction> for the six months ended June 30, 2021 and 2020, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were unrecognized compensation costs of approximately $<ix:nonFraction id="fid_70" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">446,904</ix:nonFraction> related to non-vested stock option awards under the 2016 Plan that will be recognized on a straight-line basis over the weighted average remaining vesting period of 1.57 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company used the following assumptions to estimate the fair value of options granted under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_741" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the six months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk-free interest rate (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_25" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" unitRef="Pure" decimals="INF" scale="-2">0.70</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" unitRef="Pure" decimals="INF" scale="-2">1.03</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected volatility (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_27" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" unitRef="Pure" decimals="INF" scale="-2">99.47</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" unitRef="Pure" decimals="INF" scale="-2">97.61</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_29" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" unitRef="Pure" decimals="INF" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" unitRef="Pure" decimals="INF" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:20%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Risk-Free Interest Rate</em></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The risk-free interest rate assumption was based on U.S. Treasury instruments with a term that is consistent with the expected term of the Company’s stock options.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Volatility</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected stock price volatility for the Company’s common stock was determined by examining the historical volatility and trading history for its common stock over a term consistent with the expected term of its options.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Term</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. It was calculated based on the Company’s historical experience with its stock option grants.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Dividend Yield</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected dividend yield of 0% is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not anticipate paying any dividends in the near future.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Forfeitures</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock compensation expense recognized in the statements of operations for the six months ended June 30, 2021 is based on awards ultimately expected to vest, and it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on the Company’s historical experience.</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_2c175e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>1999 Amended Stock Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In October 2000, the Company adopted the 1999 Stock Plan, as amended and restated on June 17, 2008 (the “1999 Plan”). Under the 1999 Plan, with the approval of the Compensation Committee of the Board of Directors, the Company could grant stock options, restricted stock, stock appreciation rights and new shares of common stock upon exercise of stock options. On March 13, 2014, the Company’s stockholders approved an amendment to the 1999 Plan which increased the number of shares of common stock authorized for issuance under the 1999 Plan to a total of <ix:nonFraction id="fid_285" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2015-08-20to2015-09-15_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction> shares, up from <ix:nonFraction id="fid_287" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2016-06-01to2016-06-16_tenx_StockIncentivePlan2016Member" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,000</ix:nonFraction> previously authorized. On September 15, 2015, the Company’s stockholders approved an additional amendment to the 1999 Plan which increased the number of shares of common stock authorized for issuance under the 1999 Plan to a total of <ix:nonFraction id="fid_284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2015-09-01to2015-09-15_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">250,000</ix:nonFraction> shares, up from 200,000 previously authorized. The 1999 Plan expired on June 17, 2018 and no new grants may be made under that plan after that date. However, unexpired awards granted under the 1999 Plan remain outstanding and subject to the terms of the 1999 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>1999 Plan Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stock options granted under the 1999 Plan may be either ISOs or NSOs. ISOs could be granted only to employees. NSOs could be granted to employees, consultants and directors. Stock options under the 1999 Plan could be granted with a term of up to ten years and at prices no less than fair market value for ISOs and no less than 85% of the fair market value for NSOs. Stock options granted generally vest over one to six years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the outstanding stock options under the 1999 Plan for the six months ended June 30, 2021: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><ix:nonNumeric id="fid_742" name="tenx:OutstandingStockOptionsUnderPlanTableTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">57,648</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_tenx_Amended1999StockPlanMember" unitRef="USDPShares" decimals="INF">46.34</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(13</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_40" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" unitRef="USDPShares" decimals="INF">775.85</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">57,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_tenx_Amended1999StockPlanMember" unitRef="USDPShares" decimals="INF">46.18</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company chose the “straight-line” attribution method for allocating compensation costs of each stock option over the requisite service period using the Black-Scholes Option Pricing Model to calculate the grant date fair value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company recorded compensation expense for these stock option grants of $0 and $<ix:nonFraction id="fid_69" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-01to2020-06-30_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,494</ix:nonFraction> for the three months ended June 30, 2021 and 2020, and $<ix:nonFraction id="fid_67" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,290</ix:nonFraction> and $<ix:nonFraction id="fid_271" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-01to2020-06-30_tenx_Amended1999StockPlanMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,709</ix:nonFraction> for the six months ended June 30, 2021 and 2020, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were no unrecognized compensation costs related to non-vested stock option awards under the 1999 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Inducement Stock Options</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company granted an employment inducement stock option award for <ix:nonFraction id="fid_259" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">250,000</ix:nonFraction> shares of common stock to our chief medical officer on January 15, 2021. This employment inducement stock option was awarded in accordance with the employment inducement award exemption provided by NASDAQ Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. <ix:nonNumeric id="fid_263" name="tenx:StockOptionsDescription" contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember">The option award will vest as follows: 25% upon initiation of a Phase 3 trial; 25% upon database lock; 25% upon acceptance for review of an NDA; and 25% upon approval</ix:nonNumeric>. The options have a <ix:nonNumeric id="fid_261" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember" format="ixt-sec:duryear">10</ix:nonNumeric>-year term and an exercise price of $<ix:nonFraction id="fid_260" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember" unitRef="USDPShares" decimals="INF">1.78</ix:nonFraction> per share, the January 15, 2021 closing price of the Company's common stock. As of June 30, 2021, none of the vesting milestones have been achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The estimated fair value of the inducement stock option award granted was $<ix:nonFraction id="fid_72" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_tenx_InducementStockOptionsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">402,789</ix:nonFraction> using a Black-Scholes option pricing model based on market prices and the following assumptions at the date of inducement option grant: risk-free interest rate of <ix:nonFraction id="fid_265" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" unitRef="Pure" decimals="INF" scale="-2">1.11</ix:nonFraction>%, dividend yield of <ix:nonFraction id="fid_266" name="tenx:DividendYield" contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" unitRef="Pure" decimals="INF" scale="-2">0</ix:nonFraction>%, volatility factor for our common stock of <ix:nonFraction id="fid_267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" unitRef="Pure" decimals="INF" scale="-2">103.94</ix:nonFraction>% and an expected life of <ix:nonNumeric id="fid_268" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" format="ixt-sec:duryear">10</ix:nonNumeric> years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inducement stock option compensation expense totaled $<ix:nonFraction id="fid_269" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction> for the six months ended June 30, 2021. As of June 30, 2021, there was $<ix:nonFraction id="fid_264" name="tenx:EstimatedFairValueOfInducementStockOptionAwardGranted" contextRef="AsOf2021-01-15_tenx_InducementStockOptionsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">402,789</ix:nonFraction> of remaining unrecognized compensation expense related to this inducement stock option.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonNumeric id="fid_720" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2021-01-01to2021-06-30" escape="true" continuedAt="cont_70cd03"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>NOTE 10. SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On July 6, 2021, Tenax Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) pursuant to which the Company agreed to sell and issue to the Investor <ix:nonFraction id="fid_228" name="us-gaap:SharesIssued" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,773,269</ix:nonFraction> units (“Units”) in a private placement at a purchase price of $<ix:nonFraction id="fid_229" name="tenx:PurchasePriceOfStock" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" unitRef="USDPShares" decimals="INF">2.095</ix:nonFraction> per Unit. Each Unit consisted of one unregistered pre-funded warrant to purchase one share of common stock, par value $<ix:nonFraction id="fid_230" name="tenx:CommonStockParOrStatedValuePerShares" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction> (collectively the “Unregistered Pre-Funded Warrants”) and one unregistered warrant to purchase one share of common stock (collectively the “Unregistered Warrants” and together with the Unregistered Pre-Funded Warrants, the “Warrants”). In the aggregate,<ix:nonFraction id="fid_231" name="tenx:UnregisteredPreFundedWarrants" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,546,538</ix:nonFraction> shares of the Company’s common stock are underlying the Warrants. The aggregate gross proceeds to the Company of the Offering were approximately $<ix:nonFraction id="fid_232" name="tenx:ProceedsFromOffering" contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">10</ix:nonFraction> million. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_70cd03"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Each Unregistered Pre-Funded Warrant has an exercise price of $<ix:nonFraction id="fid_233" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction> per share of common stock, is immediately exercisable, may be exercised at any time until exercised in full and is subject to customary adjustments. Each Unregistered Warrant has an exercise price of $<ix:nonFraction id="fid_234" name="tenx:UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" unitRef="USDPShares" decimals="INF">1.97</ix:nonFraction> per share of common stock, is immediately exercisable, will expire five and one-half years from the date of issuance and is subject to customary adjustments. The Warrants may not be exercised if the aggregate number of shares of the Company’s common stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% of the Company’s outstanding common stock immediately after exercise. However, the holder may increase (upon 61 days’ prior notice from the holder to the Company) or decrease such percentage, provided that in no event such percentage exceeds 9.99%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company intends to use the net proceeds from the Offering to further its clinical trials of levosimendan and imatinib for research and development and for general corporate purposes, including working capital and potential acquisitions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Also, on July 6, 2021 and in connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, pursuant to which the Company agreed to register for resale the shares of the Company’s common stock issuable upon exercise of the Warrants within 120 days following the date of the Registration Rights Agreement. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under certain circumstances, including, but not limited to, (i) if the registration statement is not filed by the earlier of 45 days after the date of the Registration Rights Agreement or 10 days after the Company files its first Form 10-Q following the Registration Rights Agreement (ii) if the registration statement has not been declared effective (A) by the 120th day after the date of the Registration Rights Agreement (or, in the event of a “full review” by the Securities and Exchange Commission (the “SEC”), the 150th day after the date of the Registration Rights Agreement) or (B) within five trading days following the date the Company is notified by the SEC that the registration statement will not be reviewed or is no longer subject to further review and comments then the Company has agreed to pay the Investor, as partial liquidated damages, an amount equal to 1.0% of the Investor’s aggregate subscription amount paid pursuant to the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">H.C. Wainwright & Co., LLC (“HCW) was entitled to fees related to the Offering under a tail provision in an engagement letter with the Company that relates to HCW’s assistance as a Placement Agent in a prior offering in July 2020 between the Investor and the Company (the “Tail Provision”). Pursuant to the Tail Provision, the Company paid HCW a cash fee equal to <ix:nonFraction id="fid_236" name="tenx:PercentageOfGrossProceedReceived" contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" unitRef="Pure" decimals="INF" scale="-2">7.5</ix:nonFraction>% of the gross proceeds received by the Company in the Offering, totaling approximately $7<ix:nonFraction id="fid_237" name="tenx:ProceedsFromOffering" contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">50,000</ix:nonFraction>. In addition, the Company has agreed to issue to HCW or its designees warrants to purchase up to <ix:nonFraction id="fid_238" name="tenx:WarrantIssuedToPurchaseCommonStock" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">357,995</ix:nonFraction> shares of common stock (representing 7.5% of the aggregate number of shares of common stock equivalents sold in the Offering) (the “HCW Warrants”). The HCW Warrants have substantially the same terms as the Unregistered Warrants, except that the HCW Warrants have an exercise price equal to $<ix:nonFraction id="fid_239" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" unitRef="USDPShares" decimals="INF">2.46</ix:nonFraction>, or <ix:nonFraction id="fid_241" name="tenx:PercentageOfOfferingPricePerShareOfCommonStock" contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" unitRef="Pure" decimals="INF" scale="-2">125</ix:nonFraction>% of the offering price per share of common stock and will be exercisable for five years from the effective date of the Offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The issuance and sale of the Units, the Warrants, the HCW Warrants and the shares of common stock issuable upon exercise of the Warrants and the HCW Warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">On July 13, 2021, Anthony A. DiTonno retired as the Chief Executive Officer of the Company and as a member of the Company’s Board of Directors (the “Board”) effective as of July 13, 2021 (the “Effective Separation Date”). In connection with his retirement, Mr. DiTonno entered into a Separation and General Release Agreement with the Company (the “Separation Agreement”), dated July 6, 2021. The terms of the Separation Agreement provided that Mr. DiTonno had the right to revoke the Separation Agreement until July 22, 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Under the Separation Agreement, Mr. DiTonno is entitled to receive severance in an amount equal to one year of his current base annual salary, and a pro-rated amount of his annual bonus that would have been received had 100% of his annual goals been achieved, approximately $<ix:nonFraction id="fid_769" name="tenx:SeveranceReceived" contextRef="AsOf2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">563,000</ix:nonFraction> (less applicable taxes and withholdings), payable in a lump sum on the 60th day following the Effective Separation Date. The Company will also reimburse COBRA premiums for coverage of Mr. DiTonno and his eligible dependents for up to 18 months if Mr. DiTonno timely and properly elects continuation coverage. The foregoing payments were contingent on Mr. DiTonno’s standard release of employment claims. In connection with his retirement and in order to ensure a smooth transition to the new CEO, Mr. DiTonno has received a stock option grant for <ix:nonFraction id="fid_770" name="tenx:dvddv" contextRef="From2021-07-01to2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">50,000</ix:nonFraction> shares of common stock.  All of Mr. DiTonno’s outstanding stock options for common stock of the Company accelerated upon the Effective Separation Date, becoming fully vested, and are exercisable until the earlier of: (i) the original expiration date of each option under such option’s respective option agreement; or (ii) July 13, 2026. The Company is additionally reimbursing Mr. DiTonno for up to $<ix:nonFraction id="fid_771" name="us-gaap:OtherExpenses" contextRef="From2021-07-01to2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,000</ix:nonFraction> in legal expenses related to the Separation Agreement. The Separation Agreement also contains such non-competition, non-solicitation, and confidentiality provisions and other terms and conditions as are usual and customary for agreements of this type. All of Mr. DiTonno’s obligations under his Employee Non-Disclosure, Inventions Assignment, and Competitive Business Activities Agreement, dated June 1, 2018, regarding confidentiality and proprietary information will continue.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="i2">ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to them. In some cases you can identify forward-looking statements by words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: the implications of interim or final results of our clinical trials, the progress of our research programs, including clinical testing, the extent to which our issued and pending patents may protect our products and technology, our ability to identify new product candidates, the potential of such product candidates to lead to the development of commercial products, our anticipated timing for initiation or completion of our clinical trials for any of our product candidates, our future operating expenses, our future losses, our future expenditures for research and development, our relationship with Orion Corporation, or Orion, our ability to raise capital, the sufficiency of our cash resources, our ability to successfully integrate operations pursuant to our merger with PH Precision Med, the impacts of the current COVID-19 pandemic and the eligibility for forgiveness of our loan, or the PPP Loan, received pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, as administered by the U.S. Small Business Administration, or the SBA. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us and described in Part II, Item 1A of this Quarterly Report on Form 10-Q, Part I, Item 1A of our Annual Report on Form 10-K, and our other filings with the Securities and Exchange Commission, or the SEC. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from those we expect. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>The following discussion and analysis should be read in conjunction with the unaudited</em><em> condensed</em><em> consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2020.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>All references in this Quarterly Report to “Tenax Therapeutics”, “we”, “our” and “us” means Tenax Therapeutics, Inc.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>The description or discussion, in this Quarterly Report on Form 10-Q of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>Overview </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Strategy </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We are a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases of high unmet medical need. On November 13, 2013, through our wholly owned subsidiary, Life Newco, Inc., or Life Newco, we acquired a license granting Life Newco an exclusive, sublicensable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada. On October 9, 2020, we entered into an amendment to the license to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan, to the scope of the license, subject to specified limitations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, through our wholly owned subsidiary, Life Newco II, Inc., or Life Newco II, we acquired 100% of the equity of PHPrecisionMed Inc., a Delaware corporation, or PHPM. In accordance with the terms of the merger agreement between Life Newco II and PHPM, Life Newco II merged with and into PHPM, with PHPM surviving as our wholly owned subsidiary. As a result of the merger, we plan to develop and commercialize pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>Our Current Programs</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Levosimendan Background</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Levosimendan was discovered and developed by Orion Corporation, a Finnish company, or Orion. Levosimendan is a <em>calcium sensitizer/K-ATP activator </em>developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It is currently approved in over 60 countries for this indication and not available in the United States or Canada. It is estimated that to date over 1.5 million patients have been treated worldwide with levosimendan<strong>. </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Levosimendan is a novel, first in class <em>calcium sensitizer/K-ATP activator</em>. The therapeutic effects of levosimendan are mediated through:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;">Increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect which is not associated with substantial increases in oxygen demand.</td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;">Opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds.</td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;">Opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">This triple mechanism of action helps to preserve heart function during cardiac surgery. Several studies have demonstrated that levosimendan protects the heart and improves tissue perfusion while minimizing tissue damage during cardiac surgery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In 2013, we acquired certain assets of Phyxius Pharma, Inc., or Phyxius, including its North American rights to develop and commercialize levosimendan for any indication in the United States and Canada. In the countries where levosimendan is marketed, levosimendan is indicated for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. In acute decompensated heart failure patients, levosimendan has been shown to significantly improve patients’ symptoms as well as acute hemodynamic measurements such as increased cardiac output, reduced preload and reduced afterload. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The European Society of Cardiology, or the ESC, recommends levosimendan as a preferable agent over dobutamine to reverse the effect of beta blockade if it is thought to be contributing to hypotension. The ESC guidelines also state that levosimendan is not appropriate for patients with systolic blood pressure less than 85mmHg or in patients in cardiogenic shock unless it is used in combination with other inotropes or vasopressors. Other unique properties of levosimendan include sustained efficacy through the formation of a long-acting metabolite, lack of impairment of diastolic function, and evidence of better compatibility with beta blockers than dobutamine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Levosimendan Development for Pulmonary Hypertension Patients </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We recently completed a Phase 2 clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. PH-HFpEF is defined hemodynamically by a mean pulmonary artery pressure, or mPAP, ≥25 mmHg, and a pulmonary capillary wedge pressure, or PCWP, >15 mmHg. Pulmonary hypertension in these patients is believed to arise from a passive backward transmission of elevated filling pressures from left-sided heart failure. These mechanical components of pulmonary venous congestion may trigger pulmonary vasoconstriction, decreased nitric oxide availability, increased endothelin expression, desensitization to natriuretic peptide induced vasodilation, and vascular remodeling. Over time, these changes often lead to advanced pulmonary arterial and venous disease, increased right ventricle afterload, and right ventricle failure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">PH-HFpEF is a common form of pulmonary hypertension with an estimated U.S. prevalence exceeding 1.5 million patients. Currently, no pharmacologic therapies are approved for treatment of PH-HFpEF. Despite the fact that many therapies have been studied in PH-HFpEF patients, including therapies approved to treat pulmonary arterial hypertension patients, no therapies have been shown to be effective in treating PH-HFpEF patients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Published pre-clinical and clinical studies indicate that levosimendan may provide important benefits to patients with pulmonary hypertension. Data from these published trials indicate that levosimendan may reduce pulmonary vascular resistance and improve important cardiovascular hemodynamics such as reduced pulmonary capillary wedge pressure and pulmonary artery pressure in patients with pulmonary hypertension. In addition, several published studies provide evidence that levosimendan may improve right ventricular dysfunction which is a common comorbidity in patients with pulmonary hypertension. While none of these studies have focused specifically on PH-HFpEF patients, the general hemodynamic improvements in these published studies of various types of pulmonary hypertension provide a basis to believe that levosimendan may be beneficial in PH-HFpEF patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In March 2018, we met with the United States Food and Drug Administration, or FDA, to discuss development of levosimendan in PH-HFpEF patients. The FDA agreed with our planned Phase 2 design, patient entry criteria, and endpoints. It was agreed the study could be conducted under the existing investigational new drug application with no additional nonclinical studies required to support full development. The FDA recognized there were no approved drug therapies to treat PH-HFpEF patients and acknowledged this provided an opportunity for a limited Phase 3 clinical program. This topic was discussed further at the End-of-Phase 2 Meeting following completion of the Phase 2 study in PH-HFpEF patients, which is known as the HELP Study – <strong>H</strong>emodynamic <strong>E</strong>valuation of <strong>L</strong>evosimendan in <strong>P</strong>H-HFpEF. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We initiated the first of our expected 10-12 HELP Study clinical sites in November 2018 and the first of 37 patients were enrolled in the HELP Study in March 2019. Enrollment in the HELP Study was completed in March 2020. The primary endpoint of the HELP Study was based on the change in PCWP during exercise versus baseline compared to placebo. The HELP Study utilized a double-blind randomized design following five weekly outpatient infusions of levosimendan. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 2, 2020, we announced preliminary, top-line data from the study. The primary efficacy analysis, pulmonary capillary wedge pressure (PCWP) during exercise did not demonstrate a statistically significant reduction from baseline. Levosimendan did demonstrate a statistically significant reduction in PCWP compared to baseline (p=<0.0017) and placebo (p=<0.0475) when the measurements at rest, with legs up and on exercise were combined. Levosimendan also demonstrated a statistically significant improvement in 6-minute walk distance as compared to placebo (p=0.0329). These findings from the HELP Study represent important discoveries related to the use of levosimendan in PH-HFpEF patients since this is the first study to evaluate levosimendan in PH-HFpEF patients and this is the first study ever conducted of any therapy in PH-HFpEF patients to show such positive improvements in hemodynamics and 6-minute walk distance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Hemodynamic Results</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Hemodynamic measurements were made at rest (supine), after leg raise on a supine bicycle (a test of rapid increase in ventricular filling) and during exercise (25 watts for 3 minutes or until the patient tired). In the initial open-label phase, 84% of the patients had a significant reduction in right atrial pressure, or RAP, pulmonary artery pressure, or PAP and PCWP at rest and during exercise. In the randomized double-blinded 6-week trial, levosimendan demonstrated a statistically significant reduction in PCWP compared to baseline (p=<0.0017) and placebo (p=<0.0475) when the measurements at rest, with legs up and on exercise were combined. While there was no significant change in PCWP during exercise, patients receiving levosimendan had reductions from baseline at Week 6 in PCWP, PAP, and RAP that were significant when patients were “at rest” and/or with their “legs raised” (p<0.05). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Clinical Results (6-Minute Walk Distance)</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The clinical efficacy was confirmed by a statistically significant improvement in 6-minute walk distance of 29 meters (p=0.0329). The 6-minute walk distance was a secondary endpoint in the trial and is a validated and accepted endpoint used in many pulmonary hypertension registration trials. Levosimendan was given in once-weekly home infusions for six weeks.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Safety</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The incidence of adverse events or serious adverse events between the control and treated groups were similar. In addition, there were no arrhythmias observed, atrial or ventricular, when comparing baseline electrocardiographic monitoring with 72-hour monitoring after five weeks of treatment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF were presented at the Heart Failure Society of America Virtual Annual Scientific Meeting on October 3, 2020 and at the American Heart Association Scientific Sessions 2020 on November 13, 2020. Additionally, the full manuscript has been accepted for publication in the peer-reviewed journal JACC:Heart Failure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Next Steps</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, we entered into an amendment, or the Amendment, to the License between the Company and Orion to include two new product formulations containing levosimendan, in a capsule solid oral dosage form, and a subcutaneously administered dosage form containing levosimendan, to the scope of the License, subject to specified limitations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We plan to study the utility of the levosimendan oral capsule dosage form in patients who have participated in the open-label extension of the HELP Study and who continue to receive weekly infusions of intravenous levosimendan. These patients are now eligible to participate in the amendment to the HELP Study that will transition them from the intravenous to an oral formulation. The investigators at the centers that participated in the HELP Study have been invited to participate and enroll their patients into this study. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In October 2020, we met with the FDA for an End-of-Phase 2 Meeting to discuss the Phase 2 clinical data and further development of levosimendan in PH-HFpEF patients. The FDA agreed that one or two Phase 3 clinical studies (depending on the size) with a primary endpoint of change in 6-minute walk distance over 12 weeks or a single Phase 3 trial with clinical worsening (e.g., death, hospitalization for heart failure, or decline in exercise capacity) over 24 weeks would be sufficient to demonstrate the effectiveness of levosimendan in PH-HFpEF. The FDA also agreed to a plan to replace weekly intravenous levosimendan dosing with daily oral levosimendan doses in a Phase 3 clinical study. The FDA expressed concern about a safety database as potentially necessary and indicated that the need for a further safety database could be dependent on the final design of the Phase 3 study. We expect that this will be addressed when the final Phase 3 protocol is submitted which will better characterize the trial design and primary endpoints.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The HELP Study design was novel in several respects. To date, no other multi-center study has evaluated levosimendan in heart failure patients with preserved ejection fraction, or HFpEF, patients or PH-HFpEF patients. Instead, all previous levosimendan heart failure studies have enrolled heart failure patients with reduced ejection fraction, or HFrEF, which specifically excluded HFpEF patients. Also, the HELP Study utilized a unique 24-hour weekly infusion regimen of 0.075- 0.1µm/kg/min. Finally, the HELP Study employed a unique home-based intravenous infusion administration via an ambulatory infusion pump. This home-based weekly intravenous administration is unlike all other chronic dosing studies of levosimendan that have typically employed a shorter duration and less frequent infusion regimen administered in a hospital setting. Despite the unique patient population, weekly dosing, and home-based administration, there have been no reported serious adverse events.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We believe that the combination of the unique HELP Study patient population, innovative weekly 24-hour dosing, unique home-based site of administration, and novel findings of efficacy and safety in PH-HFpEF patients represent unique discoveries and significant intellectual property. These discoveries, among others from the HELP Study, form the basis for a U.S. patent application that we have filed. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Imatinib Background</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Imatinib (also known as “Gleevec”), is a tyrosine kinase inhibitor, which revolutionized the treatment of chronic myeloid leukemia, or CML, in 2001. The first clinical trial of imatinib took place in 1998 and the drug received FDA approval in May 2001. Encouraged by the success of Imatinib in treating CML patients, scientists explored its effect in other cancers, and it was found to produce a similar positive effect in other cancers where tyrosine kinases were overexpressed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism, and apoptosis in response to external and internal stimuli. Deregulation of protein kinase activity has been shown to play a central role in the pathogenesis of human cancers. Imatinib, a 2-phenyl amino pyrimidine derivative, is a tyrosine kinase inhibitor with activity against ABL, BCR-ABL, PDGFRA, and c-KIT. Imatinib works by binding close to the ATP binding site therefore inhibiting the enzyme activity of the protein. Imatinib also inhibits the ABL protein of noncancer cells. Imatinib is well absorbed after oral administration with a bioavailability exceeding 90%. It is extensively metabolized, principally by cytochrome P450 (CYP)3A4 and CYP3A5 and can competitively inhibit the metabolism of drugs that are CYP3A4 or CYP3A5 substrates. Imatinib is generally well tolerated in cancer patients. Common side effects include fluid retention, headache, diarrhea, loss of appetite, weakness, nausea and vomiting, abdominal distention, edema, rash, dizziness, and muscle cramps. Serious side effects may include myelosuppression, heart failure, and liver function abnormalities. Novartis is the manufacturer of Gleevec.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Previous </em></strong><strong><em>Imatinib Development for Pulmonary Arterial Hypertension Patients</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In pulmonary arterial hypertension, or PAH, a rare disease, subjects who remain symptomatic despite available therapies have a high morbidity and mortality. Though several therapies are now available, there is no cure for the disease, and there is no data supporting that the existing therapies, all of which are pulmonary vasodilators, halt progression or induce regression of the disease. Imatinib is a tyrosine kinase inhibitor that has been shown in animal models of pulmonary hypertension to induce disease reversal by an effect on platelet derived growth factor, or PDGF, which appears to be causal in the disease. After that discovery was made, several case reports and small case series of patients with advanced PAH failing combination pulmonary vasodilator therapy were published showing a dramatic effect of imatinib on stabilizing and improving these patients. This led Novartis to develop imatinib as a treatment of PAH. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Novartis sponsored a Phase 2 proof-of-concept trial to evaluate the safety, tolerability, and efficacy of imatinib as an adjunct to PAH specific therapy in patients with PAH. This was a 24-week randomized, double-blind, placebo-controlled study of PAH subjects who remained symptomatic on one or more PAH therapies in WHO Functional Class (FC) II-IV. The Phase 2 trial of imatinib in PAH caused significant hemodynamic improvement in some patients but failed to meet the primary endpoint of an increase in 6-minute walk distance (22 meters, p=NS). Novartis then sponsored a Phase 3 trial (IMPRES) which met its primary endpoint of significant increase in 6-minute walk (32 meters, p=0.002), an effect maintained in the extension study in patients remaining on imatinib. However, the data were confounded by a high rate of dropouts in the patients randomized to imatinib attributed largely to gastric intolerance during the first eight weeks. The sponsor proposed consideration of a surrogate endpoint under the subpart H provision as a basis for approval but was denied. Consequently, Novartis chose to withdraw the Investigational New Drug application as the drug went off patent. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><strong><em>Current </em></strong><strong><em>Imatinib Development for Pulmonary Arterial Hypertension Patients</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On May 30, 2019, PHPM met with the FDA to discuss a proposal for a Phase 3 trial of imatinib for PAH. At that meeting, PHPM received agreement for a single Phase 3 trial using change in 6-minute walk distance as the primary endpoint (p<0.05). PHPM also received agreement for submission under the 505(b)(2) regulatory pathway, and thereafter received orphan designation. In August of 2019, PHPM was given preliminary advice on its plans to submit an application for Breakthrough Therapy Designation. In July 2020, PHPM received agreement from the FDA for the development of a modified release formulation that would require only a small comparative PK/bioavailability study in 12 volunteers receiving a single dose of the modified release formulation to be compared to a single dose of the existing immediate release formulation. A Phase 3 study is planned with the modified release formulation of imatinib.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Second Quarter 2021 Highlights </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following summarizes certain key financial measures for the three months ended June 30, 2021: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Cash and cash equivalents, including the fair-value of our marketable securities, were $2.2 million on June 30, 2021.</td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Our net loss from operations was $2.0 million for the second quarter of fiscal 2021 compared to $2.1 million for the three months ended June 30, 2020.</td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Net cash used in operating activities was $1.9 million and $2.2 million for the three months ended June 30, 2021 and 2020, respectively.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Opportunities and Trends </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The continued spread of COVID-19 globally could adversely affect our clinical trial operations in the United States and elsewhere, including our ability to recruit and retain patients, principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some patients may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services, or if the patients become infected with COVID-19 themselves, which would delay our ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As we focus on the development of our existing product candidates, we also continue to position ourselves to execute upon licensing and other partnering opportunities. To do so, we will need to continue to maintain our strategic direction, manage and deploy our available cash efficiently and strengthen our collaborative research development and partner relationships.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During 2021, we are focused on the following initiatives:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px">- </p></td><td style="vertical-align:top;">Working with collaborators and partners to accelerate product development, reduce our development costs, and broaden our developmental capabilities; and</td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">- </p></td><td style="vertical-align:top;">Identifying strategic alternatives, including, but not limited to, the potential acquisition of additional products or product candidates.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Financial Overview</em></strong><strong><em>                </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Results of Operations- Comparison of the Three Months Ended June 30, 2021 and 2020</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong><em>General and Administrative Expenses</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">General and administrative expenses consist primarily of compensation for executive, finance, legal and administrative personnel, including stock-based compensation. Other general and administrative expenses include facility costs not otherwise included in research and development expenses, legal and accounting services, other professional services, and consulting fees. General and administrative expenses and percentage changes for the three months ended June 30, 2021 and 2020, respectively, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Three months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>% Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>(Decrease) </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>(Decrease) </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">711,174</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">700,737</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,437</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Legal and professional fees</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">343,122</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32,879</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">376,001</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,144</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,223</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,409</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,814</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Facilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,759</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,939</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(180</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><em>Personnel costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Personnel costs remained relatively consistent for the three months ended June 30, 2021 compared to the same period in the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><em>Legal and professional fees:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Legal and professional fees consist of the costs incurred for legal fees, accounting fees, capital market expenses, consulting fees and investor relations services, as well as fees paid to our Board of Directors. Legal and professional fees increased approximately $376,000 for the three months ended June 30, 2021 compared to the same period in the prior year. This increase was due primarily to the reimbursement of approximately $358,000 in legal fees associated with arbitration proceedings in the prior year, as well as increases in Board of Directors fees and capital market expenses, partially offset by a reduction in investor relations services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Board of Director fees increased approximately $40,000 in the current period due primarily to fees paid to new directors that were not incurred during the same period in the prior year.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Capital market fees increased approximately $35,000 in the current period. This increase was due primarily to an increase in proxy related costs incurred in the current period as compared to the same period in the prior year.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Investor relations costs decreased approximately $21,000 in the current period. This decrease was primarily due to fees paid to third-party investor relations firms for direct outreach and communications in the prior year that were not incurred in the current period.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:left;"><em>Other costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other costs include costs incurred for franchise and other taxes, travel, supplies, insurance, depreciation and other miscellaneous charges. Other costs increased approximately $16,000 in the current period due primarily to an increase of approximately $25,000 in insurance premiums paid, partially offset by a decrease of approximately $11,000 in franchise taxes paid in the current period as compared to the same period of the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><em>Facilities:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Facilities expenses include costs paid for rent and utilities at our corporate headquarters in North Carolina. Facilities costs remained relatively consistent for the three months ended June 30, 2021 and 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>Research and Development Expenses</em></strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Research and development expenses include, but are not limited to, (i) expenses incurred under agreements with clinical research organizations, or CROs, and investigative sites, which conduct our clinical trials and a substantial portion of our pre-clinical studies; (ii) the cost of manufacturing and supplying clinical trial materials; (iii) payments to contract service organizations, as well as consultants; (iv) employee-related expenses, which include salaries and benefits; and (v) facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and equipment, depreciation of leasehold improvements, equipment, laboratory and other supplies. All research and development expenses are expensed as incurred. Research and development expenses and percentage changes for the three months ended June 30, 2021 and 2020, respectively, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Three months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>% Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> (Decrease)</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> (Decrease)</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Clinical and preclinical development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">548,909</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,218,156</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(669,247</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(55</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,707</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,193</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88,514</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,606</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,488</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(882</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(35</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:left;"><em>Clinical and preclinical development:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Clinical and preclinical development costs include the costs associated with our Phase 2 HELP Study for levosimendan, which was completed during fiscal year 2020, the costs associated with our IV to oral levosimendan transition study and development costs associated with the formulation for imatinib. The decrease of approximately $670,000 in clinical and preclinical development costs for the three months ended June 30, 2021 compared to the same period in the prior year was primarily due to a decrease of approximately $524,000 in expenditures for CRO costs and a reduction of approximately $261,000 in enrolled patient costs in the current period as compared to the same period in the prior year. These cost reductions were partially offset by an increase of approximately $114,000 in costs associated with formulation development of imatinib in the current period that were not incurred in the same period in the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><em>Personnel costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Personnel costs increased approximately $89,000 for the three months ended June 30, 2021 due primarily to the addition of our Chief Medical Officer in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><em>Other costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other costs remained relatively consistent for the three months ended June 30, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The process of conducting preclinical studies and clinical trials necessary to obtain approval from the FDA is costly and time consuming. The probability of success for each product candidate and clinical trial may be affected by a variety of factors, including, among other things, the quality of the product candidate’s early clinical data, investment in the program, competition, manufacturing capabilities and commercial viability. As a result of the uncertainties discussed above, uncertainty associated with clinical trial enrollment and risks inherent in the development process, we are unable to determine the duration and completion costs of current or future clinical stages of our product candidates or when, or to what extent, we will generate revenues from the commercialization and sale of any of our product candidates. Development timelines, probability of success and development costs vary widely. We are currently focused on developing our two product candidates, levosimendan and imatinib; however, we will need substantial additional capital in the future in order to complete the development and potential commercialization of levosimendan and imatinib, and to continue with the development of other potential product candidates. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>Other income and expense, net</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other income and expense include non-operating income and expense items not otherwise recorded in our condensed consolidated statement of comprehensive loss. These items include, but are not limited to, changes in the fair value of financial assets and derivative liabilities, interest income earned and fixed asset disposals. Other income and expense for the three months ended June 30, 2021 and 2020, respectively, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Three months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Increase)/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> Decrease</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other (income) expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(247,820</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,101</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(249,921</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other income increased approximately $250,000 for the three months ended June 30, 2021 compared to the same period in the prior year. This increase is due primarily to the forgiveness of our PPP Loan in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Results of Operations- Comparison of the Six Months Ended June 30, 2021 and 2020</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>General and Administrative Expenses</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">General and administrative expenses consist primarily of compensation for executive, finance, legal and administrative personnel, including stock-based compensation. Other general and administrative expenses include facility costs not otherwise included in research and development expenses, legal and accounting services, other professional services, and consulting fees. General and administrative expenses and percentage changes for the six months ended June 30, 2021 and 2020, respectively, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>% Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> (Decrease)</strong></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> (Decrease)</strong></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,506,684</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,438,007</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,677</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Legal and professional fees</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">725,670</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">324,951</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">400,719</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">123</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">330,868</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">350,002</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,134</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Facilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">81,516</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,205</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,311</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Personnel costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Personnel costs increased approximately $69,000 for the six months ended June 30, 2021 compared to the same period in the prior year. This increase was due primarily an increase of approximately $27,000 in salaries and benefits paid and an increase of approximately $42,000 in expense recognized for vested employee stock options as compared to the same period in the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Legal and professional fees:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Legal and professional fees consist of the costs incurred for legal fees, accounting fees, capital market expenses, consulting fees and investor relations services, as well as fees paid to our Board of Directors. Legal and professional fees increased approximately $401,000 for the six months ended June 30, 2021 compared to the same period in the prior year. This increase was due primarily to the reimbursement of approximately $358,000 in legal fees associated with arbitration proceedings in the prior year, as well as an increase in accounting fees, legal fees, capital market expenses and Board of Directors fees, partially offset by a reduction in investor relations services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Legal fees increased approximately $311,000 in the current period. This increase was due primarily to the reimbursement of approximately $358,000 in legal fees associated with arbitration proceedings in the prior year, as well as an increase in fees paid associated with the PHPM acquisition and our intellectual property portfolio, partially offset by costs incurred for arbitration in the prior year.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Accounting fees increased approximately $42,000 in the current period due primarily to fees associated with the PHPM transaction that were not incurred during the same period in the prior year.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Board of Director fees increased approximately $51,000 in the current period due primarily to fees paid to new directors that were not incurred during the same period in the prior year.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Capital market fees increased approximately $25,000 in the current period. This increase was due primarily to an increase in proxy related costs incurred in the current period as compared to the same period in the prior year</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px">-</p></td><td style="vertical-align:top;"><p style="margin:0px">Investor relations costs decreased approximately $33,000 in the current period. This decrease was primarily due to fees paid to third-party investor relations firms for direct outreach and communications in the prior year that were not incurred in the current period.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Other costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other costs include costs incurred for franchise and other taxes, travel, supplies, insurance, depreciation and other miscellaneous charges. Other costs decreased approximately $19,000 in the current period due primarily to a decrease in franchise taxes paid, partially offset by an increase of approximately $51,000 in insurance premiums paid in the current period as compared to the same period of the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Facilities:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Facilities expenses include costs paid for rent and utilities at our corporate headquarters in North Carolina. Facilities costs remained relatively consistent for the six months ended June 30, 2021 and 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Research and Development Expenses</em></strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Research and development expenses include, but are not limited to, (i) expenses incurred under agreements with clinical research organizations, or CROs, and investigative sites, which conduct our clinical trials and a substantial portion of our pre-clinical studies; (ii) the cost of manufacturing and supplying clinical trial materials; (iii) payments to contract service organizations, as well as consultants; (iv) employee-related expenses, which include salaries and benefits; and (v) facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and equipment, depreciation of leasehold improvements, equipment, laboratory and other supplies. All research and development expenses are expensed as incurred. Research and development expenses and percentage changes for the six months ended June 30, 2021 and 2020, respectively, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>% Increase/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> (Decrease)</strong></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> (Decrease)</strong></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Clinical and preclinical development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,049,087</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500,817</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,451,730</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(58</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">278,949</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,336</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">169,613</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">155</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other costs</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,741,388</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,210</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,734,178</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">301,445</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Clinical and preclinical development:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Clinical and preclinical development costs include the costs associated with our Phase 2 HELP Study for levosimendan, which was completed during fiscal year 2020, the costs associated with our IV to oral levosimendan transition study and development costs associated with the formulation for imatinib. The decrease of approximately $1.5 million in clinical and preclinical development costs for the six months ended June 30, 2021 compared to the same period in the prior year was primarily due to a decrease of approximately $859,000 in expenditures for CRO costs, a reduction of approximately $764,000 in enrolled patient costs and a decrease of approximately $139,000 in fees paid for clinical research associates and other direct costs to manage the Phase 2 HELP Study in the current period as compared to the same period in the prior year. These cost reductions were partially offset by an increase of approximately $260,000 in costs associated with formulation development of imatinib in the current period that were not incurred in the same period in the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Personnel costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Personnel costs increased approximately $170,000 for the six months ended June 30, 2021 due primarily to the addition of our Chief Medical Officer in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Other costs:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other costs increased approximately $21.7 million for the six months ended June 30, 2021 due primarily to the recognition of in-process research and development acquired as part of the merger with PHPM in the current period that was not incurred in the same period in the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The process of conducting preclinical studies and clinical trials necessary to obtain approval from the FDA is costly and time consuming. The probability of success for each product candidate and clinical trial may be affected by a variety of factors, including, among other things, the quality of the product candidate’s early clinical data, investment in the program, competition, manufacturing capabilities and commercial viability. As a result of the uncertainties discussed above, uncertainty associated with clinical trial enrollment and risks inherent in the development process, we are unable to determine the duration and completion costs of current or future clinical stages of our product candidates or when, or to what extent, we will generate revenues from the commercialization and sale of any of our product candidates. Development timelines, probability of success and development costs vary widely. We are currently focused on developing our two product candidates, levosimendan and imatinib; however, we will need substantial additional capital in the future in order to complete the development and potential commercialization of levosimendan and imatinib, and to continue with the development of other potential product candidates.</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Other income and expense, net</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other income and expense include non-operating income and expense items not otherwise recorded in our condensed consolidated statement of comprehensive loss. These items include, but are not limited to, changes in the fair value of financial assets and derivative liabilities, interest income earned and fixed asset disposals. Other income for the six months ended June 30, 2021 and 2020, respectively, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>(Increase)/ </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong> Decrease</strong></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other income, net</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(249,955</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,740</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(241,215</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Other income increased approximately $241,000 for the six months ended June 30, 2021 compared to the same period in the prior year. This increase is due primarily to the forgiveness of our PPP Loan in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Liquidity, Capital Resources and Plan of Operation </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">We have incurred losses since our inception, and as of June 30, 2021 we had an accumulated deficit of approximately $271 million. We will continue to incur losses until we generate sufficient revenue to offset our expenses, and we anticipate that we will continue to incur net losses for at least the next several years. We expect to incur increased expenses related to our development and potential commercialization of levosimendan for pulmonary hypertension and imatinib for pulmonary arterial hypertension, as well as identifying and developing other potential product candidates and, as a result, we will need to generate significant net product sales, royalty and other revenues to achieve profitability.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong><em>Liquidity</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We have financed our operations since September 1990 through the issuance of debt and equity securities and loans from stockholders. We had total current assets of $2,532,227 and $6,795,506 and working capital of $1,357,217 and $4,676,543 as of June 30, 2021 and December 31, 2020, respectively. Based on our working capital and the value of our investments in marketable securities on June 30, 2021 and the net proceeds from our July 2021 offering, we believe we have sufficient capital to fund our operations through the second quarter of calendar year 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong><em>Cash Flows</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table shows a summary of our cash flows for the six months ended June 30, 2021 and 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,066,239</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,899,965</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net cash (used in) provided by investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(57,231</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,911</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">544,651</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,065,366</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Net cash used in operating activities.</em> Net cash used in operating activities was approximately $5.1 million for the six months ended June 30, 2021 compared to net cash used in operating activities of approximately $4.9 million for the six months ended June 30, 2020. The increase in cash used for operating activities was due primarily to an increase in our annual insurance premiums and accrued bonuses paid in the current period as compared to the prior year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Net cash (used in) provided by investing activities</em>. Net cash used in investing activities was approximately $57,000 for the six months ended June 30, 2021 compared to approximately $14,000 provided by investing activities for the six months ended June 30, 2020. The increase in cash used investing activities was primarily due to the purchase of marketable securities in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Net cash provided by financing activities</em>. Net cash provided by financing activities was approximately $545,000 for the six months ended June 30, 2021 compared to approximately $4.1 million for the six months ended June 30, 2020. The decrease in cash provided by financing activities was due primarily to net proceeds of approximately $2.1 million from the March 2020 offering, and the issuance of 877,203 shares of common stock upon the exercise of approximately $1.7 million of outstanding warrants in the prior period, as compared with approximately $545,000 received upon the exercise of warrants in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Operating Capital and Capital Expenditure Requirements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Our future capital requirements will depend on many factors that include, but are not limited to, the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the initiation, progress, timing and completion of clinical trials for our product candidate and potential product candidates;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the outcome, timing and cost of regulatory approvals and the regulatory approval process; </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the impacts of COVID-19, including delays that may be caused by COVID-19;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">delays that may be caused by changing regulatory requirements;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the number of product candidates that we pursue;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the timing and terms of future collaboration, licensing, consulting or other arrangements that we may enter into;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the cost of procuring clinical and commercial supplies of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the extent to which we acquire or invest in businesses, products or technologies; and</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">-</p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">the possible costs of litigation.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">We believe that our existing cash and cash equivalents, along with our investment in marketable securities, will be sufficient to fund our projected operating requirements through the second quarter of calendar year 2022. We will need substantial additional capital in the future in order to complete the development and commercialization of levosimendan and imatinib, and to fund the development and commercialization of other future product candidates. Until we can generate a sufficient amount of product revenue, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. Such funding may not be available on favorable terms, if at all. In the event we are unable to obtain additional capital, we may delay or reduce the scope of our current research and development programs and other expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Critical Accounting Policies and Significant Judgments and Estimates</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Our unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions. For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Summary of Critical Accounting Policies” contained in our Annual Report on Form 10-K for the year ended December 31, 2020, and Note 2 to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Recent Accounting Pronouncements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In December 2019, the FASB issued an accounting standard intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740, Income Taxes and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. Our adoption of this new guidance did not have a material impact on our consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the FASB issued an accounting standard that amends how credit losses are measured and reported for certain financial instruments that are not accounted for at fair value through net income. This standard requires that credit losses be presented as an allowance rather than as a write-down for available-for-sale debt securities and will be effective for interim and annual reporting periods beginning January 1, 2023, with early adoption permitted. A modified retrospective approach is to be used for certain parts of this guidance, while other parts of the guidance are to be applied using a prospective approach. We do not believe the adoption of this standard will have a material impact on our consolidated financial statements and related disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Off-Balance Sheet Arrangements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Since our inception, we have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="i3">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="i4">ITEM 4. CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Evaluation of Disclosure Controls and Procedures </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As required by paragraph (b) of Rules 13a-15 and 15d-15 promulgated under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation as of the end of the period covered by this report, of the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2021, the end of the period covered by this report in that they provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Changes in Internal Control over Financial Reporting</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We routinely review our internal controls over financial reporting and from time to time make changes intended to enhance the effectiveness of our internal control over financial reporting. We will continue to evaluate the effectiveness of our disclosure controls and procedures and internal controls over financial reporting on an ongoing basis and will take action as appropriate.  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the most recently completed fiscal quarter, management reviewed all work generated in support of the financial statements and corresponding footnotes in order to determine areas which may be susceptible to human error.   The review focused on limiting manual inputs into work papers wherever possible and tying inputs to external source documents.  In addition, management also enhanced its work paper review to compare figures to prior year amounts or source documents and increased the number of calculations in the work papers that are reviewed and re-performed.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II – OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="ii1">ITEM 1. LEGAL PROCEEDINGS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">There are no material pending legal proceedings to which we are a party or to which any of our property is subject.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="ii1a">ITEM 1A. RISK FACTORS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The risks we face have not materially changed from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="ii5">ITEM 5. OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s stockholders approved Amendment No. 2 to amend the 2016 Plan to increase the number of shares that may be issued under the 2016 Plan by 750,000 shares (the “Plan Amendment”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The foregoing description of the Plan Amendment is qualified in its entirety by reference to the Plan Amendment, which is attached to this Quarterly Report on Form 10-Q as Exhibit 10.1and is incorporated herein by reference.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" style="display: inline" id="ii6">ITEM 6. EXHIBITS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following exhibits are being filed herewith and are numbered in accordance with Item 601 of Regulation S-K: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong>No.</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:90%;vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex101.htm">10.1</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex101.htm">Amendment No. 2 to 2016 Stock Incentive Plan*+</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex311.htm">31.1</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex311.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002 </a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex312.htm">31.2</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002 </a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex321.htm">32.1</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex321.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex322.htm">32.2</a></p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><a href="tenx_ex322.htm">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">101*</p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">104*</p></td><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>_________________</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>*Filed herewith</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>+ Management contract or compensatory plan or arrangement</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong></strong> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td> </td><td colspan="2"><strong>TENAX THERAPEUTICS, INC.</strong></td><td></td></tr><tr style="height:15px"><td style="width:50%;"> </td><td style="width:3%;"> </td><td style="width:35%;"> </td><td style="width:12%;"> </td></tr><tr style="height:15px"><td>Date: August 16, 2021</td><td>By:</td><td style="BORDER-BOTTOM: black 1px solid;"><p style="margin:0px 0px 0px 0in"><em>/s/ Michael B. Jebsen </em></p></td><td></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px 0px 0px 0in">Michael B. Jebsen</p></td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td><p style="margin:0px 0px 0px 0in">President and Chief Financial Officer</p></td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td><p style="margin:0px 0px 0px 0in">(On behalf of the Registrant and as Principal Financial Officer)</p></td><td> </td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p></body></html> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-10.1 <SEQUENCE>2 <FILENAME>tenx_ex101.htm <DESCRIPTION>AMENDMENT NO. 2 TO 2016 STOCK INCENTIVE PLAN <TEXT> <html><head><title>tenx_ex101.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AMENDMENT NO. 2 TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>TENAX THERAPEUTICS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2016 STOCK INCENTIVE PLAN</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">This Amendment No. 2 (the “Amendment”) to the Tenax Therapeutics, Inc. 2016 Stock Incentive Plan (the “Plan”) to increase the number of shares of common stock issuable under the Plan is made on April 27, 2021, effective as of the time provided below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong>WHEREAS</strong>, Tenax Therapeutics, Inc. (the “Company”) has heretofore adopted the Plan; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong>WHEREAS</strong>, as a result of the February 23, 2018 reverse stock split, the number of shares of the Company’s common stock issuable under the Plan was reduced from 3,000,000 to 150,000; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong>WHEREAS</strong>, on June 13, 2019, the stockholders approved Amendment No. 1 to the 2016 Plan, increasing the number of shares of common stock authorized for issuance under the 2016 Plan to a total of 750,000 shares; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong>WHEREAS, </strong>on April 27, 2021, our Board of Directors approved, subject to stockholder approval, Amendment No. 2 to the 2016 Plan to increase the number of shares of common stock authorized for issuance under the 2016 Plan to a total of 1.5 million shares, representing an increase of 750,000 shares; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong>WHEREAS</strong>, the Board of Directors of the Company has approved the Amendment contingent upon the approval of the Amendment by the stockholders of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><strong>NOW, THEREFORE</strong>, <strong>BE IT RESOLVED</strong>, that, pursuant to Section 17.1 of the Plan, the Plan is hereby amended as follows, effective as of such time as the Amendment is approved by the stockholders of the Company:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Section 4.1 of the Plan is amended by replacing “seven hundred and fifty thousand (750,000) Shares” with one million five hundred thousand (1,500,000) Shares.”</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Except as expressly amended hereby, all provisions of the Plan shall remain unamended and shall continue to be, and shall remain, in full force and effect in accordance with their respective terms.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Amendment shall have no effect until such time as it is approved by the stockholders of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The provisions of the Amendment shall be governed by and interpreted in accordance with the laws of the State of Delaware.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"> </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><body> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.1 <SEQUENCE>3 <FILENAME>tenx_ex311.htm <DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 <TEXT> <html><head><title>tenx_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong></strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">I, Christopher Giordano, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">I have reviewed this Quarterly Report on Form 10-Q of Tenax Therapeutics, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px"> </p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px"> </p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">Date: August 16, 2021</p></td> <td style="width:3%;"> <p style="margin:0px"> </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px"><em>/s/ Christopher Giordano</em></p></td> <td style="width:12%;"> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Christopher Giordano</p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em>Chief Executive Officer</em></p> <p style="margin:0px"><em>(Principal Executive Officer)</em><em></em></p></td> <td> <p style="margin:0px"> </p></td></tr></table><body> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.2 <SEQUENCE>4 <FILENAME>tenx_ex312.htm <DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 <TEXT> <html><head><title>tenx_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong></strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">I, Michael B. Jebsen, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">I have reviewed this Quarterly Report on Form 10-Q of Tenax Therapeutics, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px"> </p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px"> </p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">Date: August 16, 2021</p></td> <td style="width:3%;"> <p style="margin:0px"> </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px"><em>/s/ Michael B. Jebsen</em></p></td> <td style="width:12%;"> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Michael B. Jebsen</p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em>President and Chief Financial Officer</em></p> <p style="margin:0px"><em>(Principal Financial Officer)</em><em></em></p></td> <td> <p style="margin:0px"> </p></td></tr></table><body> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.1 <SEQUENCE>5 <FILENAME>tenx_ex321.htm <DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 <TEXT> <html><head><title>tenx_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1<br></strong></p><strong></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">In connection with the Quarterly Report of Tenax Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher Giordano, Chief Executive Officer (Principal Executive Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px"> </p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">Date: August 16, 2021</p></td> <td style="width:3%;"> <p style="margin:0px"> </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px"><em>/s/ Christopher Giordano</em></p></td> <td style="width:12%;"> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Christopher Giordano</p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em>Chief Executive Officer</em></p> <p style="margin:0px"><em>(Principal Executive Officer)</em></p></td> <td> <p style="margin:0px"> </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><body> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.2 <SEQUENCE>6 <FILENAME>tenx_ex322.htm <DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 <TEXT> <html><head><title>tenx_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> </strong></p><strong></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">In connection with the Quarterly Report of Tenax Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael B. Jebsen, President and Chief Financial Officer (Principal Financial Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px"> </p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px;text-indent:30px"> </p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">Date: August 16, 2021</p></td> <td style="width:3%;"> <p style="margin:0px"> </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px"><em>/s/ Michael B. Jebsen</em></p></td> <td style="width:12%;"> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Michael B. Jebsen</p></td> <td> <p style="margin:0px"> </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px"> </p></td> <td> <p style="margin:0px"> </p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em>President and Chief Financial Officer</em></p> <p style="margin:0px"><em>(Principal Financial Officer)</em></p></td> <td> <p style="margin:0px"> </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><body> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>7 <FILENAME>tenx-20210630.xsd <DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii" standalone="yes"?> <!--XBRL Document Created with XBRLMaster--> <!--Version: 2.3.08--> <!--Based on XBRL 2.1--> <!--Date of creation: 08/16/2021--> <!--Software architectural design and coding: Dipendra K. Singh--> <!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.--> <schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:tenx="http://tenaxthera.com/20210630" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tenaxthera.com/20210630"> <annotation> <appinfo> <link:roleType roleURI="http://tenaxthera.com/role/Cover" id="Cover"> <link:definition>000001 - Document - Cover</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets"> <link:definition>000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical"> <link:definition>000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" id="CondensedConsolidatedStatementsOfComprehensiveLossUnaudited"> <link:definition>000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"> <link:definition>000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited"> <link:definition>000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness"> <link:definition>000007 - Disclosure - DESCRIPTION OF BUSINESS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies"> <link:definition>000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/FairValue" id="FairValue"> <link:definition>000009 - Disclosure - FAIR VALUE</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/BalanceSheetComponents" id="BalanceSheetComponents"> <link:definition>000010 - Disclosure - BALANCE SHEET COMPONENTS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/LEASE" id="LEASE"> <link:definition>000011 - Disclosure - LEASE</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/NotesPayable" id="NotesPayable"> <link:definition>000012 - Disclosure - NOTES PAYABLE</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/MERGER" id="MERGER"> <link:definition>000013 - Disclosure - MERGER</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies"> <link:definition>000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquity" id="StockholdersEquity"> <link:definition>000015 - Disclosure - STOCKHOLDERS EQUITY</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SubsequentEvents" id="SubsequentEvents"> <link:definition>000016 - Disclosure - SUBSEQUENT EVENTS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies"> <link:definition>000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables"> <link:definition>000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/FairValueTables" id="FairValueTables"> <link:definition>000019 - Disclosure - FAIR VALUE (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/BalanceSheetComponentsTables" id="BalanceSheetComponentsTables"> <link:definition>000020 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/LeaseTables" id="LeaseTables"> <link:definition>000021 - Disclosure - LEASE (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/MergerTables" id="MergerTables"> <link:definition>000022 - Disclosure - MERGER (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityTables" id="StockholdersEquityTables"> <link:definition>000023 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails"> <link:definition>000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative"> <link:definition>000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/FairValueDetails" id="FairValueDetails"> <link:definition>000026 - Disclosure - FAIR VALUE (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/FairValueDetails1" id="FairValueDetails1"> <link:definition>000027 - Disclosure - FAIR VALUE (Details 1)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails" id="BalanceSheetComponentsDetails"> <link:definition>000028 - Disclosure - BALANCE SHEET COMPONENTS (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" id="BalanceSheetComponentsDetails1"> <link:definition>000029 - Disclosure - BALANCE SHEET COMPONENTS (Details 1)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" id="BalanceSheetComponentsDetailsNarrative"> <link:definition>000030 - Disclosure - BALANCE SHEET COMPONENTS (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/LeaseDetails" id="LeaseDetails"> <link:definition>000031 - Disclosure - LEASE (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/LeaseDetails1" id="LeaseDetails1"> <link:definition>000032 - Disclosure - LEASE (Details 1)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/LeaseDetailsNarrative" id="LeaseDetailsNarrative"> <link:definition>000033 - Disclosure - LEASE (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative"> <link:definition>000034 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/MergerDetails" id="MergerDetails"> <link:definition>000035 - Disclosure - MERGER (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/MergerDetailsNarrative" id="MergerDetailsNarrative"> <link:definition>000036 - Disclosure - MERGER (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative"> <link:definition>000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails"> <link:definition>000038 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1"> <link:definition>000039 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2"> <link:definition>000040 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3"> <link:definition>000041 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4"> <link:definition>000042 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative"> <link:definition>000043 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative"> <link:definition>000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:linkbaseRef xlink:type="simple" xlink:href="tenx-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> <link:linkbaseRef xlink:type="simple" xlink:href="tenx-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> <link:linkbaseRef xlink:type="simple" xlink:href="tenx-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> <link:linkbaseRef xlink:type="simple" xlink:href="tenx-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> </appinfo> </annotation> <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" /> <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" /> <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" /> <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" /> <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" /> <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" /> <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" /> <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" /> <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" /> <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" /> <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" /> <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" /> <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" /> <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" /> <import namespace="http://fasb.org/srt-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" /> <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" /> <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" /> <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" /> <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" /> <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" /> <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" /> <element id="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" name="CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" name="CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CompensationOnOptionsIssued" name="CompensationOnOptionsIssued" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockIssuedForServicesRenderedShares" name="CommonStockIssuedForServicesRenderedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockIssuedForServicesRenderedAmount" name="CommonStockIssuedForServicesRenderedAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockIssuedForConvertiblePreferredStockShares" name="CommonStockIssuedForConvertiblePreferredStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockIssuedForConvertiblePreferredStockAmount" name="CommonStockIssuedForConvertiblePreferredStockAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ExerciseOfPreFundedWarrantsShares" name="ExerciseOfPreFundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ExerciseOfPreFundedWarrantsAmount" name="ExerciseOfPreFundedWarrantsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnrealizedLossOnMarketableSecurities" name="UnrealizedLossOnMarketableSecurities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnrealizedGainOnMarketableSecurities" name="UnrealizedGainOnMarketableSecurities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" name="CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" name="CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" name="IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" name="IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_AmortizationOfPremiumOnMarketableSecurities" name="AmortizationOfPremiumOnMarketableSecurities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_SaleOfMarketableSecurities" name="SaleOfMarketableSecurities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_LiquidityAndManagementsPlanPolicyTextBlock" name="LiquidityAndManagementsPlanPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="tenx_Covid19ImpactPolicyTextBlock" name="Covid19ImpactPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ScheduleOfInvestmentsInMarketableSecurities" name="ScheduleOfInvestmentsInMarketableSecurities" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="tenx_SharesAvailableForGrantTableTextblock" name="SharesAvailableForGrantTableTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="tenx_OutstandingStockOptionsUnderPlanTableTextBlock" name="OutstandingStockOptionsUnderPlanTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" /> <element id="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" name="AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_GrossUnrealizedLosses" name="GrossUnrealizedLosses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_AvailableForSaleSecuritiesEstimatedFairValue" name="AvailableForSaleSecuritiesEstimatedFairValue" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_LessImputedInterest" name="LessImputedInterest" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_RemainingLeaseTerm" name="RemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" /> <element id="tenx_LeaseTermPeriod" name="LeaseTermPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PercentageOfAnnualIncreaseInRent" name="PercentageOfAnnualIncreaseInRent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PppLoanAmount" name="PppLoanAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PppLoanMonthlyPayment" name="PppLoanMonthlyPayment" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" name="DebtInstrumentDecreaseForgivenessAccruedInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_InProcessResearchAndDevelopmentExpense" name="InProcessResearchAndDevelopmentExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockAcquired" name="CommonStockAcquired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PercentageOfPreferredStockCarriesVotingRights" name="PercentageOfPreferredStockCarriesVotingRights" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_LicenseAgreementMaturityDate" name="LicenseAgreementMaturityDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" /> <element id="tenx_NonRefundableUpFrontPayment" name="NonRefundableUpFrontPayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_GrantPaidToAuthority" name="GrantPaidToAuthority" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_GrantPaidToAuthorityOne" name="GrantPaidToAuthorityOne" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_NonRefundableCommercializationMilestonePayment" name="NonRefundableCommercializationMilestonePayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_WarranToPurchaseOfCommonStockTerm" name="WarranToPurchaseOfCommonStockTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" /> <element id="tenx_StockOptionsGrantedVestingPeriod" name="StockOptionsGrantedVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" /> <element id="tenx_WarrantToPurchaseOfCommonStockExercisePrice" name="WarrantToPurchaseOfCommonStockExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" name="ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" name="UnregisteredCommonStockWarrantsToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" name="UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnregisteredWarrantsExercisePrice" name="UnregisteredWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" name="NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_FairValueAllocatedCommonStock" name="FairValueAllocatedCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_FairValueAllocatedPrefundedWarrants" name="FairValueAllocatedPrefundedWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_FairValueAllocatedWarrants" name="FairValueAllocatedWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" name="UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_WarrantToPurchaseOfCommonStockTerm" name="WarrantToPurchaseOfCommonStockTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" /> <element id="tenx_EstimatedFairValueofWarrantIssuedForServices" name="EstimatedFairValueofWarrantIssuedForServices" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" name="IssuedUnderwriterWarrantTopurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" name="UnderwriterWarrantToPurchaseCommonStockExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" name="UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_EstimatedFairValueofWarrantIssuedForServicese" name="EstimatedFairValueofWarrantIssuedForServicese" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" name="CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PrefundedWarrantsOutstanding" name="PrefundedWarrantsOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PreferredStockVotingRightsPercentage" name="PreferredStockVotingRightsPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PreferredStockVotingRightsPercentage1" name="PreferredStockVotingRightsPercentage1" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_StockConvertibleIntoAggregateSharesOfCommonStock" name="StockConvertibleIntoAggregateSharesOfCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_RightsPreferencesAndPrivilegesConversionIntoShare" name="RightsPreferencesAndPrivilegesConversionIntoShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_RightsPreferencesAndPrivilegesConversionIntoShare1" name="RightsPreferencesAndPrivilegesConversionIntoShare1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockParOrStatedValuePerShares" name="CommonStockParOrStatedValuePerShares" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_CommonStockSharesIssue" name="CommonStockSharesIssue" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_StockOptionsGrantedFairMarketValuePercentage" name="StockOptionsGrantedFairMarketValuePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_StockOptionsDescription" name="StockOptionsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" /> <element id="tenx_EstimatedFairValueOfInducementStockOptionAwardGranted" name="EstimatedFairValueOfInducementStockOptionAwardGranted" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_DividendYield" name="DividendYield" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_MaturityPeriod" name="MaturityPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PurchasePriceOfStock" name="PurchasePriceOfStock" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnregisteredPreFundedWarrants" name="UnregisteredPreFundedWarrants" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_ProceedsFromOffering" name="ProceedsFromOffering" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element id="tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" name="UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PercentageOfGrossProceedReceived" name="PercentageOfGrossProceedReceived" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_WarrantIssuedToPurchaseCommonStock" name="WarrantIssuedToPurchaseCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_PercentageOfOfferingPricePerShareOfCommonStock" name="PercentageOfOfferingPricePerShareOfCommonStock" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" /> <element id="tenx_dvddv" name="dvddv" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" /> <element id="tenx_SeveranceReceived" name="SeveranceReceived" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" /> <element name="StockIncentivePlan2016Member" id="tenx_StockIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="Amended1999StockPlanMember" id="tenx_Amended1999StockPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="InducementStockOptionsMember" id="tenx_InducementStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="InvestorsMember" id="tenx_InvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="WarranttoPurchaseCommonStockMember" id="tenx_WarranttoPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="SimdaxLicenseAgreementMember" id="tenx_SimdaxLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="ConvertiblePreferredSharesOutstandingMember" id="tenx_ConvertiblePreferredSharesOutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="PurchaseAgreementMember" id="tenx_PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="RegistrationRightsAgreementMember" id="tenx_RegistrationRightsAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="MarchTwentyTwentyWarrantsMember" id="tenx_MarchTwentyTwentyWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="July2020WarrantsMember" id="tenx_July2020WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="CommonStocksMember" id="tenx_CommonStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="PrefundedWarrantsToPurchaseCommonStockMember" id="tenx_PrefundedWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="SeparationAgreementMember" id="tenx_SeparationAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> <element name="MrDitonnoMember" id="tenx_MrDitonnoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" /> </schema> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.CAL <SEQUENCE>8 <FILENAME>tenx-20210630_cal.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii" standalone="yes"?> <!--XBRL Document Created with XBRLMaster--> <!--Version: 2.3.08--> <!--Based on XBRL 2.1--> <!--Date of creation: 08/16/2021--> <!--Software architectural design and coding: Dipendra K. Singh--> <!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef roleURI="http://tenaxthera.com/role/Cover" xlink:href="tenx-20210630.xsd#Cover" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tenx-20210630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="tenx-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/DescriptionOfBusiness" xlink:href="tenx-20210630.xsd#DescriptionOfBusiness" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValue" xlink:href="tenx-20210630.xsd#FairValue" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponents" xlink:href="tenx-20210630.xsd#BalanceSheetComponents" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LEASE" xlink:href="tenx-20210630.xsd#LEASE" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/NotesPayable" xlink:href="tenx-20210630.xsd#NotesPayable" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MERGER" xlink:href="tenx-20210630.xsd#MERGER" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CommitmentsAndContingencies" xlink:href="tenx-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquity" xlink:href="tenx-20210630.xsd#StockholdersEquity" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SubsequentEvents" xlink:href="tenx-20210630.xsd#SubsequentEvents" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueTables" xlink:href="tenx-20210630.xsd#FairValueTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsTables" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseTables" xlink:href="tenx-20210630.xsd#LeaseTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerTables" xlink:href="tenx-20210630.xsd#MergerTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityTables" xlink:href="tenx-20210630.xsd#StockholdersEquityTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueDetails" xlink:href="tenx-20210630.xsd#FairValueDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueDetails1" xlink:href="tenx-20210630.xsd#FairValueDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetails" xlink:href="tenx-20210630.xsd#LeaseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetails1" xlink:href="tenx-20210630.xsd#LeaseDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetailsNarrative" xlink:href="tenx-20210630.xsd#LeaseDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/NotesPayableDetailsNarrative" xlink:href="tenx-20210630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerDetails" xlink:href="tenx-20210630.xsd#MergerDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerDetailsNarrative" xlink:href="tenx-20210630.xsd#MergerDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="tenx-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails1" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails2" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails2" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails3" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails3" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails4" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails4" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" xlink:href="tenx-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" xlink:href="tenx-20210630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" xlink:title="000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" /> <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" /> <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" /> <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" /> <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" /> <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" /> <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" /> <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" /> <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" /> <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" /> <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" /> <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" /> <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" /> <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:title="000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" /> <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" /> <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss" /> <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss" xlink:type="arc" weight="1" /> <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AmortizationOfPremiumOnMarketableSecurities" xlink:label="loc_tenxAmortizationOfPremiumOnMarketableSecurities" /> <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tenxAmortizationOfPremiumOnMarketableSecurities" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" /> <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" xlink:label="loc_tenxIssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" /> <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tenxIssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" xlink:label="loc_tenxIssuanceOfCommonStockAndPreferredStockForAssetAcquisition" /> <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tenxIssuanceOfCommonStockAndPreferredStockForAssetAcquisition" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" /> <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="loc_us-gaapAmortizationOfLeasedAsset" /> <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfLeasedAsset" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable" /> <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" /> <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" /> <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" /> <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SaleOfMarketableSecurities" xlink:label="loc_tenxSaleOfMarketableSecurities" /> <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_tenxSaleOfMarketableSecurities" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" /> <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" /> <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" /> <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" /> <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" /> <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" /> <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" /> <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/DescriptionOfBusiness" xlink:title="000007 - Disclosure - DESCRIPTION OF BUSINESS" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValue" xlink:title="000009 - Disclosure - FAIR VALUE" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponents" xlink:title="000010 - Disclosure - BALANCE SHEET COMPONENTS" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LEASE" xlink:title="000011 - Disclosure - LEASE" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/NotesPayable" xlink:title="000012 - Disclosure - NOTES PAYABLE" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MERGER" xlink:title="000013 - Disclosure - MERGER" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CommitmentsAndContingencies" xlink:title="000014 - Disclosure - COMMITMENTS AND CONTINGENCIES" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquity" xlink:title="000015 - Disclosure - STOCKHOLDERS EQUITY" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SubsequentEvents" xlink:title="000016 - Disclosure - SUBSEQUENT EVENTS" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueTables" xlink:title="000019 - Disclosure - FAIR VALUE (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsTables" xlink:title="000020 - Disclosure - BALANCE SHEET COMPONENTS (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseTables" xlink:title="000021 - Disclosure - LEASE (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerTables" xlink:title="000022 - Disclosure - MERGER (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityTables" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Tables)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueDetails" xlink:title="000026 - Disclosure - FAIR VALUE (Details)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueDetails1" xlink:title="000027 - Disclosure - FAIR VALUE (Details 1)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetails" xlink:title="000028 - Disclosure - BALANCE SHEET COMPONENTS (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" xlink:title="000029 - Disclosure - BALANCE SHEET COMPONENTS (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" /> <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" /> <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" /> <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" /> </link:calculationLink> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" xlink:title="000030 - Disclosure - BALANCE SHEET COMPONENTS (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetails" xlink:title="000031 - Disclosure - LEASE (Details)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetails1" xlink:title="000032 - Disclosure - LEASE (Details 1)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetailsNarrative" xlink:title="000033 - Disclosure - LEASE (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/NotesPayableDetailsNarrative" xlink:title="000034 - Disclosure - NOTES PAYABLE (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerDetails" xlink:title="000035 - Disclosure - MERGER (Details)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerDetailsNarrative" xlink:title="000036 - Disclosure - MERGER (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails" xlink:title="000038 - Disclosure - STOCKHOLDERS EQUITY (Details)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails1" xlink:title="000039 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails2" xlink:title="000040 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails3" xlink:title="000041 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails4" xlink:title="000042 - Disclosure - STOCKHOLDERS EQUITY (Details 4)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" xlink:title="000043 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" /> <link:calculationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" xlink:title="000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" /> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>9 <FILENAME>tenx-20210630_def.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii" standalone="yes"?> <!--XBRL Document Created with XBRLMaster--> <!--Version: 2.3.08--> <!--Based on XBRL 2.1--> <!--Date of creation: 08/16/2021--> <!--Software architectural design and coding: Dipendra K. Singh--> <!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef roleURI="http://tenaxthera.com/role/Cover" xlink:href="tenx-20210630.xsd#Cover" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tenx-20210630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="tenx-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/DescriptionOfBusiness" xlink:href="tenx-20210630.xsd#DescriptionOfBusiness" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValue" xlink:href="tenx-20210630.xsd#FairValue" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponents" xlink:href="tenx-20210630.xsd#BalanceSheetComponents" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LEASE" xlink:href="tenx-20210630.xsd#LEASE" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/NotesPayable" xlink:href="tenx-20210630.xsd#NotesPayable" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MERGER" xlink:href="tenx-20210630.xsd#MERGER" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CommitmentsAndContingencies" xlink:href="tenx-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquity" xlink:href="tenx-20210630.xsd#StockholdersEquity" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SubsequentEvents" xlink:href="tenx-20210630.xsd#SubsequentEvents" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueTables" xlink:href="tenx-20210630.xsd#FairValueTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsTables" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseTables" xlink:href="tenx-20210630.xsd#LeaseTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerTables" xlink:href="tenx-20210630.xsd#MergerTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityTables" xlink:href="tenx-20210630.xsd#StockholdersEquityTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueDetails" xlink:href="tenx-20210630.xsd#FairValueDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueDetails1" xlink:href="tenx-20210630.xsd#FairValueDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetails" xlink:href="tenx-20210630.xsd#LeaseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetails1" xlink:href="tenx-20210630.xsd#LeaseDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetailsNarrative" xlink:href="tenx-20210630.xsd#LeaseDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/NotesPayableDetailsNarrative" xlink:href="tenx-20210630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerDetails" xlink:href="tenx-20210630.xsd#MergerDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerDetailsNarrative" xlink:href="tenx-20210630.xsd#MergerDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="tenx-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails1" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails2" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails2" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails3" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails3" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails4" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails4" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" xlink:href="tenx-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" xlink:href="tenx-20210630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" /> <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information"> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" xlink:title="000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="9" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:title="000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" order="21" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStocksMember" xlink:label="loc_tenxCommonStocksMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_tenxCommonStocksMember" order="22" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" order="24" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="25" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" xlink:label="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" xlink:label="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CompensationOnOptionsIssued" xlink:label="loc_tenxCompensationOnOptionsIssued" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCompensationOnOptionsIssued" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForServicesRenderedShares" xlink:label="loc_tenxCommonStockIssuedForServicesRenderedShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockIssuedForServicesRenderedShares" order="6" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForServicesRenderedAmount" xlink:label="loc_tenxCommonStockIssuedForServicesRenderedAmount" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockIssuedForServicesRenderedAmount" order="7" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForConvertiblePreferredStockShares" xlink:label="loc_tenxCommonStockIssuedForConvertiblePreferredStockShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockIssuedForConvertiblePreferredStockShares" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForConvertiblePreferredStockAmount" xlink:label="loc_tenxCommonStockIssuedForConvertiblePreferredStockAmount" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockIssuedForConvertiblePreferredStockAmount" order="9" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ExerciseOfPreFundedWarrantsShares" xlink:label="loc_tenxExerciseOfPreFundedWarrantsShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxExerciseOfPreFundedWarrantsShares" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ExerciseOfPreFundedWarrantsAmount" xlink:label="loc_tenxExerciseOfPreFundedWarrantsAmount" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxExerciseOfPreFundedWarrantsAmount" order="11" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnrealizedLossOnMarketableSecurities" xlink:label="loc_tenxUnrealizedLossOnMarketableSecurities" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnrealizedLossOnMarketableSecurities" order="12" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="13" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_tenxStockIssuedDuringPeriodSharesWarrantsExercised" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxStockIssuedDuringPeriodSharesWarrantsExercised" order="14" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_tenxStockIssuedDuringPeriodValueWarrantsExercised" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxStockIssuedDuringPeriodValueWarrantsExercised" order="15" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnrealizedGainOnMarketableSecurities" xlink:label="loc_tenxUnrealizedGainOnMarketableSecurities" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnrealizedGainOnMarketableSecurities" order="16" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" xlink:label="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionShares" order="17" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" xlink:label="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" order="18" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/DescriptionOfBusiness" xlink:title="000007 - Disclosure - DESCRIPTION OF BUSINESS" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValue" xlink:title="000009 - Disclosure - FAIR VALUE" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponents" xlink:title="000010 - Disclosure - BALANCE SHEET COMPONENTS" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LEASE" xlink:title="000011 - Disclosure - LEASE" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/NotesPayable" xlink:title="000012 - Disclosure - NOTES PAYABLE" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MERGER" xlink:title="000013 - Disclosure - MERGER" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CommitmentsAndContingencies" xlink:title="000014 - Disclosure - COMMITMENTS AND CONTINGENCIES" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquity" xlink:title="000015 - Disclosure - STOCKHOLDERS EQUITY" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SubsequentEvents" xlink:title="000016 - Disclosure - SUBSEQUENT EVENTS" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueTables" xlink:title="000019 - Disclosure - FAIR VALUE (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsTables" xlink:title="000020 - Disclosure - BALANCE SHEET COMPONENTS (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseTables" xlink:title="000021 - Disclosure - LEASE (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerTables" xlink:title="000022 - Disclosure - MERGER (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityTables" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Tables)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="60" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarranttoPurchaseCommonStockMember" xlink:label="loc_tenxWarranttoPurchaseCommonStockMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tenxWarranttoPurchaseCommonStockMember" order="41" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SimdaxLicenseAgreementMember" xlink:label="loc_tenxSimdaxLicenseAgreementMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxSimdaxLicenseAgreementMember" order="42" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ConvertiblePreferredSharesOutstandingMember" xlink:label="loc_tenxConvertiblePreferredSharesOutstandingMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tenxConvertiblePreferredSharesOutstandingMember" order="43" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PrefundedWarrantsToPurchaseCommonStockMember" xlink:label="loc_tenxPrefundedWarrantsToPurchaseCommonStockMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tenxPrefundedWarrantsToPurchaseCommonStockMember" order="44" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueDetails" xlink:title="000026 - Disclosure - FAIR VALUE (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaapAvailableForSaleSecuritiesAmortizedCost" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesAmortizedCost" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaapAccruedInvestmentIncomeReceivable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedInvestmentIncomeReceivable" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:label="loc_us-gaapAvailableForSaleSecuritiesGrossUnrealizedGains" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesGrossUnrealizedGains" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrossUnrealizedLosses" xlink:label="loc_tenxGrossUnrealizedLosses" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxGrossUnrealizedLosses" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AvailableForSaleSecuritiesEstimatedFairValue" xlink:label="loc_tenxAvailableForSaleSecuritiesEstimatedFairValue" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxAvailableForSaleSecuritiesEstimatedFairValue" order="5" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueDetails1" xlink:title="000027 - Disclosure - FAIR VALUE (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" order="22" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaapAssetsFairValueDisclosureAbstract" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosureAbstract" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaapAvailableForSaleSecurities" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecurities" order="3" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetails" xlink:title="000028 - Disclosure - BALANCE SHEET COMPONENTS (Details)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" xlink:title="000029 - Disclosure - BALANCE SHEET COMPONENTS (Details 1)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" xlink:title="000030 - Disclosure - BALANCE SHEET COMPONENTS (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetails" xlink:title="000031 - Disclosure - LEASE (Details)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetails1" xlink:title="000032 - Disclosure - LEASE (Details 1)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetailsNarrative" xlink:title="000033 - Disclosure - LEASE (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/NotesPayableDetailsNarrative" xlink:title="000034 - Disclosure - NOTES PAYABLE (Details Narrative)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerDetails" xlink:title="000035 - Disclosure - MERGER (Details)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerDetailsNarrative" xlink:title="000036 - Disclosure - MERGER (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaapSeriesBMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="loc_us-gaapSeriesBMember" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAcquired" xlink:label="loc_tenxCommonStockAcquired" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockAcquired" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfPreferredStockCarriesVotingRights" xlink:label="loc_tenxPercentageOfPreferredStockCarriesVotingRights" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPercentageOfPreferredStockCarriesVotingRights" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" order="5" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SimdaxLicenseAgreementMember" xlink:label="loc_tenxSimdaxLicenseAgreementMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxSimdaxLicenseAgreementMember" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaapLongtermPurchaseCommitmentPeriod" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongtermPurchaseCommitmentPeriod" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LicenseAgreementMaturityDate" xlink:label="loc_tenxLicenseAgreementMaturityDate" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxLicenseAgreementMaturityDate" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NonRefundableUpFrontPayment" xlink:label="loc_tenxNonRefundableUpFrontPayment" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxNonRefundableUpFrontPayment" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrantPaidToAuthority" xlink:label="loc_tenxGrantPaidToAuthority" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxGrantPaidToAuthority" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrantPaidToAuthorityOne" xlink:label="loc_tenxGrantPaidToAuthorityOne" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxGrantPaidToAuthorityOne" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NonRefundableCommercializationMilestonePayment" xlink:label="loc_tenxNonRefundableCommercializationMilestonePayment" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxNonRefundableCommercializationMilestonePayment" order="6" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails" xlink:title="000038 - Disclosure - STOCKHOLDERS EQUITY (Details)" /> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails1" xlink:title="000039 - Disclosure - STOCKHOLDERS EQUITY (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxStockIncentivePlan2016Member" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails2" xlink:title="000040 - Disclosure - STOCKHOLDERS EQUITY (Details 2)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxStockIncentivePlan2016Member" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails3" xlink:title="000041 - Disclosure - STOCKHOLDERS EQUITY (Details 3)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxStockIncentivePlan2016Member" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails4" xlink:title="000042 - Disclosure - STOCKHOLDERS EQUITY (Details 4)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Amended1999StockPlanMember" xlink:label="loc_tenxAmended1999StockPlanMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxAmended1999StockPlanMember" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" xlink:title="000043 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="40" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="60" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="60" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="70" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="70" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="80" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="90" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" order="71" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxStockIncentivePlan2016Member" order="72" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Amended1999StockPlanMember" xlink:label="loc_tenxAmended1999StockPlanMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxAmended1999StockPlanMember" order="73" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" order="74" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InvestorsMember" xlink:label="loc_tenxInvestorsMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_tenxInvestorsMember" order="75" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MarchTwentyTwentyWarrantsMember" xlink:label="loc_tenxMarchTwentyTwentyWarrantsMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_tenxMarchTwentyTwentyWarrantsMember" order="76" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_July2020WarrantsMember" xlink:label="loc_tenxJuly2020WarrantsMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_tenxJuly2020WarrantsMember" order="77" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InducementStockOptionsMember" xlink:label="loc_tenxInducementStockOptionsMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxInducementStockOptionsMember" order="78" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantToPurchaseOfCommonStockExercisePrice" xlink:label="loc_tenxWarrantToPurchaseOfCommonStockExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxWarrantToPurchaseOfCommonStockExercisePrice" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" xlink:label="loc_tenxConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" xlink:label="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStock" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" xlink:label="loc_tenxUnregisteredCommonStockWarrantsToPurchaseGrossProceeds" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnregisteredCommonStockWarrantsToPurchaseGrossProceeds" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredWarrantsExercisePrice" xlink:label="loc_tenxUnregisteredWarrantsExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnregisteredWarrantsExercisePrice" order="6" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" xlink:label="loc_tenxNetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxNetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" order="8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="9" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PrefundedWarrantsOutstanding" xlink:label="loc_tenxPrefundedWarrantsOutstanding" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPrefundedWarrantsOutstanding" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="12" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockParOrStatedValuePerShares" xlink:label="loc_tenxCommonStockParOrStatedValuePerShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockParOrStatedValuePerShares" order="13" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="14" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockSharesIssue" xlink:label="loc_tenxCommonStockSharesIssue" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockSharesIssue" order="15" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="16" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="17" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="18" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarranToPurchaseOfCommonStockTerm" xlink:label="loc_tenxWarranToPurchaseOfCommonStockTerm" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxWarranToPurchaseOfCommonStockTerm" order="19" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="21" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PreferredStockVotingRightsPercentage" xlink:label="loc_tenxPreferredStockVotingRightsPercentage" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPreferredStockVotingRightsPercentage" order="22" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PreferredStockVotingRightsPercentage1" xlink:label="loc_tenxPreferredStockVotingRightsPercentage1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPreferredStockVotingRightsPercentage1" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="24" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="25" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="26" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsGrantedVestingPeriod" xlink:label="loc_tenxStockOptionsGrantedVestingPeriod" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxStockOptionsGrantedVestingPeriod" order="27" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="28" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="29" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsGrantedFairMarketValuePercentage" xlink:label="loc_tenxStockOptionsGrantedFairMarketValuePercentage" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxStockOptionsGrantedFairMarketValuePercentage" order="30" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockConvertibleIntoAggregateSharesOfCommonStock" xlink:label="loc_tenxStockConvertibleIntoAggregateSharesOfCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxStockConvertibleIntoAggregateSharesOfCommonStock" order="31" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RightsPreferencesAndPrivilegesConversionIntoShare" xlink:label="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare" order="32" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RightsPreferencesAndPrivilegesConversionIntoShare1" xlink:label="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare1" order="33" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" order="34" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedCommonStock" xlink:label="loc_tenxFairValueAllocatedCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxFairValueAllocatedCommonStock" order="35" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedPrefundedWarrants" xlink:label="loc_tenxFairValueAllocatedPrefundedWarrants" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxFairValueAllocatedPrefundedWarrants" order="36" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedWarrants" xlink:label="loc_tenxFairValueAllocatedWarrants" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxFairValueAllocatedWarrants" order="37" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" order="38" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantToPurchaseOfCommonStockTerm" xlink:label="loc_tenxWarrantToPurchaseOfCommonStockTerm" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxWarrantToPurchaseOfCommonStockTerm" order="39" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueofWarrantIssuedForServices" xlink:label="loc_tenxEstimatedFairValueofWarrantIssuedForServices" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxEstimatedFairValueofWarrantIssuedForServices" order="40" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" xlink:label="loc_tenxIssuedUnderwriterWarrantTopurchaseCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxIssuedUnderwriterWarrantTopurchaseCommonStock" order="41" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" xlink:label="loc_tenxUnderwriterWarrantToPurchaseCommonStockExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnderwriterWarrantToPurchaseCommonStockExercisePrice" order="42" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" xlink:label="loc_tenxUnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" order="43" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" xlink:label="loc_tenxCommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" order="44" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" xlink:label="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" order="45" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueofWarrantIssuedForServicese" xlink:label="loc_tenxEstimatedFairValueofWarrantIssuedForServicese" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxEstimatedFairValueofWarrantIssuedForServicese" order="46" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="47" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="48" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="49" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsDescription" xlink:label="loc_tenxStockOptionsDescription" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxStockOptionsDescription" order="50" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueOfInducementStockOptionAwardGranted" xlink:label="loc_tenxEstimatedFairValueOfInducementStockOptionAwardGranted" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxEstimatedFairValueOfInducementStockOptionAwardGranted" order="51" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="52" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_DividendYield" xlink:label="loc_tenxDividendYield" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxDividendYield" order="53" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="54" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="55" /> </link:definitionLink> <link:definitionLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" xlink:title="000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="40" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="50" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="60" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="70" xbrldt:contextElement="segment" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="51" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PurchaseAgreementMember" xlink:label="loc_tenxPurchaseAgreementMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxPurchaseAgreementMember" order="52" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RegistrationRightsAgreementMember" xlink:label="loc_tenxRegistrationRightsAgreementMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxRegistrationRightsAgreementMember" order="53" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SeparationAgreementMember" xlink:label="loc_tenxSeparationAgreementMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tenxSeparationAgreementMember" order="54" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MrDitonnoMember" xlink:label="loc_tenxMrDitonnoMember" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_tenxMrDitonnoMember" order="55" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MaturityPeriod" xlink:label="loc_tenxMaturityPeriod" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxMaturityPeriod" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PurchasePriceOfStock" xlink:label="loc_tenxPurchasePriceOfStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPurchasePriceOfStock" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockParOrStatedValuePerShares" xlink:label="loc_tenxCommonStockParOrStatedValuePerShares" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxCommonStockParOrStatedValuePerShares" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredPreFundedWarrants" xlink:label="loc_tenxUnregisteredPreFundedWarrants" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnregisteredPreFundedWarrants" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ProceedsFromOffering" xlink:label="loc_tenxProceedsFromOffering" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxProceedsFromOffering" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" xlink:label="loc_tenxUnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxUnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfGrossProceedReceived" xlink:label="loc_tenxPercentageOfGrossProceedReceived" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPercentageOfGrossProceedReceived" order="9" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantIssuedToPurchaseCommonStock" xlink:label="loc_tenxWarrantIssuedToPurchaseCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxWarrantIssuedToPurchaseCommonStock" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfOfferingPricePerShareOfCommonStock" xlink:label="loc_tenxPercentageOfOfferingPricePerShareOfCommonStock" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxPercentageOfOfferingPricePerShareOfCommonStock" order="11" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_dvddv" xlink:label="loc_tenxdvddv" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxdvddv" order="12" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SeveranceReceived" xlink:label="loc_tenxSeveranceReceived" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tenxSeveranceReceived" order="13" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" /> <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" order="14" /> </link:definitionLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>10 <FILENAME>tenx-20210630_lab.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii" standalone="yes"?> <!--XBRL Document Created with XBRLMaster--> <!--Version: 2.3.08--> <!--Based on XBRL 2.1--> <!--Date of creation: 08/16/2021--> <!--Software architectural design and coding: Dipendra K. Singh--> <!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" /> <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" /> <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" /> <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link"> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_1f1022" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_1f1022" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_09fb8d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_09fb8d" xml:lang="en-US">ASSETS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_0d5afb" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_0d5afb" xml:lang="en-US">Current assets</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_035610" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_035610" xml:lang="en-US">Cash and cash equivalents</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl_0b39e6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl_0b39e6" xml:lang="en-US">Marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_7a074e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_7a074e" xml:lang="en-US">Prepaid expenses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_b4371f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_b4371f" xml:lang="en-US">Total current assets</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_e94b8d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_e94b8d" xml:lang="en-US">Right of use asset</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_9cb520" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_9cb520" xml:lang="en-US">Property and equipment, net</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl_ca0741" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl_ca0741" xml:lang="en-US">Other assets</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_e82421" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_e82421" xml:lang="en-US">Total assets</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_11" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_11" xml:lang="en-US">[Assets]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_ae108f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_ae108f" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS EQUITY</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_c6b0af" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_c6b0af" xml:lang="en-US">Current liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_6dc724" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_6dc724" xml:lang="en-US">Accounts payable</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_cbb774" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_cbb774" xml:lang="en-US">Accrued liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl_fa485d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl_fa485d" xml:lang="en-US">Note payable</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_93c8b0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_93c8b0" xml:lang="en-US">Total current liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_17" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_17" xml:lang="en-US">[Liabilities, Current]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl_3f7176" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl_3f7176" xml:lang="en-US">Long term liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_c76ff3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_c76ff3" xml:lang="en-US">Lease liability</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl_ef65a9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl_ef65a9" xml:lang="en-US">Note payable</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl_20" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl_20" xml:lang="en-US">[Notes Payable]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl_3ce94e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl_3ce94e" xml:lang="en-US">Total long term liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl_21" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl_21" xml:lang="en-US">[Liabilities, Noncurrent]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_846874" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_846874" xml:lang="en-US">Total liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_22" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_22" xml:lang="en-US">[Liabilities]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl_77ceb5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl_77ceb5" xml:lang="en-US">Commitments and contingencies; see Note 8</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_a9bf43" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_a9bf43" xml:lang="en-US">Stockholders' equity</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_dbedf6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_dbedf6" xml:lang="en-US">Preferred stock, undesignated, authorized 9,999,790 shares; See Note 9 Series A Preferred stock, par value $.0001, issued 5,181,346 shares; outstanding 210, respectively</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_057ee3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_057ee3" xml:lang="en-US">Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 25,201,312 and 12,619,369 respectively</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl_4ea8ce" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl_4ea8ce" xml:lang="en-US">Additional paid-in capital</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_fab061" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_fab061" xml:lang="en-US">Accumulated other comprehensive loss</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_08a270" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_08a270" xml:lang="en-US">Accumulated deficit</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_c653d8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_c653d8" xml:lang="en-US">Total stockholders equity</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_dcb287" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_dcb287" xml:lang="en-US">Total liabilities and stockholders' equity</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_31" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_31" xml:lang="en-US">[Liabilities and Equity]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_8149ad" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_8149ad" xml:lang="en-US">Statement [Table]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_33335c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_33335c" xml:lang="en-US">Statement [Line Items]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_f28b78" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_f28b78" xml:lang="en-US">Statement Class Of Stock Axis</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl_57a755" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl_57a755" xml:lang="en-US">Series A Preferred Stock</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_aff876" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_aff876" xml:lang="en-US">Stockholders' equity</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_dd43ce" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_dd43ce" xml:lang="en-US">Preferred stock, authorized</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_21466f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_21466f" xml:lang="en-US">Common stock, par value</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_cb3bba" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_cb3bba" xml:lang="en-US">Common stock, authorized</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_4342dd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_4342dd" xml:lang="en-US">Common stock, issued</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_a7efaa" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_a7efaa" xml:lang="en-US">Common stock, outstanding</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_9b0239" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_9b0239" xml:lang="en-US">Preferred stock, par value</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_889dda" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_889dda" xml:lang="en-US">Preferred stock, issued</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_0d7d5f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_0d7d5f" xml:lang="en-US">Preferred stock, outstanding</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_eb67ed" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_eb67ed" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_9a82f5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_9a82f5" xml:lang="en-US">Operating expenses</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_52925a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_52925a" xml:lang="en-US">General and administrative</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_961d13" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_961d13" xml:lang="en-US">Research and development</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_3d3cff" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_3d3cff" xml:lang="en-US">Total operating expenses</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_9d44bd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_9d44bd" xml:lang="en-US">Net operating loss</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_216053" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_216053" xml:lang="en-US">Interest expense</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_7c4ee4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_7c4ee4" xml:lang="en-US">Other (income) expense, net</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_4c4e9a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_4c4e9a" xml:lang="en-US">Net loss</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_9" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl_538d30" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl_538d30" xml:lang="en-US">Unrealized (gain) loss on marketable securities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl_48c230" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl_48c230" xml:lang="en-US">Total comprehensive loss</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl_11" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl_11" xml:lang="en-US">[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl_63e8b6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl_63e8b6" xml:lang="en-US">Net loss per share, basic and diluted</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_3be143" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_3be143" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_bb2cd5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_bb2cd5" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_e35927" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_e35927" xml:lang="en-US">Statement Equity Components [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl_280867" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl_280867" xml:lang="en-US">Preferred Stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStocksMember" xlink:label="tenx_CommonStocksMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStocksMember" xlink:to="tenx_CommonStocksMember_lbl_86d1be" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStocksMember_lbl_86d1be" xml:lang="en-US">Common Stock</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_1fd966" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_1fd966" xml:lang="en-US">Additional Paid-In Capital</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_d73f41" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_d73f41" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_4f6c30" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_4f6c30" xml:lang="en-US">Accumulated Deficit</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2d88f8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_2d88f8" xml:lang="en-US">Balance, shares</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_c731e0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_c731e0" xml:lang="en-US">Balance, amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" xlink:label="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" xlink:to="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares_lbl_6e9e6f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares_lbl_6e9e6f" xml:lang="en-US">Common stock and pre-funded warrants sold, net of offering costs, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" xlink:label="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" xlink:to="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount_lbl_a66ce4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount_lbl_a66ce4" xml:lang="en-US">Common stock and pre-funded warrants sold, net of offering costs, amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CompensationOnOptionsIssued" xlink:label="tenx_CompensationOnOptionsIssued" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CompensationOnOptionsIssued" xlink:to="tenx_CompensationOnOptionsIssued_lbl_b2bec5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CompensationOnOptionsIssued_lbl_b2bec5" xml:lang="en-US">Compensation on options issued</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForServicesRenderedShares" xlink:label="tenx_CommonStockIssuedForServicesRenderedShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockIssuedForServicesRenderedShares" xlink:to="tenx_CommonStockIssuedForServicesRenderedShares_lbl_39299d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockIssuedForServicesRenderedShares_lbl_39299d" xml:lang="en-US">Common stock issued for services rendered, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForServicesRenderedAmount" xlink:label="tenx_CommonStockIssuedForServicesRenderedAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockIssuedForServicesRenderedAmount" xlink:to="tenx_CommonStockIssuedForServicesRenderedAmount_lbl_10f631" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockIssuedForServicesRenderedAmount_lbl_10f631" xml:lang="en-US">Common stock issued for services rendered, amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForConvertiblePreferredStockShares" xlink:label="tenx_CommonStockIssuedForConvertiblePreferredStockShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockIssuedForConvertiblePreferredStockShares" xlink:to="tenx_CommonStockIssuedForConvertiblePreferredStockShares_lbl_1b71ea" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockIssuedForConvertiblePreferredStockShares_lbl_1b71ea" xml:lang="en-US">Common stock issued for convertible preferred stock, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForConvertiblePreferredStockAmount" xlink:label="tenx_CommonStockIssuedForConvertiblePreferredStockAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockIssuedForConvertiblePreferredStockAmount" xlink:to="tenx_CommonStockIssuedForConvertiblePreferredStockAmount_lbl_79c683" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockIssuedForConvertiblePreferredStockAmount_lbl_79c683" xml:lang="en-US">Common stock issued for convertible preferred stock, amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ExerciseOfPreFundedWarrantsShares" xlink:label="tenx_ExerciseOfPreFundedWarrantsShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ExerciseOfPreFundedWarrantsShares" xlink:to="tenx_ExerciseOfPreFundedWarrantsShares_lbl_4029f1" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ExerciseOfPreFundedWarrantsShares_lbl_4029f1" xml:lang="en-US">Exercise of pre-funded warrants, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ExerciseOfPreFundedWarrantsAmount" xlink:label="tenx_ExerciseOfPreFundedWarrantsAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ExerciseOfPreFundedWarrantsAmount" xlink:to="tenx_ExerciseOfPreFundedWarrantsAmount_lbl_24e9ee" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ExerciseOfPreFundedWarrantsAmount_lbl_24e9ee" xml:lang="en-US">Exercise of pre-funded warrants, amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnrealizedLossOnMarketableSecurities" xlink:label="tenx_UnrealizedLossOnMarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnrealizedLossOnMarketableSecurities" xlink:to="tenx_UnrealizedLossOnMarketableSecurities_lbl_4ffb1c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnrealizedLossOnMarketableSecurities_lbl_4ffb1c" xml:lang="en-US">Unrealized loss on marketable securities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_763f9b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_763f9b" xml:lang="en-US">Net loss</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="tenx_StockIssuedDuringPeriodSharesWarrantsExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="tenx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl_36261a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl_36261a" xml:lang="en-US">Exercise of warrants, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="tenx_StockIssuedDuringPeriodValueWarrantsExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="tenx_StockIssuedDuringPeriodValueWarrantsExercised_lbl_d396b0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockIssuedDuringPeriodValueWarrantsExercised_lbl_d396b0" xml:lang="en-US">Exercise of warrants, amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnrealizedGainOnMarketableSecurities" xlink:label="tenx_UnrealizedGainOnMarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnrealizedGainOnMarketableSecurities" xlink:to="tenx_UnrealizedGainOnMarketableSecurities_lbl_a75345" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnrealizedGainOnMarketableSecurities_lbl_a75345" xml:lang="en-US">Unrealized gain on marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" xlink:label="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" xlink:to="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares_lbl_195cfc" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares_lbl_195cfc" xml:lang="en-US">Common stock and preferred stock issued for asset acquisition, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" xlink:label="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" xlink:to="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount_lbl_d5af2f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount_lbl_d5af2f" xml:lang="en-US">Common stock and preferred stock issued for asset acquisition, amount</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_5557f4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_5557f4" xml:lang="en-US">Balance, shares</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_86d81d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_86d81d" xml:lang="en-US">Balance, amount</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_9e1030" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_9e1030" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_118eef" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_118eef" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_d28a78" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_d28a78" xml:lang="en-US">Net Loss</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_01e26c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_01e26c" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_345e91" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_345e91" xml:lang="en-US">Depreciation and amortization</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:to="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl_14b090" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable_lbl_14b090" xml:lang="en-US">Interest on debt instrument</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="us-gaap_AmortizationOfLeasedAsset" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfLeasedAsset" xlink:to="us-gaap_AmortizationOfLeasedAsset_lbl_903d99" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfLeasedAsset_lbl_903d99" xml:lang="en-US">Amortization of right of use asset</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_7fd0e1" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_7fd0e1" xml:lang="en-US">Gain on debt settlement and extinguishment</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" xlink:label="tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" xlink:to="tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition_lbl_e2e2f7" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition_lbl_e2e2f7" xml:lang="en-US">Issuance of common stock and preferred stock for asset acquisition</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" xlink:label="tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" xlink:to="tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants_lbl_0c21c7" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants_lbl_0c21c7" xml:lang="en-US">Issuance and vesting of compensatory stock options and warrants</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_5ca459" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_5ca459" xml:lang="en-US">Issuance of common stock for services rendered</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AmortizationOfPremiumOnMarketableSecurities" xlink:label="tenx_AmortizationOfPremiumOnMarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_AmortizationOfPremiumOnMarketableSecurities" xlink:to="tenx_AmortizationOfPremiumOnMarketableSecurities_lbl_db7e4c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_AmortizationOfPremiumOnMarketableSecurities_lbl_db7e4c" xml:lang="en-US">Amortization of premium on marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_25494e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_25494e" xml:lang="en-US">Changes in operating assets and liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_8e5125" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_8e5125" xml:lang="en-US">Accounts receivable, prepaid expenses and other assets</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_51b324" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_51b324" xml:lang="en-US">Accounts payable and accrued liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl_238469" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl_238469" xml:lang="en-US">Long term portion of lease liability</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_7ddb8f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_7ddb8f" xml:lang="en-US">Net cash used in operating activities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_68b12e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_68b12e" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl_832261" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl_832261" xml:lang="en-US">Purchase of marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl_19" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl_19" xml:lang="en-US">[Payments to Acquire Marketable Securities]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SaleOfMarketableSecurities" xlink:label="tenx_SaleOfMarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_SaleOfMarketableSecurities" xlink:to="tenx_SaleOfMarketableSecurities_lbl_b294e9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_SaleOfMarketableSecurities_lbl_b294e9" xml:lang="en-US">Sale of marketable securities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_52fcbb" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_52fcbb" xml:lang="en-US">Purchase of property and equipment</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_21" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_21" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_dd40dd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_dd40dd" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_22" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_22" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_affac5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_affac5" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_977945" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_977945" xml:lang="en-US">Proceeds from the exercise of warrants</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl_831e63" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl_831e63" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl_bf1912" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfMediumTermNotes_lbl_bf1912" xml:lang="en-US">Proceeds from the issuance of notes payable</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_240b2a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_240b2a" xml:lang="en-US">Net cash provided by financing activities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_457ca7" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_457ca7" xml:lang="en-US">Net change in cash and cash equivalents</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_28" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_28" xml:lang="en-US">[Cash and Cash Equivalents, Period Increase (Decrease)]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_a415f9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_a415f9" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_dafc58" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_dafc58" xml:lang="en-US">Cash and cash equivalents, end of period</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_ad96db" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_ad96db" xml:lang="en-US">Non-cash investing activity</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl_d0e1d3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl_d0e1d3" xml:lang="en-US">Addition to right of use asset obtained from new operating lease liability</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_e2c326" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_e2c326" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_548f90" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_548f90" xml:lang="en-US">1. DESCRIPTION OF BUSINESS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_08ea6d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_08ea6d" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_25fc1f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_25fc1f" xml:lang="en-US">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_2d6e1a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_2d6e1a" xml:lang="en-US">FAIR VALUE</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_88f4f4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_88f4f4" xml:lang="en-US">3. FAIR VALUE</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl_585bcf" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl_585bcf" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl_ca0294" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl_ca0294" xml:lang="en-US">4. BALANCE SHEET COMPONENTS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl_c1b5df" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl_c1b5df" xml:lang="en-US">LEASE</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_2346c3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_2346c3" xml:lang="en-US">5. LEASE</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl_adfa15" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl_adfa15" xml:lang="en-US">NOTES PAYABLE</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl_375933" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl_375933" xml:lang="en-US">6. NOTES PAYABLE</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl_7d37b2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl_7d37b2" xml:lang="en-US">MERGER</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl_367258" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl_367258" xml:lang="en-US">7. MERGER</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_938303" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_938303" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_899985" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_899985" xml:lang="en-US">8. COMMITMENTS AND CONTINGENCIES</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_ba01c9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_ba01c9" xml:lang="en-US">9. STOCKHOLDERS' EQUITY</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_f4c39d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_f4c39d" xml:lang="en-US">SUBSEQUENT EVENTS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_490c5b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_490c5b" xml:lang="en-US">10. SUBSEQUENT EVENTS</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_ad04a4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_ad04a4" xml:lang="en-US">Basis of Presentation</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_9614d2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_9614d2" xml:lang="en-US">Going Concern</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_b4a8de" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_b4a8de" xml:lang="en-US">Use of Estimates</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_8b75e0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_8b75e0" xml:lang="en-US">Principles of Consolidation</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LiquidityAndManagementsPlanPolicyTextBlock" xlink:label="tenx_LiquidityAndManagementsPlanPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_LiquidityAndManagementsPlanPolicyTextBlock" xlink:to="tenx_LiquidityAndManagementsPlanPolicyTextBlock_lbl_d90e88" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_LiquidityAndManagementsPlanPolicyTextBlock_lbl_d90e88" xml:lang="en-US">Liquidity and Management's Plan</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Covid19ImpactPolicyTextBlock" xlink:label="tenx_Covid19ImpactPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_Covid19ImpactPolicyTextBlock" xlink:to="tenx_Covid19ImpactPolicyTextBlock_lbl_d8520d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_Covid19ImpactPolicyTextBlock_lbl_d8520d" xml:lang="en-US">COVID-19 Impact and Related Risks</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_f14b27" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_f14b27" xml:lang="en-US">Net Loss per Share</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_65bb10" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_65bb10" xml:lang="en-US">Leases</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_7aef52" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_7aef52" xml:lang="en-US">Recent Accounting Pronouncements</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_9ec132" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_9ec132" xml:lang="en-US">Anti-dilutive securities</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ScheduleOfInvestmentsInMarketableSecurities" xlink:label="tenx_ScheduleOfInvestmentsInMarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ScheduleOfInvestmentsInMarketableSecurities" xlink:to="tenx_ScheduleOfInvestmentsInMarketableSecurities_lbl_9dbd98" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ScheduleOfInvestmentsInMarketableSecurities_lbl_9dbd98" xml:lang="en-US">Investments in marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl_5d7d2c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl_5d7d2c" xml:lang="en-US">Fair value on a recurring basis</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_4a8420" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_4a8420" xml:lang="en-US">Property, plant and equipment</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl_f164c3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl_f164c3" xml:lang="en-US">Accrued liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl_3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl_3" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl_a9c3fc" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl_a9c3fc" xml:lang="en-US">Lease liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_7ed6fa" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_7ed6fa" xml:lang="en-US">Maturities of operating lease liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl_f274a0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl_f274a0" xml:lang="en-US">Consideration transferred, asset acquired and liabilities assumed</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_1be6ce" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_1be6ce" xml:lang="en-US">Warrant activity</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SharesAvailableForGrantTableTextblock" xlink:label="tenx_SharesAvailableForGrantTableTextblock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_SharesAvailableForGrantTableTextblock" xlink:to="tenx_SharesAvailableForGrantTableTextblock_lbl_cffffe" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_SharesAvailableForGrantTableTextblock_lbl_cffffe" xml:lang="en-US">Shares available for grant under the 2016 Plan</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_8e245a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_8e245a" xml:lang="en-US">Options activity</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_18b688" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_18b688" xml:lang="en-US">Fair value assumptions</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_OutstandingStockOptionsUnderPlanTableTextBlock" xlink:label="tenx_OutstandingStockOptionsUnderPlanTableTextBlock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_OutstandingStockOptionsUnderPlanTableTextBlock" xlink:to="tenx_OutstandingStockOptionsUnderPlanTableTextBlock_lbl_cd57ad" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_OutstandingStockOptionsUnderPlanTableTextBlock_lbl_cd57ad" xml:lang="en-US">Outstanding stock options under the 1999 Plan</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_27564e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_27564e" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_ecc921" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_ecc921" xml:lang="en-US">Plan Name [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarranttoPurchaseCommonStockMember" xlink:label="tenx_WarranttoPurchaseCommonStockMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_WarranttoPurchaseCommonStockMember" xlink:to="tenx_WarranttoPurchaseCommonStockMember_lbl_41296b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_WarranttoPurchaseCommonStockMember_lbl_41296b" xml:lang="en-US">Warrant to Purchase Common Stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SimdaxLicenseAgreementMember" xlink:label="tenx_SimdaxLicenseAgreementMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_SimdaxLicenseAgreementMember" xlink:to="tenx_SimdaxLicenseAgreementMember_lbl_d3b1e8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_SimdaxLicenseAgreementMember_lbl_d3b1e8" xml:lang="en-US">Simdax License Agreement [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ConvertiblePreferredSharesOutstandingMember" xlink:label="tenx_ConvertiblePreferredSharesOutstandingMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ConvertiblePreferredSharesOutstandingMember" xlink:to="tenx_ConvertiblePreferredSharesOutstandingMember_lbl_1587ea" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ConvertiblePreferredSharesOutstandingMember_lbl_1587ea" xml:lang="en-US">Convertible preferred shares outstanding [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PrefundedWarrantsToPurchaseCommonStockMember" xlink:label="tenx_PrefundedWarrantsToPurchaseCommonStockMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PrefundedWarrantsToPurchaseCommonStockMember" xlink:to="tenx_PrefundedWarrantsToPurchaseCommonStockMember_lbl_3a239e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PrefundedWarrantsToPurchaseCommonStockMember_lbl_3a239e" xml:lang="en-US">Pre-funded warrants to purchase common stock [Member]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_c6e447" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_c6e447" xml:lang="en-US">Anti-dilutive securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_2" xml:lang="en-US">[Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_80c1e2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_80c1e2" xml:lang="en-US">Accumulated deficit</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_7e0089" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_7e0089" xml:lang="en-US">Net cash used in operating activities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_bbca57" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_bbca57" xml:lang="en-US">Cash and cash equivalents</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_25868b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl_25868b" xml:lang="en-US">Stockholder equity</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="us-gaap_StockholdersEquityBeforeTreasuryStock_lbl_fd1fa6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityBeforeTreasuryStock_lbl_fd1fa6" xml:lang="en-US">Stockholders' equity</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:label="us-gaap_StockholdersEquityBeforeTreasuryStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="us-gaap_StockholdersEquityBeforeTreasuryStock_lbl_6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityBeforeTreasuryStock_lbl_6" xml:lang="en-US">[Stockholders' Equity before Treasury Stock]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl_07f6c2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecurities_lbl_07f6c2" xml:lang="en-US">Marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl_7" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl_7" xml:lang="en-US">[Marketable Securities]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_lbl_443204" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement_lbl_443204" xml:lang="en-US">Private placements units sold</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl_c8dd28" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl_c8dd28" xml:lang="en-US">Purchase price of units</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" xlink:label="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" xlink:to="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds_lbl_dcba83" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds_lbl_dcba83" xml:lang="en-US">Gross proceeds</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl_acc96c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl_acc96c" xml:lang="en-US">Financial Instrument [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl_cfdcde" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl_cfdcde" xml:lang="en-US">Corporate Debt Securities</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl_aff695" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl_aff695" xml:lang="en-US">Amortized cost</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl_2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl_2" xml:lang="en-US">[Available-for-sale Securities, Amortized Cost Basis]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable_lbl_8c2164" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl_8c2164" xml:lang="en-US">Accrued interest</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable_lbl_3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl_3" xml:lang="en-US">[Accrued Investment Income Receivable]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains_lbl_704f08" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains_lbl_704f08" xml:lang="en-US">Gross unrealized gains</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrossUnrealizedLosses" xlink:label="tenx_GrossUnrealizedLosses" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_GrossUnrealizedLosses" xlink:to="tenx_GrossUnrealizedLosses_lbl_5a7be4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_GrossUnrealizedLosses_lbl_5a7be4" xml:lang="en-US">Gross unrealized losses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_AvailableForSaleSecuritiesEstimatedFairValue" xlink:to="tenx_AvailableForSaleSecuritiesEstimatedFairValue_lbl_91ed9f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tenx_AvailableForSaleSecuritiesEstimatedFairValue_lbl_91ed9f" xml:lang="en-US">Estimated fair value</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AvailableForSaleSecuritiesEstimatedFairValue" xlink:label="tenx_AvailableForSaleSecuritiesEstimatedFairValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_AvailableForSaleSecuritiesEstimatedFairValue" xlink:to="tenx_AvailableForSaleSecuritiesEstimatedFairValue_lbl_6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_AvailableForSaleSecuritiesEstimatedFairValue_lbl_6" xml:lang="en-US">[Estimated fair value]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_1c423b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_1c423b" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level Axis</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl_dd91dd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl_dd91dd" xml:lang="en-US">Level 1</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl_4c4f81" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl_4c4f81" xml:lang="en-US">Level 2</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl_b47146" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl_b47146" xml:lang="en-US">Level 3</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl_d6015d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl_d6015d" xml:lang="en-US">Current Assets</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl_634482" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl_634482" xml:lang="en-US">Cash and cash equivalents</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl_3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl_3" xml:lang="en-US">[Cash and Cash Equivalents, Fair Value Disclosure]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl_9893a4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl_9893a4" xml:lang="en-US">Marketable securities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl_4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl_4" xml:lang="en-US">[Available-for-sale Securities]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl_0e5a77" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl_0e5a77" xml:lang="en-US">Office furniture and fixtures</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl_d10053" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl_d10053" xml:lang="en-US">Computer equipment and software</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_da8cc2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_da8cc2" xml:lang="en-US">Property and equipment, gross</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_c30b84" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_c30b84" xml:lang="en-US">Less: accumulated depreciation</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_5" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_573ed6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_573ed6" xml:lang="en-US">Property and equipment, net</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl_ee79c1" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl_ee79c1" xml:lang="en-US">Employee related</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_a29996" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_a29996" xml:lang="en-US">Operating costs</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_f8c4d6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_f8c4d6" xml:lang="en-US">Lease liability</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_4" xml:lang="en-US">[Operating Lease, Liability, Current]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_db401d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_db401d" xml:lang="en-US">Total</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_051d35" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_051d35" xml:lang="en-US">Depreciation expense</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_eece8a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_eece8a" xml:lang="en-US">Current portion included in accrued liabilities</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl_5d9646" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl_5d9646" xml:lang="en-US">Long term lease liability</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_86c7ff" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_86c7ff" xml:lang="en-US">Total</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_4" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_4" xml:lang="en-US">[Operating Lease, Liability]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_5162f0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_5162f0" xml:lang="en-US">2021</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_907e33" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_907e33" xml:lang="en-US">2022</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_d87440" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_d87440" xml:lang="en-US">2023</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_0f5155" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_0f5155" xml:lang="en-US">2024</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_724d56" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_724d56" xml:lang="en-US">Total lease payments</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LessImputedInterest" xlink:label="tenx_LessImputedInterest" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_LessImputedInterest" xlink:to="tenx_LessImputedInterest_lbl_acc675" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_LessImputedInterest_lbl_acc675" xml:lang="en-US">Less: imputed interest</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_141c36" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_141c36" xml:lang="en-US">Operating lease liability</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RemainingLeaseTerm" xlink:label="tenx_RemainingLeaseTerm" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_RemainingLeaseTerm" xlink:to="tenx_RemainingLeaseTerm_lbl_f48415" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_RemainingLeaseTerm_lbl_f48415" xml:lang="en-US">Remaining lease term</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_bd1642" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_bd1642" xml:lang="en-US">Discount rate</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl_f33133" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl_f33133" xml:lang="en-US">Lease expense</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_27d6db" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_27d6db" xml:lang="en-US">Amount of common area maintenance charges</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl_bf3c2d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl_bf3c2d" xml:lang="en-US">Area of lease land</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LeaseTermPeriod" xlink:label="tenx_LeaseTermPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_LeaseTermPeriod" xlink:to="tenx_LeaseTermPeriod_lbl_d86d72" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_LeaseTermPeriod_lbl_d86d72" xml:lang="en-US">Lease term period</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl_5adfd1" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases_lbl_5adfd1" xml:lang="en-US">Description of lease contract</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl_d0a6d6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl_d0a6d6" xml:lang="en-US">Annual base rent increased</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfAnnualIncreaseInRent" xlink:label="tenx_PercentageOfAnnualIncreaseInRent" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PercentageOfAnnualIncreaseInRent" xlink:to="tenx_PercentageOfAnnualIncreaseInRent_lbl_c9c440" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PercentageOfAnnualIncreaseInRent_lbl_c9c440" xml:lang="en-US">Percentage of annual increase in rent</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PppLoanAmount" xlink:label="tenx_PppLoanAmount" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PppLoanAmount" xlink:to="tenx_PppLoanAmount_lbl_f38540" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PppLoanAmount_lbl_f38540" xml:lang="en-US">PPP loan amount</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PppLoanMonthlyPayment" xlink:label="tenx_PppLoanMonthlyPayment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PppLoanMonthlyPayment" xlink:to="tenx_PppLoanMonthlyPayment_lbl_d4815d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PppLoanMonthlyPayment_lbl_d4815d" xml:lang="en-US">PPP loan, monthly payment</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl_07c1dc" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl_07c1dc" xml:lang="en-US">PPP loan term</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl_ae7a71" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl_ae7a71" xml:lang="en-US">Interest rate</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" xlink:to="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest_lbl_c73f7f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest_lbl_c73f7f" xml:lang="en-US">Accrued interest</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" xlink:label="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" xlink:to="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest_lbl_6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest_lbl_6" xml:lang="en-US">[Accrued interest]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl_6fd982" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl_6fd982" xml:lang="en-US">PPP loan - principal payable</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl_468f82" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl_468f82" xml:lang="en-US">Fair value of shares of Common Stock issued</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl_a12122" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl_a12122" xml:lang="en-US">Fair Value of Series B Convertible Preferred Stock issued at closing</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl_1cb303" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl_1cb303" xml:lang="en-US">Total fair value of consideration transferred</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl_224c1d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl_224c1d" xml:lang="en-US">Tangible assets acquired</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl_5b18f2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl_5b18f2" xml:lang="en-US">Accounts payable assumed</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl_6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl_6" xml:lang="en-US">[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl_158a6e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl_158a6e" xml:lang="en-US">Total identifiable net assets</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InProcessResearchAndDevelopmentExpense" xlink:label="tenx_InProcessResearchAndDevelopmentExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_InProcessResearchAndDevelopmentExpense" xlink:to="tenx_InProcessResearchAndDevelopmentExpense_lbl_798c7d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_InProcessResearchAndDevelopmentExpense_lbl_798c7d" xml:lang="en-US">IPR&D expense recognized</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl_c08d88" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl_c08d88" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl_cbb384" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBMember_lbl_cbb384" xml:lang="en-US">Series B [Member]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl_e83d67" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl_e83d67" xml:lang="en-US">Conversion of stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAcquired" xlink:label="tenx_CommonStockAcquired" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockAcquired" xlink:to="tenx_CommonStockAcquired_lbl_be77ea" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockAcquired_lbl_be77ea" xml:lang="en-US">Common stock acquired</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl_9c158d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl_9c158d" xml:lang="en-US">Stock issued for conversion</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfPreferredStockCarriesVotingRights" xlink:label="tenx_PercentageOfPreferredStockCarriesVotingRights" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PercentageOfPreferredStockCarriesVotingRights" xlink:to="tenx_PercentageOfPreferredStockCarriesVotingRights_lbl_94e101" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PercentageOfPreferredStockCarriesVotingRights_lbl_94e101" xml:lang="en-US">Percentage of Preferred Stock carries voting rights</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl_efeb05" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl_efeb05" xml:lang="en-US">Convertible preferred stock</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_SimdaxLicenseAgreementMember" xlink:to="tenx_SimdaxLicenseAgreementMember_lbl_102a97" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_SimdaxLicenseAgreementMember_lbl_102a97" xml:lang="en-US">Simdax License Agreement [Member]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl_ae85ca" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl_ae85ca" xml:lang="en-US">License Term period</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LicenseAgreementMaturityDate" xlink:label="tenx_LicenseAgreementMaturityDate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_LicenseAgreementMaturityDate" xlink:to="tenx_LicenseAgreementMaturityDate_lbl_1b9992" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_LicenseAgreementMaturityDate_lbl_1b9992" xml:lang="en-US">License agreement maturity date</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NonRefundableUpFrontPayment" xlink:label="tenx_NonRefundableUpFrontPayment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_NonRefundableUpFrontPayment" xlink:to="tenx_NonRefundableUpFrontPayment_lbl_8e2799" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_NonRefundableUpFrontPayment_lbl_8e2799" xml:lang="en-US">Non refundable up front payment</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrantPaidToAuthority" xlink:label="tenx_GrantPaidToAuthority" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_GrantPaidToAuthority" xlink:to="tenx_GrantPaidToAuthority_lbl_e312b1" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_GrantPaidToAuthority_lbl_e312b1" xml:lang="en-US">Grant paid to authority</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrantPaidToAuthorityOne" xlink:label="tenx_GrantPaidToAuthorityOne" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_GrantPaidToAuthorityOne" xlink:to="tenx_GrantPaidToAuthorityOne_lbl_38f7ef" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_GrantPaidToAuthorityOne_lbl_38f7ef" xml:lang="en-US">Grant paid to canadian authority</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NonRefundableCommercializationMilestonePayment" xlink:label="tenx_NonRefundableCommercializationMilestonePayment" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_NonRefundableCommercializationMilestonePayment" xlink:to="tenx_NonRefundableCommercializationMilestonePayment_lbl_f46dcb" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_NonRefundableCommercializationMilestonePayment_lbl_f46dcb" xml:lang="en-US">Non-refundable commercialization milestone payment</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_lbl_a150ab" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_lbl_a150ab" xml:lang="en-US">Number of warrants outstanding, beginning</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_lbl_2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_lbl_2" xml:lang="en-US">[Number of warrants outstanding, beginning]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl_936e14" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl_936e14" xml:lang="en-US">Number of warrants, exercised</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_lbl_c3edbc" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_lbl_c3edbc" xml:lang="en-US">Number of warrants outstanding, ending</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_16071e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_16071e" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_5" xml:lang="en-US">[Class of Warrant or Right, Exercise Price of Warrants or Rights]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl_e511c6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_lbl_e511c6" xml:lang="en-US">Weighted average exercise price, exercised</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_2078ec" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_2078ec" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="tenx_StockIncentivePlan2016Member" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockIncentivePlan2016Member" xlink:to="tenx_StockIncentivePlan2016Member_lbl_b16d4c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockIncentivePlan2016Member_lbl_b16d4c" xml:lang="en-US">2016 Stock Incentive Plan</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_dba82e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_dba82e" xml:lang="en-US">Shares available for grant, beginning</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_2" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant_lbl_f9c156" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant_lbl_f9c156" xml:lang="en-US">Shares available for grant, additional shares reserved</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_53b875" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_53b875" xml:lang="en-US">Shares available for grant, options granted</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_df4383" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_df4383" xml:lang="en-US">Shares available for grant, ending</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_15ffd9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_15ffd9" xml:lang="en-US">Number of options outstanding, beginning</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_caf00e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_caf00e" xml:lang="en-US">Shares available for grant, options granted</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_636b92" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_636b92" xml:lang="en-US">Number of options outstanding, ending</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_309be0" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_309be0" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_5" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_3b86ba" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_3b86ba" xml:lang="en-US">Weighted average exercise price granted</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_93b3c6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_93b3c6" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_e98404" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_e98404" xml:lang="en-US">Risk-free interest rate (weighted average)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_534b95" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_534b95" xml:lang="en-US">Expected volatility (weighted average)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_d3a57c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_d3a57c" xml:lang="en-US">Expected term (in years)</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_03c545" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_03c545" xml:lang="en-US">Expected dividend yield</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Amended1999StockPlanMember" xlink:label="tenx_Amended1999StockPlanMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_Amended1999StockPlanMember" xlink:to="tenx_Amended1999StockPlanMember_lbl_b666b8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_Amended1999StockPlanMember_lbl_b666b8" xml:lang="en-US">1999 Amended Stock Plan</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod_lbl_11ae97" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod_lbl_11ae97" xml:lang="en-US">Number of options cancelled</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_aad6d2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_aad6d2" xml:lang="en-US">Weighted average exercise price cancelled</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_54c79d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_54c79d" xml:lang="en-US">Related Party Transaction [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_922dd1" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_922dd1" xml:lang="en-US">Award Date [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl_e5ff2b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl_e5ff2b" xml:lang="en-US">Series B Preferred Stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InvestorsMember" xlink:label="tenx_InvestorsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_InvestorsMember" xlink:to="tenx_InvestorsMember_lbl_ea51b6" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_InvestorsMember_lbl_ea51b6" xml:lang="en-US">Investor [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MarchTwentyTwentyWarrantsMember" xlink:label="tenx_MarchTwentyTwentyWarrantsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_MarchTwentyTwentyWarrantsMember" xlink:to="tenx_MarchTwentyTwentyWarrantsMember_lbl_09fbfe" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_MarchTwentyTwentyWarrantsMember_lbl_09fbfe" xml:lang="en-US">March 2020 Warrants [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_July2020WarrantsMember" xlink:label="tenx_July2020WarrantsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_July2020WarrantsMember" xlink:to="tenx_July2020WarrantsMember_lbl_930610" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_July2020WarrantsMember_lbl_930610" xml:lang="en-US">July 2020 Warrants</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InducementStockOptionsMember" xlink:label="tenx_InducementStockOptionsMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_InducementStockOptionsMember" xlink:to="tenx_InducementStockOptionsMember_lbl_9a3d65" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_InducementStockOptionsMember_lbl_9a3d65" xml:lang="en-US">Inducement Stock Options</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantToPurchaseOfCommonStockExercisePrice" xlink:label="tenx_WarrantToPurchaseOfCommonStockExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_WarrantToPurchaseOfCommonStockExercisePrice" xlink:to="tenx_WarrantToPurchaseOfCommonStockExercisePrice_lbl_cc0da2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_WarrantToPurchaseOfCommonStockExercisePrice_lbl_cc0da2" xml:lang="en-US">Warrant to purchase of common stock exercise price</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl_548b45" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl_548b45" xml:lang="en-US">Warrant to purchase of common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" xlink:label="tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" xlink:to="tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock_lbl_42c798" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock_lbl_42c798" xml:lang="en-US">Concurrent private placement unregistered pre-funded warrants to purchas common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" xlink:to="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock_lbl_f589cf" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock_lbl_f589cf" xml:lang="en-US">Unregistered common stock warrants to purchase common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" xlink:to="tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds_lbl_5c02eb" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds_lbl_5c02eb" xml:lang="en-US">Unregistered common stock warrants to purchase gross proceeds</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredWarrantsExercisePrice" xlink:label="tenx_UnregisteredWarrantsExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredWarrantsExercisePrice" xlink:to="tenx_UnregisteredWarrantsExercisePrice_lbl_9b3e72" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnregisteredWarrantsExercisePrice_lbl_9b3e72" xml:lang="en-US">Unregistered warrants exercise price</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" xlink:label="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" xlink:to="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses_lbl_4e1711" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses_lbl_4e1711" xml:lang="en-US">Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl_c1f0f5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl_c1f0f5" xml:lang="en-US">Warrants outstanding</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_28e6e9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_28e6e9" xml:lang="en-US">Common stock upon the exercise of outstanding warrants issued, amount</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_fe1370" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_fe1370" xml:lang="en-US">Common stock upon the exercise of outstanding warrants issued, shares</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PrefundedWarrantsOutstanding" xlink:label="tenx_PrefundedWarrantsOutstanding" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PrefundedWarrantsOutstanding" xlink:to="tenx_PrefundedWarrantsOutstanding_lbl_88ab4c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PrefundedWarrantsOutstanding_lbl_88ab4c" xml:lang="en-US">Pre-funded Warrants outstanding</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_ab2c0c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_ab2c0c" xml:lang="en-US">Preferred stock, authorized</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockParOrStatedValuePerShares" xlink:to="tenx_CommonStockParOrStatedValuePerShares_lbl_a48334" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_CommonStockParOrStatedValuePerShares_lbl_a48334" xml:lang="en-US">Common stock, par value</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockParOrStatedValuePerShares" xlink:label="tenx_CommonStockParOrStatedValuePerShares" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockParOrStatedValuePerShares" xlink:to="tenx_CommonStockParOrStatedValuePerShares_lbl_14" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockParOrStatedValuePerShares_lbl_14" xml:lang="en-US">[Common stock, par value]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_302135" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_302135" xml:lang="en-US">Common stock, authorized</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockSharesIssue" xlink:to="tenx_CommonStockSharesIssue_lbl_9be5ca" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_CommonStockSharesIssue_lbl_9be5ca" xml:lang="en-US">Common stock, issued</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockSharesIssue" xlink:label="tenx_CommonStockSharesIssue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockSharesIssue" xlink:to="tenx_CommonStockSharesIssue_lbl_16" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockSharesIssue_lbl_16" xml:lang="en-US">[Common stock, issued]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_3ac89a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_3ac89a" xml:lang="en-US">Common stock, outstanding</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_3b8d0b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_3b8d0b" xml:lang="en-US">Net proceeds from underwritten offering</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_d83e9e" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_d83e9e" xml:lang="en-US">Underwritten offering of stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarranToPurchaseOfCommonStockTerm" xlink:label="tenx_WarranToPurchaseOfCommonStockTerm" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_WarranToPurchaseOfCommonStockTerm" xlink:to="tenx_WarranToPurchaseOfCommonStockTerm_lbl_df97be" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_WarranToPurchaseOfCommonStockTerm_lbl_df97be" xml:lang="en-US">Warrant to purchase of common stock term</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_1ef05c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_1ef05c" xml:lang="en-US">Preferred stock, par value</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_5314b9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_5314b9" xml:lang="en-US">Preferred stock, issued</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PreferredStockVotingRightsPercentage" xlink:label="tenx_PreferredStockVotingRightsPercentage" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PreferredStockVotingRightsPercentage" xlink:to="tenx_PreferredStockVotingRightsPercentage_lbl_c9ace9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PreferredStockVotingRightsPercentage_lbl_c9ace9" xml:lang="en-US">Preferred Stock voting rights percentage</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PreferredStockVotingRightsPercentage1" xlink:label="tenx_PreferredStockVotingRightsPercentage1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PreferredStockVotingRightsPercentage1" xlink:to="tenx_PreferredStockVotingRightsPercentage1_lbl_4b0639" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PreferredStockVotingRightsPercentage1_lbl_4b0639" xml:lang="en-US">Preferred Stock voting rights percentage 1</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_c44ba8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_c44ba8" xml:lang="en-US">Preferred stock, outstanding</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_dd8672" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_dd8672" xml:lang="en-US">Compensation expense</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl_2f81f5" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl_2f81f5" xml:lang="en-US">Number of shares of common stock authorized for issuance</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsGrantedVestingPeriod" xlink:label="tenx_StockOptionsGrantedVestingPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockOptionsGrantedVestingPeriod" xlink:to="tenx_StockOptionsGrantedVestingPeriod_lbl_11e9b9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockOptionsGrantedVestingPeriod_lbl_11e9b9" xml:lang="en-US">Stock options granted, vesting period</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl_115f4f" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl_115f4f" xml:lang="en-US">Stock options granted, term</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_a884a2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_a884a2" xml:lang="en-US">Unrecognized compensation costs</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsGrantedFairMarketValuePercentage" xlink:label="tenx_StockOptionsGrantedFairMarketValuePercentage" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockOptionsGrantedFairMarketValuePercentage" xlink:to="tenx_StockOptionsGrantedFairMarketValuePercentage_lbl_f375cf" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockOptionsGrantedFairMarketValuePercentage_lbl_f375cf" xml:lang="en-US">Stock options granted fair market value percentage</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockConvertibleIntoAggregateSharesOfCommonStock" xlink:label="tenx_StockConvertibleIntoAggregateSharesOfCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockConvertibleIntoAggregateSharesOfCommonStock" xlink:to="tenx_StockConvertibleIntoAggregateSharesOfCommonStock_lbl_cbabb2" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockConvertibleIntoAggregateSharesOfCommonStock_lbl_cbabb2" xml:lang="en-US">Stock convertible into an aggregate shares of common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RightsPreferencesAndPrivilegesConversionIntoShare" xlink:label="tenx_RightsPreferencesAndPrivilegesConversionIntoShare" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_RightsPreferencesAndPrivilegesConversionIntoShare" xlink:to="tenx_RightsPreferencesAndPrivilegesConversionIntoShare_lbl_63abdb" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_RightsPreferencesAndPrivilegesConversionIntoShare_lbl_63abdb" xml:lang="en-US">Rights, preferences and privileges conversion into share</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RightsPreferencesAndPrivilegesConversionIntoShare1" xlink:label="tenx_RightsPreferencesAndPrivilegesConversionIntoShare1" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_RightsPreferencesAndPrivilegesConversionIntoShare1" xlink:to="tenx_RightsPreferencesAndPrivilegesConversionIntoShare1_lbl_aaab48" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_RightsPreferencesAndPrivilegesConversionIntoShare1_lbl_aaab48" xml:lang="en-US">Rights, preferences and privileges conversion into share 1</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl_e767cd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl_e767cd" xml:lang="en-US">Preferred stock voting rights</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedCommonStock" xlink:label="tenx_FairValueAllocatedCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_FairValueAllocatedCommonStock" xlink:to="tenx_FairValueAllocatedCommonStock_lbl_ffab30" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_FairValueAllocatedCommonStock_lbl_ffab30" xml:lang="en-US">Fair value allocated common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedPrefundedWarrants" xlink:label="tenx_FairValueAllocatedPrefundedWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_FairValueAllocatedPrefundedWarrants" xlink:to="tenx_FairValueAllocatedPrefundedWarrants_lbl_3a0afd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_FairValueAllocatedPrefundedWarrants_lbl_3a0afd" xml:lang="en-US">Fair value allocated pre-funded warrants</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedWarrants" xlink:label="tenx_FairValueAllocatedWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_FairValueAllocatedWarrants" xlink:to="tenx_FairValueAllocatedWarrants_lbl_9c1177" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_FairValueAllocatedWarrants_lbl_9c1177" xml:lang="en-US">Fair value allocated warrants</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl_93c9d8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl_93c9d8" xml:lang="en-US">Fair value of warrants</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_WarrantToPurchaseOfCommonStockTerm" xlink:to="tenx_WarrantToPurchaseOfCommonStockTerm_lbl_c85a13" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_WarrantToPurchaseOfCommonStockTerm_lbl_c85a13" xml:lang="en-US">Warrant to purchase of common stock term</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantToPurchaseOfCommonStockTerm" xlink:label="tenx_WarrantToPurchaseOfCommonStockTerm" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_WarrantToPurchaseOfCommonStockTerm" xlink:to="tenx_WarrantToPurchaseOfCommonStockTerm_lbl_40" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_WarrantToPurchaseOfCommonStockTerm_lbl_40" xml:lang="en-US">[Warrant to purchase of common stock term]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueofWarrantIssuedForServices" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServices" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_EstimatedFairValueofWarrantIssuedForServices" xlink:to="tenx_EstimatedFairValueofWarrantIssuedForServices_lbl_5d796b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServices_lbl_5d796b" xml:lang="en-US">Estimated fair valueof warrant issued for services</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" xlink:label="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" xlink:to="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock_lbl_386026" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock_lbl_386026" xml:lang="en-US">Issued underwriter warrant to purchase common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" xlink:label="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" xlink:to="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice_lbl_efe565" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice_lbl_efe565" xml:lang="en-US">Underwriter warrant to purchase common stock exercise price</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" xlink:label="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" xlink:to="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue_lbl_082043" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue_lbl_082043" xml:lang="en-US">Underwriter warrant to purchase common stock estimated fair value</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" xlink:label="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" xlink:to="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants_lbl_c0475a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants_lbl_c0475a" xml:lang="en-US">Common stock upon the cashless exercise of previously outstanding placement agent warrants</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" xlink:to="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2_lbl_87e423" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2_lbl_87e423" xml:lang="en-US">Unregistered common stock warrants to purchase common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" xlink:to="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2_lbl_46" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2_lbl_46" xml:lang="en-US">[Unregistered common stock warrants to purchase common stock]</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_EstimatedFairValueofWarrantIssuedForServicese" xlink:to="tenx_EstimatedFairValueofWarrantIssuedForServicese_lbl_989a55" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServicese_lbl_989a55" xml:lang="en-US">Estimated fair valueof warrant issued for services</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueofWarrantIssuedForServicese" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServicese" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_EstimatedFairValueofWarrantIssuedForServicese" xlink:to="tenx_EstimatedFairValueofWarrantIssuedForServicese_lbl_47" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServicese_lbl_47" xml:lang="en-US">[Estimated fair valueof warrant issued for services]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl_ff0f25" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl_ff0f25" xml:lang="en-US">Stock option award granted</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_d3cc3b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_d3cc3b" xml:lang="en-US">Stock options exercise price</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl_a7a5bb" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl_a7a5bb" xml:lang="en-US">Stock options exercise term</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsDescription" xlink:label="tenx_StockOptionsDescription" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_StockOptionsDescription" xlink:to="tenx_StockOptionsDescription_lbl_cbc6aa" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_StockOptionsDescription_lbl_cbc6aa" xml:lang="en-US">Stock options description</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueOfInducementStockOptionAwardGranted" xlink:label="tenx_EstimatedFairValueOfInducementStockOptionAwardGranted" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_EstimatedFairValueOfInducementStockOptionAwardGranted" xlink:to="tenx_EstimatedFairValueOfInducementStockOptionAwardGranted_lbl_5b7158" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_EstimatedFairValueOfInducementStockOptionAwardGranted_lbl_5b7158" xml:lang="en-US">Estimated fair value of the inducement stock option award granted</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_f11b5c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_f11b5c" xml:lang="en-US">Risk-free interest rate</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_DividendYield" xlink:label="tenx_DividendYield" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_DividendYield" xlink:to="tenx_DividendYield_lbl_18f041" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_DividendYield_lbl_18f041" xml:lang="en-US">Dividend yield</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_8c7ab8" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_8c7ab8" xml:lang="en-US">Vvolatility factor rate</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_8e540b" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_8e540b" xml:lang="en-US">Expected life</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_78d855" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_78d855" xml:lang="en-US">Subsequent Event Type [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_60a115" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_60a115" xml:lang="en-US">Related Party [Axis]</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_d5405d" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_d5405d" xml:lang="en-US">Subsequent Event [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PurchaseAgreementMember" xlink:label="tenx_PurchaseAgreementMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PurchaseAgreementMember" xlink:to="tenx_PurchaseAgreementMember_lbl_6f8639" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PurchaseAgreementMember_lbl_6f8639" xml:lang="en-US">Purchase Agreement [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RegistrationRightsAgreementMember" xlink:label="tenx_RegistrationRightsAgreementMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_RegistrationRightsAgreementMember" xlink:to="tenx_RegistrationRightsAgreementMember_lbl_ca34b3" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_RegistrationRightsAgreementMember_lbl_ca34b3" xml:lang="en-US">Registration Rights Agreement [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SeparationAgreementMember" xlink:label="tenx_SeparationAgreementMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_SeparationAgreementMember" xlink:to="tenx_SeparationAgreementMember_lbl_9d7f85" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_SeparationAgreementMember_lbl_9d7f85" xml:lang="en-US">Separation Agreement [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MrDitonnoMember" xlink:label="tenx_MrDitonnoMember" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_MrDitonnoMember" xlink:to="tenx_MrDitonnoMember_lbl_07ae06" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_MrDitonnoMember_lbl_07ae06" xml:lang="en-US">Mr Ditonno [Member]</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MaturityPeriod" xlink:label="tenx_MaturityPeriod" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_MaturityPeriod" xlink:to="tenx_MaturityPeriod_lbl_6c0657" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_MaturityPeriod_lbl_6c0657" xml:lang="en-US">Maturity period</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_72e55a" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl_72e55a" xml:lang="en-US">Stock issued</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PurchasePriceOfStock" xlink:label="tenx_PurchasePriceOfStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PurchasePriceOfStock" xlink:to="tenx_PurchasePriceOfStock_lbl_b40dbd" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PurchasePriceOfStock_lbl_b40dbd" xml:lang="en-US">Purchase price of stock</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_CommonStockParOrStatedValuePerShares" xlink:to="tenx_CommonStockParOrStatedValuePerShares_lbl_0f9592" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tenx_CommonStockParOrStatedValuePerShares_lbl_0f9592" xml:lang="en-US">Common stock, par value</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredPreFundedWarrants" xlink:label="tenx_UnregisteredPreFundedWarrants" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredPreFundedWarrants" xlink:to="tenx_UnregisteredPreFundedWarrants_lbl_775c47" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnregisteredPreFundedWarrants_lbl_775c47" xml:lang="en-US">Unregistered pre funded warrants</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ProceedsFromOffering" xlink:label="tenx_ProceedsFromOffering" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_ProceedsFromOffering" xlink:to="tenx_ProceedsFromOffering_lbl_6dec6c" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_ProceedsFromOffering_lbl_6dec6c" xml:lang="en-US">Proceeds from offering</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_438458" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_438458" xml:lang="en-US">Exercise price warrant</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" xlink:label="tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" xlink:to="tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock_lbl_551c40" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock_lbl_551c40" xml:lang="en-US">Unregistered Warrant has an exercise price per share of common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfGrossProceedReceived" xlink:label="tenx_PercentageOfGrossProceedReceived" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PercentageOfGrossProceedReceived" xlink:to="tenx_PercentageOfGrossProceedReceived_lbl_770639" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PercentageOfGrossProceedReceived_lbl_770639" xml:lang="en-US">Percentage of gross proceed received</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantIssuedToPurchaseCommonStock" xlink:label="tenx_WarrantIssuedToPurchaseCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_WarrantIssuedToPurchaseCommonStock" xlink:to="tenx_WarrantIssuedToPurchaseCommonStock_lbl_3ba197" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_WarrantIssuedToPurchaseCommonStock_lbl_3ba197" xml:lang="en-US">Warrant issued to purchase common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfOfferingPricePerShareOfCommonStock" xlink:label="tenx_PercentageOfOfferingPricePerShareOfCommonStock" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_PercentageOfOfferingPricePerShareOfCommonStock" xlink:to="tenx_PercentageOfOfferingPricePerShareOfCommonStock_lbl_243ca7" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_PercentageOfOfferingPricePerShareOfCommonStock_lbl_243ca7" xml:lang="en-US">Percentage of offering price per share of common stock</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_dvddv" xlink:label="tenx_dvddv" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_dvddv" xlink:to="tenx_dvddv_lbl_6d2b06" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_dvddv_lbl_6d2b06" xml:lang="en-US">Stock option granted</link:label> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SeveranceReceived" xlink:label="tenx_SeveranceReceived" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tenx_SeveranceReceived" xlink:to="tenx_SeveranceReceived_lbl_6b99a9" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tenx_SeveranceReceived_lbl_6b99a9" xml:lang="en-US">Severance received</link:label> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" /> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_4af803" xlink:type="arc" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl_4af803" xml:lang="en-US">Legal expenses</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_RightsPreferencesAndPrivilegesConversionIntoShare" xlink:to="tenx_RightsPreferencesAndPrivilegesConversionIntoShare_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_RightsPreferencesAndPrivilegesConversionIntoShare_d">Rights, preferences and privileges conversion into share.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" xlink:to="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock_d">Unregistered common stock warrants to purchase common stock.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" xlink:to="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses_d">Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_StockOptionsDescription" xlink:to="tenx_StockOptionsDescription_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_StockOptionsDescription_d">Stock options description.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_StockOptionsGrantedVestingPeriod" xlink:to="tenx_StockOptionsGrantedVestingPeriod_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_StockOptionsGrantedVestingPeriod_d">Stock options granted, vesting period</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_UnregisteredWarrantsExercisePrice" xlink:to="tenx_UnregisteredWarrantsExercisePrice_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_UnregisteredWarrantsExercisePrice_d">Unregistered warrants exercise price.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" xlink:to="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_IssuedUnderwriterWarrantTopurchaseCommonStock_d">Issued underwriter warrant to purchase common stock.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_EstimatedFairValueofWarrantIssuedForServices" xlink:to="tenx_EstimatedFairValueofWarrantIssuedForServices_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServices_d">Estimated fair valueof warrant issued for services.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_WarrantToPurchaseOfCommonStockTerm" xlink:to="tenx_WarrantToPurchaseOfCommonStockTerm_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_WarrantToPurchaseOfCommonStockTerm_d">Warrant to purchase of common stock term.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_EstimatedFairValueofWarrantIssuedForServicese" xlink:to="tenx_EstimatedFairValueofWarrantIssuedForServicese_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_EstimatedFairValueofWarrantIssuedForServicese_d">Estimated fair valueof warrant issued for services.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" xlink:to="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice_d">Underwriter warrant to purchase common stock exercise price.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" xlink:to="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue_d">Underwriter warrant to purchase common stock estimated fair value.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" xlink:to="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants_d">Common stock upon the cashless exercise of previously outstanding placement agent warrants.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_WarrantToPurchaseOfCommonStockExercisePrice" xlink:to="tenx_WarrantToPurchaseOfCommonStockExercisePrice_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_WarrantToPurchaseOfCommonStockExercisePrice_d">Exercise price per share or per unit of warrants or rights outstanding.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_CommonStockParOrStatedValuePerShares" xlink:to="tenx_CommonStockParOrStatedValuePerShares_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_CommonStockParOrStatedValuePerShares_d">Face amount or stated value per share of common stock.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_CommonStockSharesIssue" xlink:to="tenx_CommonStockSharesIssue_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_CommonStockSharesIssue_d">Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_d">Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_d">Number of non-option equity instruments exercised by participants.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_GrossUnrealizedLosses" xlink:to="tenx_GrossUnrealizedLosses_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_GrossUnrealizedLosses_d">Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_LessImputedInterest" xlink:to="tenx_LessImputedInterest_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_LessImputedInterest_d">Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_MaturityPeriod" xlink:to="tenx_MaturityPeriod_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_MaturityPeriod_d">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_ProceedsFromOffering" xlink:to="tenx_ProceedsFromOffering_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_ProceedsFromOffering_d">The cash inflow from the additional capital contribution to the entity.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_RemainingLeaseTerm" xlink:to="tenx_RemainingLeaseTerm_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_RemainingLeaseTerm_d">Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" xlink:to="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod_d">The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_LeaseTermPeriod" xlink:to="tenx_LeaseTermPeriod_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_LeaseTermPeriod_d">Term of the lessor's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" xlink:to="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds_d">The total amount of proceeds received for the sale of securities, categorized neither as held-to-maturity nor trading securities, during the reporting period.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_LicenseAgreementMaturityDate" xlink:to="tenx_LicenseAgreementMaturityDate_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_LicenseAgreementMaturityDate_d">Date the pending litigation matter was dismissed, in CCYY-MM-DD format.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_PppLoanAmount" xlink:to="tenx_PppLoanAmount_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_PppLoanAmount_d">Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_PppLoanMonthlyPayment" xlink:to="tenx_PppLoanMonthlyPayment_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_PppLoanMonthlyPayment_d">Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</link:label> <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" xlink:to="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest_d" /> <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="tenx_DebtInstrumentDecreaseForgivenessAccruedInterest_d">Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</link:label> </link:labelLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>11 <FILENAME>tenx-20210630_pre.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii" standalone="yes"?> <!--XBRL Document Created with XBRLMaster--> <!--Version: 2.3.08--> <!--Based on XBRL 2.1--> <!--Date of creation: 08/16/2021--> <!--Software architectural design and coding: Dipendra K. Singh--> <!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <link:roleRef roleURI="http://tenaxthera.com/role/Cover" xlink:href="tenx-20210630.xsd#Cover" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tenx-20210630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="tenx-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="tenx-20210630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/DescriptionOfBusiness" xlink:href="tenx-20210630.xsd#DescriptionOfBusiness" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValue" xlink:href="tenx-20210630.xsd#FairValue" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponents" xlink:href="tenx-20210630.xsd#BalanceSheetComponents" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LEASE" xlink:href="tenx-20210630.xsd#LEASE" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/NotesPayable" xlink:href="tenx-20210630.xsd#NotesPayable" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MERGER" xlink:href="tenx-20210630.xsd#MERGER" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CommitmentsAndContingencies" xlink:href="tenx-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquity" xlink:href="tenx-20210630.xsd#StockholdersEquity" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SubsequentEvents" xlink:href="tenx-20210630.xsd#SubsequentEvents" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueTables" xlink:href="tenx-20210630.xsd#FairValueTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsTables" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseTables" xlink:href="tenx-20210630.xsd#LeaseTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerTables" xlink:href="tenx-20210630.xsd#MergerTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityTables" xlink:href="tenx-20210630.xsd#StockholdersEquityTables" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tenx-20210630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueDetails" xlink:href="tenx-20210630.xsd#FairValueDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/FairValueDetails1" xlink:href="tenx-20210630.xsd#FairValueDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" xlink:href="tenx-20210630.xsd#BalanceSheetComponentsDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetails" xlink:href="tenx-20210630.xsd#LeaseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetails1" xlink:href="tenx-20210630.xsd#LeaseDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/LeaseDetailsNarrative" xlink:href="tenx-20210630.xsd#LeaseDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/NotesPayableDetailsNarrative" xlink:href="tenx-20210630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerDetails" xlink:href="tenx-20210630.xsd#MergerDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/MergerDetailsNarrative" xlink:href="tenx-20210630.xsd#MergerDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="tenx-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails1" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails1" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails2" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails2" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails3" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails3" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetails4" xlink:href="tenx-20210630.xsd#StockholdersEquityDetails4" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" xlink:href="tenx-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" /> <link:roleRef roleURI="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" xlink:href="tenx-20210630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" /> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information"> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" /> <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" /> <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" /> <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" /> <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" /> <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" /> <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" /> <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" /> <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" /> <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" /> <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" /> <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" /> <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" /> <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" /> <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" /> <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" /> <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" /> <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" /> <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" /> <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" /> <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" /> <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" /> <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" /> <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" /> <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" /> <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" /> <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" /> <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" /> <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" /> <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" /> <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" xlink:title="000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_c90baa" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_16b550" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c90baa" xlink:to="loc_us-gaapAssetsAbstract_16b550" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_0e6379" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_16b550" xlink:to="loc_us-gaapAssetsCurrentAbstract_0e6379" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_dfbda9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_dfbda9" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_c019c8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_c019c8" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_eeee2a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapPrepaidExpenseCurrent_eeee2a" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_862cc2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapAssetsCurrent_862cc2" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_25820f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_25820f" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_fcfefe" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_fcfefe" order="8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_c73961" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapOtherAssetsNoncurrent_c73961" order="9" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_3ac9da" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapAssets_3ac9da" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_8eef9b" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_0e6379" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_8eef9b" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_8eef9b" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" order="12" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_79b2e7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" xlink:to="loc_us-gaapAccountsPayableCurrent_79b2e7" order="13" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_da670c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_da670c" order="14" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_6f0a2d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" xlink:to="loc_us-gaapNotesPayableCurrent_6f0a2d" order="15" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_c91cc9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" xlink:to="loc_us-gaapLiabilitiesCurrent_c91cc9" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e7c603" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" order="17" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_f2c168" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_f2c168" order="18" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_be3211" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" xlink:to="loc_us-gaapNotesPayable_be3211" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_2264b7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" xlink:to="loc_us-gaapLiabilitiesNoncurrent_2264b7" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_e771cc" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" xlink:to="loc_us-gaapLiabilities_e771cc" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_89c869" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" xlink:to="loc_us-gaapCommitmentsAndContingencies_89c869" order="22" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_6f064e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_fe0af4" xlink:to="loc_us-gaapStockholdersEquityAbstract_6f064e" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_df23a8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapPreferredStockValue_df23a8" order="24" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_9590ef" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapCommonStockValue_9590ef" order="25" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_f6645d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_f6645d" order="26" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_afbffa" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_afbffa" order="27" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_bb78fc" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_bb78fc" order="28" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_53118e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapStockholdersEquity_53118e" order="29" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_cac30d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f064e" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_cac30d" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_bcabec" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7cdbbd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_bcabec" xlink:to="loc_us-gaapStatementTable_7cdbbd" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_46bde8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7cdbbd" xlink:to="loc_us-gaapStatementLineItems_46bde8" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_f8658c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7cdbbd" xlink:to="loc_us-gaapStatementClassOfStockAxis_f8658c" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_276234" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_f8658c" xlink:to="loc_us-gaapClassOfStockDomain_276234" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_1c19ba" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_276234" xlink:to="loc_us-gaapSeriesAPreferredStockMember_1c19ba" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_6f9f8f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46bde8" xlink:to="loc_us-gaapStockholdersEquityAbstract_6f9f8f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_fa93c5" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_fa93c5" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_407ce0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_407ce0" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_c2b42d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapCommonStockSharesAuthorized_c2b42d" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_6bd3f0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapCommonStockSharesIssued_6bd3f0" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_ba00f0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapCommonStockSharesOutstanding_ba00f0" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_d67be1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_d67be1" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_5e38b4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapPreferredStockSharesIssued_5e38b4" order="8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_799fb4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_6f9f8f" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_799fb4" order="9" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:title="000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_0d8f17" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_181bb2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_0d8f17" xlink:to="loc_us-gaapOperatingExpensesAbstract_181bb2" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_e26916" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_e26916" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_d6702f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_d6702f" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_f42f5d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapOperatingExpenses_f42f5d" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_9eb47b" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapOperatingIncomeLoss_9eb47b" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_a8355e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapInterestIncomeExpenseNet_a8355e" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_7d4091" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_7d4091" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_1c63f0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapNetIncomeLoss_1c63f0" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss_6b09af" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss_6b09af" order="9" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_d686fe" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_d686fe" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_995bc7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_995bc7" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_f06e39" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_181bb2" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_f06e39" order="12" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_3003cd" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_328f92" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_3003cd" xlink:to="loc_us-gaapStatementTable_328f92" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f4a02a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_328f92" xlink:to="loc_us-gaapStatementLineItems_f4a02a" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_38e8f5" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_328f92" xlink:to="loc_us-gaapStatementEquityComponentsAxis_38e8f5" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_a0cf85" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_38e8f5" xlink:to="loc_us-gaapEquityComponentDomain_a0cf85" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_321dfb" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a0cf85" xlink:to="loc_us-gaapPreferredStockMember_321dfb" order="21" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStocksMember" xlink:label="loc_tenxCommonStocksMember_94cbd4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a0cf85" xlink:to="loc_tenxCommonStocksMember_94cbd4" order="22" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_cdf23c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a0cf85" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_cdf23c" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_1255fa" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a0cf85" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_1255fa" order="24" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_88850a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_a0cf85" xlink:to="loc_us-gaapRetainedEarningsMember_88850a" order="25" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_d6362d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_us-gaapSharesIssued_d6362d" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_8da3d9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_us-gaapStockholdersEquity_8da3d9" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares" xlink:label="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares_c1ad65" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares_c1ad65" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount" xlink:label="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount_d1e475" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount_d1e475" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CompensationOnOptionsIssued" xlink:label="loc_tenxCompensationOnOptionsIssued_d660e0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCompensationOnOptionsIssued_d660e0" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForServicesRenderedShares" xlink:label="loc_tenxCommonStockIssuedForServicesRenderedShares_16fa4f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockIssuedForServicesRenderedShares_16fa4f" order="6" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForServicesRenderedAmount" xlink:label="loc_tenxCommonStockIssuedForServicesRenderedAmount_90ffa1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockIssuedForServicesRenderedAmount_90ffa1" order="7" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForConvertiblePreferredStockShares" xlink:label="loc_tenxCommonStockIssuedForConvertiblePreferredStockShares_657f1e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockIssuedForConvertiblePreferredStockShares_657f1e" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockIssuedForConvertiblePreferredStockAmount" xlink:label="loc_tenxCommonStockIssuedForConvertiblePreferredStockAmount_a47bc2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockIssuedForConvertiblePreferredStockAmount_a47bc2" order="9" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ExerciseOfPreFundedWarrantsShares" xlink:label="loc_tenxExerciseOfPreFundedWarrantsShares_364d66" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxExerciseOfPreFundedWarrantsShares_364d66" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ExerciseOfPreFundedWarrantsAmount" xlink:label="loc_tenxExerciseOfPreFundedWarrantsAmount_d92f32" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxExerciseOfPreFundedWarrantsAmount_d92f32" order="11" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnrealizedLossOnMarketableSecurities" xlink:label="loc_tenxUnrealizedLossOnMarketableSecurities_ddc831" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxUnrealizedLossOnMarketableSecurities_ddc831" order="12" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_e4978d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_us-gaapNetIncomeLoss_e4978d" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_tenxStockIssuedDuringPeriodSharesWarrantsExercised_814f7a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxStockIssuedDuringPeriodSharesWarrantsExercised_814f7a" order="14" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_tenxStockIssuedDuringPeriodValueWarrantsExercised_496e53" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxStockIssuedDuringPeriodValueWarrantsExercised_496e53" order="15" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnrealizedGainOnMarketableSecurities" xlink:label="loc_tenxUnrealizedGainOnMarketableSecurities_4a5d4a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxUnrealizedGainOnMarketableSecurities_4a5d4a" order="16" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares" xlink:label="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionShares_0bb956" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionShares_0bb956" order="17" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount" xlink:label="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionAmount_696f0e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_tenxCommonStockAndPreferredStockIssuedForAssetAcquisitionAmount_696f0e" order="18" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_1924b3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_us-gaapSharesIssued_1924b3" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_f96ad8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f4a02a" xlink:to="loc_us-gaapStockholdersEquity_f96ad8" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_f4df5e" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_e82558" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f4df5e" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_e82558" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_10f551" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_e82558" xlink:to="loc_us-gaapProfitLoss_10f551" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_e82558" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_b4afef" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_us-gaapDepreciationAndAmortization_b4afef" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable_4f8b24" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_us-gaapIncreaseDecreaseInInterestAndDividendsReceivable_4f8b24" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="loc_us-gaapAmortizationOfLeasedAsset_0bace3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_us-gaapAmortizationOfLeasedAsset_0bace3" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_abe374" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_abe374" order="7" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition" xlink:label="loc_tenxIssuanceOfCommonStockAndPreferredStockForAssetAcquisition_fff038" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_tenxIssuanceOfCommonStockAndPreferredStockForAssetAcquisition_fff038" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants" xlink:label="loc_tenxIssuanceAndVestingOfCompensatoryStockOptionsAndWarrants_c59cf0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_tenxIssuanceAndVestingOfCompensatoryStockOptionsAndWarrants_c59cf0" order="9" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_eecab3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_eecab3" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AmortizationOfPremiumOnMarketableSecurities" xlink:label="loc_tenxAmortizationOfPremiumOnMarketableSecurities_3b62af" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_tenxAmortizationOfPremiumOnMarketableSecurities_3b62af" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eec472" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" order="12" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ffce25" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ffce25" order="13" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_de2c57" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_de2c57" order="14" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities_5f223e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities_5f223e" order="15" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_3ecfb2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_3ecfb2" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d59784" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" order="17" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities_bb93e5" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities_bb93e5" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SaleOfMarketableSecurities" xlink:label="loc_tenxSaleOfMarketableSecurities_f2263e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" xlink:to="loc_tenxSaleOfMarketableSecurities_f2263e" order="19" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_629b58" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_629b58" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_35c999" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_35c999" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_cd91bd" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" order="22" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_5bfe52" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapProceedsFromWarrantExercises_5bfe52" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_238341" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_238341" order="24" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes_822774" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapProceedsFromIssuanceOfMediumTermNotes_822774" order="25" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_a1c9b4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_a1c9b4" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_49415a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_49415a" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_709cb1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_709cb1" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_76c4b8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_76c4b8" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_f421af" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_f9ce87" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_f421af" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f3366" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_f421af" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f3366" order="31" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/DescriptionOfBusiness" xlink:title="000007 - Disclosure - DESCRIPTION OF BUSINESS"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7843b0" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock_79a02e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7843b0" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock_79a02e" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_439232" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_07fa81" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_439232" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_07fa81" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValue" xlink:title="000009 - Disclosure - FAIR VALUE"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_4702cd" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_3aa622" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_4702cd" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_3aa622" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponents" xlink:title="000010 - Disclosure - BALANCE SHEET COMPONENTS"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_050389" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock_0f9e38" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_050389" xlink:to="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock_0f9e38" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LEASE" xlink:title="000011 - Disclosure - LEASE"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_74e57a" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock_c3a0f2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_74e57a" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock_c3a0f2" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/NotesPayable" xlink:title="000012 - Disclosure - NOTES PAYABLE"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract_f02c1e" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock_9611f3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_f02c1e" xlink:to="loc_us-gaapDebtDisclosureTextBlock_9611f3" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MERGER" xlink:title="000013 - Disclosure - MERGER"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract_ebf40c" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock_f97961" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_ebf40c" xlink:to="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock_f97961" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CommitmentsAndContingencies" xlink:title="000014 - Disclosure - COMMITMENTS AND CONTINGENCIES"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_6c678f" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_51039c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_6c678f" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_51039c" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquity" xlink:title="000015 - Disclosure - STOCKHOLDERS EQUITY"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_243d34" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_b06af3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_243d34" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_b06af3" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SubsequentEvents" xlink:title="000016 - Disclosure - SUBSEQUENT EVENTS"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_b470d4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_bbed09" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_b470d4" xlink:to="loc_us-gaapSubsequentEventsTextBlock_bbed09" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_915637" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_52cbf9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_52cbf9" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_9b5f77" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_9b5f77" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_27c8da" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapUseOfEstimates_27c8da" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_60c0ee" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_60c0ee" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LiquidityAndManagementsPlanPolicyTextBlock" xlink:label="loc_tenxLiquidityAndManagementsPlanPolicyTextBlock_98bef8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_tenxLiquidityAndManagementsPlanPolicyTextBlock_98bef8" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Covid19ImpactPolicyTextBlock" xlink:label="loc_tenxCovid19ImpactPolicyTextBlock_6c25b2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_tenxCovid19ImpactPolicyTextBlock_6c25b2" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_41e03d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_41e03d" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_8fa3a7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_8fa3a7" order="8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_d553db" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_915637" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_d553db" order="9" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_9247a0" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc3000" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_9247a0" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc3000" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueTables" xlink:title="000019 - Disclosure - FAIR VALUE (Tables)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_320371" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ScheduleOfInvestmentsInMarketableSecurities" xlink:label="loc_tenxScheduleOfInvestmentsInMarketableSecurities_850e1f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_320371" xlink:to="loc_tenxScheduleOfInvestmentsInMarketableSecurities_850e1f" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock_559dae" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_320371" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock_559dae" order="2" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsTables" xlink:title="000020 - Disclosure - BALANCE SHEET COMPONENTS (Tables)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_72f89d" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_bf1be7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_72f89d" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_bf1be7" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock_6edd9f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_72f89d" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock_6edd9f" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseTables" xlink:title="000021 - Disclosure - LEASE (Tables)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_3dd4e0" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock_3133bb" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_3dd4e0" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock_3133bb" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_f50d0c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_3dd4e0" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_f50d0c" order="2" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerTables" xlink:title="000022 - Disclosure - MERGER (Tables)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract_4e97d5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_420343" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_4e97d5" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_420343" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityTables" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Tables)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_ef97c6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7664f1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ef97c6" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7664f1" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SharesAvailableForGrantTableTextblock" xlink:label="loc_tenxSharesAvailableForGrantTableTextblock_571999" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ef97c6" xlink:to="loc_tenxSharesAvailableForGrantTableTextblock_571999" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_45469e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ef97c6" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_45469e" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_887372" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ef97c6" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_887372" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_OutstandingStockOptionsUnderPlanTableTextBlock" xlink:label="loc_tenxOutstandingStockOptionsUnderPlanTableTextBlock_bf78e4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ef97c6" xlink:to="loc_tenxOutstandingStockOptionsUnderPlanTableTextBlock_bf78e4" order="5" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_d2cca1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3e9a9f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_d2cca1" xlink:to="loc_us-gaapStatementTable_3e9a9f" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d49bee" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3e9a9f" xlink:to="loc_us-gaapStatementLineItems_d49bee" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_05025e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3e9a9f" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_05025e" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_c3fd3c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_05025e" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_c3fd3c" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_223901" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3e9a9f" xlink:to="loc_us-gaapPlanNameAxis_223901" order="40" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_18a159" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_223901" xlink:to="loc_us-gaapPlanNameDomain_18a159" order="40" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarranttoPurchaseCommonStockMember" xlink:label="loc_tenxWarranttoPurchaseCommonStockMember_8bcac9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c3fd3c" xlink:to="loc_tenxWarranttoPurchaseCommonStockMember_8bcac9" order="41" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SimdaxLicenseAgreementMember" xlink:label="loc_tenxSimdaxLicenseAgreementMember_f77c10" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_18a159" xlink:to="loc_tenxSimdaxLicenseAgreementMember_f77c10" order="42" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ConvertiblePreferredSharesOutstandingMember" xlink:label="loc_tenxConvertiblePreferredSharesOutstandingMember_be9eb7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c3fd3c" xlink:to="loc_tenxConvertiblePreferredSharesOutstandingMember_be9eb7" order="43" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PrefundedWarrantsToPurchaseCommonStockMember" xlink:label="loc_tenxPrefundedWarrantsToPurchaseCommonStockMember_759cfa" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_c3fd3c" xlink:to="loc_tenxPrefundedWarrantsToPurchaseCommonStockMember_759cfa" order="44" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_810a68" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d49bee" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_810a68" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_8b6603" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_7c8d8a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_7c8d8a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_b80d47" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_b80d47" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_486b7f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_486b7f" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_419763" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapStockholdersEquity_419763" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:label="loc_us-gaapStockholdersEquityBeforeTreasuryStock_030ad2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapStockholdersEquityBeforeTreasuryStock_030ad2" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities_f9904f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapMarketableSecurities_f9904f" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="loc_us-gaapPartnersCapitalAccountUnitsSoldInPrivatePlacement_0e4eb5" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapPartnersCapitalAccountUnitsSoldInPrivatePlacement_0e4eb5" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaapAcceleratedShareRepurchasesInitialPricePaidPerShare_deb2f8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_us-gaapAcceleratedShareRepurchasesInitialPricePaidPerShare_deb2f8" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds" xlink:label="loc_tenxAvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds_cf9ca4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8b6603" xlink:to="loc_tenxAvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds_cf9ca4" order="9" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueDetails" xlink:title="000026 - Disclosure - FAIR VALUE (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_e11261" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_de0d31" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e11261" xlink:to="loc_us-gaapStatementTable_de0d31" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b3a754" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_de0d31" xlink:to="loc_us-gaapStatementLineItems_b3a754" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_d38d0e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_de0d31" xlink:to="loc_us-gaapFinancialInstrumentAxis_d38d0e" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59f984" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_d38d0e" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59f984" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_380b22" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59f984" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_380b22" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaapAvailableForSaleSecuritiesAmortizedCost_c7ac24" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3a754" xlink:to="loc_us-gaapAvailableForSaleSecuritiesAmortizedCost_c7ac24" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaapAccruedInvestmentIncomeReceivable_69fa58" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3a754" xlink:to="loc_us-gaapAccruedInvestmentIncomeReceivable_69fa58" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:label="loc_us-gaapAvailableForSaleSecuritiesGrossUnrealizedGains_278622" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3a754" xlink:to="loc_us-gaapAvailableForSaleSecuritiesGrossUnrealizedGains_278622" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrossUnrealizedLosses" xlink:label="loc_tenxGrossUnrealizedLosses_bc7ccd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3a754" xlink:to="loc_tenxGrossUnrealizedLosses_bc7ccd" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_AvailableForSaleSecuritiesEstimatedFairValue" xlink:label="loc_tenxAvailableForSaleSecuritiesEstimatedFairValue_3e0449" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3a754" xlink:to="loc_tenxAvailableForSaleSecuritiesEstimatedFairValue_3e0449" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/FairValueDetails1" xlink:title="000027 - Disclosure - FAIR VALUE (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_e665ee" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7c6bd3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e665ee" xlink:to="loc_us-gaapStatementTable_7c6bd3" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f50ed0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7c6bd3" xlink:to="loc_us-gaapStatementLineItems_f50ed0" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_6fc1da" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7c6bd3" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_6fc1da" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_59ffc1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_6fc1da" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_59ffc1" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_7e8366" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_59ffc1" xlink:to="loc_us-gaapFairValueInputsLevel1Member_7e8366" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_6ab3b1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_59ffc1" xlink:to="loc_us-gaapFairValueInputsLevel2Member_6ab3b1" order="22" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_c8ba1c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_59ffc1" xlink:to="loc_us-gaapFairValueInputsLevel3Member_c8ba1c" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaapAssetsFairValueDisclosureAbstract_bbfa62" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f50ed0" xlink:to="loc_us-gaapAssetsFairValueDisclosureAbstract_bbfa62" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_121a05" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsFairValueDisclosureAbstract_bbfa62" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_121a05" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaapAvailableForSaleSecurities_2f1b7d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsFairValueDisclosureAbstract_bbfa62" xlink:to="loc_us-gaapAvailableForSaleSecurities_2f1b7d" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetails" xlink:title="000028 - Disclosure - BALANCE SHEET COMPONENTS (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_4ef2d7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross_f8e9c4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_4ef2d7" xlink:to="loc_us-gaapFurnitureAndFixturesGross_f8e9c4" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross_1bda6a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_4ef2d7" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross_1bda6a" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_bc7aee" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_4ef2d7" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_bc7aee" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa4105" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_4ef2d7" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa4105" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_2df346" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_4ef2d7" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_2df346" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetails1" xlink:title="000029 - Disclosure - BALANCE SHEET COMPONENTS (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_94f580" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_ab72ab" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_94f580" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_ab72ab" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_8b83b8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_94f580" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_8b83b8" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_71b1a4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_94f580" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_71b1a4" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_ee1e40" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_94f580" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_ee1e40" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" xlink:title="000030 - Disclosure - BALANCE SHEET COMPONENTS (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_cafb82" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_4a86b2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract_cafb82" xlink:to="loc_us-gaapDepreciation_4a86b2" order="1" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetails" xlink:title="000031 - Disclosure - LEASE (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_fbbfc8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_d4f775" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_fbbfc8" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_d4f775" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaapDeferredTaxLiabilitiesNoncurrent_c3f8fb" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_fbbfc8" xlink:to="loc_us-gaapDeferredTaxLiabilitiesNoncurrent_c3f8fb" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_3b7b0f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_fbbfc8" xlink:to="loc_us-gaapOperatingLeaseLiability_3b7b0f" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetails1" xlink:title="000032 - Disclosure - LEASE (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_b5144c" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b51b1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b51b1" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_2171d7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_2171d7" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_3b1622" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_3b1622" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_4bebaf" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_4bebaf" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_19c54c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_19c54c" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LessImputedInterest" xlink:label="loc_tenxLessImputedInterest_35865a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_tenxLessImputedInterest_35865a" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_7c464e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b5144c" xlink:to="loc_us-gaapOperatingLeaseLiability_7c464e" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/LeaseDetailsNarrative" xlink:title="000033 - Disclosure - LEASE (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_0fde71" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RemainingLeaseTerm" xlink:label="loc_tenxRemainingLeaseTerm_fe70f6" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_tenxRemainingLeaseTerm_fe70f6" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_31cd5a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_31cd5a" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_39d6ec" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_us-gaapLeaseCost_39d6ec" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_5ef451" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_5ef451" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_4ffc24" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_us-gaapAreaOfLand_4ffc24" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LeaseTermPeriod" xlink:label="loc_tenxLeaseTermPeriod_a5c8a7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_tenxLeaseTermPeriod_a5c8a7" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsOperatingLeases_3b87c8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsOperatingLeases_3b87c8" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet_f0e10c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet_f0e10c" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfAnnualIncreaseInRent" xlink:label="loc_tenxPercentageOfAnnualIncreaseInRent_443f48" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_0fde71" xlink:to="loc_tenxPercentageOfAnnualIncreaseInRent_443f48" order="9" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/NotesPayableDetailsNarrative" xlink:title="000034 - Disclosure - NOTES PAYABLE (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract_7f7ced" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PppLoanAmount" xlink:label="loc_tenxPppLoanAmount_c1c475" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_7f7ced" xlink:to="loc_tenxPppLoanAmount_c1c475" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PppLoanMonthlyPayment" xlink:label="loc_tenxPppLoanMonthlyPayment_4fbfb9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_7f7ced" xlink:to="loc_tenxPppLoanMonthlyPayment_4fbfb9" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_3bfd47" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_7f7ced" xlink:to="loc_us-gaapDebtInstrumentTerm_3bfd47" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_822c65" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_7f7ced" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_822c65" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_DebtInstrumentDecreaseForgivenessAccruedInterest" xlink:label="loc_tenxDebtInstrumentDecreaseForgivenessAccruedInterest_04083f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_7f7ced" xlink:to="loc_tenxDebtInstrumentDecreaseForgivenessAccruedInterest_04083f" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt_d97770" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract_7f7ced" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt_d97770" order="6" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerDetails" xlink:title="000035 - Disclosure - MERGER (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract_77c82f" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_200c3e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_200c3e" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_f920ff" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_f920ff" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_75f5c4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_75f5c4" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_bfbe3e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_bfbe3e" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a899bd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a899bd" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b2e08" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b2e08" order="6" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InProcessResearchAndDevelopmentExpense" xlink:label="loc_tenxInProcessResearchAndDevelopmentExpense_1c7a73" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_77c82f" xlink:to="loc_tenxInProcessResearchAndDevelopmentExpense_1c7a73" order="7" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/MergerDetailsNarrative" xlink:title="000036 - Disclosure - MERGER (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract_6ca36b" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_abbf1a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_6ca36b" xlink:to="loc_us-gaapStatementTable_abbf1a" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_083600" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_abbf1a" xlink:to="loc_us-gaapStatementLineItems_083600" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis_e29afb" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_abbf1a" xlink:to="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis_e29afb" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain_83def9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesAxis_e29afb" xlink:to="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain_83def9" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaapSeriesBMember_532a7f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAuctionMarketPreferredSecuritiesStockSeriesTitleDomain_83def9" xlink:to="loc_us-gaapSeriesBMember_532a7f" order="21" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_c2f2f9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_083600" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_c2f2f9" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockAcquired" xlink:label="loc_tenxCommonStockAcquired_70390d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_083600" xlink:to="loc_tenxCommonStockAcquired_70390d" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_f6126a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_083600" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_f6126a" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfPreferredStockCarriesVotingRights" xlink:label="loc_tenxPercentageOfPreferredStockCarriesVotingRights_157696" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_083600" xlink:to="loc_tenxPercentageOfPreferredStockCarriesVotingRights_157696" order="4" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_c8857c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_083600" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_c8857c" order="5" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f98c85" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_04ca49" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f98c85" xlink:to="loc_us-gaapStatementTable_04ca49" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8c041a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_04ca49" xlink:to="loc_us-gaapStatementLineItems_8c041a" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_bbabdd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_04ca49" xlink:to="loc_us-gaapPlanNameAxis_bbabdd" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_5c4e1e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_bbabdd" xlink:to="loc_us-gaapPlanNameDomain_5c4e1e" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SimdaxLicenseAgreementMember" xlink:label="loc_tenxSimdaxLicenseAgreementMember_1dc148" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_5c4e1e" xlink:to="loc_tenxSimdaxLicenseAgreementMember_1dc148" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaapLongtermPurchaseCommitmentPeriod_984573" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c041a" xlink:to="loc_us-gaapLongtermPurchaseCommitmentPeriod_984573" order="1" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_LicenseAgreementMaturityDate" xlink:label="loc_tenxLicenseAgreementMaturityDate_c187d9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c041a" xlink:to="loc_tenxLicenseAgreementMaturityDate_c187d9" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NonRefundableUpFrontPayment" xlink:label="loc_tenxNonRefundableUpFrontPayment_87c9a7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c041a" xlink:to="loc_tenxNonRefundableUpFrontPayment_87c9a7" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrantPaidToAuthority" xlink:label="loc_tenxGrantPaidToAuthority_f9cfc6" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c041a" xlink:to="loc_tenxGrantPaidToAuthority_f9cfc6" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_GrantPaidToAuthorityOne" xlink:label="loc_tenxGrantPaidToAuthorityOne_aa37b4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c041a" xlink:to="loc_tenxGrantPaidToAuthorityOne_aa37b4" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NonRefundableCommercializationMilestonePayment" xlink:label="loc_tenxNonRefundableCommercializationMilestonePayment_665920" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c041a" xlink:to="loc_tenxNonRefundableCommercializationMilestonePayment_665920" order="6" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails" xlink:title="000038 - Disclosure - STOCKHOLDERS EQUITY (Details)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_ab966d" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_4f77a8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ab966d" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_4f77a8" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_9d585a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ab966d" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_9d585a" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_5621e4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ab966d" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber_5621e4" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1e2783" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ab966d" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1e2783" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_tenxShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_3525f4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ab966d" xlink:to="loc_tenxShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_3525f4" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3cb110" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ab966d" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3cb110" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails1" xlink:title="000039 - Disclosure - STOCKHOLDERS EQUITY (Details 1)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_a73bfb" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_65c3ef" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a73bfb" xlink:to="loc_us-gaapStatementTable_65c3ef" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f918b4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_65c3ef" xlink:to="loc_us-gaapStatementLineItems_f918b4" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_7dd816" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_65c3ef" xlink:to="loc_us-gaapPlanNameAxis_7dd816" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_3cf652" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_7dd816" xlink:to="loc_us-gaapPlanNameDomain_3cf652" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member_fd92e8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_3cf652" xlink:to="loc_tenxStockIncentivePlan2016Member_fd92e8" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b11535" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f918b4" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b11535" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant_36d8c2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f918b4" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant_36d8c2" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29ce4f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f918b4" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29ce4f" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e69bb9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f918b4" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e69bb9" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails2" xlink:title="000040 - Disclosure - STOCKHOLDERS EQUITY (Details 2)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_2a44fd" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_df0dc7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_2a44fd" xlink:to="loc_us-gaapStatementTable_df0dc7" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f42724" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_df0dc7" xlink:to="loc_us-gaapStatementLineItems_f42724" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_2e6ea6" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_df0dc7" xlink:to="loc_us-gaapPlanNameAxis_2e6ea6" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_27f1c9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_2e6ea6" xlink:to="loc_us-gaapPlanNameDomain_27f1c9" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member_9ed94a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_27f1c9" xlink:to="loc_tenxStockIncentivePlan2016Member_9ed94a" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5b140c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f42724" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5b140c" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37bf00" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f42724" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37bf00" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a71eb8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f42724" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a71eb8" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_651b63" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f42724" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_651b63" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ad5652" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f42724" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ad5652" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a25a94" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f42724" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a25a94" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails3" xlink:title="000041 - Disclosure - STOCKHOLDERS EQUITY (Details 3)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_a970ef" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0019eb" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a970ef" xlink:to="loc_us-gaapStatementTable_0019eb" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7ac2b1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0019eb" xlink:to="loc_us-gaapStatementLineItems_7ac2b1" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_aecaff" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0019eb" xlink:to="loc_us-gaapPlanNameAxis_aecaff" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_a3a509" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_aecaff" xlink:to="loc_us-gaapPlanNameDomain_a3a509" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member_874d64" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_a3a509" xlink:to="loc_tenxStockIncentivePlan2016Member_874d64" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8680dc" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7ac2b1" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8680dc" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86f787" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7ac2b1" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86f787" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0f5249" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7ac2b1" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0f5249" order="3" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a2b858" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7ac2b1" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a2b858" order="4" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetails4" xlink:title="000042 - Disclosure - STOCKHOLDERS EQUITY (Details 4)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_92b3ac" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_00a589" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_92b3ac" xlink:to="loc_us-gaapStatementTable_00a589" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3b0cfa" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_00a589" xlink:to="loc_us-gaapStatementLineItems_3b0cfa" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_b4b7f0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_00a589" xlink:to="loc_us-gaapPlanNameAxis_b4b7f0" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_a13f6a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_b4b7f0" xlink:to="loc_us-gaapPlanNameDomain_a13f6a" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Amended1999StockPlanMember" xlink:label="loc_tenxAmended1999StockPlanMember_8f4ba8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_a13f6a" xlink:to="loc_tenxAmended1999StockPlanMember_8f4ba8" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb40bd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b0cfa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb40bd" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod" xlink:label="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod_a34307" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b0cfa" xlink:to="loc_tenxShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod_a34307" order="2" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_775595" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b0cfa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_775595" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c5bdd9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b0cfa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c5bdd9" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d00796" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b0cfa" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d00796" order="5" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ffaec4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3b0cfa" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ffaec4" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" xlink:title="000043 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_0cfc2f" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5f1ede" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0cfc2f" xlink:to="loc_us-gaapStatementTable_5f1ede" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0b3009" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f1ede" xlink:to="loc_us-gaapStatementLineItems_0b3009" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_a07004" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f1ede" xlink:to="loc_us-gaapStatementClassOfStockAxis_a07004" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_1f9748" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_a07004" xlink:to="loc_us-gaapClassOfStockDomain_1f9748" order="10" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_94616b" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f1ede" xlink:to="loc_us-gaapPlanNameAxis_94616b" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_2f3467" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_94616b" xlink:to="loc_us-gaapPlanNameDomain_2f3467" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_7f8f60" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f1ede" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_7f8f60" order="40" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_e4ae83" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_7f8f60" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_e4ae83" order="40" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_cc4166" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f1ede" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_cc4166" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_e08b1a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_cc4166" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_e08b1a" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_80c022" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f1ede" xlink:to="loc_us-gaapAwardDateAxis_80c022" order="70" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_cf822d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_80c022" xlink:to="loc_us-gaapAwardDateDomain_cf822d" order="70" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_8c42ad" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_1f9748" xlink:to="loc_us-gaapSeriesAPreferredStockMember_8c42ad" order="71" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockIncentivePlan2016Member" xlink:label="loc_tenxStockIncentivePlan2016Member_d7484e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_2f3467" xlink:to="loc_tenxStockIncentivePlan2016Member_d7484e" order="72" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_Amended1999StockPlanMember" xlink:label="loc_tenxAmended1999StockPlanMember_66a5e7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_2f3467" xlink:to="loc_tenxAmended1999StockPlanMember_66a5e7" order="73" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_81736a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_1f9748" xlink:to="loc_us-gaapSeriesBPreferredStockMember_81736a" order="74" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InvestorsMember" xlink:label="loc_tenxInvestorsMember_301585" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_e4ae83" xlink:to="loc_tenxInvestorsMember_301585" order="75" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MarchTwentyTwentyWarrantsMember" xlink:label="loc_tenxMarchTwentyTwentyWarrantsMember_5bfee4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_e08b1a" xlink:to="loc_tenxMarchTwentyTwentyWarrantsMember_5bfee4" order="76" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_July2020WarrantsMember" xlink:label="loc_tenxJuly2020WarrantsMember_edc208" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_cf822d" xlink:to="loc_tenxJuly2020WarrantsMember_edc208" order="77" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_InducementStockOptionsMember" xlink:label="loc_tenxInducementStockOptionsMember_49ea3c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_2f3467" xlink:to="loc_tenxInducementStockOptionsMember_49ea3c" order="78" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantToPurchaseOfCommonStockExercisePrice" xlink:label="loc_tenxWarrantToPurchaseOfCommonStockExercisePrice_baffae" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxWarrantToPurchaseOfCommonStockExercisePrice_baffae" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5e90be" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5e90be" order="2" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock" xlink:label="loc_tenxConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock_be7511" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock_be7511" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock" xlink:label="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStock_708784" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStock_708784" order="4" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds" xlink:label="loc_tenxUnregisteredCommonStockWarrantsToPurchaseGrossProceeds_5af7cd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxUnregisteredCommonStockWarrantsToPurchaseGrossProceeds_5af7cd" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredWarrantsExercisePrice" xlink:label="loc_tenxUnregisteredWarrantsExercisePrice_dad6dd" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxUnregisteredWarrantsExercisePrice_dad6dd" order="6" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses" xlink:label="loc_tenxNetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses_458ddf" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxNetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses_458ddf" order="7" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_d41837" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_d41837" order="8" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_29f18f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_29f18f" order="9" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_af9f5b" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_af9f5b" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PrefundedWarrantsOutstanding" xlink:label="loc_tenxPrefundedWarrantsOutstanding_1fee54" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxPrefundedWarrantsOutstanding_1fee54" order="11" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_735389" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_735389" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockParOrStatedValuePerShares" xlink:label="loc_tenxCommonStockParOrStatedValuePerShares_3d4b65" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxCommonStockParOrStatedValuePerShares_3d4b65" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_34cc84" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapCommonStockSharesAuthorized_34cc84" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockSharesIssue" xlink:label="loc_tenxCommonStockSharesIssue_406607" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxCommonStockSharesIssue_406607" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_cf71de" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapCommonStockSharesOutstanding_cf71de" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_33a270" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_33a270" order="17" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_aa1854" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_aa1854" order="18" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarranToPurchaseOfCommonStockTerm" xlink:label="loc_tenxWarranToPurchaseOfCommonStockTerm_861d7f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxWarranToPurchaseOfCommonStockTerm_861d7f" order="19" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_c69fc8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_c69fc8" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_88f275" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapPreferredStockSharesIssued_88f275" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PreferredStockVotingRightsPercentage" xlink:label="loc_tenxPreferredStockVotingRightsPercentage_79a35e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxPreferredStockVotingRightsPercentage_79a35e" order="22" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PreferredStockVotingRightsPercentage1" xlink:label="loc_tenxPreferredStockVotingRightsPercentage1_dca3b7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxPreferredStockVotingRightsPercentage1_dca3b7" order="23" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_b60906" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_b60906" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_c6f4b8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_c6f4b8" order="25" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_16dff1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_16dff1" order="26" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsGrantedVestingPeriod" xlink:label="loc_tenxStockOptionsGrantedVestingPeriod_aadf1c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxStockOptionsGrantedVestingPeriod_aadf1c" order="27" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_f4e0c8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_f4e0c8" order="28" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_269518" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_269518" order="29" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsGrantedFairMarketValuePercentage" xlink:label="loc_tenxStockOptionsGrantedFairMarketValuePercentage_102ab7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxStockOptionsGrantedFairMarketValuePercentage_102ab7" order="30" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockConvertibleIntoAggregateSharesOfCommonStock" xlink:label="loc_tenxStockConvertibleIntoAggregateSharesOfCommonStock_ff97a1" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxStockConvertibleIntoAggregateSharesOfCommonStock_ff97a1" order="31" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RightsPreferencesAndPrivilegesConversionIntoShare" xlink:label="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare_222d00" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare_222d00" order="32" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RightsPreferencesAndPrivilegesConversionIntoShare1" xlink:label="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare1_b76ad4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxRightsPreferencesAndPrivilegesConversionIntoShare1_b76ad4" order="33" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_f629ce" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapPreferredStockVotingRights_f629ce" order="34" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedCommonStock" xlink:label="loc_tenxFairValueAllocatedCommonStock_e8b253" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxFairValueAllocatedCommonStock_e8b253" order="35" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedPrefundedWarrants" xlink:label="loc_tenxFairValueAllocatedPrefundedWarrants_91b071" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxFairValueAllocatedPrefundedWarrants_91b071" order="36" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_FairValueAllocatedWarrants" xlink:label="loc_tenxFairValueAllocatedWarrants_4377a4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxFairValueAllocatedWarrants_4377a4" order="37" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_85e3a9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_85e3a9" order="38" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantToPurchaseOfCommonStockTerm" xlink:label="loc_tenxWarrantToPurchaseOfCommonStockTerm_58a7e0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxWarrantToPurchaseOfCommonStockTerm_58a7e0" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueofWarrantIssuedForServices" xlink:label="loc_tenxEstimatedFairValueofWarrantIssuedForServices_7905e2" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxEstimatedFairValueofWarrantIssuedForServices_7905e2" order="40" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_IssuedUnderwriterWarrantTopurchaseCommonStock" xlink:label="loc_tenxIssuedUnderwriterWarrantTopurchaseCommonStock_2db7e7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxIssuedUnderwriterWarrantTopurchaseCommonStock_2db7e7" order="41" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice" xlink:label="loc_tenxUnderwriterWarrantToPurchaseCommonStockExercisePrice_688dd0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxUnderwriterWarrantToPurchaseCommonStockExercisePrice_688dd0" order="42" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue" xlink:label="loc_tenxUnderwriterWarrantToPurchaseCommonStockEstimatedFairValue_ca6d22" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxUnderwriterWarrantToPurchaseCommonStockEstimatedFairValue_ca6d22" order="43" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants" xlink:label="loc_tenxCommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants_4ddd05" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxCommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants_4ddd05" order="44" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2" xlink:label="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2_42961c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxUnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2_42961c" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueofWarrantIssuedForServicese" xlink:label="loc_tenxEstimatedFairValueofWarrantIssuedForServicese_087187" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxEstimatedFairValueofWarrantIssuedForServicese_087187" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_8ea36c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_8ea36c" order="47" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_245c53" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_245c53" order="48" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6a64c3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6a64c3" order="49" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_StockOptionsDescription" xlink:label="loc_tenxStockOptionsDescription_a3a5da" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxStockOptionsDescription_a3a5da" order="50" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_EstimatedFairValueOfInducementStockOptionAwardGranted" xlink:label="loc_tenxEstimatedFairValueOfInducementStockOptionAwardGranted_99ae1d" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxEstimatedFairValueOfInducementStockOptionAwardGranted_99ae1d" order="51" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_525001" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_525001" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_DividendYield" xlink:label="loc_tenxDividendYield_ba42bb" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_tenxDividendYield_ba42bb" order="53" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_05562e" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_05562e" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_494021" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0b3009" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_494021" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> </link:presentationLink> <link:presentationLink xlink:type="extended" xlink:role="http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" xlink:title="000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)"> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_5461ea" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c96832" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_5461ea" xlink:to="loc_us-gaapStatementTable_c96832" order="100" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_092268" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c96832" xlink:to="loc_us-gaapStatementLineItems_092268" order="2000" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_ffe596" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c96832" xlink:to="loc_us-gaapSubsequentEventTypeAxis_ffe596" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_a82dc3" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_ffe596" xlink:to="loc_us-gaapSubsequentEventTypeDomain_a82dc3" order="20" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_f06120" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c96832" xlink:to="loc_us-gaapPlanNameAxis_f06120" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_326bae" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_f06120" xlink:to="loc_us-gaapPlanNameDomain_326bae" order="30" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_4927e9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c96832" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_4927e9" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_ad49a6" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_4927e9" xlink:to="loc_us-gaapRelatedPartyDomain_ad49a6" order="50" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_1fda3f" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_a82dc3" xlink:to="loc_us-gaapSubsequentEventMember_1fda3f" order="51" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PurchaseAgreementMember" xlink:label="loc_tenxPurchaseAgreementMember_c9f66b" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_326bae" xlink:to="loc_tenxPurchaseAgreementMember_c9f66b" order="52" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_RegistrationRightsAgreementMember" xlink:label="loc_tenxRegistrationRightsAgreementMember_fc897c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_326bae" xlink:to="loc_tenxRegistrationRightsAgreementMember_fc897c" order="53" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SeparationAgreementMember" xlink:label="loc_tenxSeparationAgreementMember_c68b30" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_326bae" xlink:to="loc_tenxSeparationAgreementMember_c68b30" order="54" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MrDitonnoMember" xlink:label="loc_tenxMrDitonnoMember_ea15ba" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_ad49a6" xlink:to="loc_tenxMrDitonnoMember_ea15ba" order="55" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_MaturityPeriod" xlink:label="loc_tenxMaturityPeriod_d8c389" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxMaturityPeriod_d8c389" order="1" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_caed26" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_us-gaapSharesIssued_caed26" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PurchasePriceOfStock" xlink:label="loc_tenxPurchasePriceOfStock_9fb71c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxPurchasePriceOfStock_9fb71c" order="3" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_CommonStockParOrStatedValuePerShares" xlink:label="loc_tenxCommonStockParOrStatedValuePerShares_9332e7" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxCommonStockParOrStatedValuePerShares_9332e7" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredPreFundedWarrants" xlink:label="loc_tenxUnregisteredPreFundedWarrants_116ef8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxUnregisteredPreFundedWarrants_116ef8" order="5" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_ProceedsFromOffering" xlink:label="loc_tenxProceedsFromOffering_40fdb8" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxProceedsFromOffering_40fdb8" order="6" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_df34f6" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_df34f6" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock" xlink:label="loc_tenxUnregisteredWarrantHasAnExercisePricePerShareOfCommonStock_554fa0" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxUnregisteredWarrantHasAnExercisePricePerShareOfCommonStock_554fa0" order="8" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfGrossProceedReceived" xlink:label="loc_tenxPercentageOfGrossProceedReceived_181c9b" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxPercentageOfGrossProceedReceived_181c9b" order="9" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_WarrantIssuedToPurchaseCommonStock" xlink:label="loc_tenxWarrantIssuedToPurchaseCommonStock_48321a" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxWarrantIssuedToPurchaseCommonStock_48321a" order="10" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_PercentageOfOfferingPricePerShareOfCommonStock" xlink:label="loc_tenxPercentageOfOfferingPricePerShareOfCommonStock_c343ba" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxPercentageOfOfferingPricePerShareOfCommonStock_c343ba" order="11" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_dvddv" xlink:label="loc_tenxdvddv_2bf90c" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxdvddv_2bf90c" order="12" /> <link:loc xlink:type="locator" xlink:href="tenx-20210630.xsd#tenx_SeveranceReceived" xlink:label="loc_tenxSeveranceReceived_9c76a4" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_tenxSeveranceReceived_9c76a4" order="13" /> <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_90eef9" /> <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_092268" xlink:to="loc_us-gaapOtherExpenses_90eef9" order="14" /> </link:presentationLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>12 <FILENAME>tenx_10q_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version="1.0" encoding="utf-8"?> <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tenx="http://tenaxthera.com/20210630" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink"> <link:schemaRef xlink:href="tenx-20210630.xsd" xlink:type="simple"/> <context id="From2021-01-01to2021-06-30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SeparationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tenx:MrDitonnoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-07-13</instant> </period> </context> <context id="From2021-07-01to2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SeparationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tenx:MrDitonnoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-07-01</startDate> <endDate>2021-07-13</endDate> </period> </context> <context id="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:RegistrationRightsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-07-06</instant> </period> </context> <context id="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:PurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-07-06</instant> </period> </context> <context id="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:RegistrationRightsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-07-01</startDate> <endDate>2021-07-06</endDate> </period> </context> <context id="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:PurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-07-01</startDate> <endDate>2021-07-06</endDate> </period> </context> <context id="AsOf2021-01-15_tenx_InducementStockOptionsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-01-15</instant> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-01-15</endDate> </period> </context> <context id="AsOf2021-06-30_tenx_InducementStockOptionsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:InducementStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2020-04-01to2020-06-30_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2021-04-01to2021-06-30_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2020-01-01to2020-06-30_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="AsOf2021-06-10_us-gaap_SeriesBPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-10</instant> </period> </context> <context id="From2021-01-01to2021-06-30_us-gaap_SeriesBPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_July2020WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">tenx:July2020WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_MarchTwentyTwentyWarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:MarchTwentyTwentyWarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2020-07-31_tenx_July2020WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">tenx:July2020WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-07-31</instant> </period> </context> <context id="AsOf2020-03-31_tenx_MarchTwentyTwentyWarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:MarchTwentyTwentyWarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">tenx:July2020WarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-07-01</startDate> <endDate>2020-07-31</endDate> </period> </context> <context id="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:MarchTwentyTwentyWarrantsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-03-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="From2020-07-01to2020-07-08_tenx_InvestorsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-07-01</startDate> <endDate>2020-07-08</endDate> </period> </context> <context id="AsOf2020-07-08_tenx_InvestorsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-07-08</instant> </period> </context> <context id="From2018-12-01to2018-12-11_tenx_InvestorsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2018-12-01</startDate> <endDate>2018-12-11</endDate> </period> </context> <context id="AsOf2018-12-11_tenx_InvestorsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tenx:InvestorsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-12-11</instant> </period> </context> <context id="AsOf2020-03-13"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2020-03-13</instant> </period> </context> <context id="From2020-07-01to2020-07-08"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2020-07-01</startDate> <endDate>2020-07-08</endDate> </period> </context> <context id="AsOf2020-07-08"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2020-07-08</instant> </period> </context> <context id="AsOf2018-12-11"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2018-12-11</instant> </period> </context> <context id="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-01-15</instant> </period> </context> <context id="From2021-05-20to2021-06-09_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-05-20</startDate> <endDate>2021-06-09</endDate> </period> </context> <context id="From2019-05-20to2019-06-12_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-05-20</startDate> <endDate>2019-06-12</endDate> </period> </context> <context id="From2015-08-20to2015-09-15_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2015-08-20</startDate> <endDate>2015-09-15</endDate> </period> </context> <context id="From2015-09-01to2015-09-15_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2015-09-01</startDate> <endDate>2015-09-15</endDate> </period> </context> <context id="From2020-04-01to2020-06-30_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2021-06-01to2021-06-10_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-06-01</startDate> <endDate>2021-06-10</endDate> </period> </context> <context id="From2016-06-01to2016-06-16_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2016-06-01</startDate> <endDate>2016-06-16</endDate> </period> </context> <context id="From2021-04-01to2021-06-30_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2018-12-11_us-gaap_SeriesAPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-12-11</instant> </period> </context> <context id="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2018-12-01</startDate> <endDate>2018-12-11</endDate> </period> </context> <context id="AsOf2021-06-30_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2020-12-31_tenx_Amended1999StockPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:Amended1999StockPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="AsOf2021-06-30_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2020-12-31_tenx_StockIncentivePlan2016Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:StockIncentivePlan2016Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="From2013-11-01to2013-11-13_tenx_SimdaxLicenseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2013-11-01</startDate> <endDate>2013-11-13</endDate> </period> </context> <context id="From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-10-01</startDate> <endDate>2020-10-09</endDate> </period> </context> <context id="AsOf2021-06-30_us-gaap_SeriesBMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2015-08-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2015-08-31</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2021-01-01to2021-06-30_us-gaap_CorporateDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2020-01-01to2020-06-30_tenx_ConvertiblePreferredSharesOutstandingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:ConvertiblePreferredSharesOutstandingMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_PrefundedWarrantsToPurchaseCommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:PrefundedWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_ConvertiblePreferredSharesOutstandingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:ConvertiblePreferredSharesOutstandingMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2020-01-01to2020-06-30_tenx_SimdaxLicenseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tenx:SimdaxLicenseAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2020-01-01to2020-06-30_tenx_WarranttoPurchaseCommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:WarranttoPurchaseCommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2021-01-01to2021-06-30_tenx_WarranttoPurchaseCommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tenx:WarranttoPurchaseCommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2021-06-30_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2021-06-30_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="From2021-04-01to2021-06-30_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-04-01to2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-04-01to2021-06-30_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-04-01to2021-06-30_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="From2021-04-01to2021-06-30_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2021-03-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2021-03-31</instant> </period> </context> <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-03-31</instant> </period> </context> <context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-03-31</instant> </period> </context> <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-03-31</instant> </period> </context> <context id="AsOf2021-03-31_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-03-31</instant> </period> </context> <context id="AsOf2021-03-31_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-03-31</instant> </period> </context> <context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-03-31</endDate> </period> </context> <context id="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-03-31</endDate> </period> </context> <context id="From2021-01-01to2021-03-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-03-31</endDate> </period> </context> <context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-03-31</endDate> </period> </context> <context id="From2021-01-01to2021-03-31_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-03-31</endDate> </period> </context> <context id="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-01-01</startDate> <endDate>2021-03-31</endDate> </period> </context> <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2020-12-31_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2020-06-30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2020-06-30</instant> </period> </context> <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-06-30</instant> </period> </context> <context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-06-30</instant> </period> </context> <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-06-30</instant> </period> </context> <context id="AsOf2020-06-30_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-06-30</instant> </period> </context> <context id="AsOf2020-06-30_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-06-30</instant> </period> </context> <context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2020-04-01to2020-06-30_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="AsOf2020-03-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="AsOf2020-03-31_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="AsOf2020-03-31_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="From2020-01-01to2020-03-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="From2020-01-01to2020-03-31_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="AsOf2019-12-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="AsOf2019-12-31_tenx_CommonStocksMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tenx:CommonStocksMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="AsOf2019-12-31_us-gaap_PreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="From2020-01-01to2020-06-30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2020-04-01to2020-06-30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2020-04-01</startDate> <endDate>2020-06-30</endDate> </period> </context> <context id="From2021-04-01to2021-06-30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <startDate>2021-04-01</startDate> <endDate>2021-06-30</endDate> </period> </context> <context id="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2020-12-31"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2020-12-31</instant> </period> </context> <context id="AsOf2021-06-30"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2021-06-30</instant> </period> </context> <context id="AsOf2021-08-12"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000034956</identifier> </entity> <period> <instant>2021-08-12</instant> </period> </context> <unit id="USD"> <measure>iso4217:USD</measure> </unit> <unit id="Shares"> <measure>shares</measure> </unit> <unit id="USDPShares"> <divide> <unitNumerator> <measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>shares</measure> </unitDenominator> </divide> </unit> <unit id="Pure"> <measure>pure</measure> </unit> <unit id="sqft"> <measure>utr:sqft</measure> </unit> <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-06-30">0000034956</dei:EntityCentralIndexKey> <dei:AmendmentFlag contextRef="From2021-01-01to2021-06-30">false</dei:AmendmentFlag> <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-06-30">--12-31</dei:CurrentFiscalYearEndDate> <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityEmergingGrowthCompany> <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-06-30">Q2</dei:DocumentFiscalPeriodFocus> <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-06-30">2021</dei:DocumentFiscalYearFocus> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="0" unitRef="Shares">9999790</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="Shares">5181346</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="Shares">210</us-gaap:PreferredStockSharesOutstanding> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-06-30" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">12619369</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="0" unitRef="Shares">25210312</us-gaap:CommonStockSharesOutstanding> <us-gaap:NetIncomeLoss contextRef="From2021-04-01to2021-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD">-2279868</us-gaap:NetIncomeLoss> <us-gaap:Depreciation contextRef="From2020-01-01to2020-06-30" decimals="0" unitRef="USD">2000</us-gaap:Depreciation> <us-gaap:Depreciation contextRef="From2020-04-01to2020-06-30" decimals="0" unitRef="USD">1000</us-gaap:Depreciation> <us-gaap:DebtInstrumentTerm contextRef="From2021-01-01to2021-06-30">P2Y</us-gaap:DebtInstrumentTerm> <tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised contextRef="From2021-01-01to2021-06-30" decimals="0" unitRef="Shares">-801576</tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised> <tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber contextRef="AsOf2021-06-30" decimals="0" unitRef="Shares">15797503</tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-03-31" decimals="INF" unitRef="USDPShares">1.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" decimals="0" unitRef="Shares">-13</tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-12-11_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2020-04-01to2020-06-30_tenx_Amended1999StockPlanMember" decimals="0" unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <tenx:StockOptionsGrantedVestingPeriod contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member">Stock options granted generally vest over three to four years.</tenx:StockOptionsGrantedVestingPeriod> <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <tenx:WarrantToPurchaseOfCommonStockExercisePrice contextRef="AsOf2018-12-11" decimals="INF" unitRef="USDPShares">11.93</tenx:WarrantToPurchaseOfCommonStockExercisePrice> <tenx:WarrantToPurchaseOfCommonStockExercisePrice contextRef="AsOf2018-12-11_tenx_InvestorsMember" decimals="INF" unitRef="USDPShares">1.04</tenx:WarrantToPurchaseOfCommonStockExercisePrice> <tenx:FairValueAllocatedPrefundedWarrants contextRef="AsOf2018-12-11_tenx_InvestorsMember" decimals="0" unitRef="USD">1100000.0</tenx:FairValueAllocatedPrefundedWarrants> <tenx:FairValueAllocatedWarrants contextRef="From2018-12-01to2018-12-11_tenx_InvestorsMember" decimals="0" unitRef="USD">1100000.0</tenx:FairValueAllocatedWarrants> <tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStock contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="Shares">2360313</tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStock> <tenx:UnregisteredWarrantsExercisePrice contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="INF" unitRef="USDPShares">1.04</tenx:UnregisteredWarrantsExercisePrice> <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="USD">1100000.0</us-gaap:FairValueAdjustmentOfWarrants> <tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2 contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="0" unitRef="Shares">7783616</tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2> <tenx:UnregisteredWarrantsExercisePrice contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="INF" unitRef="USDPShares">0.903</tenx:UnregisteredWarrantsExercisePrice> <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="0" unitRef="USD">3500000.0</us-gaap:FairValueAdjustmentOfWarrants> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="Shares">177023</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight> <tenx:WarrantToPurchaseOfCommonStockExercisePrice contextRef="AsOf2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="INF" unitRef="USDPShares">1.4564</tenx:WarrantToPurchaseOfCommonStockExercisePrice> <tenx:WarrantToPurchaseOfCommonStockTerm contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember">P5Y</tenx:WarrantToPurchaseOfCommonStockTerm> <tenx:EstimatedFairValueofWarrantIssuedForServices contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="USD">66201</tenx:EstimatedFairValueofWarrantIssuedForServices> <tenx:IssuedUnderwriterWarrantTopurchaseCommonStock contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="Shares">94413</tenx:IssuedUnderwriterWarrantTopurchaseCommonStock> <tenx:UnderwriterWarrantToPurchaseCommonStockExercisePrice contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="INF" unitRef="USDPShares">1.4564</tenx:UnderwriterWarrantToPurchaseCommonStockExercisePrice> <tenx:UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue contextRef="From2020-03-01to2020-03-31_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="USD">35308</tenx:UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-07-31_tenx_July2020WarrantsMember" decimals="0" unitRef="Shares">583771</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight> <tenx:WarrantToPurchaseOfCommonStockExercisePrice contextRef="AsOf2020-07-31_tenx_July2020WarrantsMember" decimals="INF" unitRef="USDPShares">1.2848</tenx:WarrantToPurchaseOfCommonStockExercisePrice> <tenx:WarrantToPurchaseOfCommonStockTerm contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember">P5Y</tenx:WarrantToPurchaseOfCommonStockTerm> <tenx:EstimatedFairValueofWarrantIssuedForServicese contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="0" unitRef="USD">399445</tenx:EstimatedFairValueofWarrantIssuedForServicese> <tenx:IssuedUnderwriterWarrantTopurchaseCommonStock contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="0" unitRef="Shares">311345</tenx:IssuedUnderwriterWarrantTopurchaseCommonStock> <tenx:UnderwriterWarrantToPurchaseCommonStockExercisePrice contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="INF" unitRef="USDPShares">1.2848</tenx:UnderwriterWarrantToPurchaseCommonStockExercisePrice> <tenx:UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue contextRef="From2020-07-01to2020-07-31_tenx_July2020WarrantsMember" decimals="0" unitRef="USD">213038</tenx:UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-01-01to2021-06-30" decimals="0" unitRef="USD">545000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-01-01to2021-06-30" decimals="0" unitRef="Shares">282202</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> <tenx:CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants contextRef="From2021-01-01to2021-06-30_tenx_MarchTwentyTwentyWarrantsMember" decimals="0" unitRef="Shares">119491</tenx:CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants> <tenx:CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants contextRef="From2021-01-01to2021-06-30_tenx_July2020WarrantsMember" decimals="0" unitRef="Shares">399883</tenx:CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants> <tenx:PrefundedWarrantsOutstanding contextRef="AsOf2021-06-30" decimals="0" unitRef="Shares">5260005</tenx:PrefundedWarrantsOutstanding> <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="Shares">10232</us-gaap:PreferredStockSharesIssued> <tenx:RightsPreferencesAndPrivilegesConversionIntoShare contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="Shares">882</tenx:RightsPreferencesAndPrivilegesConversionIntoShare> <tenx:RightsPreferencesAndPrivilegesConversionIntoShare1 contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="Shares">119</tenx:RightsPreferencesAndPrivilegesConversionIntoShare1> <tenx:StockConvertibleIntoAggregateSharesOfCommonStock contextRef="AsOf2021-06-10_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="Shares">10232000</tenx:StockConvertibleIntoAggregateSharesOfCommonStock> <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding> <tenx:CommonStockParOrStatedValuePerShares contextRef="AsOf2020-03-13" decimals="INF" unitRef="USDPShares">1.1651</tenx:CommonStockParOrStatedValuePerShares> <tenx:CommonStockParOrStatedValuePerShares contextRef="AsOf2021-06-30" decimals="INF" unitRef="USDPShares">0.0001</tenx:CommonStockParOrStatedValuePerShares> <tenx:CommonStockSharesIssue contextRef="AsOf2020-03-13" decimals="0" unitRef="Shares">750000</tenx:CommonStockSharesIssue> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-04-01to2021-06-30_tenx_Amended1999StockPlanMember" decimals="0" unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-06-30_tenx_Amended1999StockPlanMember" decimals="0" unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" decimals="0" unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <tenx:StockOptionsGrantedFairMarketValuePercentage contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" decimals="INF" unitRef="Pure">0.85</tenx:StockOptionsGrantedFairMarketValuePercentage> <tenx:MaturityPeriod contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember">P5Y6M</tenx:MaturityPeriod> <tenx:MaturityPeriod contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember">P5Y</tenx:MaturityPeriod> <dei:DocumentType contextRef="From2021-01-01to2021-06-30">10-Q</dei:DocumentType> <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-06-30">true</dei:DocumentQuarterlyReport> <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-06-30">2021-06-30</dei:DocumentPeriodEndDate> <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-06-30">false</dei:DocumentTransitionReport> <dei:EntityFileNumber contextRef="From2021-01-01to2021-06-30">001-34600</dei:EntityFileNumber> <dei:EntityRegistrantName contextRef="From2021-01-01to2021-06-30">TENAX THERAPEUTICS, INC</dei:EntityRegistrantName> <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-06-30">DE</dei:EntityIncorporationStateCountryCode> <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-06-30">26-2593535</dei:EntityTaxIdentificationNumber> <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-06-30">ONE Copley Parkway</dei:EntityAddressAddressLine1> <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-06-30">Suite 490</dei:EntityAddressAddressLine2> <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-06-30">Morrisville</dei:EntityAddressCityOrTown> <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-06-30">NC</dei:EntityAddressStateOrProvince> <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-06-30">27560</dei:EntityAddressPostalZipCode> <dei:CityAreaCode contextRef="From2021-01-01to2021-06-30">919</dei:CityAreaCode> <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-06-30">855-2100</dei:LocalPhoneNumber> <dei:Security12bTitle contextRef="From2021-01-01to2021-06-30">Common Stock, $0.0001 par value per share</dei:Security12bTitle> <dei:TradingSymbol contextRef="From2021-01-01to2021-06-30">TENX</dei:TradingSymbol> <dei:SecurityExchangeName contextRef="From2021-01-01to2021-06-30">NASDAQ</dei:SecurityExchangeName> <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityCurrentReportingStatus> <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityInteractiveDataCurrent> <dei:EntityFilerCategory contextRef="From2021-01-01to2021-06-30">Non-accelerated Filer</dei:EntityFilerCategory> <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-06-30">true</dei:EntitySmallBusiness> <dei:EntityShellCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityShellCompany> <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-08-12" decimals="INF" unitRef="Shares">25201312</dei:EntityCommonStockSharesOutstanding> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" id="fid_354" unitRef="USD">1671422</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" id="fid_355" unitRef="USD">6250241</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_356" unitRef="USD">510943</us-gaap:MarketableSecuritiesCurrent> <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_357" unitRef="USD">462687</us-gaap:MarketableSecuritiesCurrent> <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_358" unitRef="USD">349862</us-gaap:PrepaidExpenseCurrent> <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_359" unitRef="USD">82578</us-gaap:PrepaidExpenseCurrent> <us-gaap:AssetsCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_360" unitRef="USD">2532227</us-gaap:AssetsCurrent> <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_361" unitRef="USD">6795506</us-gaap:AssetsCurrent> <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-06-30" decimals="0" id="fid_362" unitRef="USD">338698</us-gaap:OperatingLeaseRightOfUseAsset> <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" id="fid_363" unitRef="USD">58778</us-gaap:OperatingLeaseRightOfUseAsset> <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" id="fid_364" unitRef="USD">5821</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" id="fid_365" unitRef="USD">5972</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_366" unitRef="USD">8435</us-gaap:OtherAssetsNoncurrent> <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_367" unitRef="USD">8435</us-gaap:OtherAssetsNoncurrent> <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" id="fid_368" unitRef="USD">2885181</us-gaap:Assets> <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" id="fid_369" unitRef="USD">6868691</us-gaap:Assets> <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_372" unitRef="USD">791947</us-gaap:AccountsPayableCurrent> <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_373" unitRef="USD">757856</us-gaap:AccountsPayableCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_374" unitRef="USD">383063</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_375" unitRef="USD">1240616</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:NotesPayableCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_376" unitRef="USD">0</us-gaap:NotesPayableCurrent> <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_377" unitRef="USD">120491</us-gaap:NotesPayableCurrent> <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_378" unitRef="USD">1175010</us-gaap:LiabilitiesCurrent> <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_379" unitRef="USD">2118963</us-gaap:LiabilitiesCurrent> <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_381" unitRef="USD">239039</us-gaap:OperatingLeaseLiabilityNoncurrent> <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_382" unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent> <us-gaap:NotesPayable contextRef="AsOf2021-06-30" decimals="0" id="fid_757" unitRef="USD">0</us-gaap:NotesPayable> <us-gaap:NotesPayable contextRef="AsOf2020-12-31" decimals="0" id="fid_756" unitRef="USD">124166</us-gaap:NotesPayable> <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_385" unitRef="USD">239039</us-gaap:LiabilitiesNoncurrent> <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_386" unitRef="USD">124166</us-gaap:LiabilitiesNoncurrent> <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" id="fid_387" unitRef="USD">1414049</us-gaap:Liabilities> <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" id="fid_388" unitRef="USD">2243129</us-gaap:Liabilities> <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="0" id="fid_640" unitRef="Shares">9999790</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="fid_636" unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" decimals="0" id="fid_642" unitRef="Shares">5181346</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" decimals="0" id="fid_646" unitRef="Shares">210</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockValue contextRef="AsOf2021-06-30" decimals="0" id="fid_392" unitRef="USD">0</us-gaap:PreferredStockValue> <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" decimals="0" id="fid_393" unitRef="USD">0</us-gaap:PreferredStockValue> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" decimals="INF" id="fid_650" unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="0" id="fid_652" unitRef="Shares">400000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="0" id="fid_655" unitRef="Shares">25201312</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="0" id="fid_654" unitRef="Shares">12619369</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockValue contextRef="AsOf2021-06-30" decimals="0" id="fid_394" unitRef="USD">2520</us-gaap:CommonStockValue> <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" id="fid_395" unitRef="USD">1262</us-gaap:CommonStockValue> <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-06-30" decimals="0" id="fid_396" unitRef="USD">272953869</us-gaap:AdditionalPaidInCapitalCommonStock> <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" id="fid_397" unitRef="USD">250644197</us-gaap:AdditionalPaidInCapitalCommonStock> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-06-30" decimals="0" id="fid_398" unitRef="USD">-274</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31" decimals="0" id="fid_399" unitRef="USD">-70</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" id="fid_400" unitRef="USD">-271484983</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" id="fid_401" unitRef="USD">-246019827</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" id="fid_402" unitRef="USD">1471132</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" id="fid_403" unitRef="USD">4625562</us-gaap:StockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" id="fid_404" unitRef="USD">2885181</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" id="fid_405" unitRef="USD">6868691</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_407" unitRef="USD">1271278</us-gaap:SellingGeneralAndAdministrativeExpense> <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_408" unitRef="USD">869206</us-gaap:SellingGeneralAndAdministrativeExpense> <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_409" unitRef="USD">2644738</us-gaap:SellingGeneralAndAdministrativeExpense> <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_410" unitRef="USD">2192165</us-gaap:SellingGeneralAndAdministrativeExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_411" unitRef="USD">693222</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_412" unitRef="USD">1274837</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_413" unitRef="USD">23069424</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_414" unitRef="USD">2617363</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:OperatingExpenses contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_415" unitRef="USD">1964500</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_416" unitRef="USD">2144043</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_417" unitRef="USD">25714162</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_418" unitRef="USD">4809528</us-gaap:OperatingExpenses> <us-gaap:OperatingIncomeLoss contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_419" unitRef="USD">1964500</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_420" unitRef="USD">2144043</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_421" unitRef="USD">25714162</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_422" unitRef="USD">4809528</us-gaap:OperatingIncomeLoss> <us-gaap:InterestIncomeExpenseNet contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_423" unitRef="USD">336</us-gaap:InterestIncomeExpenseNet> <us-gaap:InterestIncomeExpenseNet contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_424" unitRef="USD">406</us-gaap:InterestIncomeExpenseNet> <us-gaap:InterestIncomeExpenseNet contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_425" unitRef="USD">949</us-gaap:InterestIncomeExpenseNet> <us-gaap:InterestIncomeExpenseNet contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_426" unitRef="USD">406</us-gaap:InterestIncomeExpenseNet> <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_427" unitRef="USD">-247820</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_428" unitRef="USD">2101</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_429" unitRef="USD">-249955</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_430" unitRef="USD">-8740</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:NetIncomeLoss contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_431" unitRef="USD">1717016</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_432" unitRef="USD">2146550</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_433" unitRef="USD">25465156</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_434" unitRef="USD">4801194</us-gaap:NetIncomeLoss> <us-gaap:MarketableSecuritiesGainLoss contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_435" unitRef="USD">-128</us-gaap:MarketableSecuritiesGainLoss> <us-gaap:MarketableSecuritiesGainLoss contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_436" unitRef="USD">-3238</us-gaap:MarketableSecuritiesGainLoss> <us-gaap:MarketableSecuritiesGainLoss contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_437" unitRef="USD">204</us-gaap:MarketableSecuritiesGainLoss> <us-gaap:MarketableSecuritiesGainLoss contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_438" unitRef="USD">-1616</us-gaap:MarketableSecuritiesGainLoss> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_439" unitRef="USD">1716888</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_440" unitRef="USD">2143312</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_441" unitRef="USD">25465360</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_442" unitRef="USD">4799578</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2021-04-01to2021-06-30" decimals="INF" id="fid_443" unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-04-01to2020-06-30" decimals="INF" id="fid_444" unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2021-01-01to2021-06-30" decimals="INF" id="fid_445" unitRef="USDPShares">-1.60</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-06-30" decimals="INF" id="fid_446" unitRef="USDPShares">-0.59</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_447" unitRef="Shares">17218103</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_448" unitRef="Shares">9339309</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_449" unitRef="Shares">15874062</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_450" unitRef="Shares">8156848</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:SharesIssued contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" decimals="0" id="fid_451" unitRef="Shares">38606</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" decimals="0" id="fid_453" unitRef="USD">4</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2019-12-31_tenx_CommonStocksMember" decimals="0" id="fid_452" unitRef="Shares">6741860</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_tenx_CommonStocksMember" decimals="0" id="fid_454" unitRef="USD">674</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_455" unitRef="USD">239939797</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_456" unitRef="USD">458</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="fid_457" unitRef="USD">-236168436</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" id="fid_458" unitRef="USD">3772497</us-gaap:StockholdersEquity> <tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_460" unitRef="Shares">750000</tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares> <tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_462" unitRef="USD">75</tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount> <tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_463" unitRef="USD">2129930</tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount> <tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_466" unitRef="USD">2130005</tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount> <tenx:CompensationOnOptionsIssued contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_468" unitRef="USD">0</tenx:CompensationOnOptionsIssued> <tenx:CompensationOnOptionsIssued contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_469" unitRef="USD">72376</tenx:CompensationOnOptionsIssued> <tenx:CompensationOnOptionsIssued contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_472" unitRef="USD">72376</tenx:CompensationOnOptionsIssued> <tenx:CommonStockIssuedForServicesRenderedShares contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_474" unitRef="Shares">77987</tenx:CommonStockIssuedForServicesRenderedShares> <tenx:CommonStockIssuedForServicesRenderedAmount contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_476" unitRef="USD">8</tenx:CommonStockIssuedForServicesRenderedAmount> <tenx:CommonStockIssuedForServicesRenderedAmount contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_477" unitRef="USD">99992</tenx:CommonStockIssuedForServicesRenderedAmount> <tenx:CommonStockIssuedForServicesRenderedAmount contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_480" unitRef="USD">100000</tenx:CommonStockIssuedForServicesRenderedAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockShares contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_481" unitRef="Shares">-38396</tenx:CommonStockIssuedForConvertiblePreferredStockShares> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_483" unitRef="USD">-4</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockShares contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_482" unitRef="Shares">38396</tenx:CommonStockIssuedForConvertiblePreferredStockShares> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_484" unitRef="USD">4</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_485" unitRef="USD">0</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_488" unitRef="USD">0</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:ExerciseOfPreFundedWarrantsShares contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_490" unitRef="Shares">400000</tenx:ExerciseOfPreFundedWarrantsShares> <tenx:ExerciseOfPreFundedWarrantsAmount contextRef="From2020-01-01to2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_492" unitRef="USD">40</tenx:ExerciseOfPreFundedWarrantsAmount> <tenx:ExerciseOfPreFundedWarrantsAmount contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_493" unitRef="USD">0</tenx:ExerciseOfPreFundedWarrantsAmount> <tenx:ExerciseOfPreFundedWarrantsAmount contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_496" unitRef="USD">40</tenx:ExerciseOfPreFundedWarrantsAmount> <tenx:UnrealizedLossOnMarketableSecurities contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_500" unitRef="USD">-1622</tenx:UnrealizedLossOnMarketableSecurities> <tenx:UnrealizedLossOnMarketableSecurities contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_502" unitRef="USD">-1622</tenx:UnrealizedLossOnMarketableSecurities> <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" decimals="0" id="fid_507" unitRef="USD">-2654644</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" decimals="0" id="fid_508" unitRef="USD">-2654644</us-gaap:NetIncomeLoss> <us-gaap:SharesIssued contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_509" unitRef="Shares">210</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_511" unitRef="USD">0</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_510" unitRef="Shares">8008243</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_tenx_CommonStocksMember" decimals="0" id="fid_512" unitRef="USD">801</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_513" unitRef="USD">242242095</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_514" unitRef="USD">-1164</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" decimals="0" id="fid_515" unitRef="USD">-238823080</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" id="fid_516" unitRef="USD">3418652</us-gaap:StockholdersEquity> <tenx:CompensationOnOptionsIssued contextRef="From2020-04-01to2020-06-30_tenx_CommonStocksMember" decimals="0" id="fid_518" unitRef="USD">0</tenx:CompensationOnOptionsIssued> <tenx:CompensationOnOptionsIssued contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_519" unitRef="USD">63166</tenx:CompensationOnOptionsIssued> <tenx:CompensationOnOptionsIssued contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_522" unitRef="USD">63166</tenx:CompensationOnOptionsIssued> <tenx:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2020-04-01to2020-06-30_tenx_CommonStocksMember" decimals="0" id="fid_524" unitRef="Shares">2087515</tenx:StockIssuedDuringPeriodSharesWarrantsExercised> <tenx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2020-04-01to2020-06-30_tenx_CommonStocksMember" decimals="0" id="fid_526" unitRef="USD">209</tenx:StockIssuedDuringPeriodValueWarrantsExercised> <tenx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_527" unitRef="USD">1690455</tenx:StockIssuedDuringPeriodValueWarrantsExercised> <tenx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_530" unitRef="USD">1690664</tenx:StockIssuedDuringPeriodValueWarrantsExercised> <tenx:UnrealizedGainOnMarketableSecurities contextRef="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_534" unitRef="USD">3238</tenx:UnrealizedGainOnMarketableSecurities> <tenx:UnrealizedGainOnMarketableSecurities contextRef="From2020-04-01to2020-06-30" decimals="0" id="fid_536" unitRef="USD">3238</tenx:UnrealizedGainOnMarketableSecurities> <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" decimals="0" id="fid_541" unitRef="USD">-2146550</us-gaap:NetIncomeLoss> <us-gaap:SharesIssued contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" decimals="0" id="fid_543" unitRef="Shares">210</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" decimals="0" id="fid_545" unitRef="USD">0</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2020-06-30_tenx_CommonStocksMember" decimals="0" id="fid_544" unitRef="Shares">10095758</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_tenx_CommonStocksMember" decimals="0" id="fid_546" unitRef="USD">1010</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_547" unitRef="USD">243995716</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_548" unitRef="USD">2074</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" decimals="0" id="fid_549" unitRef="USD">-240969630</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" id="fid_550" unitRef="USD">3029170</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="0" id="fid_551" unitRef="Shares">210</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="0" id="fid_553" unitRef="USD">0</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2020-12-31_tenx_CommonStocksMember" decimals="0" id="fid_552" unitRef="Shares">12619369</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_tenx_CommonStocksMember" decimals="0" id="fid_554" unitRef="USD">1262</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_555" unitRef="USD">250644197</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_556" unitRef="USD">-70</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="fid_557" unitRef="USD">-246019827</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" id="fid_558" unitRef="USD">4625562</us-gaap:StockholdersEquity> <tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionShares contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_559" unitRef="Shares">10232</tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionShares> <tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_561" unitRef="USD">1</tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount> <tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionShares contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" decimals="0" id="fid_560" unitRef="Shares">1892905</tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionShares> <tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" decimals="0" id="fid_562" unitRef="USD">189</tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount> <tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_563" unitRef="USD">21582141</tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount> <tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount contextRef="From2021-01-01to2021-03-31" decimals="0" id="fid_566" unitRef="USD">21582331</tenx:CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount> <tenx:CompensationOnOptionsIssued contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_569" unitRef="USD">91609</tenx:CompensationOnOptionsIssued> <tenx:CompensationOnOptionsIssued contextRef="From2021-01-01to2021-03-31" decimals="0" id="fid_572" unitRef="USD">91609</tenx:CompensationOnOptionsIssued> <tenx:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" decimals="0" id="fid_574" unitRef="Shares">457038</tenx:StockIssuedDuringPeriodSharesWarrantsExercised> <tenx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2021-01-01to2021-03-31_tenx_CommonStocksMember" decimals="0" id="fid_576" unitRef="USD">46</tenx:StockIssuedDuringPeriodValueWarrantsExercised> <tenx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_577" unitRef="USD">544605</tenx:StockIssuedDuringPeriodValueWarrantsExercised> <tenx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2021-01-01to2021-03-31" decimals="0" id="fid_580" unitRef="USD">544651</tenx:StockIssuedDuringPeriodValueWarrantsExercised> <tenx:UnrealizedLossOnMarketableSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_584" unitRef="USD">-332</tenx:UnrealizedLossOnMarketableSecurities> <tenx:UnrealizedLossOnMarketableSecurities contextRef="From2021-01-01to2021-03-31" decimals="0" id="fid_586" unitRef="USD">-332</tenx:UnrealizedLossOnMarketableSecurities> <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" decimals="0" id="fid_591" unitRef="USD">-23748140</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31" decimals="0" id="fid_592" unitRef="USD">-23748140</us-gaap:NetIncomeLoss> <us-gaap:SharesIssued contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_593" unitRef="Shares">10442</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" decimals="0" id="fid_595" unitRef="USD">1</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2021-03-31_tenx_CommonStocksMember" decimals="0" id="fid_594" unitRef="Shares">14969312</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_tenx_CommonStocksMember" decimals="0" id="fid_596" unitRef="USD">1497</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_597" unitRef="USD">272862552</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_598" unitRef="USD">-402</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" decimals="0" id="fid_599" unitRef="USD">-269767967</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" id="fid_600" unitRef="USD">3095681</us-gaap:StockholdersEquity> <tenx:CommonStockIssuedForConvertiblePreferredStockShares contextRef="From2021-04-01to2021-06-30_us-gaap_PreferredStockMember" decimals="0" id="fid_601" unitRef="Shares">-10232</tenx:CommonStockIssuedForConvertiblePreferredStockShares> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2021-04-01to2021-06-30_us-gaap_PreferredStockMember" decimals="0" id="fid_603" unitRef="USD">-1</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockShares contextRef="From2021-04-01to2021-06-30_tenx_CommonStocksMember" decimals="0" id="fid_602" unitRef="Shares">10232000</tenx:CommonStockIssuedForConvertiblePreferredStockShares> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2021-04-01to2021-06-30_tenx_CommonStocksMember" decimals="0" id="fid_604" unitRef="USD">1023</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2021-04-01to2021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_605" unitRef="USD">-1022</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CommonStockIssuedForConvertiblePreferredStockAmount contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_608" unitRef="USD">0</tenx:CommonStockIssuedForConvertiblePreferredStockAmount> <tenx:CompensationOnOptionsIssued contextRef="From2021-04-01to2021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_611" unitRef="USD">92339</tenx:CompensationOnOptionsIssued> <tenx:CompensationOnOptionsIssued contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_614" unitRef="USD">92339</tenx:CompensationOnOptionsIssued> <tenx:UnrealizedGainOnMarketableSecurities contextRef="From2021-04-01to2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_618" unitRef="USD">128</tenx:UnrealizedGainOnMarketableSecurities> <tenx:UnrealizedGainOnMarketableSecurities contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_620" unitRef="USD">128</tenx:UnrealizedGainOnMarketableSecurities> <us-gaap:SharesIssued contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" decimals="0" id="fid_627" unitRef="Shares">210</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" decimals="0" id="fid_629" unitRef="USD">0</us-gaap:StockholdersEquity> <us-gaap:SharesIssued contextRef="AsOf2021-06-30_tenx_CommonStocksMember" decimals="0" id="fid_628" unitRef="Shares">25201312</us-gaap:SharesIssued> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_tenx_CommonStocksMember" decimals="0" id="fid_630" unitRef="USD">2520</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="fid_631" unitRef="USD">272953869</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="fid_632" unitRef="USD">-274</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" decimals="0" id="fid_633" unitRef="USD">-271484983</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" id="fid_634" unitRef="USD">1471132</us-gaap:StockholdersEquity> <us-gaap:ProfitLoss contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_659" unitRef="USD">-25465156</us-gaap:ProfitLoss> <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_660" unitRef="USD">-4801194</us-gaap:ProfitLoss> <us-gaap:DepreciationAndAmortization contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_662" unitRef="USD">2026</us-gaap:DepreciationAndAmortization> <us-gaap:DepreciationAndAmortization contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_663" unitRef="USD">2150</us-gaap:DepreciationAndAmortization> <us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_664" unitRef="USD">949</us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable> <us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_665" unitRef="USD">406</us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable> <us-gaap:AmortizationOfLeasedAsset contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_666" unitRef="USD">53859</us-gaap:AmortizationOfLeasedAsset> <us-gaap:AmortizationOfLeasedAsset contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_667" unitRef="USD">54223</us-gaap:AmortizationOfLeasedAsset> <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_668" unitRef="USD">-247233</us-gaap:GainsLossesOnExtinguishmentOfDebt> <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_669" unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt> <tenx:IssuanceOfCommonStockAndPreferredStockForAssetAcquisition contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_670" unitRef="USD">21582331</tenx:IssuanceOfCommonStockAndPreferredStockForAssetAcquisition> <tenx:IssuanceOfCommonStockAndPreferredStockForAssetAcquisition contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_671" unitRef="USD">0</tenx:IssuanceOfCommonStockAndPreferredStockForAssetAcquisition> <tenx:IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_672" unitRef="USD">183948</tenx:IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants> <tenx:IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_673" unitRef="USD">135542</tenx:IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants> <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_674" unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims> <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_675" unitRef="USD">50000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims> <tenx:AmortizationOfPremiumOnMarketableSecurities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_676" unitRef="USD">6896</tenx:AmortizationOfPremiumOnMarketableSecurities> <tenx:AmortizationOfPremiumOnMarketableSecurities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_677" unitRef="USD">2647</tenx:AmortizationOfPremiumOnMarketableSecurities> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_679" unitRef="USD">-267284</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_680" unitRef="USD">170046</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_681" unitRef="USD">-923295</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities> <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_682" unitRef="USD">-453406</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities> <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_683" unitRef="USD">6720</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities> <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_684" unitRef="USD">-60379</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_685" unitRef="USD">-5066239</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_686" unitRef="USD">-4899965</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_688" unitRef="USD">345540</us-gaap:PaymentsToAcquireMarketableSecurities> <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_689" unitRef="USD">351138</us-gaap:PaymentsToAcquireMarketableSecurities> <tenx:SaleOfMarketableSecurities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_690" unitRef="USD">290184</tenx:SaleOfMarketableSecurities> <tenx:SaleOfMarketableSecurities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_691" unitRef="USD">365049</tenx:SaleOfMarketableSecurities> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_692" unitRef="USD">1875</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_693" unitRef="USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_694" unitRef="USD">-57231</us-gaap:NetCashProvidedByUsedInInvestingActivities> <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_695" unitRef="USD">13911</us-gaap:NetCashProvidedByUsedInInvestingActivities> <us-gaap:ProceedsFromWarrantExercises contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_697" unitRef="USD">544651</us-gaap:ProceedsFromWarrantExercises> <us-gaap:ProceedsFromWarrantExercises contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_698" unitRef="USD">1690704</us-gaap:ProceedsFromWarrantExercises> <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_699" unitRef="USD">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity> <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_700" unitRef="USD">2130005</us-gaap:ProceedsFromIssuanceOrSaleOfEquity> <us-gaap:ProceedsFromIssuanceOfMediumTermNotes contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_701" unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfMediumTermNotes> <us-gaap:ProceedsFromIssuanceOfMediumTermNotes contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_702" unitRef="USD">244657</us-gaap:ProceedsFromIssuanceOfMediumTermNotes> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_703" unitRef="USD">544651</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_704" unitRef="USD">4065366</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_705" unitRef="USD">-4578819</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_706" unitRef="USD">-820688</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" id="fid_707" unitRef="USD">6250241</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" decimals="0" id="fid_708" unitRef="USD">4905993</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" id="fid_709" unitRef="USD">1671422</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" decimals="0" id="fid_710" unitRef="USD">4085305</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_761" unitRef="USD">333779</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability> <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2020-01-01to2020-06-30" decimals="0" id="fid_762" unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability> <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_711"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 1. DESCRIPTION OF BUSINESS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Tenax Therapeutics, Inc. (the “Company”) was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David &amp; Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. On June 17, 2008, the stockholders of Synthetic Blood International approved the Agreement and Plan of Merger dated April 28, 2008, between Synthetic Blood International and Oxygen Biotherapeutics, Inc., a Delaware corporation. Oxygen Biotherapeutics was formed on April 17, 2008 by Synthetic Blood International to participate in the merger for the purpose of changing the state of domicile of Synthetic Blood International from New Jersey to Delaware. Certificates of Merger were filed with the states of New Jersey and Delaware and the merger was effective June 30, 2008. Under the Plan of Merger, Oxygen Biotherapeutics was the surviving corporation and each share of Synthetic Blood International common stock outstanding on June 30, 2008 was converted to one share of Oxygen Biotherapeutics common stock. On September 19, 2014, the Company changed its name to Tenax Therapeutics, Inc. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 18, 2013, the Company created a wholly owned subsidiary, Life Newco, Inc., a Delaware corporation (“Life Newco”), to acquire certain assets of Phyxius Pharma, Inc., a Delaware corporation (“Phyxius”) pursuant to an Asset Purchase Agreement, dated October 21, 2013 (the “Asset Purchase Agreement”), by and among the Company, Life Newco, Phyxius and the stockholders of Phyxius (the “Phyxius Stockholders”). As further discussed in Note 8 below, on November 13, 2013, under the terms and subject to the conditions of the Asset Purchase Agreement, Life Newco acquired certain assets, including a license granting Life Newco an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, the Company entered into an Amendment (the “Amendment”) to the License between the Company and Orion Corporation, a global healthcare company incorporated under the laws of Finland (“Orion”), to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan to the scope of the License, subject to specified limitations. The Amendment also amends the tiered royalty payments based on net sales of the Product in the Territory (each as defined in the License, as amended by the Amendment) made by the Company and its sublicensees. Pursuant to the Amendment, the term of the License has been extended until 10 years after the launch of the Product in the Territory, provided that the License will continue after the end of the term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. In the event that no regulatory approval for the Product has been granted in the United States on or before September 20, 2028, however, either party will have the right to terminate the License with immediate effect. The Company intends to conduct an upcoming Phase 3 study in pulmonary hypertension patients utilizing one of these oral formulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, the Company, Life Newco II, Inc., a Delaware corporation and a wholly-owned, direct subsidiary of the Company (“Life Newco II”), PHPrecisionMed Inc., a Delaware corporation (“PHPM,”) and Dr. Stuart Rich, solely in his capacity as holders’ representative (in such capacity, the “Representative”), entered into an Agreement and Plan of Merger, dated January 15, 2021 (the “Merger Agreement”), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company would acquire 100% of the equity of PHPM. Under the terms of the Merger Agreement, Life Newco II would merge with and into PHPM, with PHPM surviving as a wholly owned subsidiary of the Company (the “Merger”). On January 15, 2021, the Company completed the acquisition contemplated by the Merger Agreement (the “Acquisition”). As a result of the Acquisition the Company intends to develop pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States and the rest of the world.</p></us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock> <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_712"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Basis of Presentation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet on December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the period ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) rules and regulations. Operating results for the three and six-month period ended June 30, 2021 are not necessarily indicative of results for the full year or any other future periods. As such, it is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Management believes the accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $271 million on June 30, 2021 and $246 million on December 31, 2020 and used cash in operations of $5.1 million and $4.9 million during the six months ended June 30, 2021 and 2020, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 10 below, the Company sold 4,773,269 units ("Units") in a private placement at a purchase price of $2.095 per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of common stock and one unregistered warrant to purchase one share of common stock for gross proceeds of approximately $10 million. The Company requires substantial additional funds to complete its planned clinical trials and to pursue regulatory approvals. Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying June 30, 2021 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, to maintain present financing, and to generate cash from future operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Use of Estimates</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In preparing the unaudited condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Principles of Consolidation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying condensed consolidated financial statements include the accounts and transactions of the Company, Life Newco and Life Newco II. All material intercompany transactions and balances have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Liquidity and Management’s Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 30, 2021, the Company had cash and cash equivalents, including the fair value of its marketable securities, of approximately $2.2 million. The Company used $5.1 million of cash for operating activities during the six months ended June 30, 2021 and had stockholders’ equity of $1.5 million, versus $4.6 million on December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company expects to continue to incur expenses related to development of imatinib for pulmonary arterial hypertension and levosimendan for pulmonary hypertension and to continue with the development of other potential product candidates. Based on its resources on June 30, 2021 and including the net proceeds from its July 2021 offering (as discussed in Note 10 below), the Company believes that it has sufficient capital to fund its planned operations through the second quarter of calendar year 2022. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>COVID-19 Impact and Related Risks</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The continued spread of COVID-19 globally could adversely affect the Company’s ability to retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some of these investigators and site staff may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede movement or interrupt healthcare services, or if they become infected with COVID-19 themselves, which would delay the Company’s ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The full extent to which the COVID-19 pandemic and the various responses to it might impact the Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond the Company’s control.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Loss per Share</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Basic net loss per share, which excludes antidilutive securities, is computed by dividing net loss by the weighted-average number of common shares outstanding for that particular period. In contrast, diluted net loss per share considers the potential dilution that could occur from other equity instruments that would increase the total number of outstanding shares of common stock. Such amounts include shares potentially issuable under outstanding options, convertible preferred shares and warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following outstanding options, convertible preferred shares and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,797,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,274,492</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,260,005</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Leases</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in the Company’s condensed consolidated balance sheets. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. The Company’s leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that the Company will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to account for leases with an initial term of 12 months or less similar to previous guidance for operating leases, under which the Company will recognize those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Recent Accounting Pronouncements </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In December 2019, the Financial Accounting Standards Board (“FASB”) issued an accounting standard intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740, Income Taxes and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the FASB issued an accounting standard that amends how credit losses are measured and reported for certain financial instruments that are not accounted for at fair value through net income. This standard requires that credit losses be presented as an allowance rather than as a write-down for available-for-sale debt securities and will be effective for interim and annual reporting periods beginning January 1, 2023, with early adoption permitted. A modified retrospective approach is to be used for certain parts of this guidance, while other parts of the guidance are to be applied using a prospective approach. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p></us-gaap:SignificantAccountingPoliciesTextBlock> <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_721"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet on December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the period ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) rules and regulations. Operating results for the three and six-month period ended June 30, 2021 are not necessarily indicative of results for the full year or any other future periods. As such, it is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. </p></us-gaap:BasisOfAccountingPolicyPolicyTextBlock> <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_722"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Management believes the accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $271 million on June 30, 2021 and $246 million on December 31, 2020 and used cash in operations of $5.1 million and $4.9 million during the six months ended June 30, 2021 and 2020, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 10 below, the Company sold 4,773,269 units ("Units") in a private placement at a purchase price of $2.095 per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of common stock and one unregistered warrant to purchase one share of common stock for gross proceeds of approximately $10 million. The Company requires substantial additional funds to complete its planned clinical trials and to pursue regulatory approvals. Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying June 30, 2021 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, to maintain present financing, and to generate cash from future operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p></us-gaap:SubstantialDoubtAboutGoingConcernTextBlock> <us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_766" unitRef="Shares">4773269</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement> <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare contextRef="From2021-01-01to2021-06-30" decimals="INF" id="fid_767" unitRef="USDPShares">2.095</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare> <tenx:AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds contextRef="From2021-01-01to2021-06-30" decimals="-6" id="fid_768" unitRef="USD">10000000</tenx:AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds> <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-06-30" id="fid_723"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In preparing the unaudited condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p></us-gaap:UseOfEstimates> <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_724"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying condensed consolidated financial statements include the accounts and transactions of the Company, Life Newco and Life Newco II. All material intercompany transactions and balances have been eliminated in consolidation.</p></us-gaap:ConsolidationPolicyTextBlock> <tenx:LiquidityAndManagementsPlanPolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_725"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 30, 2021, the Company had cash and cash equivalents, including the fair value of its marketable securities, of approximately $2.2 million. The Company used $5.1 million of cash for operating activities during the six months ended June 30, 2021 and had stockholders’ equity of $1.5 million, versus $4.6 million on December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company expects to continue to incur expenses related to development of imatinib for pulmonary arterial hypertension and levosimendan for pulmonary hypertension and to continue with the development of other potential product candidates. Based on its resources on June 30, 2021 and including the net proceeds from its July 2021 offering (as discussed in Note 10 below), the Company believes that it has sufficient capital to fund its planned operations through the second quarter of calendar year 2022. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p></tenx:LiquidityAndManagementsPlanPolicyTextBlock> <us-gaap:MarketableSecurities contextRef="AsOf2021-06-30" decimals="-5" id="fid_138" unitRef="USD">2200000</us-gaap:MarketableSecurities> <us-gaap:StockholdersEquityBeforeTreasuryStock contextRef="AsOf2020-12-31" decimals="-5" id="fid_743" unitRef="USD">1500000</us-gaap:StockholdersEquityBeforeTreasuryStock> <tenx:Covid19ImpactPolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_726"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The continued spread of COVID-19 globally could adversely affect the Company’s ability to retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some of these investigators and site staff may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede movement or interrupt healthcare services, or if they become infected with COVID-19 themselves, which would delay the Company’s ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The full extent to which the COVID-19 pandemic and the various responses to it might impact the Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond the Company’s control.</p></tenx:Covid19ImpactPolicyTextBlock> <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_727"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Basic net loss per share, which excludes antidilutive securities, is computed by dividing net loss by the weighted-average number of common shares outstanding for that particular period. In contrast, diluted net loss per share considers the potential dilution that could occur from other equity instruments that would increase the total number of outstanding shares of common stock. Such amounts include shares potentially issuable under outstanding options, convertible preferred shares and warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following outstanding options, convertible preferred shares and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,797,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,274,492</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,260,005</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:EarningsPerSharePolicyTextBlock> <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_730"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,797,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,274,492</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,260,005</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-06-30_tenx_WarranttoPurchaseCommonStockMember" decimals="0" id="fid_123" unitRef="Shares">15797503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-06-30_tenx_WarranttoPurchaseCommonStockMember" decimals="0" id="fid_124" unitRef="Shares">12274492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-06-30_tenx_PrefundedWarrantsToPurchaseCommonStockMember" decimals="0" id="fid_764" unitRef="Shares">5260005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" decimals="0" id="fid_125" unitRef="Shares">779885</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-06-30_tenx_SimdaxLicenseAgreementMember" decimals="0" id="fid_126" unitRef="Shares">450203</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-06-30_tenx_ConvertiblePreferredSharesOutstandingMember" decimals="0" id="fid_127" unitRef="Shares">210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-06-30_tenx_ConvertiblePreferredSharesOutstandingMember" decimals="0" id="fid_128" unitRef="Shares">210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_728"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in the Company’s condensed consolidated balance sheets. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. The Company’s leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that the Company will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to account for leases with an initial term of 12 months or less similar to previous guidance for operating leases, under which the Company will recognize those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term.</p></us-gaap:LesseeLeasesPolicyTextBlock> <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_729"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In December 2019, the Financial Accounting Standards Board (“FASB”) issued an accounting standard intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740, Income Taxes and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the FASB issued an accounting standard that amends how credit losses are measured and reported for certain financial instruments that are not accounted for at fair value through net income. This standard requires that credit losses be presented as an allowance rather than as a write-down for available-for-sale debt securities and will be effective for interim and annual reporting periods beginning January 1, 2023, with early adoption permitted. A modified retrospective approach is to be used for certain parts of this guidance, while other parts of the guidance are to be applied using a prospective approach. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock> <us-gaap:FairValueDisclosuresTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_713"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 3. FAIR VALUE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines the fair value of its financial assets and liabilities in accordance with the Accounting Standards Codification (“ASC”) 820 Fair Value Measurements. The Company’s balance sheet includes the following financial instruments: cash and cash equivalents, investments in marketable securities, and warrant liabilities. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to the short-term nature of these instruments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Accounting for fair value measurements involves a single definition of fair value, along with a conceptual framework to measure fair value, with a fair value defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” The fair value measurement hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level one</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Quoted market prices in active markets for identical assets or liabilities;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level two</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inputs other than level one inputs that are either directly or indirectly observable; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level three</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company applies valuation techniques that (1) place greater reliance on observable inputs and less reliance on unobservable inputs and (2) are consistent with the market approach, the income approach and/or the cost approach, and include enhanced disclosures of fair value measurements in the Company’s condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Investments in Marketable Securities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive income/(loss), unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in other income in the condensed consolidated statements of comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. As of June 30, 2021, the Company believes that the costs of its investments are recoverable in all material respects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments is classified as Level 2 in the fair value hierarchy as defined in GAAP. These fair values are obtained from independent pricing services which utilize Level 2 inputs:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="18" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amortized </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accrued </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized Gains</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized losses</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Corporate debt securities </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total investments </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">All of the Company’s investments have scheduled maturities of less than one year as of June 30, 2021 and December 31, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following tables summarize information regarding assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of June 30, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of December 31, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">There were no significant transfers between levels in the six months ended June 30, 2021.</p></us-gaap:FairValueDisclosuresTextBlock> <tenx:ScheduleOfInvestmentsInMarketableSecurities contextRef="From2021-01-01to2021-06-30" id="fid_731"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="18" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amortized </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accrued </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized Gains</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized losses</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Corporate debt securities </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total investments </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></tenx:ScheduleOfInvestmentsInMarketableSecurities> <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" decimals="0" id="fid_140" unitRef="USD">506530</us-gaap:AvailableForSaleSecuritiesAmortizedCost> <us-gaap:AccruedInvestmentIncomeReceivable contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" decimals="0" id="fid_142" unitRef="USD">4690</us-gaap:AccruedInvestmentIncomeReceivable> <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains contextRef="From2021-01-01to2021-06-30_us-gaap_CorporateDebtSecuritiesMember" decimals="0" id="fid_144" unitRef="USD">46</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains> <tenx:GrossUnrealizedLosses contextRef="From2021-01-01to2021-06-30_us-gaap_CorporateDebtSecuritiesMember" decimals="0" id="fid_146" unitRef="USD">-323</tenx:GrossUnrealizedLosses> <tenx:AvailableForSaleSecuritiesEstimatedFairValue contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" decimals="0" id="fid_148" unitRef="USD">510943</tenx:AvailableForSaleSecuritiesEstimatedFairValue> <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="AsOf2021-06-30" decimals="0" id="fid_139" unitRef="USD">506530</us-gaap:AvailableForSaleSecuritiesAmortizedCost> <us-gaap:AccruedInvestmentIncomeReceivable contextRef="AsOf2021-06-30" decimals="0" id="fid_141" unitRef="USD">4690</us-gaap:AccruedInvestmentIncomeReceivable> <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_143" unitRef="USD">46</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains> <tenx:GrossUnrealizedLosses contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_145" unitRef="USD">-323</tenx:GrossUnrealizedLosses> <tenx:AvailableForSaleSecuritiesEstimatedFairValue contextRef="AsOf2021-06-30" decimals="0" id="fid_147" unitRef="USD">510943</tenx:AvailableForSaleSecuritiesEstimatedFairValue> <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_732"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of June 30, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of December 31, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2021-06-30" decimals="0" id="fid_151" unitRef="USD">1671422</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" decimals="0" id="fid_152" unitRef="USD">1671422</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" decimals="0" id="fid_154" unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" decimals="0" id="fid_156" unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2021-06-30" decimals="0" id="fid_159" unitRef="USD">510943</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" decimals="0" id="fid_160" unitRef="USD">0</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" decimals="0" id="fid_162" unitRef="USD">510943</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" decimals="0" id="fid_164" unitRef="USD">0</us-gaap:AvailableForSaleSecurities> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2020-12-31" decimals="0" id="fid_150" unitRef="USD">6250241</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" decimals="0" id="fid_153" unitRef="USD">6250241</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" decimals="0" id="fid_155" unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" decimals="0" id="fid_157" unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31" decimals="0" id="fid_158" unitRef="USD">462687</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" decimals="0" id="fid_161" unitRef="USD">0</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" decimals="0" id="fid_163" unitRef="USD">462687</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" decimals="0" id="fid_165" unitRef="USD">0</us-gaap:AvailableForSaleSecurities> <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_714"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 4. BALANCE SHEET COMPONENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Property and equipment, net </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Property and equipment consist of the following as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Office furniture and fixtures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Computer equipment and software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,631</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,307</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,664</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,843</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,368</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,821</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Depreciation expense was approximately $1,000 for each of the three-month periods ended June 30, 2021 and 2020. Depreciation expense was approximately $2,000 for each of the six-month periods ended June 30, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Accrued liabilities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Accrued liabilities consist of the following as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Employee related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,551</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">860,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Operating costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,051</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">319,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">383,063</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,240,616</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:SupplementalBalanceSheetDisclosuresTextBlock> <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_733"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Office furniture and fixtures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Computer equipment and software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,631</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,307</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,664</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,843</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,368</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,821</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:PropertyPlantAndEquipmentTextBlock> <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2021-06-30" decimals="0" id="fid_167" unitRef="USD">43033</us-gaap:FurnitureAndFixturesGross> <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2020-12-31" decimals="0" id="fid_166" unitRef="USD">43033</us-gaap:FurnitureAndFixturesGross> <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2021-06-30" decimals="0" id="fid_169" unitRef="USD">23631</us-gaap:CapitalizedComputerSoftwareGross> <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2020-12-31" decimals="0" id="fid_168" unitRef="USD">23307</us-gaap:CapitalizedComputerSoftwareGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-06-30" decimals="0" id="fid_171" unitRef="USD">66664</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" id="fid_170" unitRef="USD">66340</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-06-30" decimals="0" id="fid_173" unitRef="USD">60843</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment> <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" id="fid_172" unitRef="USD">60368</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment> <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" id="fid_175" unitRef="USD">5821</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" id="fid_174" unitRef="USD">5972</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:Depreciation contextRef="From2021-04-01to2021-06-30" decimals="0" id="fid_185" unitRef="USD">1000</us-gaap:Depreciation> <us-gaap:Depreciation contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_184" unitRef="USD">2000</us-gaap:Depreciation> <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_734"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Employee related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,551</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">860,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Operating costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,051</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">319,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">383,063</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,240,616</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock> <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_177" unitRef="USD">127551</us-gaap:EmployeeRelatedLiabilitiesCurrent> <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_176" unitRef="USD">860629</us-gaap:EmployeeRelatedLiabilitiesCurrent> <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_179" unitRef="USD">154051</us-gaap:OtherAccruedLiabilitiesCurrent> <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_178" unitRef="USD">319608</us-gaap:OtherAccruedLiabilitiesCurrent> <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_181" unitRef="USD">101461</us-gaap:OperatingLeaseLiabilityCurrent> <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_180" unitRef="USD">60379</us-gaap:OperatingLeaseLiabilityCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_183" unitRef="USD">383063</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_182" unitRef="USD">1240616</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_715"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 5. LEASE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In January 2011, the Company entered into the Lease with Concourse Associates, LLC for office facilities located at the premises in Morrisville, North Carolina (the “Lease”). The Lease was amended in August 2015 to extend the term for the 5,954 square foot rental. The current term began on March 1, 2016 and continues for 64 months to June 30, 2021. Rent payments began on July 1, 2016, following the conclusion of a four-month rent abatement period. The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease thirty-six months after the commencement of the initial term if no additional space (“Expansion Space”) became available. On April 2, 2021, the Company negotiated a 3-year extension to the existing lease term, commencing July 1, 2021. Beginning on the commencement date, the annual base rent will be increased to $125,034 and will increase 2.5% annually for lease years 2 and 3. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and determined that, except for the Lease described above, none of the Company’s contracts contain a lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The balance sheet classification of our lease liabilities was as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">239,039</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the maturities of our operating lease liabilities were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Year ending December 31, </strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,517</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,702</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">384,628</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,128</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Operating lease liability</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Operating lease liabilities are based on the net present value of the remaining Lease payments over the remaining Lease term. In determining the present value of lease payments, the Company used the incremental borrowing rate based on the information available at the Lease commencement date. As of June 30, 2021, the remaining Lease term is 36 months and the discount rate used to determine the operating lease liability was 8.0%. For the six months ending June 30, 2021, the Company paid $67,765 in total lease expenses, including $5,963 for common area maintenance charges. </p></us-gaap:LeasesOfLesseeDisclosureTextBlock> <us-gaap:AreaOfLand contextRef="AsOf2015-08-31" decimals="INF" id="fid_198" unitRef="sqft">5954</us-gaap:AreaOfLand> <tenx:LeaseTermPeriod contextRef="From2021-01-01to2021-06-30" id="fid_199">P64Y</tenx:LeaseTermPeriod> <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases contextRef="From2021-01-01to2021-06-30" id="fid_200">The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease thirty-six months after the commencement of the initial term if no additional space (“Expansion Space”) became available. On April 2, 2021, the Company negotiated a 3-year extension to the existing lease term, commencing July 1, 2021</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases> <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_201" unitRef="USD">125034</us-gaap:OperatingLeasesRentExpenseNet> <tenx:PercentageOfAnnualIncreaseInRent contextRef="From2021-01-01to2021-06-30" decimals="INF" id="fid_202" unitRef="Pure">0.025</tenx:PercentageOfAnnualIncreaseInRent> <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_735"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">239,039</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:LesseeOperatingLeasesTextBlock> <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_191" unitRef="USD">101461</us-gaap:OperatingLeaseLiabilityCurrent> <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_188" unitRef="USD">60379</us-gaap:OperatingLeaseLiabilityCurrent> <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="AsOf2021-06-30" decimals="0" id="fid_189" unitRef="USD">239039</us-gaap:DeferredTaxLiabilitiesNoncurrent> <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="0" id="fid_190" unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesNoncurrent> <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-06-30" decimals="0" id="fid_193" unitRef="USD">340500</us-gaap:OperatingLeaseLiability> <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" decimals="0" id="fid_192" unitRef="USD">60379</us-gaap:OperatingLeaseLiability> <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_736"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Year ending December 31, </strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,517</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,702</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">384,628</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,128</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Operating lease liability</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-06-30" decimals="0" id="fid_748" unitRef="USD">62517</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2021-06-30" decimals="0" id="fid_749" unitRef="USD">126612</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2021-06-30" decimals="0" id="fid_750" unitRef="USD">129797</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2021-06-30" decimals="0" id="fid_751" unitRef="USD">65702</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-06-30" decimals="0" id="fid_752" unitRef="USD">384628</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue> <tenx:LessImputedInterest contextRef="AsOf2021-06-30" decimals="0" id="fid_753" unitRef="USD">-44128</tenx:LessImputedInterest> <tenx:RemainingLeaseTerm contextRef="From2021-01-01to2021-06-30" id="fid_351">P36Y</tenx:RemainingLeaseTerm> <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-06-30" decimals="INF" id="fid_195" unitRef="Pure">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent> <us-gaap:LeaseCost contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_196" unitRef="USD">67765</us-gaap:LeaseCost> <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_716"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 6. NOTE PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Payroll Protection Program Loan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On April 30, 2020, the Company received a loan pursuant to the Paycheck Protection Program (the “PPP Loan”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), as administered by the U.S. Small Business Administration (“SBA”). The PPP Loan in the principal amount of $244,657 was disbursed by First Horizon Bank (the “Lender”) pursuant to a promissory note issued by us (the “Note”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The PPP Loan has a two-year term and bears interest at a rate of 1.00% per annum. Monthly principal and interest payments are deferred for sixteen months. Beginning September 30, 2021, the Company is required to make monthly payments of principal and interest of approximately $31,100 to the Lender. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations, and material adverse effects. The Company may prepay the principal of the PPP Loan at any time, subject to certain notice requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the terms of the CARES Act, Paycheck Protection Program loan recipients can apply for and be granted forgiveness for all or a portion of a loan granted under the program. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The Company is using the proceeds from the PPP Loan to fund payroll costs in accordance with the relevant terms and conditions of the CARES Act. However, no assurance is provided that forgiveness for any portion of the PPP Loan will be obtained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On May 28, 2021, the Company received notice from the SBA that the SBA had remitted $244,657 in principal and $2,576 in interest to the Lender in full forgiveness of the Company’s PPP Loan pursuant to the Company’s application to the SBA for forgiveness of the PPP Loan. The total amount was recorded as other income in the Company's condensed consolidated statement of comprehensive loss.</p></us-gaap:DebtDisclosureTextBlock> <tenx:PppLoanAmount contextRef="AsOf2021-06-30" decimals="0" id="fid_203" unitRef="USD">244657</tenx:PppLoanAmount> <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2021-06-30" decimals="INF" id="fid_206" unitRef="Pure">0.0100</us-gaap:DebtInstrumentInterestRateEffectivePercentage> <tenx:PppLoanMonthlyPayment contextRef="AsOf2021-06-30" decimals="0" id="fid_204" unitRef="USD">31100</tenx:PppLoanMonthlyPayment> <us-gaap:RepaymentsOfLongTermDebt contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_208" unitRef="USD">244657</us-gaap:RepaymentsOfLongTermDebt> <tenx:DebtInstrumentDecreaseForgivenessAccruedInterest contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_207" unitRef="USD">2576</tenx:DebtInstrumentDecreaseForgivenessAccruedInterest> <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_717"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>NOTE 7. MERGER</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, the Company, Life Newco II, PHPM, and Dr. Stuart Rich, solely in his capacity as Representative, entered into the Merger Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company would acquire 100% of the equity of PHPM. Under the terms of the Merger Agreement, Life Newco II would merge with and into PHPM, with PHPM surviving as a wholly owned subsidiary of the Company. On January 15, 2021, the Company completed the Acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As consideration for the Merger, the stockholders of PHPM received (i) 1,892,905 shares of the Company’s common stock (“Common Stock”), and (ii) 10,232 shares of the Company’s Series B convertible preferred stock, which are convertible into up to an aggregate of 10,232,000 shares of Common Stock (“Preferred Stock”) (collectively, the “Merger Consideration”). The issuance of 1,212,492 shares of Common Stock issuable upon conversion of the Preferred Stock, representing approximately 10% of the Merger Consideration, will be delayed as security for closing adjustments and post-closing indemnification obligations of PHPM and the stockholders of PHPM. Following receipt of the approval of the stockholders of the Company for the Conversion (as defined herein), each share of Preferred Stock will automatically convert into (i) 881.5 shares of Common Stock, and (ii) 118.5 shares of Common Stock to be delivered 24 months after the date of issuance of the Preferred Stock, subject to reduction for indemnification claims. The number of shares of Common Stock into which the Preferred Stock converts is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The Preferred Stock does not carry dividends or a liquidation preference. The Preferred Stock carries voting rights aggregating 4.99% of the Company’s Common Stock voting power immediately prior to the closing of the Merger. The rights, preferences and privileges of the Preferred Stock are set forth in the Certificate of Designation of Series B Convertible Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on January 15, 2021 (the “Certificate of Designation”). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pursuant to the Merger Agreement, the Board of Directors, at its Annual Meeting of Shareholders held on June 10, 2021, recommended to the Company’s shareholders, and the shareholders approved, the conversion of the Preferred Stock pursuant to the Certificate of Designation (the “Conversion”). In addition, (i) at the Company’s first regularly scheduled Board meeting following the closing of the Merger, the Board must appoint one director designated by the Representative to serve on the Board, and (ii) as promptly as practicable after the Company has obtained stockholder approval for the Conversion, the Board must appoint two additional directors designated by the Representative to serve on the Board. Dr. Stuart Rich, the co-founder and Chief Executive Officer, and a stockholder of PHPM, and Dr. Michael Davidson and Dr. Declan Doogan, the two other designees of the Representative, were appointed to the Board on February 25, 2021. In connection with the closing of the Merger, Dr. Stuart Rich was also appointed Chief Medical Officer of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company evaluated this acquisition in accordance with ASC 805, Business Combinations, to determine whether the assets and operations of PHPM met the definition of a business. Included in the in-process research and development project is the historical know-how, formula protocols, designs, and procedures expected to be needed to complete the related phase of testing. The Company concluded that the in-process research and development project is an identifiable intangible asset that would be accounted for as a single asset in a business combination. The Company also qualitatively concluded that there is no fair value associated with the clinical research organization contract and the clinical manufacturing organization contract because the services are being provided at market rates and could be provided by multiple vendors in the marketplace. Therefore, all of the consideration in the transaction will be allocated to the in-process research and development project. As such, the Company concluded that substantially all of the fair value of the gross assets acquired is concentrated in the single in-process research and development asset and the set is not a business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company is planning to use the acquired asset to further its clinical develop in an upcoming phase 3 clinical trial for the treatment of patients with PAH. Although the acquired asset may have utility in other patient populations, future development decisions for the acquired asset will be contingent upon the results of the contemplated phase 3 program for PAH. As such, the acquired asset does not have an alternative future use at the acquisition date. In accordance with ASC 730, Research and Development, the Company concluded the entire Purchase Price for the asset acquisition will be recorded as an expense on the acquisition date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The consideration transferred, assets acquired and liabilities assumed were recognized as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of shares of Common Stock issued</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,369,371</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair Value of Series B Convertible Preferred Stock issued at closing</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,212,960</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Total fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tangible assets acquired</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable assumed</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IPR&amp;D expense recognized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,732,331</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total fair value of consideration</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock> <tenx:CommonStockAcquired contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_217" unitRef="Shares">1892905</tenx:CommonStockAcquired> <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2021-06-30_us-gaap_SeriesBMember" decimals="0" id="fid_219" unitRef="Shares">10232</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion> <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_216" unitRef="Shares">10232000</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_218" unitRef="Shares">1212492</us-gaap:ConversionOfStockSharesIssued1> <tenx:PercentageOfPreferredStockCarriesVotingRights contextRef="From2021-01-01to2021-06-30" decimals="INF" id="fid_220" unitRef="Pure">0.0499</tenx:PercentageOfPreferredStockCarriesVotingRights> <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_737"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of shares of Common Stock issued</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,369,371</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair Value of Series B Convertible Preferred Stock issued at closing</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,212,960</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Total fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tangible assets acquired</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable assumed</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IPR&amp;D expense recognized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,732,331</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total fair value of consideration</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock> <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_209" unitRef="USD">3369371</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable> <us-gaap:BusinessCombinationConsiderationTransferredOther1 contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_210" unitRef="USD">18212960</us-gaap:BusinessCombinationConsiderationTransferredOther1> <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_211" unitRef="USD">21582331</us-gaap:BusinessCombinationConsiderationTransferred1> <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2021-06-30" decimals="0" id="fid_212" unitRef="USD">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets> <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="AsOf2021-06-30" decimals="0" id="fid_213" unitRef="USD">150000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable> <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2021-06-30" decimals="0" id="fid_214" unitRef="USD">-21732331</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet> <tenx:InProcessResearchAndDevelopmentExpense contextRef="From2021-01-01to2021-06-30" decimals="0" id="fid_215" unitRef="USD">21582331</tenx:InProcessResearchAndDevelopmentExpense> <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_718"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 8. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Simdax license agreement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On November 13, 2013, the Company acquired, through its wholly owned subsidiary, Life Newco, that certain License Agreement (the “License”), dated September 20, 2013 by and between Phyxius and Orion Corporation, a global healthcare company incorporated under the laws of Finland (“Orion”), and that certain Side Letter, dated October 15, 2013 by and between Phyxius and Orion. The License grants the Company an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan (the “Product”) in the United States and Canada (the “Territory”) from Orion. Pursuant to the License, the Company must use Orion’s “Simdax®” trademark to commercialize the Product. The License also grants to the Company a right of first refusal to commercialize new developments of the Product, including developments as to the formulation, presentation, means of delivery, route of administration, dosage or indication, i.e., line extension products. Orion’s ongoing role under the License includes sublicense approval, serving as the sole source of manufacture, holding a first right to enforce intellectual property rights in the Territory, and certain regulatory participation rights. Additionally, the Company must grant back to Orion a broad non-exclusive license to any patents or clinical trial data related to the Product developed by the Company under the License. The License has a fifteen (15) year term, provided, however, that the License will continue after the end of the fifteen-year term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, the Company entered into the Amendment to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan to the scope of the License, subject to specified limitations. The Amendment also amends the tiered royalty payments based on net sales of the Product in the Territory (each as defined in the License, as amended by the Amendment) made by the Company and its sublicensees. Pursuant to the Amendment, the term of the License has been extended until 10 years after the launch of the Product in the Territory, provided that the License will continue after the end of the term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. In the event that no regulatory approval for the Product has been granted in the United States on or before September 20, 2028, however, either party will have the right to terminate the License with immediate effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pursuant to the terms of the License, the Company paid to Orion a non-refundable up-front payment in the amount of $1.0 million. The License also includes the following development milestones for which the Company shall make non-refundable payments to Orion no later than twenty-eight (28) days after the occurrence of the applicable milestone event: (1) $2.0 million upon the grant of United States Food and Drug Administration approval, including all registrations, licenses, authorizations and necessary approvals, to develop and/or commercialize the Product in the United States; and (2) $1.0 million upon the grant of regulatory approval for the Product in Canada. Once commercialized, the Company is obligated to make certain non-refundable commercialization milestone payments to Orion, aggregating up to $13.0 million, contingent upon achievement of certain cumulative net sales amounts in the Territory. The Company must also pay Orion tiered royalties based on net sales of the Product in the Territory made by the Company and its sublicensees. After the end of the term of the License, the Company must pay Orion a royalty based on net sales of the Product in the Territory for as long as the Company sells the Product in the Territory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the Company has not met any of the developmental milestones and, accordingly, has not recorded any liability for the contingent payments due to Orion.</p></us-gaap:CommitmentsAndContingenciesDisclosureTextBlock> <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="From2013-11-01to2013-11-13_tenx_SimdaxLicenseAgreementMember" id="fid_227">P15Y</us-gaap:LongtermPurchaseCommitmentPeriod> <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember" id="fid_221">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod> <tenx:LicenseAgreementMaturityDate contextRef="From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember" id="fid_222">2028-09-20</tenx:LicenseAgreementMaturityDate> <tenx:NonRefundableUpFrontPayment contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" decimals="-5" id="fid_223" unitRef="USD">1000000.0</tenx:NonRefundableUpFrontPayment> <tenx:GrantPaidToAuthority contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" decimals="-5" id="fid_224" unitRef="USD">2000000.0</tenx:GrantPaidToAuthority> <tenx:GrantPaidToAuthorityOne contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" decimals="-5" id="fid_225" unitRef="USD">1000000.0</tenx:GrantPaidToAuthorityOne> <tenx:NonRefundableCommercializationMilestonePayment contextRef="From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember" decimals="-5" id="fid_226" unitRef="USD">13000000.0</tenx:NonRefundableCommercializationMilestonePayment> <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_719"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 9. STOCKHOLDERS’ EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Preferred Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the Company’s Certificate of Incorporation, the Board is authorized, without further stockholder action, to provide for the issuance of up to 10,000,000 shares of preferred stock, par value $0.0001 per share, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Series B Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 7 above, on January 15, 2021 the Company issued 10,232 shares of its Series B Stock, which were convertible into an aggregate of 10,232,000 shares of common stock, to the stockholders of PHPM as partial consideration for the Merger with PHPM pursuant to the Merger Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The rights, preferences and privileges of the Series B Stock are set forth in the Certificate of Designation. Following receipt of the approval of the stockholders of the Company for the Conversion, each share of Series B Stock will automatically convert into (i) 881.5 shares of Common Stock and (ii) 118.5 shares of Common Stock, to be delivered 24 months after the date of issuance of the Preferred Stock, subject to reduction for indemnification claims. The number of shares of Common Stock into which the Preferred Stock converts is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The Preferred Stock does not carry dividends or a liquidation preference. The Preferred Stock carries voting rights aggregating 4.99% of the Company’s Common Stock voting power immediately prior to the closing of the Merger.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s shareholders approved the conversion of our outstanding Series B Stock into shares of common stock. As a result of the approval, all outstanding shares of Series B Stock were automatically converted into an aggregate of 10,232,000 shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were no shares of Series B Stock outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 22.5pt; text-align:left;"><em>Series A Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On December 11, 2018, the Company closed its underwritten offering of 5,181,346 units for net proceeds of approximately $9 million. Each unit consists of (1) one share of the Company’s Series A convertible preferred stock, par value $0.0001 per share (the “Series A Stock”), (2) a two-year warrant to purchase one share of common stock at an exercise price of $1.93, and (3) a five-year warrant to purchase one share of common stock at an exercise price of $1.93. In accordance with ASC 480, the estimated fair value of $1,800,016 for the beneficial conversion feature was recognized as a deemed dividend on the Series A Stock during the year ended December 31, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The table below sets forth a summary of the designation, powers, preferences and rights of the Series A Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:15%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"> Conversion</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Subject to the ownership limitations described below, the Series A Stock is convertible at any time at the option of the holder into shares of the Company’s common stock at a conversion ratio determined by dividing the stated value of the Series A Stock by a conversion price of $1.93 per share. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company will not affect any conversion of the Series A Stock, nor shall a holder convert its shares of Series A Stock, to the extent that such conversion would cause the holder to have acquired, through conversion of the Series A Stock or otherwise, beneficial ownership of a number shares of common stock in excess of 4.99% (or, at the election of the holder prior to the issuance of any shares of Series A Stock, 9.99%) of the common stock outstanding after giving effect to such exercise.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividends </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In the event the Company pays dividends on its shares of common stock, the holders of the Series A Stock will be entitled to receive dividends on shares of Series A Stock equal, on an as-if-converted basis, to and in the same form as paid on the common stock. No other dividends will be paid on the shares of Series A Stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Liquidation</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Upon any liquidation, dissolution or winding up of the Company after payment or provision for payment of debts and other liabilities of the Company, the holders of Series A Stock shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount equal to the amount that a holder of common stock would receive if the Series A Stock were fully converted to common stock, which amounts will be paid pari passu with all holders of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Voting rights</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares of Series A Stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the then outstanding Series A Stock will be required to amend the terms of the Series A Stock or to take other action that adversely affects the rights of the holders of Series A Stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were 210 shares of Series A Stock outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company’s Certificate of Incorporation authorizes it to issue 400,000,000 shares of $0.0001 par value common stock. As of June 30, 2021, and December 31, 2020, there were 25,201,312 and 12,619,369 shares of common stock issued and outstanding, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On March 13, 2020, the Company completed a registered direct offering to a single healthcare-focused institutional investor (the “Investor”) for the issuance and sale of 750,000 shares of its common stock at a purchase price of $1.1651 per share and pre-funded warrants to purchase up to 1,610,313 shares of its common stock, at a purchase price of $1.1650 per pre-funded warrant (which represents the per share offering price for the common stock less $0.0001, the exercise price of each pre-funded warrant), for gross proceeds of approximately $2.75 million, priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company issued to the Investor unregistered warrants to purchase up to 2,360,313 shares of its common stock. The unregistered warrants have an exercise price of $1.04 per share and exercise period commencing immediately upon the issuance date and a term of five and one-half years. The net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses were approximately $2.125 million. The fair value allocated to the common stock, pre-funded warrants and warrants was $0.5 million, $1.1 million and $1.1 million, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On July 8, 2020, the Company completed a registered direct offering with the Investor for the issuance and sale of 2,523,611 shares of its common stock at a purchase price of $1.0278 per share and pre-funded warrants to purchase up to 652,313 shares of its common stock, at a purchase price of $1.0277 per pre-funded warrant (which represents the per share offering price for the common stock less $0.0001, the exercise price of each pre-funded warrant). The Company issued in a concurrent private placement unregistered pre-funded warrants to purchase up to 4,607,692 shares of common stock at the same purchase price as the registered pre-funded warrants, and unregistered common stock warrants to purchase up to 7,783,616 shares of common stock for aggregate gross proceeds of approximately $8.0 million, priced at-the-market under Nasdaq rules. The unregistered warrants have an exercise price of $0.903 per share and exercise period commencing immediately upon the issuance date and a term of five and one-half years. The net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses were approximately $6.5 million. The fair value allocated to the common stock, pre-funded warrants and warrants was $1.5 million, $3.0 million and $3.5 million, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were 5,260,005 pre-funded warrants outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Warrants</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>March 2020 Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As part of the March 2020 registered direct offering, the Company issued unregistered warrants to purchase 2,360,313 shares of its common stock at an exercise price of $1.04 per share and contractual term of five and one-half years. The unregistered warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. In accordance with ASC 480, these warrants are classified as equity and their relative fair value of approximately $1.1 million was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>July 2020 Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As part of the July 2020 offering, the Company issued unregistered warrants to purchase 7,783,616 shares of its common stock at an exercise price of $0.903 per share and contractual term of five and one-half years. The unregistered warrants were offered in a private placement under Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. In accordance with ASC 480, these warrants are classified as equity and their relative fair value of approximately $3.5 million was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Warrants Issued for Services</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In connection with the March 2020 offering described above, the Company issued designees of the placement agent warrants to purchase 177,023 shares of common stock at an exercise price of $1.4564 and a contractual term of five years. In accordance with ASC 815, these warrants are classified as equity and its estimated fair value of $66,201 was recognized as additional paid in capital. Additionally, the Company issued to its previous underwriter a warrant to purchase 94,413 shares of common stock at an exercise price of $1.4564 per share and contractual term of five years. In accordance with ASC 815, this warrant is classified as equity and its estimated fair value of $35,308 was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In connection with the July 2020 offering described above, the Company issued designees of the placement agent warrants to purchase 583,771 shares of common stock at an exercise price of $1.2848 and a contractual term of five years. In accordance with ASC 815, these warrants are classified as equity and its estimated fair value of $399,445 was recognized as additional paid in capital. Additionally, the Company issued to its previous underwriter a warrant to purchase 311,345 shares of common stock at an exercise price of $1.2848 per share and contractual term of five years. In accordance with ASC 815, this warrant is classified as equity and its estimated fair value of $213,038 was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company received approximately $545,000 and issued 282,202 shares of common stock upon the exercise of previously outstanding warrants issued in connection with the Company’s December 2018 offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company issued 119,491 shares of common stock upon the cashless exercise of previously outstanding placement agent warrants issued in connection with the Company’s March 2020 offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company issued 399,883 shares of common stock upon the cashless exercise of previously outstanding placement agent warrants issued in connection with the Company’s July 2020 offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the Company has 15,797,503 warrants outstanding. The following table summarizes the Company’s warrant activity for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>16,599,079</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.29</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(801,576</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.54</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at June 30, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>15,797,503</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.27</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em><strong>2016 Stock Incentive Plan</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the Company adopted the 2016 Stock Incentive Plan (the “2016 Plan”). Under the 2016 Plan, with the approval of the Compensation Committee of the Board of Directors, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, cash-based awards or other stock-based awards. On June 16, 2016, the Company’s stockholders approved the 2016 Plan and authorized for issuance under the 2016 Plan a total of 150,000 shares of common stock. On June 13, 2019, the Company’s stockholders approved an amendment to the 2016 Plan which increased the number of shares of common stock authorized for issuance under the 2016 Plan to a total of 750,000 shares, up from 150,000 previously authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s stockholders approved an amendment to the 2016 Plan which increased the number of shares of common stock authorized for issuance under the 2016 Plan to a total of 1.5 million shares, up from 750,000 previously authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the shares available for grant under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Available </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>for Grant</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">356,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">750,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(328,750</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">777,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>2016 Plan Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stock options granted under the 2016 Plan may be either incentive stock options (“ISOs”), or nonqualified stock options (“NSOs”). ISOs may be granted only to employees. NSOs may be granted to employees, consultants and directors. Stock options under the 2016 Plan may be granted with a term of up to ten years and at prices no less than fair market value at the time of grant. Stock options granted generally vest over three to four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the outstanding stock options under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">328,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">722,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.83</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company chose the “straight-line” attribution method for allocating compensation costs of each stock option over the requisite service period using the Black-Scholes Option Pricing Model to calculate the grant date fair value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company recorded compensation expense for these stock option grants of $92,339 and $52,672 for the three months ended June 30, 2021 and 2020, and $182,658 and $112,833 for the six months ended June 30, 2021 and 2020, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were unrecognized compensation costs of approximately $446,904 related to non-vested stock option awards under the 2016 Plan that will be recognized on a straight-line basis over the weighted average remaining vesting period of 1.57 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company used the following assumptions to estimate the fair value of options granted under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the six months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk-free interest rate (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.03</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected volatility (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99.47</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.61</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:20%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Risk-Free Interest Rate</em></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The risk-free interest rate assumption was based on U.S. Treasury instruments with a term that is consistent with the expected term of the Company’s stock options.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Volatility</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected stock price volatility for the Company’s common stock was determined by examining the historical volatility and trading history for its common stock over a term consistent with the expected term of its options.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Term</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. It was calculated based on the Company’s historical experience with its stock option grants.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Dividend Yield</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected dividend yield of 0% is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not anticipate paying any dividends in the near future.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Forfeitures</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock compensation expense recognized in the statements of operations for the six months ended June 30, 2021 is based on awards ultimately expected to vest, and it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on the Company’s historical experience.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>1999 Amended Stock Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In October 2000, the Company adopted the 1999 Stock Plan, as amended and restated on June 17, 2008 (the “1999 Plan”). Under the 1999 Plan, with the approval of the Compensation Committee of the Board of Directors, the Company could grant stock options, restricted stock, stock appreciation rights and new shares of common stock upon exercise of stock options. On March 13, 2014, the Company’s stockholders approved an amendment to the 1999 Plan which increased the number of shares of common stock authorized for issuance under the 1999 Plan to a total of 200,000 shares, up from 15,000 previously authorized. On September 15, 2015, the Company’s stockholders approved an additional amendment to the 1999 Plan which increased the number of shares of common stock authorized for issuance under the 1999 Plan to a total of 250,000 shares, up from 200,000 previously authorized. The 1999 Plan expired on June 17, 2018 and no new grants may be made under that plan after that date. However, unexpired awards granted under the 1999 Plan remain outstanding and subject to the terms of the 1999 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>1999 Plan Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stock options granted under the 1999 Plan may be either ISOs or NSOs. ISOs could be granted only to employees. NSOs could be granted to employees, consultants and directors. Stock options under the 1999 Plan could be granted with a term of up to ten years and at prices no less than fair market value for ISOs and no less than 85% of the fair market value for NSOs. Stock options granted generally vest over one to six years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the outstanding stock options under the 1999 Plan for the six months ended June 30, 2021: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,648</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(13</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">775.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,635</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company chose the “straight-line” attribution method for allocating compensation costs of each stock option over the requisite service period using the Black-Scholes Option Pricing Model to calculate the grant date fair value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company recorded compensation expense for these stock option grants of $0 and $10,494 for the three months ended June 30, 2021 and 2020, and $1,290 and $22,709 for the six months ended June 30, 2021 and 2020, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were no unrecognized compensation costs related to non-vested stock option awards under the 1999 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Inducement Stock Options</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company granted an employment inducement stock option award for 250,000 shares of common stock to our chief medical officer on January 15, 2021. This employment inducement stock option was awarded in accordance with the employment inducement award exemption provided by NASDAQ Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award will vest as follows: 25% upon initiation of a Phase 3 trial; 25% upon database lock; 25% upon acceptance for review of an NDA; and 25% upon approval. The options have a 10-year term and an exercise price of $1.78 per share, the January 15, 2021 closing price of the Company's common stock. As of June 30, 2021, none of the vesting milestones have been achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The estimated fair value of the inducement stock option award granted was $402,789 using a Black-Scholes option pricing model based on market prices and the following assumptions at the date of inducement option grant: risk-free interest rate of 1.11%, dividend yield of 0%, volatility factor for our common stock of 103.94% and an expected life of 10 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inducement stock option compensation expense totaled $0 for the six months ended June 30, 2021. As of June 30, 2021, there was $402,789 of remaining unrecognized compensation expense related to this inducement stock option.</p></us-gaap:StockholdersEquityNoteDisclosureTextBlock> <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" decimals="0" id="fid_80" unitRef="Shares">10232</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockVotingRights contextRef="From2021-01-01to2021-06-30_us-gaap_SeriesBPreferredStockMember" id="fid_86">(i) 881.5 shares of Common Stock and (ii) 118.5 shares of Common Stock, to be delivered 24 months after the date of issuance of the Preferred Stock</us-gaap:PreferredStockVotingRights> <tenx:PreferredStockVotingRightsPercentage contextRef="AsOf2021-06-30_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="fid_83" unitRef="Pure">0.0499</tenx:PreferredStockVotingRightsPercentage> <tenx:StockConvertibleIntoAggregateSharesOfCommonStock contextRef="AsOf2021-01-15_us-gaap_SeriesBPreferredStockMember" decimals="0" id="fid_79" unitRef="Shares">10232000</tenx:StockConvertibleIntoAggregateSharesOfCommonStock> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember" decimals="0" id="fid_91" unitRef="USD">5181346</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember" decimals="-6" id="fid_90" unitRef="USD">9000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering> <tenx:WarranToPurchaseOfCommonStockTerm contextRef="From2018-12-01to2018-12-11_us-gaap_SeriesAPreferredStockMember" id="fid_94">P2Y</tenx:WarranToPurchaseOfCommonStockTerm> <tenx:PreferredStockVotingRightsPercentage contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="fid_97" unitRef="Pure">0.0499</tenx:PreferredStockVotingRightsPercentage> <tenx:PreferredStockVotingRightsPercentage1 contextRef="AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="fid_98" unitRef="Pure">0.0999</tenx:PreferredStockVotingRightsPercentage1> <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="0" id="fid_60" unitRef="Shares">400000000</us-gaap:CommonStockSharesAuthorized> <tenx:CommonStockSharesIssue contextRef="AsOf2021-06-30" decimals="0" id="fid_62" unitRef="Shares">25201312</tenx:CommonStockSharesIssue> <tenx:WarrantToPurchaseOfCommonStockExercisePrice contextRef="AsOf2020-03-13" decimals="INF" id="fid_106" unitRef="USDPShares">1.1651</tenx:WarrantToPurchaseOfCommonStockExercisePrice> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-03-13" decimals="0" id="fid_104" unitRef="Shares">1610313</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2018-12-11_tenx_InvestorsMember" decimals="0" id="fid_111" unitRef="Shares">2360313</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight> <tenx:NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses contextRef="AsOf2018-12-11_tenx_InvestorsMember" decimals="-3" id="fid_116" unitRef="USD">2125000</tenx:NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses> <tenx:FairValueAllocatedCommonStock contextRef="AsOf2018-12-11_tenx_InvestorsMember" decimals="-5" id="fid_118" unitRef="USD">500000</tenx:FairValueAllocatedCommonStock> <tenx:CommonStockParOrStatedValuePerShares contextRef="AsOf2020-07-08" decimals="INF" id="fid_245" unitRef="USDPShares">1.0278</tenx:CommonStockParOrStatedValuePerShares> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-07-08" decimals="0" id="fid_246" unitRef="Shares">652313</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight> <tenx:WarrantToPurchaseOfCommonStockExercisePrice contextRef="AsOf2020-07-08" decimals="INF" id="fid_247" unitRef="USDPShares">1.0277</tenx:WarrantToPurchaseOfCommonStockExercisePrice> <tenx:ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock contextRef="From2020-07-01to2020-07-08" decimals="0" id="fid_249" unitRef="Shares">4607692</tenx:ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock> <tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStock contextRef="From2020-07-01to2020-07-08" decimals="0" id="fid_250" unitRef="Shares">7783616</tenx:UnregisteredCommonStockWarrantsToPurchaseCommonStock> <tenx:UnregisteredCommonStockWarrantsToPurchaseGrossProceeds contextRef="From2020-07-01to2020-07-08" decimals="-5" id="fid_251" unitRef="USD">8000000.0</tenx:UnregisteredCommonStockWarrantsToPurchaseGrossProceeds> <tenx:UnregisteredWarrantsExercisePrice contextRef="From2020-07-01to2020-07-08" decimals="INF" id="fid_252" unitRef="USDPShares">0.903</tenx:UnregisteredWarrantsExercisePrice> <tenx:NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses contextRef="AsOf2020-07-08" decimals="-5" id="fid_254" unitRef="USD">6500000</tenx:NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses> <tenx:FairValueAllocatedCommonStock contextRef="AsOf2020-07-08_tenx_InvestorsMember" decimals="-5" id="fid_255" unitRef="USD">1500000</tenx:FairValueAllocatedCommonStock> <tenx:FairValueAllocatedPrefundedWarrants contextRef="AsOf2020-07-08_tenx_InvestorsMember" decimals="-5" id="fid_256" unitRef="USD">3000000.0</tenx:FairValueAllocatedPrefundedWarrants> <tenx:FairValueAllocatedWarrants contextRef="From2020-07-01to2020-07-08_tenx_InvestorsMember" decimals="-5" id="fid_257" unitRef="USD">3500000</tenx:FairValueAllocatedWarrants> <tenx:CommonStockSharesIssue contextRef="AsOf2020-07-08" decimals="0" id="fid_244" unitRef="Shares">5260005</tenx:CommonStockSharesIssue> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-06-30" decimals="0" id="fid_258" unitRef="Shares">15797503</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_738"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>16,599,079</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.29</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(801,576</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.54</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at June 30, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>15,797,503</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.27</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock> <tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber contextRef="AsOf2020-12-31" decimals="0" id="fid_0" unitRef="Shares">16599079</tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-12-31" decimals="INF" id="fid_5" unitRef="USDPShares">1.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <tenx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-06-30" decimals="INF" id="fid_7" unitRef="USDPShares">1.54</tenx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-06-30" decimals="INF" id="fid_9" unitRef="USDPShares">1.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2019-05-20to2019-06-12_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_291" unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2021-05-20to2021-06-09_tenx_StockIncentivePlan2016Member" decimals="-5" id="fid_293" unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2021-06-01to2021-06-10_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_289" unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <tenx:SharesAvailableForGrantTableTextblock contextRef="From2021-01-01to2021-06-30" id="fid_739"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Available </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>for Grant</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">356,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">750,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(328,750</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">777,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></tenx:SharesAvailableForGrantTableTextblock> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-12-31_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_10" unitRef="Shares">356500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_74" unitRef="Shares">750000</tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_76" unitRef="Shares">328750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_75" unitRef="Shares">777750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_740"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">328,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">722,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.83</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_15" unitRef="Shares">393500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_20" unitRef="USDPShares">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_17" unitRef="Shares">328750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_22" unitRef="USDPShares">1.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_19" unitRef="Shares">722250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_24" unitRef="USDPShares">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-04-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_272" unitRef="USD">92339</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-04-01to2020-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_68" unitRef="USD">52672</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_66" unitRef="USD">182658</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_296" unitRef="USD">112833</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-06-30_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_70" unitRef="USD">446904</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized> <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_741"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the six months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk-free interest rate (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.03</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected volatility (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99.47</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.61</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_25" unitRef="Pure">0.0070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_26" unitRef="Pure">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_27" unitRef="Pure">0.9947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_28" unitRef="Pure">0.9761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" id="fid_29">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" id="fid_30">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_31" unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-01-01to2020-06-30_tenx_StockIncentivePlan2016Member" decimals="INF" id="fid_32" unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2015-08-20to2015-09-15_tenx_Amended1999StockPlanMember" decimals="0" id="fid_285" unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2016-06-01to2016-06-16_tenx_StockIncentivePlan2016Member" decimals="0" id="fid_287" unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2015-09-01to2015-09-15_tenx_Amended1999StockPlanMember" decimals="0" id="fid_284" unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <tenx:OutstandingStockOptionsUnderPlanTableTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_742"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,648</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(13</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">775.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,635</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table></tenx:OutstandingStockOptionsUnderPlanTableTextBlock> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_tenx_Amended1999StockPlanMember" decimals="0" id="fid_33" unitRef="Shares">57648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_tenx_Amended1999StockPlanMember" decimals="INF" id="fid_38" unitRef="USDPShares">46.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" decimals="INF" id="fid_40" unitRef="USDPShares">775.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-06-30_tenx_Amended1999StockPlanMember" decimals="0" id="fid_37" unitRef="Shares">57635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-06-30_tenx_Amended1999StockPlanMember" decimals="INF" id="fid_42" unitRef="USDPShares">46.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-04-01to2020-06-30_tenx_Amended1999StockPlanMember" decimals="0" id="fid_69" unitRef="USD">10494</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-06-30_tenx_Amended1999StockPlanMember" decimals="0" id="fid_67" unitRef="USD">1290</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-06-30_tenx_Amended1999StockPlanMember" decimals="0" id="fid_271" unitRef="USD">22709</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember" decimals="0" id="fid_259" unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross> <tenx:StockOptionsDescription contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" id="fid_263">The option award will vest as follows: 25% upon initiation of a Phase 3 trial; 25% upon database lock; 25% upon acceptance for review of an NDA; and 25% upon approval</tenx:StockOptionsDescription> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember" id="fid_261">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-01-15_tenx_InducementStockOptionsMember" decimals="INF" id="fid_260" unitRef="USDPShares">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-06-30_tenx_InducementStockOptionsMember" decimals="0" id="fid_72" unitRef="USD">402789</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" decimals="INF" id="fid_265" unitRef="Pure">0.0111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <tenx:DividendYield contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" decimals="INF" id="fid_266" unitRef="Pure">0</tenx:DividendYield> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" decimals="INF" id="fid_267" unitRef="Pure">1.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" id="fid_268">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-06-30_tenx_InducementStockOptionsMember" decimals="0" id="fid_269" unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense> <tenx:EstimatedFairValueOfInducementStockOptionAwardGranted contextRef="AsOf2021-01-15_tenx_InducementStockOptionsMember" decimals="0" id="fid_264" unitRef="USD">402789</tenx:EstimatedFairValueOfInducementStockOptionAwardGranted> <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-06-30" id="fid_720"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>NOTE 10. SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On July 6, 2021, Tenax Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) pursuant to which the Company agreed to sell and issue to the Investor 4,773,269 units (“Units”) in a private placement at a purchase price of $2.095 per Unit. Each Unit consisted of one unregistered pre-funded warrant to purchase one share of common stock, par value $0.0001 (collectively the “Unregistered Pre-Funded Warrants”) and one unregistered warrant to purchase one share of common stock (collectively the “Unregistered Warrants” and together with the Unregistered Pre-Funded Warrants, the “Warrants”). In the aggregate,9,546,538 shares of the Company’s common stock are underlying the Warrants. The aggregate gross proceeds to the Company of the Offering were approximately $10 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Each Unregistered Pre-Funded Warrant has an exercise price of $0.0001 per share of common stock, is immediately exercisable, may be exercised at any time until exercised in full and is subject to customary adjustments. Each Unregistered Warrant has an exercise price of $1.97 per share of common stock, is immediately exercisable, will expire five and one-half years from the date of issuance and is subject to customary adjustments. The Warrants may not be exercised if the aggregate number of shares of the Company’s common stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% of the Company’s outstanding common stock immediately after exercise. However, the holder may increase (upon 61 days’ prior notice from the holder to the Company) or decrease such percentage, provided that in no event such percentage exceeds 9.99%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company intends to use the net proceeds from the Offering to further its clinical trials of levosimendan and imatinib for research and development and for general corporate purposes, including working capital and potential acquisitions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Also, on July 6, 2021 and in connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, pursuant to which the Company agreed to register for resale the shares of the Company’s common stock issuable upon exercise of the Warrants within 120 days following the date of the Registration Rights Agreement. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under certain circumstances, including, but not limited to, (i) if the registration statement is not filed by the earlier of 45 days after the date of the Registration Rights Agreement or 10 days after the Company files its first Form 10-Q following the Registration Rights Agreement (ii) if the registration statement has not been declared effective (A) by the 120th day after the date of the Registration Rights Agreement (or, in the event of a “full review” by the Securities and Exchange Commission (the “SEC”), the 150th day after the date of the Registration Rights Agreement) or (B) within five trading days following the date the Company is notified by the SEC that the registration statement will not be reviewed or is no longer subject to further review and comments then the Company has agreed to pay the Investor, as partial liquidated damages, an amount equal to 1.0% of the Investor’s aggregate subscription amount paid pursuant to the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">H.C. Wainwright &amp; Co., LLC (“HCW) was entitled to fees related to the Offering under a tail provision in an engagement letter with the Company that relates to HCW’s assistance as a Placement Agent in a prior offering in July 2020 between the Investor and the Company (the “Tail Provision”). Pursuant to the Tail Provision, the Company paid HCW a cash fee equal to 7.5% of the gross proceeds received by the Company in the Offering, totaling approximately $750,000. In addition, the Company has agreed to issue to HCW or its designees warrants to purchase up to 357,995 shares of common stock (representing 7.5% of the aggregate number of shares of common stock equivalents sold in the Offering) (the “HCW Warrants”). The HCW Warrants have substantially the same terms as the Unregistered Warrants, except that the HCW Warrants have an exercise price equal to $2.46, or 125% of the offering price per share of common stock and will be exercisable for five years from the effective date of the Offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The issuance and sale of the Units, the Warrants, the HCW Warrants and the shares of common stock issuable upon exercise of the Warrants and the HCW Warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">On July 13, 2021, Anthony A. DiTonno retired as the Chief Executive Officer of the Company and as a member of the Company’s Board of Directors (the “Board”) effective as of July 13, 2021 (the “Effective Separation Date”). In connection with his retirement, Mr. DiTonno entered into a Separation and General Release Agreement with the Company (the “Separation Agreement”), dated July 6, 2021. The terms of the Separation Agreement provided that Mr. DiTonno had the right to revoke the Separation Agreement until July 22, 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Under the Separation Agreement, Mr. DiTonno is entitled to receive severance in an amount equal to one year of his current base annual salary, and a pro-rated amount of his annual bonus that would have been received had 100% of his annual goals been achieved, approximately $563,000 (less applicable taxes and withholdings), payable in a lump sum on the 60th day following the Effective Separation Date. The Company will also reimburse COBRA premiums for coverage of Mr. DiTonno and his eligible dependents for up to 18 months if Mr. DiTonno timely and properly elects continuation coverage. The foregoing payments were contingent on Mr. DiTonno’s standard release of employment claims. In connection with his retirement and in order to ensure a smooth transition to the new CEO, Mr. DiTonno has received a stock option grant for 50,000 shares of common stock.  All of Mr. DiTonno’s outstanding stock options for common stock of the Company accelerated upon the Effective Separation Date, becoming fully vested, and are exercisable until the earlier of: (i) the original expiration date of each option under such option’s respective option agreement; or (ii) July 13, 2026. The Company is additionally reimbursing Mr. DiTonno for up to $5,000 in legal expenses related to the Separation Agreement. The Separation Agreement also contains such non-competition, non-solicitation, and confidentiality provisions and other terms and conditions as are usual and customary for agreements of this type. All of Mr. DiTonno’s obligations under his Employee Non-Disclosure, Inventions Assignment, and Competitive Business Activities Agreement, dated June 1, 2018, regarding confidentiality and proprietary information will continue.</p></us-gaap:SubsequentEventsTextBlock> <us-gaap:SharesIssued contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="0" id="fid_228" unitRef="Shares">4773269</us-gaap:SharesIssued> <tenx:PurchasePriceOfStock contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="INF" id="fid_229" unitRef="USDPShares">2.095</tenx:PurchasePriceOfStock> <tenx:CommonStockParOrStatedValuePerShares contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="INF" id="fid_230" unitRef="USDPShares">0.0001</tenx:CommonStockParOrStatedValuePerShares> <tenx:UnregisteredPreFundedWarrants contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="0" id="fid_231" unitRef="Shares">9546538</tenx:UnregisteredPreFundedWarrants> <tenx:ProceedsFromOffering contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="-6" id="fid_232" unitRef="USD">10000000</tenx:ProceedsFromOffering> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="INF" id="fid_233" unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <tenx:UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember" decimals="INF" id="fid_234" unitRef="USDPShares">1.97</tenx:UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock> <tenx:PercentageOfGrossProceedReceived contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" decimals="INF" id="fid_236" unitRef="Pure">0.075</tenx:PercentageOfGrossProceedReceived> <tenx:ProceedsFromOffering contextRef="From2021-07-01to2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" decimals="-6" id="fid_237" unitRef="USD">50000000000</tenx:ProceedsFromOffering> <tenx:WarrantIssuedToPurchaseCommonStock contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" decimals="0" id="fid_238" unitRef="Shares">357995</tenx:WarrantIssuedToPurchaseCommonStock> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" decimals="INF" id="fid_239" unitRef="USDPShares">2.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <tenx:PercentageOfOfferingPricePerShareOfCommonStock contextRef="AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_RegistrationRightsAgreementMember" decimals="INF" id="fid_241" unitRef="Pure">1.25</tenx:PercentageOfOfferingPricePerShareOfCommonStock> <tenx:SeveranceReceived contextRef="AsOf2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember" decimals="0" id="fid_769" unitRef="USD">563000</tenx:SeveranceReceived> <tenx:dvddv contextRef="From2021-07-01to2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember" decimals="0" id="fid_770" unitRef="Shares">50000</tenx:dvddv> <us-gaap:OtherExpenses contextRef="From2021-07-01to2021-07-13_us-gaap_SubsequentEventMember_tenx_SeparationAgreementMember_tenx_MrDitonnoMember" decimals="0" id="fid_771" unitRef="USD">5000</us-gaap:OtherExpenses> </xbrl> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>13 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505618866552"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Aug. 12, 2021</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td> <td class="text">TENAX THERAPEUTICS, INC<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td> <td class="text">0000034956<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td> <td class="text">10-Q<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td> <td class="text">--12-31<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td> <td class="text">Jun. 30, 2021<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td> <td class="text">Non-accelerated Filer<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td> <td class="text">Q2<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td> <td class="text">2021<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td> <td class="text"> <span></span> </td> <td class="nump">25,201,312<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td> <td class="text">001-34600<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td> <td class="text">DE<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td> <td class="text">26-2593535<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td> <td class="text">ONE Copley Parkway<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td> <td class="text">Suite 490<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td> <td class="text">Morrisville<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td> <td class="text">NC<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td> <td class="text">919<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td> <td class="text">855-2100<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td> <td class="text">Common Stock, $0.0001 par value per share<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td> <td class="text">TENX<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td> <td class="text">NASDAQ<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td> <td class="text">27560<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AmendmentFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CityAreaCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CoverAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gMonthDayItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fiscalPeriodItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentTransitionReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentType</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:submissionTypeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:stateOrProvinceItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:centralIndexKeyItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFileNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fileNumberItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFilerCategory</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:filerCategoryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarStateCountryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityRegistrantName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityShellCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntitySmallBusiness</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:employerIdItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LocalPhoneNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_Security12bTitle</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:securityTitleItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_SecurityExchangeName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarExchangeCodeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_TradingSymbol</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:tradingSymbolItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>14 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619089752"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump">$ 1,671,422<span></span> </td> <td class="nump">$ 6,250,241<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td> <td class="nump">510,943<span></span> </td> <td class="nump">462,687<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td> <td class="nump">349,862<span></span> </td> <td class="nump">82,578<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td> <td class="nump">2,532,227<span></span> </td> <td class="nump">6,795,506<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td> <td class="nump">338,698<span></span> </td> <td class="nump">58,778<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td> <td class="nump">5,821<span></span> </td> <td class="nump">5,972<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td> <td class="nump">8,435<span></span> </td> <td class="nump">8,435<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td> <td class="nump">2,885,181<span></span> </td> <td class="nump">6,868,691<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td> <td class="nump">791,947<span></span> </td> <td class="nump">757,856<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td> <td class="nump">383,063<span></span> </td> <td class="nump">1,240,616<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td> <td class="nump">0<span></span> </td> <td class="nump">120,491<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td> <td class="nump">1,175,010<span></span> </td> <td class="nump">2,118,963<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td> <td class="nump">239,039<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td> <td class="nump">0<span></span> </td> <td class="nump">124,166<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td> <td class="nump">239,039<span></span> </td> <td class="nump">124,166<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td> <td class="nump">1,414,049<span></span> </td> <td class="nump">2,243,129<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, undesignated, authorized 9,999,790 shares; See Note 9 Series A Preferred stock, par value $.0001, issued 5,181,346 shares; outstanding 210, respectively</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 25,201,312 and 12,619,369 respectively</a></td> <td class="nump">2,520<span></span> </td> <td class="nump">1,262<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td> <td class="nump">272,953,869<span></span> </td> <td class="nump">250,644,197<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td> <td class="num">(274)<span></span> </td> <td class="num">(70)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="num">(271,484,983)<span></span> </td> <td class="num">(246,019,827)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td> <td class="nump">1,471,132<span></span> </td> <td class="nump">4,625,562<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td> <td class="nump">$ 2,885,181<span></span> </td> <td class="nump">$ 6,868,691<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Assets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Liabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NotesPayable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>15 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619441928"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td> <td class="nump">9,999,790<span></span> </td> <td class="nump">9,999,790<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td> <td class="nump">$ 0.0001<span></span> </td> <td class="nump">$ 0.0001<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td> <td class="nump">400,000,000<span></span> </td> <td class="nump">400,000,000<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td> <td class="nump">25,201,312<span></span> </td> <td class="nump">12,619,369<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td> <td class="nump">25,210,312<span></span> </td> <td class="nump">12,619,369<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td> <td class="nump">$ 0.0001<span></span> </td> <td class="nump">$ 0.0001<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td> <td class="nump">5,181,346<span></span> </td> <td class="nump">5,181,346<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td> <td class="nump">210<span></span> </td> <td class="nump">210<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>16 <FILENAME>R4.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619450904"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td> <td class="nump">$ 1,271,278<span></span> </td> <td class="nump">$ 869,206<span></span> </td> <td class="nump">$ 2,644,738<span></span> </td> <td class="nump">$ 2,192,165<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td> <td class="nump">693,222<span></span> </td> <td class="nump">1,274,837<span></span> </td> <td class="nump">23,069,424<span></span> </td> <td class="nump">2,617,363<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td> <td class="nump">1,964,500<span></span> </td> <td class="nump">2,144,043<span></span> </td> <td class="nump">25,714,162<span></span> </td> <td class="nump">4,809,528<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating loss</a></td> <td class="nump">1,964,500<span></span> </td> <td class="nump">2,144,043<span></span> </td> <td class="nump">25,714,162<span></span> </td> <td class="nump">4,809,528<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td> <td class="nump">336<span></span> </td> <td class="nump">406<span></span> </td> <td class="nump">949<span></span> </td> <td class="nump">406<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td> <td class="num">(247,820)<span></span> </td> <td class="nump">2,101<span></span> </td> <td class="num">(249,955)<span></span> </td> <td class="num">(8,740)<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">1,717,016<span></span> </td> <td class="nump">2,146,550<span></span> </td> <td class="nump">25,465,156<span></span> </td> <td class="nump">4,801,194<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Unrealized (gain) loss on marketable securities</a></td> <td class="num">(128)<span></span> </td> <td class="num">(3,238)<span></span> </td> <td class="nump">204<span></span> </td> <td class="num">(1,616)<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td> <td class="nump">$ 1,716,888<span></span> </td> <td class="nump">$ 2,143,312<span></span> </td> <td class="nump">$ 25,465,360<span></span> </td> <td class="nump">$ 4,799,578<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td> <td class="num">$ (0.10)<span></span> </td> <td class="num">$ (0.23)<span></span> </td> <td class="num">$ (1.60)<span></span> </td> <td class="num">$ (0.59)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td> <td class="nump">17,218,103<span></span> </td> <td class="nump">9,339,309<span></span> </td> <td class="nump">15,874,062<span></span> </td> <td class="nump">8,156,848<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>17 <FILENAME>R5.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505613422296"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited) - USD ($)<br></strong></div></th> <th class="th"><div>Total</div></th> <th class="th"><div>Preferred Stock</div></th> <th class="th"><div>Common Stock</div></th> <th class="th"><div>Additional Paid-In Capital</div></th> <th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th> <th class="th"><div>Accumulated Deficit</div></th> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td> <td class="text"> <span></span> </td> <td class="nump">38,606<span></span> </td> <td class="nump">6,741,860<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2019</a></td> <td class="nump">$ 3,772,497<span></span> </td> <td class="nump">$ 4<span></span> </td> <td class="nump">$ 674<span></span> </td> <td class="nump">$ 239,939,797<span></span> </td> <td class="nump">$ 458<span></span> </td> <td class="num">$ (236,168,436)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares', window );">Common stock and pre-funded warrants sold, net of offering costs, shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">750,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount', window );">Common stock and pre-funded warrants sold, net of offering costs, amount</a></td> <td class="nump">2,130,005<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 75<span></span> </td> <td class="nump">2,129,930<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CompensationOnOptionsIssued', window );">Compensation on options issued</a></td> <td class="nump">72,376<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">72,376<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockIssuedForServicesRenderedShares', window );">Common stock issued for services rendered, shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">77,987<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockIssuedForServicesRenderedAmount', window );">Common stock issued for services rendered, amount</a></td> <td class="nump">100,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 8<span></span> </td> <td class="nump">99,992<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockIssuedForConvertiblePreferredStockShares', window );">Common stock issued for convertible preferred stock, shares</a></td> <td class="text"> <span></span> </td> <td class="num">(38,396)<span></span> </td> <td class="nump">38,396<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockIssuedForConvertiblePreferredStockAmount', window );">Common stock issued for convertible preferred stock, amount</a></td> <td class="nump">0<span></span> </td> <td class="num">$ (4)<span></span> </td> <td class="nump">$ 4<span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ExerciseOfPreFundedWarrantsShares', window );">Exercise of pre-funded warrants, shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">400,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ExerciseOfPreFundedWarrantsAmount', window );">Exercise of pre-funded warrants, amount</a></td> <td class="nump">40<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 40<span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnrealizedLossOnMarketableSecurities', window );">Unrealized loss on marketable securities</a></td> <td class="num">(1,622)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(1,622)<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num">(2,654,644)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(2,654,644)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">8,008,243<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2020</a></td> <td class="nump">3,418,652<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 801<span></span> </td> <td class="nump">242,242,095<span></span> </td> <td class="num">(1,164)<span></span> </td> <td class="num">(238,823,080)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td> <td class="text"> <span></span> </td> <td class="nump">38,606<span></span> </td> <td class="nump">6,741,860<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2019</a></td> <td class="nump">3,772,497<span></span> </td> <td class="nump">$ 4<span></span> </td> <td class="nump">$ 674<span></span> </td> <td class="nump">239,939,797<span></span> </td> <td class="nump">458<span></span> </td> <td class="num">(236,168,436)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">4,801,194<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2020</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">10,095,758<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2020</a></td> <td class="nump">3,029,170<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 1,010<span></span> </td> <td class="nump">243,995,716<span></span> </td> <td class="nump">2,074<span></span> </td> <td class="num">(240,969,630)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">8,008,243<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2020</a></td> <td class="nump">3,418,652<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 801<span></span> </td> <td class="nump">242,242,095<span></span> </td> <td class="num">(1,164)<span></span> </td> <td class="num">(238,823,080)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CompensationOnOptionsIssued', window );">Compensation on options issued</a></td> <td class="nump">63,166<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">63,166<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">2,146,550<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(2,146,550)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2,087,515<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants, amount</a></td> <td class="nump">1,690,664<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 209<span></span> </td> <td class="nump">1,690,455<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnrealizedGainOnMarketableSecurities', window );">Unrealized gain on marketable securities</a></td> <td class="nump">3,238<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">3,238<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2020</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">10,095,758<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2020</a></td> <td class="nump">3,029,170<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 1,010<span></span> </td> <td class="nump">243,995,716<span></span> </td> <td class="nump">2,074<span></span> </td> <td class="num">(240,969,630)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">12,619,369<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td> <td class="nump">4,625,562<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 1,262<span></span> </td> <td class="nump">250,644,197<span></span> </td> <td class="num">(70)<span></span> </td> <td class="num">(246,019,827)<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CompensationOnOptionsIssued', window );">Compensation on options issued</a></td> <td class="nump">91,609<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">91,609<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnrealizedLossOnMarketableSecurities', window );">Unrealized loss on marketable securities</a></td> <td class="num">(332)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(332)<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num">(23,748,140)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(23,748,140)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">457,038<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants, amount</a></td> <td class="nump">544,651<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 46<span></span> </td> <td class="nump">544,605<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares', window );">Common stock and preferred stock issued for asset acquisition, shares</a></td> <td class="text"> <span></span> </td> <td class="nump">10,232<span></span> </td> <td class="nump">1,892,905<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount', window );">Common stock and preferred stock issued for asset acquisition, amount</a></td> <td class="nump">21,582,331<span></span> </td> <td class="nump">$ 1<span></span> </td> <td class="nump">$ 189<span></span> </td> <td class="nump">21,582,141<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td> <td class="text"> <span></span> </td> <td class="nump">10,442<span></span> </td> <td class="nump">14,969,312<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2021</a></td> <td class="nump">3,095,681<span></span> </td> <td class="nump">$ 1<span></span> </td> <td class="nump">$ 1,497<span></span> </td> <td class="nump">272,862,552<span></span> </td> <td class="num">(402)<span></span> </td> <td class="num">(269,767,967)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">12,619,369<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td> <td class="nump">4,625,562<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 1,262<span></span> </td> <td class="nump">250,644,197<span></span> </td> <td class="num">(70)<span></span> </td> <td class="num">(246,019,827)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">25,465,156<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2021</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">25,201,312<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2021</a></td> <td class="nump">1,471,132<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 2,520<span></span> </td> <td class="nump">272,953,869<span></span> </td> <td class="num">(274)<span></span> </td> <td class="num">(271,484,983)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td> <td class="text"> <span></span> </td> <td class="nump">10,442<span></span> </td> <td class="nump">14,969,312<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2021</a></td> <td class="nump">3,095,681<span></span> </td> <td class="nump">$ 1<span></span> </td> <td class="nump">$ 1,497<span></span> </td> <td class="nump">272,862,552<span></span> </td> <td class="num">(402)<span></span> </td> <td class="num">(269,767,967)<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CompensationOnOptionsIssued', window );">Compensation on options issued</a></td> <td class="nump">92,339<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">92,339<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockIssuedForConvertiblePreferredStockShares', window );">Common stock issued for convertible preferred stock, shares</a></td> <td class="text"> <span></span> </td> <td class="num">(10,232)<span></span> </td> <td class="nump">10,232,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockIssuedForConvertiblePreferredStockAmount', window );">Common stock issued for convertible preferred stock, amount</a></td> <td class="nump">0<span></span> </td> <td class="num">$ (1)<span></span> </td> <td class="nump">$ 1,023<span></span> </td> <td class="num">(1,022)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">1,717,016<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(2,279,868)<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnrealizedGainOnMarketableSecurities', window );">Unrealized gain on marketable securities</a></td> <td class="nump">128<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">128<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2021</a></td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="nump">25,201,312<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2021</a></td> <td class="nump">$ 1,471,132<span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 2,520<span></span> </td> <td class="nump">$ 272,953,869<span></span> </td> <td class="num">$ (274)<span></span> </td> <td class="num">$ (271,484,983)<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockIssuedForConvertiblePreferredStockAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockIssuedForConvertiblePreferredStockAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockIssuedForConvertiblePreferredStockShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockIssuedForConvertiblePreferredStockShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockIssuedForServicesRenderedAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockIssuedForServicesRenderedAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockIssuedForServicesRenderedShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockIssuedForServicesRenderedShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CompensationOnOptionsIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CompensationOnOptionsIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ExerciseOfPreFundedWarrantsAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ExerciseOfPreFundedWarrantsAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ExerciseOfPreFundedWarrantsShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ExerciseOfPreFundedWarrantsShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_StockIssuedDuringPeriodSharesWarrantsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_StockIssuedDuringPeriodSharesWarrantsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_StockIssuedDuringPeriodValueWarrantsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_StockIssuedDuringPeriodValueWarrantsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnrealizedGainOnMarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnrealizedGainOnMarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnrealizedLossOnMarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnrealizedLossOnMarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>18 <FILENAME>R6.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505618741496"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td> <td class="num">$ (25,465,156)<span></span> </td> <td class="num">$ (4,801,194)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td> <td class="nump">2,026<span></span> </td> <td class="nump">2,150<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable', window );">Interest on debt instrument</a></td> <td class="nump">949<span></span> </td> <td class="nump">406<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfLeasedAsset', window );">Amortization of right of use asset</a></td> <td class="nump">53,859<span></span> </td> <td class="nump">54,223<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt settlement and extinguishment</a></td> <td class="num">(247,233)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition', window );">Issuance of common stock and preferred stock for asset acquisition</a></td> <td class="nump">21,582,331<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants', window );">Issuance and vesting of compensatory stock options and warrants</a></td> <td class="nump">183,948<span></span> </td> <td class="nump">135,542<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock for services rendered</a></td> <td class="nump">0<span></span> </td> <td class="nump">50,000<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_AmortizationOfPremiumOnMarketableSecurities', window );">Amortization of premium on marketable securities</a></td> <td class="nump">6,896<span></span> </td> <td class="nump">2,647<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Accounts receivable, prepaid expenses and other assets</a></td> <td class="num">(267,284)<span></span> </td> <td class="nump">170,046<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td> <td class="num">(923,295)<span></span> </td> <td class="num">(453,406)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Long term portion of lease liability</a></td> <td class="nump">6,720<span></span> </td> <td class="num">(60,379)<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td> <td class="num">(5,066,239)<span></span> </td> <td class="num">(4,899,965)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td> <td class="num">(345,540)<span></span> </td> <td class="num">(351,138)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_SaleOfMarketableSecurities', window );">Sale of marketable securities</a></td> <td class="nump">290,184<span></span> </td> <td class="nump">365,049<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td> <td class="num">(1,875)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td> <td class="num">(57,231)<span></span> </td> <td class="nump">13,911<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td> <td class="nump">544,651<span></span> </td> <td class="nump">1,690,704<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</a></td> <td class="nump">0<span></span> </td> <td class="nump">2,130,005<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from the issuance of notes payable</a></td> <td class="nump">0<span></span> </td> <td class="nump">244,657<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td> <td class="nump">544,651<span></span> </td> <td class="nump">4,065,366<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td> <td class="num">(4,578,819)<span></span> </td> <td class="num">(820,688)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td> <td class="nump">6,250,241<span></span> </td> <td class="nump">4,905,993<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td> <td class="nump">1,671,422<span></span> </td> <td class="nump">4,085,305<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Addition to right of use asset obtained from new operating lease liability</a></td> <td class="nump">$ 333,779<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_AmortizationOfPremiumOnMarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_AmortizationOfPremiumOnMarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_SaleOfMarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_SaleOfMarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfLeasedAsset"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121569800&loc=d3e45031-112735<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AmortizationOfLeasedAsset</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProfitLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>19 <FILENAME>R7.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616353560"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>DESCRIPTION OF BUSINESS</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">1. DESCRIPTION OF BUSINESS</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 1. DESCRIPTION OF BUSINESS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Tenax Therapeutics, Inc. (the “Company”) was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. On June 17, 2008, the stockholders of Synthetic Blood International approved the Agreement and Plan of Merger dated April 28, 2008, between Synthetic Blood International and Oxygen Biotherapeutics, Inc., a Delaware corporation. Oxygen Biotherapeutics was formed on April 17, 2008 by Synthetic Blood International to participate in the merger for the purpose of changing the state of domicile of Synthetic Blood International from New Jersey to Delaware. Certificates of Merger were filed with the states of New Jersey and Delaware and the merger was effective June 30, 2008. Under the Plan of Merger, Oxygen Biotherapeutics was the surviving corporation and each share of Synthetic Blood International common stock outstanding on June 30, 2008 was converted to one share of Oxygen Biotherapeutics common stock. On September 19, 2014, the Company changed its name to Tenax Therapeutics, Inc. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 18, 2013, the Company created a wholly owned subsidiary, Life Newco, Inc., a Delaware corporation (“Life Newco”), to acquire certain assets of Phyxius Pharma, Inc., a Delaware corporation (“Phyxius”) pursuant to an Asset Purchase Agreement, dated October 21, 2013 (the “Asset Purchase Agreement”), by and among the Company, Life Newco, Phyxius and the stockholders of Phyxius (the “Phyxius Stockholders”). As further discussed in Note 8 below, on November 13, 2013, under the terms and subject to the conditions of the Asset Purchase Agreement, Life Newco acquired certain assets, including a license granting Life Newco an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, the Company entered into an Amendment (the “Amendment”) to the License between the Company and Orion Corporation, a global healthcare company incorporated under the laws of Finland (“Orion”), to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan to the scope of the License, subject to specified limitations. The Amendment also amends the tiered royalty payments based on net sales of the Product in the Territory (each as defined in the License, as amended by the Amendment) made by the Company and its sublicensees. Pursuant to the Amendment, the term of the License has been extended until 10 years after the launch of the Product in the Territory, provided that the License will continue after the end of the term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. In the event that no regulatory approval for the Product has been granted in the United States on or before September 20, 2028, however, either party will have the right to terminate the License with immediate effect. The Company intends to conduct an upcoming Phase 3 study in pulmonary hypertension patients utilizing one of these oral formulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, the Company, Life Newco II, Inc., a Delaware corporation and a wholly-owned, direct subsidiary of the Company (“Life Newco II”), PHPrecisionMed Inc., a Delaware corporation (“PHPM,”) and Dr. Stuart Rich, solely in his capacity as holders’ representative (in such capacity, the “Representative”), entered into an Agreement and Plan of Merger, dated January 15, 2021 (the “Merger Agreement”), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company would acquire 100% of the equity of PHPM. Under the terms of the Merger Agreement, Life Newco II would merge with and into PHPM, with PHPM surviving as a wholly owned subsidiary of the Company (the “Merger”). On January 15, 2021, the Company completed the acquisition contemplated by the Merger Agreement (the “Acquisition”). As a result of the Acquisition the Company intends to develop pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States and the rest of the world.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&trid=2134479<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>20 <FILENAME>R8.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505615042952"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Basis of Presentation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet on December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the period ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) rules and regulations. Operating results for the three and six-month period ended June 30, 2021 are not necessarily indicative of results for the full year or any other future periods. As such, it is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Management believes the accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $271 million on June 30, 2021 and $246 million on December 31, 2020 and used cash in operations of $5.1 million and $4.9 million during the six months ended June 30, 2021 and 2020, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 10 below, the Company sold 4,773,269 units ("Units") in a private placement at a purchase price of $2.095 per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of common stock and one unregistered warrant to purchase one share of common stock for gross proceeds of approximately $10 million. The Company requires substantial additional funds to complete its planned clinical trials and to pursue regulatory approvals. Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying June 30, 2021 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, to maintain present financing, and to generate cash from future operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Use of Estimates</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In preparing the unaudited condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Principles of Consolidation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying condensed consolidated financial statements include the accounts and transactions of the Company, Life Newco and Life Newco II. All material intercompany transactions and balances have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Liquidity and Management’s Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 30, 2021, the Company had cash and cash equivalents, including the fair value of its marketable securities, of approximately $2.2 million. The Company used $5.1 million of cash for operating activities during the six months ended June 30, 2021 and had stockholders’ equity of $1.5 million, versus $4.6 million on December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company expects to continue to incur expenses related to development of imatinib for pulmonary arterial hypertension and levosimendan for pulmonary hypertension and to continue with the development of other potential product candidates. Based on its resources on June 30, 2021 and including the net proceeds from its July 2021 offering (as discussed in Note 10 below), the Company believes that it has sufficient capital to fund its planned operations through the second quarter of calendar year 2022. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>COVID-19 Impact and Related Risks</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The continued spread of COVID-19 globally could adversely affect the Company’s ability to retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some of these investigators and site staff may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede movement or interrupt healthcare services, or if they become infected with COVID-19 themselves, which would delay the Company’s ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The full extent to which the COVID-19 pandemic and the various responses to it might impact the Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond the Company’s control.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Loss per Share</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Basic net loss per share, which excludes antidilutive securities, is computed by dividing net loss by the weighted-average number of common shares outstanding for that particular period. In contrast, diluted net loss per share considers the potential dilution that could occur from other equity instruments that would increase the total number of outstanding shares of common stock. Such amounts include shares potentially issuable under outstanding options, convertible preferred shares and warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following outstanding options, convertible preferred shares and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,797,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,274,492</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,260,005</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Leases</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in the Company’s condensed consolidated balance sheets. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. The Company’s leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that the Company will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to account for leases with an initial term of 12 months or less similar to previous guidance for operating leases, under which the Company will recognize those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Recent Accounting Pronouncements </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In December 2019, the Financial Accounting Standards Board (“FASB”) issued an accounting standard intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740, Income Taxes and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the FASB issued an accounting standard that amends how credit losses are measured and reported for certain financial instruments that are not accounted for at fair value through net income. This standard requires that credit losses be presented as an allowance rather than as a write-down for available-for-sale debt securities and will be effective for interim and annual reporting periods beginning January 1, 2023, with early adoption permitted. A modified retrospective approach is to be used for certain parts of this guidance, while other parts of the guidance are to be applied using a prospective approach. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&trid=2122369<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>21 <FILENAME>R9.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616382296"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">3. FAIR VALUE</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 3. FAIR VALUE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines the fair value of its financial assets and liabilities in accordance with the Accounting Standards Codification (“ASC”) 820 Fair Value Measurements. The Company’s balance sheet includes the following financial instruments: cash and cash equivalents, investments in marketable securities, and warrant liabilities. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to the short-term nature of these instruments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Accounting for fair value measurements involves a single definition of fair value, along with a conceptual framework to measure fair value, with a fair value defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” The fair value measurement hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level one</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Quoted market prices in active markets for identical assets or liabilities;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level two</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inputs other than level one inputs that are either directly or indirectly observable; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Level three</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company applies valuation techniques that (1) place greater reliance on observable inputs and less reliance on unobservable inputs and (2) are consistent with the market approach, the income approach and/or the cost approach, and include enhanced disclosures of fair value measurements in the Company’s condensed consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Investments in Marketable Securities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive income/(loss), unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in other income in the condensed consolidated statements of comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. As of June 30, 2021, the Company believes that the costs of its investments are recoverable in all material respects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments is classified as Level 2 in the fair value hierarchy as defined in GAAP. These fair values are obtained from independent pricing services which utilize Level 2 inputs:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="18" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amortized </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accrued </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized Gains</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized losses</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Corporate debt securities </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total investments </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">All of the Company’s investments have scheduled maturities of less than one year as of June 30, 2021 and December 31, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following tables summarize information regarding assets and liabilities measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of June 30, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of December 31, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">There were no significant transfers between levels in the six months ended June 30, 2021.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>22 <FILENAME>R10.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505615042952"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">4. BALANCE SHEET COMPONENTS</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 4. BALANCE SHEET COMPONENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Property and equipment, net </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Property and equipment consist of the following as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Office furniture and fixtures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Computer equipment and software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,631</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,307</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,664</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,843</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,368</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,821</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Depreciation expense was approximately $1,000 for each of the three-month periods ended June 30, 2021 and 2020. Depreciation expense was approximately $2,000 for each of the six-month periods ended June 30, 2021 and 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Accrued liabilities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Accrued liabilities consist of the following as of June 30, 2021 and December 31, 2020:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Employee related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,551</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">860,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Operating costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,051</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">319,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">383,063</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,240,616</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&trid=2122208<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>23 <FILENAME>R11.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616353560"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">5. LEASE</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 5. LEASE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In January 2011, the Company entered into the Lease with Concourse Associates, LLC for office facilities located at the premises in Morrisville, North Carolina (the “Lease”). The Lease was amended in August 2015 to extend the term for the 5,954 square foot rental. The current term began on March 1, 2016 and continues for 64 months to June 30, 2021. Rent payments began on July 1, 2016, following the conclusion of a four-month rent abatement period. The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease thirty-six months after the commencement of the initial term if no additional space (“Expansion Space”) became available. On April 2, 2021, the Company negotiated a 3-year extension to the existing lease term, commencing July 1, 2021. Beginning on the commencement date, the annual base rent will be increased to $125,034 and will increase 2.5% annually for lease years 2 and 3. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and determined that, except for the Lease described above, none of the Company’s contracts contain a lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The balance sheet classification of our lease liabilities was as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">239,039</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the maturities of our operating lease liabilities were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Year ending December 31, </strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,517</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,702</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">384,628</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,128</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Operating lease liability</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Operating lease liabilities are based on the net present value of the remaining Lease payments over the remaining Lease term. In determining the present value of lease payments, the Company used the incremental borrowing rate based on the information available at the Lease commencement date. As of June 30, 2021, the remaining Lease term is 36 months and the discount rate used to determine the operating lease liability was 8.0%. For the six months ending June 30, 2021, the Company paid $67,765 in total lease expenses, including $5,963 for common area maintenance charges. </p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&trid=2208923<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>24 <FILENAME>R12.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614872760"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>NOTES PAYABLE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">6. NOTES PAYABLE</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 6. NOTE PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Payroll Protection Program Loan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On April 30, 2020, the Company received a loan pursuant to the Paycheck Protection Program (the “PPP Loan”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), as administered by the U.S. Small Business Administration (“SBA”). The PPP Loan in the principal amount of $244,657 was disbursed by First Horizon Bank (the “Lender”) pursuant to a promissory note issued by us (the “Note”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The PPP Loan has a two-year term and bears interest at a rate of 1.00% per annum. Monthly principal and interest payments are deferred for sixteen months. Beginning September 30, 2021, the Company is required to make monthly payments of principal and interest of approximately $31,100 to the Lender. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations, and material adverse effects. The Company may prepay the principal of the PPP Loan at any time, subject to certain notice requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the terms of the CARES Act, Paycheck Protection Program loan recipients can apply for and be granted forgiveness for all or a portion of a loan granted under the program. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The Company is using the proceeds from the PPP Loan to fund payroll costs in accordance with the relevant terms and conditions of the CARES Act. However, no assurance is provided that forgiveness for any portion of the PPP Loan will be obtained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On May 28, 2021, the Company received notice from the SBA that the SBA had remitted $244,657 in principal and $2,576 in interest to the Lender in full forgiveness of the Company’s PPP Loan pursuant to the Company’s application to the SBA for forgiveness of the PPP Loan. The total amount was recorded as other income in the Company's condensed consolidated statement of comprehensive loss.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&trid=2208564<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>25 <FILENAME>R13.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616353560"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>MERGER</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">7. MERGER</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>NOTE 7. MERGER</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 15, 2021, the Company, Life Newco II, PHPM, and Dr. Stuart Rich, solely in his capacity as Representative, entered into the Merger Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company would acquire 100% of the equity of PHPM. Under the terms of the Merger Agreement, Life Newco II would merge with and into PHPM, with PHPM surviving as a wholly owned subsidiary of the Company. On January 15, 2021, the Company completed the Acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As consideration for the Merger, the stockholders of PHPM received (i) 1,892,905 shares of the Company’s common stock (“Common Stock”), and (ii) 10,232 shares of the Company’s Series B convertible preferred stock, which are convertible into up to an aggregate of 10,232,000 shares of Common Stock (“Preferred Stock”) (collectively, the “Merger Consideration”). The issuance of 1,212,492 shares of Common Stock issuable upon conversion of the Preferred Stock, representing approximately 10% of the Merger Consideration, will be delayed as security for closing adjustments and post-closing indemnification obligations of PHPM and the stockholders of PHPM. Following receipt of the approval of the stockholders of the Company for the Conversion (as defined herein), each share of Preferred Stock will automatically convert into (i) 881.5 shares of Common Stock, and (ii) 118.5 shares of Common Stock to be delivered 24 months after the date of issuance of the Preferred Stock, subject to reduction for indemnification claims. The number of shares of Common Stock into which the Preferred Stock converts is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The Preferred Stock does not carry dividends or a liquidation preference. The Preferred Stock carries voting rights aggregating 4.99% of the Company’s Common Stock voting power immediately prior to the closing of the Merger. The rights, preferences and privileges of the Preferred Stock are set forth in the Certificate of Designation of Series B Convertible Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on January 15, 2021 (the “Certificate of Designation”). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pursuant to the Merger Agreement, the Board of Directors, at its Annual Meeting of Shareholders held on June 10, 2021, recommended to the Company’s shareholders, and the shareholders approved, the conversion of the Preferred Stock pursuant to the Certificate of Designation (the “Conversion”). In addition, (i) at the Company’s first regularly scheduled Board meeting following the closing of the Merger, the Board must appoint one director designated by the Representative to serve on the Board, and (ii) as promptly as practicable after the Company has obtained stockholder approval for the Conversion, the Board must appoint two additional directors designated by the Representative to serve on the Board. Dr. Stuart Rich, the co-founder and Chief Executive Officer, and a stockholder of PHPM, and Dr. Michael Davidson and Dr. Declan Doogan, the two other designees of the Representative, were appointed to the Board on February 25, 2021. In connection with the closing of the Merger, Dr. Stuart Rich was also appointed Chief Medical Officer of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company evaluated this acquisition in accordance with ASC 805, Business Combinations, to determine whether the assets and operations of PHPM met the definition of a business. Included in the in-process research and development project is the historical know-how, formula protocols, designs, and procedures expected to be needed to complete the related phase of testing. The Company concluded that the in-process research and development project is an identifiable intangible asset that would be accounted for as a single asset in a business combination. The Company also qualitatively concluded that there is no fair value associated with the clinical research organization contract and the clinical manufacturing organization contract because the services are being provided at market rates and could be provided by multiple vendors in the marketplace. Therefore, all of the consideration in the transaction will be allocated to the in-process research and development project. As such, the Company concluded that substantially all of the fair value of the gross assets acquired is concentrated in the single in-process research and development asset and the set is not a business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company is planning to use the acquired asset to further its clinical develop in an upcoming phase 3 clinical trial for the treatment of patients with PAH. Although the acquired asset may have utility in other patient populations, future development decisions for the acquired asset will be contingent upon the results of the contemplated phase 3 program for PAH. As such, the acquired asset does not have an alternative future use at the acquisition date. In accordance with ASC 730, Research and Development, the Company concluded the entire Purchase Price for the asset acquisition will be recorded as an expense on the acquisition date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The consideration transferred, assets acquired and liabilities assumed were recognized as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of shares of Common Stock issued</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,369,371</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair Value of Series B Convertible Preferred Stock issued at closing</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,212,960</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Total fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tangible assets acquired</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable assumed</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IPR&D expense recognized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,732,331</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total fair value of consideration</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&trid=2303972<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>26 <FILENAME>R14.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616271544"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">8. COMMITMENTS AND CONTINGENCIES</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.9pt; text-align:left;"><strong>NOTE 8. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Simdax license agreement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On November 13, 2013, the Company acquired, through its wholly owned subsidiary, Life Newco, that certain License Agreement (the “License”), dated September 20, 2013 by and between Phyxius and Orion Corporation, a global healthcare company incorporated under the laws of Finland (“Orion”), and that certain Side Letter, dated October 15, 2013 by and between Phyxius and Orion. The License grants the Company an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan (the “Product”) in the United States and Canada (the “Territory”) from Orion. Pursuant to the License, the Company must use Orion’s “Simdax®” trademark to commercialize the Product. The License also grants to the Company a right of first refusal to commercialize new developments of the Product, including developments as to the formulation, presentation, means of delivery, route of administration, dosage or indication, i.e., line extension products. Orion’s ongoing role under the License includes sublicense approval, serving as the sole source of manufacture, holding a first right to enforce intellectual property rights in the Territory, and certain regulatory participation rights. Additionally, the Company must grant back to Orion a broad non-exclusive license to any patents or clinical trial data related to the Product developed by the Company under the License. The License has a fifteen (15) year term, provided, however, that the License will continue after the end of the fifteen-year term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On October 9, 2020, the Company entered into the Amendment to include two new oral products containing levosimendan, in capsule and solid dosage form, and a subcutaneously administered product containing levosimendan to the scope of the License, subject to specified limitations. The Amendment also amends the tiered royalty payments based on net sales of the Product in the Territory (each as defined in the License, as amended by the Amendment) made by the Company and its sublicensees. Pursuant to the Amendment, the term of the License has been extended until 10 years after the launch of the Product in the Territory, provided that the License will continue after the end of the term in each country in the Territory until the expiration of Orion’s patent rights in the Product in such country. In the event that no regulatory approval for the Product has been granted in the United States on or before September 20, 2028, however, either party will have the right to terminate the License with immediate effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pursuant to the terms of the License, the Company paid to Orion a non-refundable up-front payment in the amount of $1.0 million. The License also includes the following development milestones for which the Company shall make non-refundable payments to Orion no later than twenty-eight (28) days after the occurrence of the applicable milestone event: (1) $2.0 million upon the grant of United States Food and Drug Administration approval, including all registrations, licenses, authorizations and necessary approvals, to develop and/or commercialize the Product in the United States; and (2) $1.0 million upon the grant of regulatory approval for the Product in Canada. Once commercialized, the Company is obligated to make certain non-refundable commercialization milestone payments to Orion, aggregating up to $13.0 million, contingent upon achievement of certain cumulative net sales amounts in the Territory. The Company must also pay Orion tiered royalties based on net sales of the Product in the Territory made by the Company and its sublicensees. After the end of the term of the License, the Company must pay Orion a royalty based on net sales of the Product in the Territory for as long as the Company sells the Product in the Territory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the Company has not met any of the developmental milestones and, accordingly, has not recorded any liability for the contingent payments due to Orion.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>27 <FILENAME>R15.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616382296"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">9. STOCKHOLDERS' EQUITY</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 9. STOCKHOLDERS’ EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Preferred Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the Company’s Certificate of Incorporation, the Board is authorized, without further stockholder action, to provide for the issuance of up to 10,000,000 shares of preferred stock, par value $0.0001 per share, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Series B Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 7 above, on January 15, 2021 the Company issued 10,232 shares of its Series B Stock, which were convertible into an aggregate of 10,232,000 shares of common stock, to the stockholders of PHPM as partial consideration for the Merger with PHPM pursuant to the Merger Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The rights, preferences and privileges of the Series B Stock are set forth in the Certificate of Designation. Following receipt of the approval of the stockholders of the Company for the Conversion, each share of Series B Stock will automatically convert into (i) 881.5 shares of Common Stock and (ii) 118.5 shares of Common Stock, to be delivered 24 months after the date of issuance of the Preferred Stock, subject to reduction for indemnification claims. The number of shares of Common Stock into which the Preferred Stock converts is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The Preferred Stock does not carry dividends or a liquidation preference. The Preferred Stock carries voting rights aggregating 4.99% of the Company’s Common Stock voting power immediately prior to the closing of the Merger.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s shareholders approved the conversion of our outstanding Series B Stock into shares of common stock. As a result of the approval, all outstanding shares of Series B Stock were automatically converted into an aggregate of 10,232,000 shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were no shares of Series B Stock outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 22.5pt; text-align:left;"><em>Series A Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On December 11, 2018, the Company closed its underwritten offering of 5,181,346 units for net proceeds of approximately $9 million. Each unit consists of (1) one share of the Company’s Series A convertible preferred stock, par value $0.0001 per share (the “Series A Stock”), (2) a two-year warrant to purchase one share of common stock at an exercise price of $1.93, and (3) a five-year warrant to purchase one share of common stock at an exercise price of $1.93. In accordance with ASC 480, the estimated fair value of $1,800,016 for the beneficial conversion feature was recognized as a deemed dividend on the Series A Stock during the year ended December 31, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The table below sets forth a summary of the designation, powers, preferences and rights of the Series A Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:15%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"> Conversion</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Subject to the ownership limitations described below, the Series A Stock is convertible at any time at the option of the holder into shares of the Company’s common stock at a conversion ratio determined by dividing the stated value of the Series A Stock by a conversion price of $1.93 per share. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company will not affect any conversion of the Series A Stock, nor shall a holder convert its shares of Series A Stock, to the extent that such conversion would cause the holder to have acquired, through conversion of the Series A Stock or otherwise, beneficial ownership of a number shares of common stock in excess of 4.99% (or, at the election of the holder prior to the issuance of any shares of Series A Stock, 9.99%) of the common stock outstanding after giving effect to such exercise.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividends </p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In the event the Company pays dividends on its shares of common stock, the holders of the Series A Stock will be entitled to receive dividends on shares of Series A Stock equal, on an as-if-converted basis, to and in the same form as paid on the common stock. No other dividends will be paid on the shares of Series A Stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Liquidation</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Upon any liquidation, dissolution or winding up of the Company after payment or provision for payment of debts and other liabilities of the Company, the holders of Series A Stock shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount equal to the amount that a holder of common stock would receive if the Series A Stock were fully converted to common stock, which amounts will be paid pari passu with all holders of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Voting rights</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Shares of Series A Stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the then outstanding Series A Stock will be required to amend the terms of the Series A Stock or to take other action that adversely affects the rights of the holders of Series A Stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were 210 shares of Series A Stock outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company’s Certificate of Incorporation authorizes it to issue 400,000,000 shares of $0.0001 par value common stock. As of June 30, 2021, and December 31, 2020, there were 25,201,312 and 12,619,369 shares of common stock issued and outstanding, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On March 13, 2020, the Company completed a registered direct offering to a single healthcare-focused institutional investor (the “Investor”) for the issuance and sale of 750,000 shares of its common stock at a purchase price of $1.1651 per share and pre-funded warrants to purchase up to 1,610,313 shares of its common stock, at a purchase price of $1.1650 per pre-funded warrant (which represents the per share offering price for the common stock less $0.0001, the exercise price of each pre-funded warrant), for gross proceeds of approximately $2.75 million, priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company issued to the Investor unregistered warrants to purchase up to 2,360,313 shares of its common stock. The unregistered warrants have an exercise price of $1.04 per share and exercise period commencing immediately upon the issuance date and a term of five and one-half years. The net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses were approximately $2.125 million. The fair value allocated to the common stock, pre-funded warrants and warrants was $0.5 million, $1.1 million and $1.1 million, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On July 8, 2020, the Company completed a registered direct offering with the Investor for the issuance and sale of 2,523,611 shares of its common stock at a purchase price of $1.0278 per share and pre-funded warrants to purchase up to 652,313 shares of its common stock, at a purchase price of $1.0277 per pre-funded warrant (which represents the per share offering price for the common stock less $0.0001, the exercise price of each pre-funded warrant). The Company issued in a concurrent private placement unregistered pre-funded warrants to purchase up to 4,607,692 shares of common stock at the same purchase price as the registered pre-funded warrants, and unregistered common stock warrants to purchase up to 7,783,616 shares of common stock for aggregate gross proceeds of approximately $8.0 million, priced at-the-market under Nasdaq rules. The unregistered warrants have an exercise price of $0.903 per share and exercise period commencing immediately upon the issuance date and a term of five and one-half years. The net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses were approximately $6.5 million. The fair value allocated to the common stock, pre-funded warrants and warrants was $1.5 million, $3.0 million and $3.5 million, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were 5,260,005 pre-funded warrants outstanding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Warrants</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>March 2020 Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As part of the March 2020 registered direct offering, the Company issued unregistered warrants to purchase 2,360,313 shares of its common stock at an exercise price of $1.04 per share and contractual term of five and one-half years. The unregistered warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. In accordance with ASC 480, these warrants are classified as equity and their relative fair value of approximately $1.1 million was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>July 2020 Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As part of the July 2020 offering, the Company issued unregistered warrants to purchase 7,783,616 shares of its common stock at an exercise price of $0.903 per share and contractual term of five and one-half years. The unregistered warrants were offered in a private placement under Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. In accordance with ASC 480, these warrants are classified as equity and their relative fair value of approximately $3.5 million was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Warrants Issued for Services</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In connection with the March 2020 offering described above, the Company issued designees of the placement agent warrants to purchase 177,023 shares of common stock at an exercise price of $1.4564 and a contractual term of five years. In accordance with ASC 815, these warrants are classified as equity and its estimated fair value of $66,201 was recognized as additional paid in capital. Additionally, the Company issued to its previous underwriter a warrant to purchase 94,413 shares of common stock at an exercise price of $1.4564 per share and contractual term of five years. In accordance with ASC 815, this warrant is classified as equity and its estimated fair value of $35,308 was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In connection with the July 2020 offering described above, the Company issued designees of the placement agent warrants to purchase 583,771 shares of common stock at an exercise price of $1.2848 and a contractual term of five years. In accordance with ASC 815, these warrants are classified as equity and its estimated fair value of $399,445 was recognized as additional paid in capital. Additionally, the Company issued to its previous underwriter a warrant to purchase 311,345 shares of common stock at an exercise price of $1.2848 per share and contractual term of five years. In accordance with ASC 815, this warrant is classified as equity and its estimated fair value of $213,038 was recognized as additional paid in capital. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company received approximately $545,000 and issued 282,202 shares of common stock upon the exercise of previously outstanding warrants issued in connection with the Company’s December 2018 offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company issued 119,491 shares of common stock upon the cashless exercise of previously outstanding placement agent warrants issued in connection with the Company’s March 2020 offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">During the six months ended June 30, 2021, the Company issued 399,883 shares of common stock upon the cashless exercise of previously outstanding placement agent warrants issued in connection with the Company’s July 2020 offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, the Company has 15,797,503 warrants outstanding. The following table summarizes the Company’s warrant activity for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>16,599,079</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.29</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(801,576</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.54</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at June 30, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>15,797,503</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.27</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em><strong>2016 Stock Incentive Plan</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the Company adopted the 2016 Stock Incentive Plan (the “2016 Plan”). Under the 2016 Plan, with the approval of the Compensation Committee of the Board of Directors, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, cash-based awards or other stock-based awards. On June 16, 2016, the Company’s stockholders approved the 2016 Plan and authorized for issuance under the 2016 Plan a total of 150,000 shares of common stock. On June 13, 2019, the Company’s stockholders approved an amendment to the 2016 Plan which increased the number of shares of common stock authorized for issuance under the 2016 Plan to a total of 750,000 shares, up from 150,000 previously authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 10, 2021, the Company’s stockholders approved an amendment to the 2016 Plan which increased the number of shares of common stock authorized for issuance under the 2016 Plan to a total of 1.5 million shares, up from 750,000 previously authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the shares available for grant under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Available </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>for Grant</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">356,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">750,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(328,750</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">777,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>2016 Plan Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stock options granted under the 2016 Plan may be either incentive stock options (“ISOs”), or nonqualified stock options (“NSOs”). ISOs may be granted only to employees. NSOs may be granted to employees, consultants and directors. Stock options under the 2016 Plan may be granted with a term of up to ten years and at prices no less than fair market value at the time of grant. Stock options granted generally vest over three to four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the outstanding stock options under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">328,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">722,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.83</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company chose the “straight-line” attribution method for allocating compensation costs of each stock option over the requisite service period using the Black-Scholes Option Pricing Model to calculate the grant date fair value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company recorded compensation expense for these stock option grants of $92,339 and $52,672 for the three months ended June 30, 2021 and 2020, and $182,658 and $112,833 for the six months ended June 30, 2021 and 2020, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were unrecognized compensation costs of approximately $446,904 related to non-vested stock option awards under the 2016 Plan that will be recognized on a straight-line basis over the weighted average remaining vesting period of 1.57 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company used the following assumptions to estimate the fair value of options granted under the 2016 Plan for the six months ended June 30, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the six months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk-free interest rate (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.03</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected volatility (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99.47</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.61</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:20%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Risk-Free Interest Rate</em></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The risk-free interest rate assumption was based on U.S. Treasury instruments with a term that is consistent with the expected term of the Company’s stock options.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Volatility</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected stock price volatility for the Company’s common stock was determined by examining the historical volatility and trading history for its common stock over a term consistent with the expected term of its options.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Term</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. It was calculated based on the Company’s historical experience with its stock option grants.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Expected Dividend Yield</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The expected dividend yield of 0% is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not anticipate paying any dividends in the near future.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>Forfeitures</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock compensation expense recognized in the statements of operations for the six months ended June 30, 2021 is based on awards ultimately expected to vest, and it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on the Company’s historical experience.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>1999 Amended Stock Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In October 2000, the Company adopted the 1999 Stock Plan, as amended and restated on June 17, 2008 (the “1999 Plan”). Under the 1999 Plan, with the approval of the Compensation Committee of the Board of Directors, the Company could grant stock options, restricted stock, stock appreciation rights and new shares of common stock upon exercise of stock options. On March 13, 2014, the Company’s stockholders approved an amendment to the 1999 Plan which increased the number of shares of common stock authorized for issuance under the 1999 Plan to a total of 200,000 shares, up from 15,000 previously authorized. On September 15, 2015, the Company’s stockholders approved an additional amendment to the 1999 Plan which increased the number of shares of common stock authorized for issuance under the 1999 Plan to a total of 250,000 shares, up from 200,000 previously authorized. The 1999 Plan expired on June 17, 2018 and no new grants may be made under that plan after that date. However, unexpired awards granted under the 1999 Plan remain outstanding and subject to the terms of the 1999 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>1999 Plan Stock Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stock options granted under the 1999 Plan may be either ISOs or NSOs. ISOs could be granted only to employees. NSOs could be granted to employees, consultants and directors. Stock options under the 1999 Plan could be granted with a term of up to ten years and at prices no less than fair market value for ISOs and no less than 85% of the fair market value for NSOs. Stock options granted generally vest over one to six years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following table summarizes the outstanding stock options under the 1999 Plan for the six months ended June 30, 2021: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,648</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(13</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">775.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,635</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company chose the “straight-line” attribution method for allocating compensation costs of each stock option over the requisite service period using the Black-Scholes Option Pricing Model to calculate the grant date fair value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company recorded compensation expense for these stock option grants of $0 and $10,494 for the three months ended June 30, 2021 and 2020, and $1,290 and $22,709 for the six months ended June 30, 2021 and 2020, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As of June 30, 2021, there were no unrecognized compensation costs related to non-vested stock option awards under the 1999 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Inducement Stock Options</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company granted an employment inducement stock option award for 250,000 shares of common stock to our chief medical officer on January 15, 2021. This employment inducement stock option was awarded in accordance with the employment inducement award exemption provided by NASDAQ Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award will vest as follows: 25% upon initiation of a Phase 3 trial; 25% upon database lock; 25% upon acceptance for review of an NDA; and 25% upon approval. The options have a 10-year term and an exercise price of $1.78 per share, the January 15, 2021 closing price of the Company's common stock. As of June 30, 2021, none of the vesting milestones have been achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The estimated fair value of the inducement stock option award granted was $402,789 using a Black-Scholes option pricing model based on market prices and the following assumptions at the date of inducement option grant: risk-free interest rate of 1.11%, dividend yield of 0%, volatility factor for our common stock of 103.94% and an expected life of 10 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inducement stock option compensation expense totaled $0 for the six months ended June 30, 2021. As of June 30, 2021, there was $402,789 of remaining unrecognized compensation expense related to this inducement stock option.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&trid=2208762<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>28 <FILENAME>R16.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614904536"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">10. SUBSEQUENT EVENTS</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>NOTE 10. SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On July 6, 2021, Tenax Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) pursuant to which the Company agreed to sell and issue to the Investor 4,773,269 units (“Units”) in a private placement at a purchase price of $2.095 per Unit. Each Unit consisted of one unregistered pre-funded warrant to purchase one share of common stock, par value $0.0001 (collectively the “Unregistered Pre-Funded Warrants”) and one unregistered warrant to purchase one share of common stock (collectively the “Unregistered Warrants” and together with the Unregistered Pre-Funded Warrants, the “Warrants”). In the aggregate,9,546,538 shares of the Company’s common stock are underlying the Warrants. The aggregate gross proceeds to the Company of the Offering were approximately $10 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Each Unregistered Pre-Funded Warrant has an exercise price of $0.0001 per share of common stock, is immediately exercisable, may be exercised at any time until exercised in full and is subject to customary adjustments. Each Unregistered Warrant has an exercise price of $1.97 per share of common stock, is immediately exercisable, will expire five and one-half years from the date of issuance and is subject to customary adjustments. The Warrants may not be exercised if the aggregate number of shares of the Company’s common stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% of the Company’s outstanding common stock immediately after exercise. However, the holder may increase (upon 61 days’ prior notice from the holder to the Company) or decrease such percentage, provided that in no event such percentage exceeds 9.99%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company intends to use the net proceeds from the Offering to further its clinical trials of levosimendan and imatinib for research and development and for general corporate purposes, including working capital and potential acquisitions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Also, on July 6, 2021 and in connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, pursuant to which the Company agreed to register for resale the shares of the Company’s common stock issuable upon exercise of the Warrants within 120 days following the date of the Registration Rights Agreement. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under certain circumstances, including, but not limited to, (i) if the registration statement is not filed by the earlier of 45 days after the date of the Registration Rights Agreement or 10 days after the Company files its first Form 10-Q following the Registration Rights Agreement (ii) if the registration statement has not been declared effective (A) by the 120th day after the date of the Registration Rights Agreement (or, in the event of a “full review” by the Securities and Exchange Commission (the “SEC”), the 150th day after the date of the Registration Rights Agreement) or (B) within five trading days following the date the Company is notified by the SEC that the registration statement will not be reviewed or is no longer subject to further review and comments then the Company has agreed to pay the Investor, as partial liquidated damages, an amount equal to 1.0% of the Investor’s aggregate subscription amount paid pursuant to the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">H.C. Wainwright & Co., LLC (“HCW) was entitled to fees related to the Offering under a tail provision in an engagement letter with the Company that relates to HCW’s assistance as a Placement Agent in a prior offering in July 2020 between the Investor and the Company (the “Tail Provision”). Pursuant to the Tail Provision, the Company paid HCW a cash fee equal to 7.5% of the gross proceeds received by the Company in the Offering, totaling approximately $750,000. In addition, the Company has agreed to issue to HCW or its designees warrants to purchase up to 357,995 shares of common stock (representing 7.5% of the aggregate number of shares of common stock equivalents sold in the Offering) (the “HCW Warrants”). The HCW Warrants have substantially the same terms as the Unregistered Warrants, except that the HCW Warrants have an exercise price equal to $2.46, or 125% of the offering price per share of common stock and will be exercisable for five years from the effective date of the Offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The issuance and sale of the Units, the Warrants, the HCW Warrants and the shares of common stock issuable upon exercise of the Warrants and the HCW Warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">On July 13, 2021, Anthony A. DiTonno retired as the Chief Executive Officer of the Company and as a member of the Company’s Board of Directors (the “Board”) effective as of July 13, 2021 (the “Effective Separation Date”). In connection with his retirement, Mr. DiTonno entered into a Separation and General Release Agreement with the Company (the “Separation Agreement”), dated July 6, 2021. The terms of the Separation Agreement provided that Mr. DiTonno had the right to revoke the Separation Agreement until July 22, 2021.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Under the Separation Agreement, Mr. DiTonno is entitled to receive severance in an amount equal to one year of his current base annual salary, and a pro-rated amount of his annual bonus that would have been received had 100% of his annual goals been achieved, approximately $563,000 (less applicable taxes and withholdings), payable in a lump sum on the 60th day following the Effective Separation Date. The Company will also reimburse COBRA premiums for coverage of Mr. DiTonno and his eligible dependents for up to 18 months if Mr. DiTonno timely and properly elects continuation coverage. The foregoing payments were contingent on Mr. DiTonno’s standard release of employment claims. In connection with his retirement and in order to ensure a smooth transition to the new CEO, Mr. DiTonno has received a stock option grant for 50,000 shares of common stock.  All of Mr. DiTonno’s outstanding stock options for common stock of the Company accelerated upon the Effective Separation Date, becoming fully vested, and are exercisable until the earlier of: (i) the original expiration date of each option under such option’s respective option agreement; or (ii) July 13, 2026. The Company is additionally reimbursing Mr. DiTonno for up to $5,000 in legal expenses related to the Separation Agreement. The Separation Agreement also contains such non-competition, non-solicitation, and confidentiality provisions and other terms and conditions as are usual and customary for agreements of this type. All of Mr. DiTonno’s obligations under his Employee Non-Disclosure, Inventions Assignment, and Competitive Business Activities Agreement, dated June 1, 2018, regarding confidentiality and proprietary information will continue.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>29 <FILENAME>R17.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505700484280"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet on December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the period ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) rules and regulations. Operating results for the three and six-month period ended June 30, 2021 are not necessarily indicative of results for the full year or any other future periods. As such, it is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. </p><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Management believes the accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $271 million on June 30, 2021 and $246 million on December 31, 2020 and used cash in operations of $5.1 million and $4.9 million during the six months ended June 30, 2021 and 2020, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As further discussed in Note 10 below, the Company sold 4,773,269 units ("Units") in a private placement at a purchase price of $2.095 per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of common stock and one unregistered warrant to purchase one share of common stock for gross proceeds of approximately $10 million. The Company requires substantial additional funds to complete its planned clinical trials and to pursue regulatory approvals. Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying June 30, 2021 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, to maintain present financing, and to generate cash from future operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p><span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In preparing the unaudited condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying condensed consolidated financial statements include the accounts and transactions of the Company, Life Newco and Life Newco II. All material intercompany transactions and balances have been eliminated in consolidation.</p><span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_LiquidityAndManagementsPlanPolicyTextBlock', window );">Liquidity and Management's Plan</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 30, 2021, the Company had cash and cash equivalents, including the fair value of its marketable securities, of approximately $2.2 million. The Company used $5.1 million of cash for operating activities during the six months ended June 30, 2021 and had stockholders’ equity of $1.5 million, versus $4.6 million on December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company expects to continue to incur expenses related to development of imatinib for pulmonary arterial hypertension and levosimendan for pulmonary hypertension and to continue with the development of other potential product candidates. Based on its resources on June 30, 2021 and including the net proceeds from its July 2021 offering (as discussed in Note 10 below), the Company believes that it has sufficient capital to fund its planned operations through the second quarter of calendar year 2022. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p><span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_Covid19ImpactPolicyTextBlock', window );">COVID-19 Impact and Related Risks</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The continued spread of COVID-19 globally could adversely affect the Company’s ability to retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, some of these investigators and site staff may be unable to comply with clinical trial protocols if quarantines or travel restrictions impede movement or interrupt healthcare services, or if they become infected with COVID-19 themselves, which would delay the Company’s ability to initiate and/or complete planned clinical and preclinical studies in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The full extent to which the COVID-19 pandemic and the various responses to it might impact the Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond the Company’s control.</p><span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Basic net loss per share, which excludes antidilutive securities, is computed by dividing net loss by the weighted-average number of common shares outstanding for that particular period. In contrast, diluted net loss per share considers the potential dilution that could occur from other equity instruments that would increase the total number of outstanding shares of common stock. Such amounts include shares potentially issuable under outstanding options, convertible preferred shares and warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The following outstanding options, convertible preferred shares and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,797,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,274,492</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,260,005</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company determines if an arrangement includes a lease at inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and long-term lease liabilities in the Company’s condensed consolidated balance sheets. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. The Company’s leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that the Company will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to account for leases with an initial term of 12 months or less similar to previous guidance for operating leases, under which the Company will recognize those lease payments in the consolidated statements of operations and comprehensive loss on a straight-line basis over the lease term.</p><span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td> <td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In December 2019, the Financial Accounting Standards Board (“FASB”) issued an accounting standard intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740, Income Taxes and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">In June 2016, the FASB issued an accounting standard that amends how credit losses are measured and reported for certain financial instruments that are not accounted for at fair value through net income. This standard requires that credit losses be presented as an allowance rather than as a write-down for available-for-sale debt securities and will be effective for interim and annual reporting periods beginning January 1, 2023, with early adoption permitted. A modified retrospective approach is to be used for certain parts of this guidance, while other parts of the guidance are to be applied using a prospective approach. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_Covid19ImpactPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_Covid19ImpactPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_LiquidityAndManagementsPlanPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_LiquidityAndManagementsPlanPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&trid=51888271<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>30 <FILENAME>R18.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614808184"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive securities</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,797,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,274,492</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrants to purchase common stock</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,260,005</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options to purchase common stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">779,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible preferred shares outstanding</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>31 <FILENAME>R19.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616432808"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ScheduleOfInvestmentsInMarketableSecurities', window );">Investments in marketable securities</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="18" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amortized </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accrued </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized Gains</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gross Unrealized losses</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Estimated </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Corporate debt securities </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total investments </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">506,530</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,690</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">46</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(323</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair value on a recurring basis</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of June 30, 2021 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,671,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,943</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: black 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value Measurements at Reporting Date Using </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Balance as of December 31, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted prices in Active Markets for Identical Securities (Level 1) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Other Observable Inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant Unobservable Inputs (Level 3) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current Assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,250,241</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Marketable securities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,687</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ScheduleOfInvestmentsInMarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ScheduleOfInvestmentsInMarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>32 <FILENAME>R20.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616202888"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Office furniture and fixtures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Computer equipment and software</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,631</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,307</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,664</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,340</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,843</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,368</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,821</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued liabilities</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Employee related</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,551</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">860,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Operating costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,051</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">319,608</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">383,063</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,240,616</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>33 <FILENAME>R21.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614998824"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE (Tables)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease liabilities</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,461</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">239,039</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">60,379</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of operating lease liabilities</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Year ending December 31, </strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,517</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">65,702</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">384,628</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,128</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Operating lease liability</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">340,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&trid=77888251<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>34 <FILENAME>R22.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616432264"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER (Tables)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>MERGER</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Consideration transferred, asset acquired and liabilities assumed</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of shares of Common Stock issued</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,369,371</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair Value of Series B Convertible Preferred Stock issued at closing</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,212,960</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Total fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tangible assets acquired</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable assumed</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total identifiable net assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(150,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IPR&D expense recognized</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,732,331</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total fair value of consideration</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">21,582,331</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>35 <FILENAME>R23.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614690056"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"><div>Jun. 30, 2021</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrant activity</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>16,599,079</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.29</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(801,576</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.54</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Outstanding at June 30, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>15,797,503</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>1.27</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_SharesAvailableForGrantTableTextblock', window );">Shares available for grant under the 2016 Plan</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Available </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>for Grant</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">356,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Additional shares reserved</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">750,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(328,750</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances, at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">777,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Options activity</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">328,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">722,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.83</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair value assumptions</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the six months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk-free interest rate (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.70</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.03</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected volatility (weighted average)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99.47</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97.61</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_OutstandingStockOptionsUnderPlanTableTextBlock', window );">Outstanding stock options under the 1999 Plan</a></td> <td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 1pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,648</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(13</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">775.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balances at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,635</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_OutstandingStockOptionsUnderPlanTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_OutstandingStockOptionsUnderPlanTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_SharesAvailableForGrantTableTextblock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_SharesAvailableForGrantTableTextblock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>36 <FILENAME>R24.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619357496"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares<br></strong></div></th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tenx_SimdaxLicenseAgreementMember', window );">Simdax License Agreement [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td> <td class="nump">779,885<span></span> </td> <td class="nump">450,203<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_WarranttoPurchaseCommonStockMember', window );">Warrant to Purchase Common Stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td> <td class="nump">15,797,503<span></span> </td> <td class="nump">12,274,492<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_ConvertiblePreferredSharesOutstandingMember', window );">Convertible preferred shares outstanding [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td> <td class="nump">210<span></span> </td> <td class="nump">210<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_PrefundedWarrantsToPurchaseCommonStockMember', window );">Pre-funded warrants to purchase common stock [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td> <td class="nump">5,260,005<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_SimdaxLicenseAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_SimdaxLicenseAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_WarranttoPurchaseCommonStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tenx_WarranttoPurchaseCommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_ConvertiblePreferredSharesOutstandingMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tenx_ConvertiblePreferredSharesOutstandingMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_PrefundedWarrantsToPurchaseCommonStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tenx_PrefundedWarrantsToPurchaseCommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>37 <FILENAME>R25.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619109320"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="2">6 Months Ended</th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> <th class="th"><div>Mar. 31, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="num">$ (271,484,983)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">$ (246,019,827)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td> <td class="num">(5,066,239)<span></span> </td> <td class="num">$ (4,899,965)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump">1,671,422<span></span> </td> <td class="nump">4,085,305<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">6,250,241<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 4,905,993<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholder equity</a></td> <td class="nump">1,471,132<span></span> </td> <td class="nump">$ 3,029,170<span></span> </td> <td class="nump">$ 3,095,681<span></span> </td> <td class="nump">4,625,562<span></span> </td> <td class="nump">$ 3,418,652<span></span> </td> <td class="nump">$ 3,772,497<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td> <td class="nump">$ 2,200,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Private placements units sold</a></td> <td class="nump">4,773,269<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Purchase price of units</a></td> <td class="nump">$ 2.095<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds', window );">Gross proceeds</a></td> <td class="nump">$ 10,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of proceeds received for the sale of securities, categorized neither as held-to-maturity nor trading securities, during the reporting period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MarketableSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>38 <FILENAME>R26.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619168760"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Details)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized cost</a></td> <td class="nump">$ 506,530<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest</a></td> <td class="nump">4,690<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross unrealized gains</a></td> <td class="nump">46<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_GrossUnrealizedLosses', window );">Gross unrealized losses</a></td> <td class="num">(323)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_AvailableForSaleSecuritiesEstimatedFairValue', window );">Estimated fair value</a></td> <td class="nump">510,943<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized cost</a></td> <td class="nump">506,530<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest</a></td> <td class="nump">4,690<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross unrealized gains</a></td> <td class="nump">46<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_GrossUnrealizedLosses', window );">Gross unrealized losses</a></td> <td class="num">(323)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_AvailableForSaleSecuritiesEstimatedFairValue', window );">Estimated fair value</a></td> <td class="nump">$ 510,943<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_AvailableForSaleSecuritiesEstimatedFairValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_AvailableForSaleSecuritiesEstimatedFairValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_GrossUnrealizedLosses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_GrossUnrealizedLosses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>39 <FILENAME>R27.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505618291992"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE (Details 1) - USD ($)<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current Assets</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td> <td class="nump">$ 1,671,422<span></span> </td> <td class="nump">$ 6,250,241<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td> <td class="nump">510,943<span></span> </td> <td class="nump">462,687<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current Assets</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td> <td class="nump">1,671,422<span></span> </td> <td class="nump">6,250,241<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current Assets</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td> <td class="nump">510,943<span></span> </td> <td class="nump">462,687<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current Assets</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>40 <FILENAME>R28.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505612944024"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Details) - USD ($)<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Office furniture and fixtures</a></td> <td class="nump">$ 43,033<span></span> </td> <td class="nump">$ 43,033<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer equipment and software</a></td> <td class="nump">23,631<span></span> </td> <td class="nump">23,307<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td> <td class="nump">66,664<span></span> </td> <td class="nump">66,340<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td> <td class="num">(60,843)<span></span> </td> <td class="num">(60,368)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td> <td class="nump">$ 5,821<span></span> </td> <td class="nump">$ 5,972<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>41 <FILENAME>R29.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505612924008"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Details 1) - USD ($)<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related</a></td> <td class="nump">$ 127,551<span></span> </td> <td class="nump">$ 860,629<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Operating costs</a></td> <td class="nump">154,051<span></span> </td> <td class="nump">319,608<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td> <td class="nump">101,461<span></span> </td> <td class="nump">60,379<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td> <td class="nump">$ 383,063<span></span> </td> <td class="nump">$ 1,240,616<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>42 <FILENAME>R30.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505618949176"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>BALANCE SHEET COMPONENTS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td> <td class="nump">$ 1,000<span></span> </td> <td class="nump">$ 1,000<span></span> </td> <td class="nump">$ 2,000<span></span> </td> <td class="nump">$ 2,000<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Depreciation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>43 <FILENAME>R31.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505726313928"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE (Details) - USD ($)<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in accrued liabilities</a></td> <td class="nump">$ 101,461<span></span> </td> <td class="nump">$ 60,379<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long term lease liability</a></td> <td class="nump">239,039<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td> <td class="nump">$ 340,500<span></span> </td> <td class="nump">$ 60,379<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31958-109318<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>44 <FILENAME>R32.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614697336"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE (Details 1) - USD ($)<br></strong></div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td> <td class="nump">$ 62,517<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td> <td class="nump">126,612<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td> <td class="nump">129,797<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td> <td class="nump">65,702<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td> <td class="nump">384,628<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_LessImputedInterest', window );">Less: imputed interest</a></td> <td class="num">(44,128)<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td> <td class="nump">$ 340,500<span></span> </td> <td class="nump">$ 60,379<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_LessImputedInterest"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_LessImputedInterest</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>45 <FILENAME>R33.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505619106568"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE (Details Narrative)<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">6 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"> <div>Jun. 30, 2021 </div> <div>USD ($)</div> </th> <th class="th"> <div>Jun. 30, 2020 </div> <div>USD ($)</div> </th> <th class="th"> <div>Jun. 30, 2021 </div> <div>USD ($)</div> </th> <th class="th"> <div>Jun. 30, 2020 </div> <div>USD ($)</div> </th> <th class="th"> <div>Aug. 31, 2015 </div> <div>ft²</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_RemainingLeaseTerm', window );">Remaining lease term</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">36 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td> <td class="nump">8.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">8.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease expense</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 67,765<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Amount of common area maintenance charges</a></td> <td class="num">$ (247,820)<span></span> </td> <td class="nump">$ 2,101<span></span> </td> <td class="num">$ (249,955)<span></span> </td> <td class="num">$ (8,740)<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of lease land | ft²</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,954<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_LeaseTermPeriod', window );">Lease term period</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">64 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases', window );">Description of lease contract</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease thirty-six months after the commencement of the initial term if no additional space (“Expansion Space”) became available. On April 2, 2021, the Company negotiated a 3-year extension to the existing lease term, commencing July 1, 2021<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Annual base rent increased</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 125,034<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PercentageOfAnnualIncreaseInRent', window );">Percentage of annual increase in rent</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2.50%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_LeaseTermPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessor's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_LeaseTermPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PercentageOfAnnualIncreaseInRent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PercentageOfAnnualIncreaseInRent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_RemainingLeaseTerm"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_RemainingLeaseTerm</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AreaOfLand</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:areaItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1)<br> -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeaseCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>46 <FILENAME>R34.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505613470056"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>NOTES PAYABLE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PppLoanAmount', window );">PPP loan amount</a></td> <td class="nump">$ 244,657<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PppLoanMonthlyPayment', window );">PPP loan, monthly payment</a></td> <td class="nump">$ 31,100<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">PPP loan term</a></td> <td class="text">2 years<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td> <td class="nump">1.00%<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_DebtInstrumentDecreaseForgivenessAccruedInterest', window );">Accrued interest</a></td> <td class="nump">$ 2,576<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">PPP loan - principal payable</a></td> <td class="nump">$ 244,657<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_DebtInstrumentDecreaseForgivenessAccruedInterest"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_DebtInstrumentDecreaseForgivenessAccruedInterest</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PppLoanAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PppLoanAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PppLoanMonthlyPayment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PppLoanMonthlyPayment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>47 <FILENAME>R35.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505612920120"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER (Details)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>MERGER</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of shares of Common Stock issued</a></td> <td class="nump">$ 3,369,371<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair Value of Series B Convertible Preferred Stock issued at closing</a></td> <td class="nump">18,212,960<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total fair value of consideration transferred</a></td> <td class="nump">21,582,331<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Tangible assets acquired</a></td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable assumed</a></td> <td class="num">(150,000)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td> <td class="num">(21,732,331)<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_InProcessResearchAndDevelopmentExpense', window );">IPR&D expense recognized</a></td> <td class="nump">$ 21,582,331<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_InProcessResearchAndDevelopmentExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_InProcessResearchAndDevelopmentExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>48 <FILENAME>R36.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505612968104"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER (Details Narrative)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>shares</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock</a></td> <td class="nump">10,232,000<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockAcquired', window );">Common stock acquired</a></td> <td class="nump">1,892,905<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued for conversion</a></td> <td class="nump">1,212,492<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PercentageOfPreferredStockCarriesVotingRights', window );">Percentage of Preferred Stock carries voting rights</a></td> <td class="nump">4.99%<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember', window );">Series B [Member]</a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock</a></td> <td class="nump">10,232<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockAcquired"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockAcquired</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PercentageOfPreferredStockCarriesVotingRights"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PercentageOfPreferredStockCarriesVotingRights</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>49 <FILENAME>R37.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614989624"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - Simdax License Agreement [Member] - USD ($)<br> $ in Millions</strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr> <th class="th"><div>Oct. 09, 2020</div></th> <th class="th"><div>Nov. 13, 2013</div></th> <th class="th"><div>Jun. 30, 2021</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">License Term period</a></td> <td class="text">10 years<span></span> </td> <td class="text">15 years<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_LicenseAgreementMaturityDate', window );">License agreement maturity date</a></td> <td class="text">Sep. 20, 2028<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_NonRefundableUpFrontPayment', window );">Non refundable up front payment</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.0<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_GrantPaidToAuthority', window );">Grant paid to authority</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2.0<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_GrantPaidToAuthorityOne', window );">Grant paid to canadian authority</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1.0<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_NonRefundableCommercializationMilestonePayment', window );">Non-refundable commercialization milestone payment</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 13.0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_GrantPaidToAuthority"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_GrantPaidToAuthority</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_GrantPaidToAuthorityOne"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_GrantPaidToAuthorityOne</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_LicenseAgreementMaturityDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the pending litigation matter was dismissed, in CCYY-MM-DD format.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_LicenseAgreementMaturityDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_NonRefundableCommercializationMilestonePayment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_NonRefundableCommercializationMilestonePayment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_NonRefundableUpFrontPayment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_NonRefundableUpFrontPayment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_SimdaxLicenseAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_SimdaxLicenseAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>50 <FILENAME>R38.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505613015336"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>$ / shares </div> <div>shares</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber', window );">Number of warrants outstanding, beginning | shares</a></td> <td class="nump">16,599,079<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised', window );">Number of warrants, exercised | shares</a></td> <td class="num">(801,576)<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber', window );">Number of warrants outstanding, ending | shares</a></td> <td class="nump">15,797,503<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td> <td class="nump">$ 1.29<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td> <td class="nump">1.54<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td> <td class="nump">$ 1.27<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>51 <FILENAME>R39.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505616316248"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - 2016 Stock Incentive Plan<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>shares</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, beginning</a></td> <td class="nump">356,500<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant', window );">Shares available for grant, additional shares reserved</a></td> <td class="nump">750,000<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares available for grant, options granted</a></td> <td class="nump">328,750<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, ending</a></td> <td class="nump">777,750<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>52 <FILENAME>R40.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505614690056"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - 2016 Stock Incentive Plan<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>$ / shares </div> <div>shares</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning | shares</a></td> <td class="nump">393,500<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares available for grant, options granted | shares</a></td> <td class="nump">328,750<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending | shares</a></td> <td class="nump">722,250<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td> <td class="nump">$ 1.81<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted | $ / shares</a></td> <td class="nump">1.86<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td> <td class="nump">$ 1.83<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>53 <FILENAME>R41.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505612926968"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3) - 2016 Stock Incentive Plan<br></strong></div></th> <th class="th" colspan="2">6 Months Ended</th> </tr> <tr> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (weighted average)</a></td> <td class="nump">0.70%<span></span> </td> <td class="nump">1.03%<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (weighted average)</a></td> <td class="nump">99.47%<span></span> </td> <td class="nump">97.61%<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td> <td class="text">7 years<span></span> </td> <td class="text">7 years<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td> <td class="nump">0.00%<span></span> </td> <td class="nump">0.00%<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>54 <FILENAME>R42.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505612915800"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 4) - 1999 Amended Stock Plan<br></strong></div></th> <th class="th" colspan="1">6 Months Ended</th> </tr> <tr><th class="th"> <div>Jun. 30, 2021 </div> <div>$ / shares </div> <div>shares</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning | shares</a></td> <td class="nump">57,648<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod', window );">Number of options cancelled | shares</a></td> <td class="num">(13)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending | shares</a></td> <td class="nump">57,635<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td> <td class="nump">$ 46.34<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price cancelled | $ / shares</a></td> <td class="nump">775.85<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td> <td class="nump">$ 46.18<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_Amended1999StockPlanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_Amended1999StockPlanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>55 <FILENAME>R43.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505603305928"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="7">1 Months Ended</th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">6 Months Ended</th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Jun. 10, 2021</div></th> <th class="th"><div>Jan. 15, 2021</div></th> <th class="th"><div>Jul. 08, 2020</div></th> <th class="th"><div>Dec. 11, 2018</div></th> <th class="th"><div>Jun. 09, 2021</div></th> <th class="th"><div>Jul. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Jun. 12, 2019</div></th> <th class="th"><div>Jun. 16, 2016</div></th> <th class="th"><div>Sep. 15, 2015</div></th> <th class="th"><div>Sep. 15, 2015</div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Jun. 30, 2020</div></th> <th class="th"><div>Dec. 31, 2020</div></th> <th class="th"><div>Mar. 13, 2020</div></th> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantToPurchaseOfCommonStockExercisePrice', window );">Warrant to purchase of common stock exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.0277<span></span> </td> <td class="nump">$ 11.93<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.1651<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase of common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">652,313<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1,610,313<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock', window );">Concurrent private placement unregistered pre-funded warrants to purchas common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">4,607,692<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock', window );">Unregistered common stock warrants to purchase common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">7,783,616<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds', window );">Unregistered common stock warrants to purchase gross proceeds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 8,000,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredWarrantsExercisePrice', window );">Unregistered warrants exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.903<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses', window );">Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 6,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">15,797,503<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">15,797,503<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock upon the exercise of outstanding warrants issued, amount</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 545,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock upon the exercise of outstanding warrants issued, shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">282,202<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PrefundedWarrantsOutstanding', window );">Pre-funded Warrants outstanding</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,260,005<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,260,005<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">9,999,790<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">9,999,790<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">9,999,790<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockParOrStatedValuePerShares', window );">Common stock, par value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.0278<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.1651<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">400,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">400,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">400,000,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockSharesIssue', window );">Common stock, issued</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,260,005<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">25,201,312<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">25,201,312<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">750,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">25,210,312<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">25,210,312<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">12,619,369<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=tenx_July2020WarrantsMember', window );">July 2020 Warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantToPurchaseOfCommonStockExercisePrice', window );">Warrant to purchase of common stock exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.2848<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase of common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">583,771<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredWarrantsExercisePrice', window );">Unregistered warrants exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.903<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 3,500,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantToPurchaseOfCommonStockTerm', window );">Warrant to purchase of common stock term</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">5 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_IssuedUnderwriterWarrantTopurchaseCommonStock', window );">Issued underwriter warrant to purchase common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">311,345<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice', window );">Underwriter warrant to purchase common stock exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.2848<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue', window );">Underwriter warrant to purchase common stock estimated fair value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 213,038<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants', window );">Common stock upon the cashless exercise of previously outstanding placement agent warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">399,883<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2', window );">Unregistered common stock warrants to purchase common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">7,783,616<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_EstimatedFairValueofWarrantIssuedForServicese', window );">Estimated fair valueof warrant issued for services</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 399,445<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_MarchTwentyTwentyWarrantsMember', window );">March 2020 Warrants [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantToPurchaseOfCommonStockExercisePrice', window );">Warrant to purchase of common stock exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.4564<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase of common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">177,023<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock', window );">Unregistered common stock warrants to purchase common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2,360,313<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredWarrantsExercisePrice', window );">Unregistered warrants exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.04<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1,100,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantToPurchaseOfCommonStockTerm', window );">Warrant to purchase of common stock term</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">5 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_EstimatedFairValueofWarrantIssuedForServices', window );">Estimated fair valueof warrant issued for services</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 66,201<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_IssuedUnderwriterWarrantTopurchaseCommonStock', window );">Issued underwriter warrant to purchase common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">94,413<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice', window );">Underwriter warrant to purchase common stock exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.4564<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue', window );">Underwriter warrant to purchase common stock estimated fair value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 35,308<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants', window );">Common stock upon the cashless exercise of previously outstanding placement agent warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">119,491<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=tenx_InvestorsMember', window );">Investor [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantToPurchaseOfCommonStockExercisePrice', window );">Warrant to purchase of common stock exercise price</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.04<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase of common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2,360,313<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses', window );">Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 2,125,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_FairValueAllocatedCommonStock', window );">Fair value allocated common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1,500,000<span></span> </td> <td class="nump">500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_FairValueAllocatedPrefundedWarrants', window );">Fair value allocated pre-funded warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">3,000,000.0<span></span> </td> <td class="nump">1,100,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_FairValueAllocatedWarrants', window );">Fair value allocated warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 3,500,000<span></span> </td> <td class="nump">1,100,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member', window );">2016 Stock Incentive Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 92,339<span></span> </td> <td class="nump">$ 52,672<span></span> </td> <td class="nump">$ 182,658<span></span> </td> <td class="nump">$ 112,833<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares of common stock authorized for issuance</a></td> <td class="nump">750,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">750,000<span></span> </td> <td class="nump">15,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockOptionsGrantedVestingPeriod', window );">Stock options granted, vesting period</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">Stock options granted generally vest over three to four years.<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Stock options granted, term</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">10 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">446,904<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 446,904<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0.70%<span></span> </td> <td class="nump">1.03%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Vvolatility factor rate</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">99.47%<span></span> </td> <td class="nump">97.61%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">7 years<span></span> </td> <td class="text">7 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tenx_Amended1999StockPlanMember', window );">1999 Amended Stock Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="nump">$ 10,494<span></span> </td> <td class="nump">$ 1,290<span></span> </td> <td class="nump">$ 22,709<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares of common stock authorized for issuance</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">200,000<span></span> </td> <td class="nump">250,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">15,000<span></span> </td> <td class="nump">200,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockOptionsGrantedFairMarketValuePercentage', window );">Stock options granted fair market value percentage</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">85.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tenx_InducementStockOptionsMember', window );">Inducement Stock Options</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 402,789<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 402,789<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock option award granted</a></td> <td class="text"> <span></span> </td> <td class="nump">250,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock options exercise price</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 1.78<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options exercise term</a></td> <td class="text"> <span></span> </td> <td class="text">10 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockOptionsDescription', window );">Stock options description</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">The option award will vest as follows: 25% upon initiation of a Phase 3 trial; 25% upon database lock; 25% upon acceptance for review of an NDA; and 25% upon approval<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_EstimatedFairValueOfInducementStockOptionAwardGranted', window );">Estimated fair value of the inducement stock option award granted</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 402,789<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1.11%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_DividendYield', window );">Dividend yield</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Vvolatility factor rate</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">103.94%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">10 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from underwritten offering</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">9,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Underwritten offering of stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 5,181,346<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarranToPurchaseOfCommonStockTerm', window );">Warrant to purchase of common stock term</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">2 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,181,346<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,181,346<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">5,181,346<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PreferredStockVotingRightsPercentage', window );">Preferred Stock voting rights percentage</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">4.99%<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">4.99%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PreferredStockVotingRightsPercentage1', window );">Preferred Stock voting rights percentage 1</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">9.99%<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">9.99%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">210<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td> <td class="text"> <span></span> </td> <td class="nump">10,232<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PreferredStockVotingRightsPercentage', window );">Preferred Stock voting rights percentage</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">4.99%<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">4.99%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td> <td class="text"> <span></span> </td> <td class="nump">10,232<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_StockConvertibleIntoAggregateSharesOfCommonStock', window );">Stock convertible into an aggregate shares of common stock</a></td> <td class="nump">10,232,000<span></span> </td> <td class="nump">10,232,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_RightsPreferencesAndPrivilegesConversionIntoShare', window );">Rights, preferences and privileges conversion into share</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">882<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">882<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_RightsPreferencesAndPrivilegesConversionIntoShare1', window );">Rights, preferences and privileges conversion into share 1</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">119<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">119<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">(i) 881.5 shares of Common Stock and (ii) 118.5 shares of Common Stock, to be delivered 24 months after the date of issuance of the Preferred Stock<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockParOrStatedValuePerShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockParOrStatedValuePerShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockSharesIssue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockSharesIssue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock upon the cashless exercise of previously outstanding placement agent warrants.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_DividendYield"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_DividendYield</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_EstimatedFairValueOfInducementStockOptionAwardGranted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_EstimatedFairValueOfInducementStockOptionAwardGranted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_EstimatedFairValueofWarrantIssuedForServices"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair valueof warrant issued for services.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_EstimatedFairValueofWarrantIssuedForServices</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_EstimatedFairValueofWarrantIssuedForServicese"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair valueof warrant issued for services.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_EstimatedFairValueofWarrantIssuedForServicese</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_FairValueAllocatedCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_FairValueAllocatedCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_FairValueAllocatedPrefundedWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_FairValueAllocatedPrefundedWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_FairValueAllocatedWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_FairValueAllocatedWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_IssuedUnderwriterWarrantTopurchaseCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issued underwriter warrant to purchase common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_IssuedUnderwriterWarrantTopurchaseCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PreferredStockVotingRightsPercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PreferredStockVotingRightsPercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PreferredStockVotingRightsPercentage1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PreferredStockVotingRightsPercentage1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PrefundedWarrantsOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PrefundedWarrantsOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_RightsPreferencesAndPrivilegesConversionIntoShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rights, preferences and privileges conversion into share.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_RightsPreferencesAndPrivilegesConversionIntoShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_RightsPreferencesAndPrivilegesConversionIntoShare1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_RightsPreferencesAndPrivilegesConversionIntoShare1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_StockConvertibleIntoAggregateSharesOfCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_StockConvertibleIntoAggregateSharesOfCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_StockOptionsDescription"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options description.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_StockOptionsDescription</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_StockOptionsGrantedFairMarketValuePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_StockOptionsGrantedFairMarketValuePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_StockOptionsGrantedVestingPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options granted, vesting period</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_StockOptionsGrantedVestingPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriter warrant to purchase common stock estimated fair value.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriter warrant to purchase common stock exercise price.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unregistered common stock warrants to purchase common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnregisteredWarrantsExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unregistered warrants exercise price.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnregisteredWarrantsExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_WarranToPurchaseOfCommonStockTerm"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_WarranToPurchaseOfCommonStockTerm</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_WarrantToPurchaseOfCommonStockExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_WarrantToPurchaseOfCommonStockExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_WarrantToPurchaseOfCommonStockTerm"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant to purchase of common stock term.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_WarrantToPurchaseOfCommonStockTerm</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=tenx_July2020WarrantsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardDateAxis=tenx_July2020WarrantsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tenx_MarchTwentyTwentyWarrantsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tenx_MarchTwentyTwentyWarrantsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tenx_InvestorsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tenx_InvestorsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_StockIncentivePlan2016Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_Amended1999StockPlanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_Amended1999StockPlanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_InducementStockOptionsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_InducementStockOptionsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>56 <FILENAME>R44.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140505698565800"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th> <th class="th"><div>Jul. 13, 2021</div></th> <th class="th"><div>Jul. 06, 2021</div></th> <th class="th"><div>Jun. 30, 2021</div></th> <th class="th"><div>Mar. 31, 2021</div></th> <th class="th"><div>Dec. 31, 2020</div></th> <th class="th"><div>Jul. 08, 2020</div></th> <th class="th"><div>Mar. 13, 2020</div></th> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockParOrStatedValuePerShares', window );">Common stock, par value</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.0278<span></span> </td> <td class="nump">$ 1.1651<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price warrant</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1.27<span></span> </td> <td class="nump">$ 1.27<span></span> </td> <td class="nump">$ 1.29<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_MaturityPeriod', window );">Maturity period</a></td> <td class="text"> <span></span> </td> <td class="text">5 years 6 months<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issued</a></td> <td class="text"> <span></span> </td> <td class="nump">4,773,269<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PurchasePriceOfStock', window );">Purchase price of stock</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 2.095<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_CommonStockParOrStatedValuePerShares', window );">Common stock, par value</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredPreFundedWarrants', window );">Unregistered pre funded warrants</a></td> <td class="text"> <span></span> </td> <td class="nump">9,546,538<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ProceedsFromOffering', window );">Proceeds from offering</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 10,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price warrant</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 0.0001<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock', window );">Unregistered Warrant has an exercise price per share of common stock</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 1.97<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Registration Rights Agreement [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_MaturityPeriod', window );">Maturity period</a></td> <td class="text"> <span></span> </td> <td class="text">5 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_ProceedsFromOffering', window );">Proceeds from offering</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 50,000,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price warrant</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 2.46<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PercentageOfGrossProceedReceived', window );">Percentage of gross proceed received</a></td> <td class="text"> <span></span> </td> <td class="nump">7.50%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_WarrantIssuedToPurchaseCommonStock', window );">Warrant issued to purchase common stock</a></td> <td class="text"> <span></span> </td> <td class="nump">357,995<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_PercentageOfOfferingPricePerShareOfCommonStock', window );">Percentage of offering price per share of common stock</a></td> <td class="text"> <span></span> </td> <td class="nump">125.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Separation Agreement [Member] | Mr Ditonno [Member]</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_dvddv', window );">Stock option granted</a></td> <td class="nump">50,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tenx_SeveranceReceived', window );">Severance received</a></td> <td class="nump">$ 563,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Legal expenses</a></td> <td class="nump">$ 5,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_CommonStockParOrStatedValuePerShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_CommonStockParOrStatedValuePerShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_MaturityPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_MaturityPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PercentageOfGrossProceedReceived"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PercentageOfGrossProceedReceived</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PercentageOfOfferingPricePerShareOfCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PercentageOfOfferingPricePerShareOfCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_ProceedsFromOffering"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_ProceedsFromOffering</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_PurchasePriceOfStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_PurchasePriceOfStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_SeveranceReceived"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_SeveranceReceived</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnregisteredPreFundedWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnregisteredPreFundedWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_WarrantIssuedToPurchaseCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_WarrantIssuedToPurchaseCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tenx_dvddv"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tenx_dvddv</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tenx_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherExpenses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_PurchaseAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_PurchaseAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_RegistrationRightsAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_RegistrationRightsAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tenx_SeparationAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=tenx_SeparationAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tenx_MrDitonnoMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tenx_MrDitonnoMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>57 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xlsx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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>58 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>59 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>60 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version='1.0' encoding='utf-8'?> <FilingSummary> <Version>3.21.2</Version> <ProcessingTime/> <ReportFormat>html</ReportFormat> <ContextCount>131</ContextCount> <ElementCount>343</ElementCount> <EntityCount>1</EntityCount> <FootnotesReported>false</FootnotesReported> <SegmentCount>27</SegmentCount> <ScenarioCount>0</ScenarioCount> <TuplesReported>false</TuplesReported> <UnitCount>5</UnitCount> <MyReports> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R1.htm</HtmlFileName> <LongName>000001 - Document - Cover</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/Cover</Role> <ShortName>Cover</ShortName> <MenuCategory>Cover</MenuCategory> <Position>1</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R2.htm</HtmlFileName> <LongName>000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets</Role> <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName> <MenuCategory>Statements</MenuCategory> <Position>2</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R3.htm</HtmlFileName> <LongName>000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role> <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>3</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R4.htm</HtmlFileName> <LongName>000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited</Role> <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>4</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R5.htm</HtmlFileName> <LongName>000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role> <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>5</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R6.htm</HtmlFileName> <LongName>000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role> <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>6</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R7.htm</HtmlFileName> <LongName>000007 - Disclosure - DESCRIPTION OF BUSINESS</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/DescriptionOfBusiness</Role> <ShortName>DESCRIPTION OF BUSINESS</ShortName> <MenuCategory>Notes</MenuCategory> <Position>7</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R8.htm</HtmlFileName> <LongName>000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies</Role> <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName> <MenuCategory>Notes</MenuCategory> <Position>8</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R9.htm</HtmlFileName> <LongName>000009 - Disclosure - FAIR VALUE</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/FairValue</Role> <ShortName>FAIR VALUE</ShortName> <MenuCategory>Notes</MenuCategory> <Position>9</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R10.htm</HtmlFileName> <LongName>000010 - Disclosure - BALANCE SHEET COMPONENTS</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/BalanceSheetComponents</Role> <ShortName>BALANCE SHEET COMPONENTS</ShortName> <MenuCategory>Notes</MenuCategory> <Position>10</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R11.htm</HtmlFileName> <LongName>000011 - Disclosure - LEASE</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/LEASE</Role> <ShortName>LEASE</ShortName> <MenuCategory>Notes</MenuCategory> <Position>11</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R12.htm</HtmlFileName> <LongName>000012 - Disclosure - NOTES PAYABLE</LongName> <ReportType>Notes</ReportType> <Role>http://tenaxthera.com/role/NotesPayable</Role> <ShortName>NOTES PAYABLE</ShortName> <MenuCategory>Notes</MenuCategory> <Position>12</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R13.htm</HtmlFileName> <LongName>000013 - Disclosure - MERGER</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/MERGER</Role> <ShortName>MERGER</ShortName> <MenuCategory>Notes</MenuCategory> <Position>13</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R14.htm</HtmlFileName> <LongName>000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CommitmentsAndContingencies</Role> <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName> <MenuCategory>Notes</MenuCategory> <Position>14</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R15.htm</HtmlFileName> <LongName>000015 - Disclosure - STOCKHOLDERS EQUITY</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquity</Role> <ShortName>STOCKHOLDERS EQUITY</ShortName> <MenuCategory>Notes</MenuCategory> <Position>15</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R16.htm</HtmlFileName> <LongName>000016 - Disclosure - SUBSEQUENT EVENTS</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SubsequentEvents</Role> <ShortName>SUBSEQUENT EVENTS</ShortName> <MenuCategory>Notes</MenuCategory> <Position>16</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R17.htm</HtmlFileName> <LongName>000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role> <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName> <MenuCategory>Policies</MenuCategory> <Position>17</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R18.htm</HtmlFileName> <LongName>000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables</Role> <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies</ParentRole> <Position>18</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R19.htm</HtmlFileName> <LongName>000019 - Disclosure - FAIR VALUE (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/FairValueTables</Role> <ShortName>FAIR VALUE (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://tenaxthera.com/role/FairValue</ParentRole> <Position>19</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R20.htm</HtmlFileName> <LongName>000020 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/BalanceSheetComponentsTables</Role> <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://tenaxthera.com/role/BalanceSheetComponents</ParentRole> <Position>20</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R21.htm</HtmlFileName> <LongName>000021 - Disclosure - LEASE (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/LeaseTables</Role> <ShortName>LEASE (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://tenaxthera.com/role/LEASE</ParentRole> <Position>21</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R22.htm</HtmlFileName> <LongName>000022 - Disclosure - MERGER (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/MergerTables</Role> <ShortName>MERGER (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://tenaxthera.com/role/MERGER</ParentRole> <Position>22</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R23.htm</HtmlFileName> <LongName>000023 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityTables</Role> <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquity</ParentRole> <Position>23</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R24.htm</HtmlFileName> <LongName>000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role> <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole> <Position>24</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R25.htm</HtmlFileName> <LongName>000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role> <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole> <Position>25</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R26.htm</HtmlFileName> <LongName>000026 - Disclosure - FAIR VALUE (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/FairValueDetails</Role> <ShortName>FAIR VALUE (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/FairValueTables</ParentRole> <Position>26</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R27.htm</HtmlFileName> <LongName>000027 - Disclosure - FAIR VALUE (Details 1)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/FairValueDetails1</Role> <ShortName>FAIR VALUE (Details 1)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/FairValueTables</ParentRole> <Position>27</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R28.htm</HtmlFileName> <LongName>000028 - Disclosure - BALANCE SHEET COMPONENTS (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/BalanceSheetComponentsDetails</Role> <ShortName>BALANCE SHEET COMPONENTS (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/BalanceSheetComponentsTables</ParentRole> <Position>28</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R29.htm</HtmlFileName> <LongName>000029 - Disclosure - BALANCE SHEET COMPONENTS (Details 1)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/BalanceSheetComponentsDetails1</Role> <ShortName>BALANCE SHEET COMPONENTS (Details 1)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/BalanceSheetComponentsTables</ParentRole> <Position>29</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R30.htm</HtmlFileName> <LongName>000030 - Disclosure - BALANCE SHEET COMPONENTS (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative</Role> <ShortName>BALANCE SHEET COMPONENTS (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/BalanceSheetComponentsTables</ParentRole> <Position>30</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R31.htm</HtmlFileName> <LongName>000031 - Disclosure - LEASE (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/LeaseDetails</Role> <ShortName>LEASE (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/LeaseTables</ParentRole> <Position>31</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R32.htm</HtmlFileName> <LongName>000032 - Disclosure - LEASE (Details 1)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/LeaseDetails1</Role> <ShortName>LEASE (Details 1)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/LeaseTables</ParentRole> <Position>32</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R33.htm</HtmlFileName> <LongName>000033 - Disclosure - LEASE (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/LeaseDetailsNarrative</Role> <ShortName>LEASE (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/LeaseTables</ParentRole> <Position>33</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R34.htm</HtmlFileName> <LongName>000034 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName> <ReportType>Notes</ReportType> <Role>http://tenaxthera.com/role/NotesPayableDetailsNarrative</Role> <ShortName>NOTES PAYABLE (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/NotesPayable</ParentRole> <Position>34</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R35.htm</HtmlFileName> <LongName>000035 - Disclosure - MERGER (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/MergerDetails</Role> <ShortName>MERGER (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/MergerTables</ParentRole> <Position>35</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R36.htm</HtmlFileName> <LongName>000036 - Disclosure - MERGER (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/MergerDetailsNarrative</Role> <ShortName>MERGER (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/MergerTables</ParentRole> <Position>36</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R37.htm</HtmlFileName> <LongName>000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative</Role> <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/CommitmentsAndContingencies</ParentRole> <Position>37</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R38.htm</HtmlFileName> <LongName>000038 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityDetails</Role> <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquityTables</ParentRole> <Position>38</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R39.htm</HtmlFileName> <LongName>000039 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityDetails1</Role> <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquityTables</ParentRole> <Position>39</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R40.htm</HtmlFileName> <LongName>000040 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityDetails2</Role> <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquityTables</ParentRole> <Position>40</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R41.htm</HtmlFileName> <LongName>000041 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityDetails3</Role> <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquityTables</ParentRole> <Position>41</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R42.htm</HtmlFileName> <LongName>000042 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityDetails4</Role> <ShortName>STOCKHOLDERS EQUITY (Details 4)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquityTables</ParentRole> <Position>42</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R43.htm</HtmlFileName> <LongName>000043 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/StockholdersEquityDetailsNarrative</Role> <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/StockholdersEquityTables</ParentRole> <Position>43</Position> </Report> <Report instance="tenx_10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R44.htm</HtmlFileName> <LongName>000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName> <ReportType>Sheet</ReportType> <Role>http://tenaxthera.com/role/SubsequentEventsDetailsNarrative</Role> <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://tenaxthera.com/role/SubsequentEvents</ParentRole> <Position>44</Position> </Report> <Report> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <LongName>All Reports</LongName> <ReportType>Book</ReportType> <ShortName>All Reports</ShortName> </Report> </MyReports> <InputFiles> <File doctype="10-Q" original="tenx_10q.htm">tenx_10q.htm</File> <File>tenx-20210630.xsd</File> <File>tenx-20210630_cal.xml</File> <File>tenx-20210630_def.xml</File> <File>tenx-20210630_lab.xml</File> <File>tenx-20210630_pre.xml</File> <File>tenx_ex101.htm</File> <File>tenx_ex311.htm</File> <File>tenx_ex312.htm</File> <File>tenx_ex321.htm</File> <File>tenx_ex322.htm</File> </InputFiles> <SupplementalFiles/> <BaseTaxonomies> <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy> <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy> </BaseTaxonomies> <HasPresentationLinkbase>true</HasPresentationLinkbase> <HasCalculationLinkbase>true</HasCalculationLinkbase> </FilingSummary> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>63 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> { "instance": { "tenx_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 131, "dts": { "calculationLink": { "local": [ "tenx-20210630_cal.xml" ] }, "definitionLink": { "local": [ "tenx-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tenx_10q.htm" ] }, "labelLink": { "local": [ "tenx-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tenx-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "tenx-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 357, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 27, "http://tenaxthera.com/20210630": 36, "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 69 }, "keyCustom": 88, "keyStandard": 255, "memberCustom": 15, "memberStandard": 12, "nsprefix": "tenx", "nsuri": "http://tenaxthera.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://tenaxthera.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - BALANCE SHEET COMPONENTS", "role": "http://tenaxthera.com/role/BalanceSheetComponents", "shortName": "BALANCE SHEET COMPONENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - LEASE", "role": "http://tenaxthera.com/role/LEASE", "shortName": "LEASE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - NOTES PAYABLE", "role": "http://tenaxthera.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - MERGER", "role": "http://tenaxthera.com/role/MERGER", "shortName": "MERGER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://tenaxthera.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - STOCKHOLDERS EQUITY", "role": "http://tenaxthera.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SUBSEQUENT EVENTS", "role": "http://tenaxthera.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tenx:ScheduleOfInvestmentsInMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - FAIR VALUE (Tables)", "role": "http://tenaxthera.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tenx:ScheduleOfInvestmentsInMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - BALANCE SHEET COMPONENTS (Tables)", "role": "http://tenaxthera.com/role/BalanceSheetComponentsTables", "shortName": "BALANCE SHEET COMPONENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - LEASE (Tables)", "role": "http://tenaxthera.com/role/LeaseTables", "shortName": "LEASE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - MERGER (Tables)", "role": "http://tenaxthera.com/role/MergerTables", "shortName": "MERGER (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "role": "http://tenaxthera.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30_tenx_SimdaxLicenseAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "tenx:LiquidityAndManagementsPlanPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:StockholdersEquityBeforeTreasuryStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tenx:ScheduleOfInvestmentsInMarketableSecurities", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - FAIR VALUE (Details)", "role": "http://tenaxthera.com/role/FairValueDetails", "shortName": "FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tenx:ScheduleOfInvestmentsInMarketableSecurities", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - FAIR VALUE (Details 1)", "role": "http://tenaxthera.com/role/FairValueDetails1", "shortName": "FAIR VALUE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - BALANCE SHEET COMPONENTS (Details)", "role": "http://tenaxthera.com/role/BalanceSheetComponentsDetails", "shortName": "BALANCE SHEET COMPONENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - BALANCE SHEET COMPONENTS (Details 1)", "role": "http://tenaxthera.com/role/BalanceSheetComponentsDetails1", "shortName": "BALANCE SHEET COMPONENTS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-04-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - BALANCE SHEET COMPONENTS (Details Narrative)", "role": "http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative", "shortName": "BALANCE SHEET COMPONENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-04-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - LEASE (Details)", "role": "http://tenaxthera.com/role/LeaseDetails", "shortName": "LEASE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeasesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - LEASE (Details 1)", "role": "http://tenaxthera.com/role/LeaseDetails1", "shortName": "LEASE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tenx:RemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - LEASE (Details Narrative)", "role": "http://tenaxthera.com/role/LeaseDetailsNarrative", "shortName": "LEASE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tenx:RemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "tenx:PppLoanAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://tenaxthera.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "tenx:PppLoanAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - MERGER (Details)", "role": "http://tenaxthera.com/role/MergerDetails", "shortName": "MERGER (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - MERGER (Details Narrative)", "role": "http://tenaxthera.com/role/MergerDetailsNarrative", "shortName": "MERGER (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongtermPurchaseCommitmentPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2020-10-01to2020-10-09_tenx_SimdaxLicenseAgreementMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongtermPurchaseCommitmentPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - STOCKHOLDERS EQUITY (Details)", "role": "http://tenaxthera.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "tenx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tenx:SharesAvailableForGrantTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31_tenx_StockIncentivePlan2016Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - STOCKHOLDERS EQUITY (Details 1)", "role": "http://tenaxthera.com/role/StockholdersEquityDetails1", "shortName": "STOCKHOLDERS EQUITY (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tenx:SharesAvailableForGrantTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31_tenx_StockIncentivePlan2016Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-04-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)", "role": "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-04-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31_tenx_StockIncentivePlan2016Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - STOCKHOLDERS EQUITY (Details 2)", "role": "http://tenaxthera.com/role/StockholdersEquityDetails2", "shortName": "STOCKHOLDERS EQUITY (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31_tenx_StockIncentivePlan2016Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - STOCKHOLDERS EQUITY (Details 3)", "role": "http://tenaxthera.com/role/StockholdersEquityDetails3", "shortName": "STOCKHOLDERS EQUITY (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30_tenx_StockIncentivePlan2016Member", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tenx:OutstandingStockOptionsUnderPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31_tenx_Amended1999StockPlanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - STOCKHOLDERS EQUITY (Details 4)", "role": "http://tenaxthera.com/role/StockholdersEquityDetails4", "shortName": "STOCKHOLDERS EQUITY (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tenx:OutstandingStockOptionsUnderPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-12-31_tenx_Amended1999StockPlanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-07-08", "decimals": "INF", "first": true, "lang": null, "name": "tenx:WarrantToPurchaseOfCommonStockExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "role": "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-07-08", "decimals": "INF", "first": true, "lang": null, "name": "tenx:WarrantToPurchaseOfCommonStockExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2020-07-08", "decimals": "INF", "first": true, "lang": null, "name": "tenx:CommonStockParOrStatedValuePerShares", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2021-07-06_us-gaap_SubsequentEventMember_tenx_PurchaseAgreementMember", "decimals": "0", "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)", "role": "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2020-01-01to2020-03-31_tenx_CommonStocksMember", "decimals": "0", "lang": null, "name": "tenx:CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - DESCRIPTION OF BUSINESS", "role": "http://tenaxthera.com/role/DescriptionOfBusiness", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - FAIR VALUE", "role": "http://tenaxthera.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tenx_10q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 27, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tenaxthera.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "tenx_Amended1999StockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1999 Amended Stock Plan" } } }, "localname": "Amended1999StockPlanMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails4", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_AmortizationOfPremiumOnMarketableSecurities": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization of premium on marketable securities" } } }, "localname": "AmortizationOfPremiumOnMarketableSecurities", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_AvailableForSaleSecuritiesEstimatedFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Estimated fair value]", "periodEndLabel": "Estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesEstimatedFairValue", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "tenx_AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of proceeds received for the sale of securities, categorized neither as held-to-maturity nor trading securities, during the reporting period.", "label": "Gross proceeds" } } }, "localname": "AvailableForSaleSecuritiesGrossRealizedGainsLossesProceeds", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_CommonStockAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock acquired" } } }, "localname": "CommonStockAcquired", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants sold, net of offering costs, amount" } } }, "localname": "CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsAmount", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants sold, net of offering costs, shares" } } }, "localname": "CommonStockAndPreFundedWarrantsSoldNetOfOfferingCostsShares", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock and preferred stock issued for asset acquisition, amount" } } }, "localname": "CommonStockAndPreferredStockIssuedForAssetAcquisitionAmount", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_CommonStockAndPreferredStockIssuedForAssetAcquisitionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock and preferred stock issued for asset acquisition, shares" } } }, "localname": "CommonStockAndPreferredStockIssuedForAssetAcquisitionShares", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "tenx_CommonStockIssuedForConvertiblePreferredStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for convertible preferred stock, amount" } } }, "localname": "CommonStockIssuedForConvertiblePreferredStockAmount", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_CommonStockIssuedForConvertiblePreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for convertible preferred stock, shares" } } }, "localname": "CommonStockIssuedForConvertiblePreferredStockShares", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "tenx_CommonStockIssuedForServicesRenderedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for services rendered, amount" } } }, "localname": "CommonStockIssuedForServicesRenderedAmount", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_CommonStockIssuedForServicesRenderedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for services rendered, shares" } } }, "localname": "CommonStockIssuedForServicesRenderedShares", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "tenx_CommonStockParOrStatedValuePerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "[Common stock, par value]", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShares", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "tenx_CommonStockSharesIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and", "label": "[Common stock, issued]", "verboseLabel": "Common stock, issued" } } }, "localname": "CommonStockSharesIssue", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock upon the cashless exercise of previously outstanding placement agent warrants.", "label": "Common stock upon the cashless exercise of previously outstanding placement agent warrants" } } }, "localname": "CommonStockUponTheCashlessExerciseOfPreviouslyOutstandingPlacementAgentWarrants", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_CommonStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "localname": "CommonStocksMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "tenx_CompensationOnOptionsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Compensation on options issued" } } }, "localname": "CompensationOnOptionsIssued", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concurrent private placement unregistered pre-funded warrants to purchas common stock" } } }, "localname": "ConcurrentPrivatePlacementUnregisteredPrefundedWarrantsToPurchasCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_ConvertiblePreferredSharesOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible preferred shares outstanding [Member]" } } }, "localname": "ConvertiblePreferredSharesOutstandingMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "tenx_Covid19ImpactPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COVID-19 Impact and Related Risks" } } }, "localname": "Covid19ImpactPolicyTextBlock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "tenx_DebtInstrumentDecreaseForgivenessAccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "[Accrued interest]", "verboseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentDecreaseForgivenessAccruedInterest", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_DividendYield": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend yield" } } }, "localname": "DividendYield", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_EstimatedFairValueOfInducementStockOptionAwardGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Estimated fair value of the inducement stock option award granted" } } }, "localname": "EstimatedFairValueOfInducementStockOptionAwardGranted", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_EstimatedFairValueofWarrantIssuedForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated fair valueof warrant issued for services.", "label": "Estimated fair valueof warrant issued for services" } } }, "localname": "EstimatedFairValueofWarrantIssuedForServices", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_EstimatedFairValueofWarrantIssuedForServicese": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated fair valueof warrant issued for services.", "label": "[Estimated fair valueof warrant issued for services]", "verboseLabel": "Estimated fair valueof warrant issued for services" } } }, "localname": "EstimatedFairValueofWarrantIssuedForServicese", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_ExerciseOfPreFundedWarrantsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exercise of pre-funded warrants, amount" } } }, "localname": "ExerciseOfPreFundedWarrantsAmount", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_ExerciseOfPreFundedWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of pre-funded warrants, shares" } } }, "localname": "ExerciseOfPreFundedWarrantsShares", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "tenx_FairValueAllocatedCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value allocated common stock" } } }, "localname": "FairValueAllocatedCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_FairValueAllocatedPrefundedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value allocated pre-funded warrants" } } }, "localname": "FairValueAllocatedPrefundedWarrants", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_FairValueAllocatedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value allocated warrants" } } }, "localname": "FairValueAllocatedWarrants", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_GrantPaidToAuthority": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Grant paid to authority" } } }, "localname": "GrantPaidToAuthority", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_GrantPaidToAuthorityOne": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Grant paid to canadian authority" } } }, "localname": "GrantPaidToAuthorityOne", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_GrossUnrealizedLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.", "label": "Gross unrealized losses" } } }, "localname": "GrossUnrealizedLosses", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "tenx_InProcessResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "IPR&D expense recognized" } } }, "localname": "InProcessResearchAndDevelopmentExpense", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "tenx_InducementStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inducement Stock Options" } } }, "localname": "InducementStockOptionsMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investor [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance and vesting of compensatory stock options and warrants" } } }, "localname": "IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_IssuanceOfCommonStockAndPreferredStockForAssetAcquisition": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock and preferred stock for asset acquisition" } } }, "localname": "IssuanceOfCommonStockAndPreferredStockForAssetAcquisition", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_IssuedUnderwriterWarrantTopurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued underwriter warrant to purchase common stock.", "label": "Issued underwriter warrant to purchase common stock" } } }, "localname": "IssuedUnderwriterWarrantTopurchaseCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_July2020WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 2020 Warrants" } } }, "localname": "July2020WarrantsMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_LeaseTermPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of the lessor's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Lease term period" } } }, "localname": "LeaseTermPeriod", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "durationItemType" }, "tenx_LessImputedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: imputed interest" } } }, "localname": "LessImputedInterest", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "tenx_LicenseAgreementMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the pending litigation matter was dismissed, in CCYY-MM-DD format.", "label": "License agreement maturity date" } } }, "localname": "LicenseAgreementMaturityDate", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "tenx_LiquidityAndManagementsPlanPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity and Management's Plan" } } }, "localname": "LiquidityAndManagementsPlanPolicyTextBlock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "tenx_MarchTwentyTwentyWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2020 Warrants [Member]" } } }, "localname": "MarchTwentyTwentyWarrantsMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_MaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maturity period" } } }, "localname": "MaturityPeriod", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "durationItemType" }, "tenx_MrDitonnoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr Ditonno [Member]" } } }, "localname": "MrDitonnoMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses.", "label": "Net proceeds from the offerings, after deducting placement agent fees and other direct offering expenses" } } }, "localname": "NetProceedsFromOfferingsAfterDeductingPlacementAgentFeesAndOtherDirectOfferingExpenses", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_NonRefundableCommercializationMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-refundable commercialization milestone payment" } } }, "localname": "NonRefundableCommercializationMilestonePayment", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_NonRefundableUpFrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non refundable up front payment" } } }, "localname": "NonRefundableUpFrontPayment", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_OutstandingStockOptionsUnderPlanTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding stock options under the 1999 Plan" } } }, "localname": "OutstandingStockOptionsUnderPlanTableTextBlock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "tenx_PercentageOfAnnualIncreaseInRent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of annual increase in rent" } } }, "localname": "PercentageOfAnnualIncreaseInRent", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_PercentageOfGrossProceedReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of gross proceed received" } } }, "localname": "PercentageOfGrossProceedReceived", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_PercentageOfOfferingPricePerShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of offering price per share of common stock" } } }, "localname": "PercentageOfOfferingPricePerShareOfCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_PercentageOfPreferredStockCarriesVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of Preferred Stock carries voting rights" } } }, "localname": "PercentageOfPreferredStockCarriesVotingRights", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_PppLoanAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "PPP loan amount" } } }, "localname": "PppLoanAmount", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_PppLoanMonthlyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "PPP loan, monthly payment" } } }, "localname": "PppLoanMonthlyPayment", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_PreferredStockVotingRightsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock voting rights percentage" } } }, "localname": "PreferredStockVotingRightsPercentage", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_PreferredStockVotingRightsPercentage1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock voting rights percentage 1" } } }, "localname": "PreferredStockVotingRightsPercentage1", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_PrefundedWarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-funded Warrants outstanding" } } }, "localname": "PrefundedWarrantsOutstanding", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_PrefundedWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-funded warrants to purchase common stock [Member]" } } }, "localname": "PrefundedWarrantsToPurchaseCommonStockMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "tenx_ProceedsFromOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from offering" } } }, "localname": "ProceedsFromOffering", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_PurchasePriceOfStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase price of stock" } } }, "localname": "PurchasePriceOfStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "tenx_RegistrationRightsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Registration Rights Agreement [Member]" } } }, "localname": "RegistrationRightsAgreementMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_RemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term" } } }, "localname": "RemainingLeaseTerm", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "durationItemType" }, "tenx_RightsPreferencesAndPrivilegesConversionIntoShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights, preferences and privileges conversion into share.", "label": "Rights, preferences and privileges conversion into share" } } }, "localname": "RightsPreferencesAndPrivilegesConversionIntoShare", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_RightsPreferencesAndPrivilegesConversionIntoShare1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights, preferences and privileges conversion into share 1" } } }, "localname": "RightsPreferencesAndPrivilegesConversionIntoShare1", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_SaleOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Sale of marketable securities" } } }, "localname": "SaleOfMarketableSecurities", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_ScheduleOfInvestmentsInMarketableSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments in marketable securities" } } }, "localname": "ScheduleOfInvestmentsInMarketableSecurities", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "tenx_SeparationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Separation Agreement [Member]" } } }, "localname": "SeparationAgreementMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_SeveranceReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Severance received" } } }, "localname": "SeveranceReceived", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of warrants, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "[Number of warrants outstanding, beginning]", "periodEndLabel": "Number of warrants outstanding, ending", "periodStartLabel": "Number of warrants outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquitysInstrumentsOutstandingNumber", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares available for grant, additional shares reserved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAvailableForGrant", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "tenx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriod", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails4" ], "xbrltype": "sharesItemType" }, "tenx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "tenx_SharesAvailableForGrantTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares available for grant under the 2016 Plan" } } }, "localname": "SharesAvailableForGrantTableTextblock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "tenx_SimdaxLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Simdax License Agreement [Member]", "verboseLabel": "Simdax License Agreement [Member]" } } }, "localname": "SimdaxLicenseAgreementMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "tenx_StockConvertibleIntoAggregateSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock convertible into an aggregate shares of common stock" } } }, "localname": "StockConvertibleIntoAggregateSharesOfCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_StockIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2016 Stock Incentive Plan" } } }, "localname": "StockIncentivePlan2016Member", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails1", "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "tenx_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of warrants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "tenx_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exercise of warrants, amount" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_StockOptionsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options description.", "label": "Stock options description" } } }, "localname": "StockOptionsDescription", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "tenx_StockOptionsGrantedFairMarketValuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock options granted fair market value percentage" } } }, "localname": "StockOptionsGrantedFairMarketValuePercentage", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "tenx_StockOptionsGrantedVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options granted, vesting period", "label": "Stock options granted, vesting period" } } }, "localname": "StockOptionsGrantedVestingPeriod", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "tenx_UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Underwriter warrant to purchase common stock estimated fair value.", "label": "Underwriter warrant to purchase common stock estimated fair value" } } }, "localname": "UnderwriterWarrantToPurchaseCommonStockEstimatedFairValue", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_UnderwriterWarrantToPurchaseCommonStockExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriter warrant to purchase common stock exercise price.", "label": "Underwriter warrant to purchase common stock exercise price" } } }, "localname": "UnderwriterWarrantToPurchaseCommonStockExercisePrice", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "tenx_UnrealizedGainOnMarketableSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain on marketable securities" } } }, "localname": "UnrealizedGainOnMarketableSecurities", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_UnrealizedLossOnMarketableSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized loss on marketable securities" } } }, "localname": "UnrealizedLossOnMarketableSecurities", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unregistered common stock warrants to purchase common stock.", "label": "Unregistered common stock warrants to purchase common stock" } } }, "localname": "UnregisteredCommonStockWarrantsToPurchaseCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Unregistered common stock warrants to purchase common stock]", "verboseLabel": "Unregistered common stock warrants to purchase common stock" } } }, "localname": "UnregisteredCommonStockWarrantsToPurchaseCommonStockdeece2", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_UnregisteredCommonStockWarrantsToPurchaseGrossProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unregistered common stock warrants to purchase gross proceeds" } } }, "localname": "UnregisteredCommonStockWarrantsToPurchaseGrossProceeds", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "tenx_UnregisteredPreFundedWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unregistered pre funded warrants" } } }, "localname": "UnregisteredPreFundedWarrants", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unregistered Warrant has an exercise price per share of common stock" } } }, "localname": "UnregisteredWarrantHasAnExercisePricePerShareOfCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "tenx_UnregisteredWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unregistered warrants exercise price.", "label": "Unregistered warrants exercise price" } } }, "localname": "UnregisteredWarrantsExercisePrice", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "tenx_WarranToPurchaseOfCommonStockTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant to purchase of common stock term" } } }, "localname": "WarranToPurchaseOfCommonStockTerm", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "tenx_WarrantIssuedToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant issued to purchase common stock" } } }, "localname": "WarrantIssuedToPurchaseCommonStock", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "tenx_WarrantToPurchaseOfCommonStockExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant to purchase of common stock exercise price" } } }, "localname": "WarrantToPurchaseOfCommonStockExercisePrice", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "tenx_WarrantToPurchaseOfCommonStockTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase of common stock term.", "label": "[Warrant to purchase of common stock term]", "verboseLabel": "Warrant to purchase of common stock term" } } }, "localname": "WarrantToPurchaseOfCommonStockTerm", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "tenx_WarranttoPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant to Purchase Common Stock" } } }, "localname": "WarranttoPurchaseCommonStockMember", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "tenx_dvddv": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock option granted" } } }, "localname": "dvddv", "nsuri": "http://tenaxthera.com/20210630", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.", "label": "Purchase price of units" } } }, "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r23", "r297", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "[Accrued Investment Income Receivable]", "periodEndLabel": "Accrued interest" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "verboseLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails1", "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r140" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r46", "r47", "r48", "r309", "r322", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r45", "r48", "r49", "r79", "r80", "r81", "r217", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r79", "r80", "r81", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r173", "r188", "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfLeasedAsset": { "auth_ref": [ "r68", "r237" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.", "label": "Amortization of right of use asset" } } }, "localname": "AmortizationOfLeasedAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "[Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount]", "verboseLabel": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of lease land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r77", "r112", "r114", "r118", "r125", "r212", "r218", "r225", "r298", "r307" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r43", "r77", "r125", "r212", "r218", "r225" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": { "auth_ref": [ "r21", "r152", "r154", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Information by title of series or issue of auction market preferred securities.", "label": "Auction Market Preferred Securities, Stock Series [Axis]" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": { "auth_ref": [ "r21", "r152", "r154", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both)." } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "[Available-for-sale Securities]", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "[Available-for-sale Securities, Amortized Cost Basis]", "periodEndLabel": "Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.", "label": "Gross unrealized gains" } } }, "localname": "AvailableForSaleSecuritiesGrossUnrealizedGains", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r174", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEET COMPONENTS" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r206", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Total fair value of consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r206", "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Fair value of shares of Common Stock issued" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Fair Value of Series B Convertible Preferred Stock issued at closing" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Tangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable]", "negatedLabel": "Accounts payable assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r203", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MERGER" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r78", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "1. DESCRIPTION OF BUSINESS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Computer equipment and software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r30", "r70" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets", "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash and Cash Equivalents, Fair Value Disclosure]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r75", "r77", "r91", "r92", "r93", "r95", "r97", "r101", "r102", "r103", "r125", "r225" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r161", "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "[Class of Warrant or Right, Exercise Price of Warrants or Rights]", "periodEndLabel": "Weighted average exercise price outstanding, ending", "periodStartLabel": "Weighted average exercise price outstanding, beginning", "verboseLabel": "Exercise price warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Warrant to purchase of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r145", "r301", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies; see Note 8" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "8. COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized", "verboseLabel": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r153" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, outstanding", "verboseLabel": "Common stock, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 25,201,312 and 12,619,369 respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r56", "r304", "r316" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r74", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock issued for conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r20", "r21", "r154", "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r163", "r171", "r324" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "6. NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r40", "r147", "r233" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "PPP loan term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r198", "r199", "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Long term lease liability" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r68", "r138" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r68", "r138" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.", "label": "Description of lease contract" } } }, "localname": "DescriptionOfLesseeLeasingArrangementsOperatingLeases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r74", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails1": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee related" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r79", "r80", "r81", "r83", "r88", "r90", "r100", "r126", "r153", "r158", "r191", "r192", "r193", "r201", "r202", "r226", "r227", "r228", "r229", "r230", "r231", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r68", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r223", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "3. FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r163", "r164", "r169", "r171", "r223", "r257" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r163", "r164", "r169", "r171", "r223", "r258" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r223", "r259" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r123", "r124", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Office furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r68", "r148", "r149" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on debt settlement and extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": { "auth_ref": [ "r67" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends.", "label": "Interest on debt instrument" } } }, "localname": "IncreaseDecreaseInInterestAndDividendsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Long term portion of lease liability" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Accounts receivable, prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r305" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r68" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of common stock for services rendered" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r244", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASE" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "5. LEASE" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LEASE" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Maturities of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lease liabilities" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r77", "r115", "r125", "r213", "r218", "r219", "r225" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r77", "r125", "r225", "r300", "r311" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r77", "r125", "r213", "r218", "r219", "r225" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r13", "r14", "r15", "r18", "r19", "r77", "r125", "r213", "r218", "r219", "r225" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "[Liabilities, Noncurrent]", "totalLabel": "Total long term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "License Term period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "[Marketable Securities]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r5", "r37" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 7.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Unrealized (gain) loss on marketable securities" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r1", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "7. MERGER" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MERGER" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r66", "r69" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r50", "r52", "r55", "r69", "r77", "r82", "r84", "r85", "r86", "r87", "r89", "r90", "r94", "r112", "r113", "r116", "r117", "r119", "r125", "r225", "r303", "r315" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 8.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing activity" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r18", "r299", "r308" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "[Notes Payable]", "verboseLabel": "Note payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r112", "r113", "r116", "r117", "r119" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Net operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "[Operating Lease, Liability]", "terseLabel": "Operating lease liability", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetails", "http://tenaxthera.com/role/LeaseDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r240" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails1": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "[Operating Lease, Liability, Current]", "terseLabel": "Current portion included in accrued liabilities", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails1", "http://tenaxthera.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r240" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r239" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r243", "r246" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Annual base rent increased" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r38" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails1": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Operating costs" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r58", "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Legal expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (income) expense, net", "verboseLabel": "Amount of common area maintenance charges" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://tenaxthera.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement": { "auth_ref": [ "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.", "label": "Private placements units sold" } } }, "localname": "PartnersCapitalAccountUnitsSoldInPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r121" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "[Payments to Acquire Marketable Securities]", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r174", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://tenaxthera.com/role/StockholdersEquityDetails1", "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetails4", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://tenaxthera.com/role/StockholdersEquityDetails1", "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetails4", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized", "verboseLabel": "Preferred stock, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued", "verboseLabel": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding", "verboseLabel": "Preferred stock, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, undesignated, authorized 9,999,790 shares; See Note 9 Series A Preferred stock, par value $.0001, issued 5,181,346 shares; outstanding 210, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r21", "r154" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r136", "r137" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Net proceeds from underwritten offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": { "auth_ref": [ "r62" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.", "label": "Proceeds from the issuance of notes payable" } } }, "localname": "ProceedsFromIssuanceOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r61" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r61" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from the exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r50", "r52", "r64", "r77", "r82", "r89", "r90", "r112", "r113", "r116", "r117", "r119", "r125", "r211", "r215", "r216", "r220", "r221", "r225", "r306" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r139" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r141", "r313" ], "calculation": { "http://tenaxthera.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsDetails", "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r170", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r170", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r170", "r248", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "PPP loan - principal payable" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r197", "r325" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r158", "r194", "r310", "r321", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r79", "r80", "r81", "r83", "r88", "r90", "r126", "r191", "r192", "r193", "r201", "r202", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r242", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Addition to right of use asset obtained from new operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Anti-dilutive securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Consideration transferred, asset acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r176", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair value assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r161", "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Warrant activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A.", "label": "Series B [Member]" } } }, "localname": "SeriesBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/MergerDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails3" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility (weighted average)", "verboseLabel": "Vvolatility factor rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate (weighted average)", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Number of shares of common stock authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant]", "periodEndLabel": "Shares available for grant, ending", "periodStartLabel": "Shares available for grant, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares available for grant, options granted", "verboseLabel": "Shares available for grant, options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails1", "http://tenaxthera.com/role/StockholdersEquityDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r178", "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of options outstanding, ending", "periodStartLabel": "Number of options outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price outstanding, ending", "periodStartLabel": "Weighted average exercise price outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Stock options exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock options exercise term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r184", "r195" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)", "verboseLabel": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock options granted, term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "verboseLabel": "Stock issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r75", "r77", "r91", "r92", "r93", "r95", "r97", "r101", "r102", "r103", "r125", "r153", "r225" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock Axis" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r79", "r80", "r81", "r83", "r88", "r90", "r100", "r126", "r153", "r158", "r191", "r192", "r193", "r201", "r202", "r226", "r227", "r228", "r229", "r230", "r231", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://tenaxthera.com/role/FairValueDetails", "http://tenaxthera.com/role/FairValueDetails1", "http://tenaxthera.com/role/MergerDetailsNarrative", "http://tenaxthera.com/role/StockholdersEquityDetails1", "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetails4", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r100", "r284" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://tenaxthera.com/role/FairValueDetails", "http://tenaxthera.com/role/FairValueDetails1", "http://tenaxthera.com/role/MergerDetailsNarrative", "http://tenaxthera.com/role/StockholdersEquityDetails1", "http://tenaxthera.com/role/StockholdersEquityDetails2", "http://tenaxthera.com/role/StockholdersEquityDetails3", "http://tenaxthera.com/role/StockholdersEquityDetails4", "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative", "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r153", "r158" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock option award granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r153", "r158", "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock upon the exercise of outstanding warrants issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r153", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Underwritten offering of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r42", "r153", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock upon the exercise of outstanding warrants issued, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r27", "r28", "r77", "r120", "r125", "r225" ], "calculation": { "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total stockholders equity", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "verboseLabel": "Stockholder equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets", "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheets", "http://tenaxthera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "[Stockholders' Equity before Treasury Stock]", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r76", "r158", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "9. STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r232", "r252" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r232", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r232", "r252" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r251", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "10. SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "4. BALANCE SHEET COMPONENTS" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r123", "r124", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r104", "r105", "r106", "r107", "r108", "r109", "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://tenaxthera.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31958-109318" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 1)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45031-112735" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r326": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r327": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r328": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r329": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r331": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" } }, "version": "2.1" } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>64 <FILENAME>0001654954-21-009088-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 0001654954-21-009088-xbrl.zip M4$L#!!0 ( /6#$%.-%QOU*A$ /^V 1 =&5N>"TR,#(Q,#8S,"YX M<V3M75]SVS82?[^9^PX\/[4S)\NR$S?)).W0EISH*DLZ24Z;IPY,0A*F%*D MH&SUT]\"%"G^!TDY)3/'/#@2L0OL[F\![ (@]/Z7YXVE[3!EQ+$_G/7.+\XT M;!N.2>S5AS.7=1 S"#G3&$>VB2S'QA_.]IB=_?+S/__Q_E^=SN\WLY'6=PQW M@VVNW5*,.#:U)\+7FBBZ1XQCVND<J#][[;S3+L^OSB_>!,]O$ ,NQY8\4-@+ M2OI0G^8L-4/4+%DOWG1[U]W+B\LCT=Q9\B=$L8:HL28<&]RER-),S,C*UD!P MS5/HG=8G6VR;%&F_GFMS>+(.ZKAUMGM*5FNN_6#\J(GJM6%G/%AH-RXC-F9, MFSN6*T1@_]:&MG&NZ9:ES00'TV:88;K#YKE7'3/6>(,TL*S-WCU;'\[6G&_? M=;M/3T_GSX_4.G?H"C2XN.K^/B+VGV<'2HJ7F:3772CU"0V74@!I'U!+2H:- M\Y6SZ_JEPD87G8M>YZKG,P*>*X2V'<1YP+M$[%&V<BCL0B$ECRX'E ]LC!CI M34%!2BOXV5BGTXN2% 9B[S#CZ2Q>&3#UKJ),-EX)7\NTV-LN=2S</9 %7(@8 M++TE620:^BEA-+[?8I9J,5F2HA+C6YIA,R@1K;R),$34>+KRE>AU?[\?S:4[ MG07^!"Z31MY[^_9M5Y;ZI G*J/.)XD?H>4'-4$IRZ(DM1@$C0F_&8#L0O^YZ MA1%2DDIZ[9&2P+D=U^8TR[>]PC37YC3'%: T0(;R+#R#HI3Z34S218*"%'+; MW:2+8W+:%6UT@0)38@0,CEV Q[$[,3Z.[>> "[Z@9[[&%)T;SD8.DA?75S"D M!WWZSJ&;/EXBUP+@7/NKBRRR)*)_8 N+,3Q"$"KFB*XP'Z,-9EMD8&63, YJ MVGMDVPZ7 [?\+IYLM\1>.H>O\$!XX3O151>@H28^/,R&6=7++GWKP'QUIA'H M^]['H#*_.A,OB4UDLQ?B7T_K'">ICB:YWG?CI/%:7)B4)O;/\O.6PA!O>ZJ( M,?O ?2#)XS209;A6!<:C9-E\AZ>^^4ZSJFUB&ZJ'#\RQB"F&S1MDB1X_7V/, MF6]R)9T2CTL 80[&Q#X@DW%_,)X/^N+3?#(:]O4%?+G11_KX=J#-/PT&BWD+ M6%G IA 3V<#%">A4%+THDQ+*JRI0:C]$6OFQA;8 M(&5V61YZVS "FN@(3L\ M<AA[L)%K$AGH9,)<L (EY*^*03Y?P'_W@S' /;F#HOOI;/ )Z(:?!]IH,@<G M"-IL':"L \RY8_RY=BP3,JK!5Y?P?5D/R*M!Z0*OJ[C ?#&Y_?739-0?S.;: MX+\/P\67U@=.&0006]]9SE/YSI]D5")^7:G3Z_-/VMUH\EO;V7. [F-F4+(5 M[4V6_G*#!V5ZD1*LGT2\2YAA.<RE6'P9S&]GP^EB.!D+7&X>YL/Q8-Z&5#$D MYNYF@^@>!D>RLB'Q,9#-=4,FG<1>3:$O&00?H"E(J\3J31RK^</]O3[[(D?, MX<?Q\&YXJX\7FGY[.WD8+X;CC]H4NMOM<-#"%X/O#A'Z&5DN]A Z?E6"\#8. MPIT^G&F?]='#H#5RU,CA9$%$D8XM)A7/XAEE*O/W+N+FCZ0+,G:<C,6DTH(1 M!6,TT.<#S_;>1Z6I>W%32[[6KE&[CAV.(1/>HT?K,)A$GBBM?!FW\GBR&,RU MJ?Y%OQFUUHY9^WXP^SB8>78^?%9:^"IN88^Q-6T\B=AL")=QOVZ+A$ $)]@^ MAC%Y!$H07L5!@)'Z?KCPXG]]+',#$;$,QFVXDA)M)C+P0V29?*Y$XG4BBDPF MVZW]X]'^(\-?75!RL#O&,(FG2MM?)R/XFSF8''J!-OC<ABU5\ZPJ^5;AO*N7 MR)&+YUW:#WXS[5I&)607(HHJA>N!0XGJ"=FT]H/72(MI5EH=ABW^4(E,3HK= M6KY4KAV&(9="A<EEX;R[12@K <>(1?I%^('2_NG)>&OLK#P1TQ6F86M'GBC- MG<C*O9RQM7?A!"4R<6>5*G%(Y.ZI.X,M*"=$6'W,$;%*A5@^BQ*^1-9?)L8Z MM-+">@JL8T0IJ+3#%? ]\BJ!3BXJE =:"]IK(<^*JR.=-?%4"5-B_2$<6;?] MK9CQ>^G6[ZG-GUA(2#&_UFL!*)3;1+I"/HD2F,1:0'9VT_:2"B#U"J!4H/\D M%@:4,+6]J1Q0L7"A(*T*N*L2JP=M,%!H(2$R^D6>*,'(6DIH1S:UO7M)@ZO' MK:O$:D+4XNT@E6OSV)B47J3$(+&2$,.@'6^*G'!)AR270HE,8I$@<@*F1:CH M:F=D2H@^4F*0R-_]]<YV4BA@\EAWR"A3@I#(SF,@M#V@RN&E=(S*,"B!2^3U MN8>;6CRK["=$EZDSBY58);?]TW84VF&O)"X]!3 %HN1$=I^'3!LS%\?F4H'- MI1*;5XD$/A>;RQ:;HMA<*;"Y4F.3R.=SL;EJL2F*S2L%-J_4V"0R_UQL7K78 M%,4FOJ^IIE-B5>RL01N[E3TLG;43K:!2XI5RN"!VF/K_%"WQ1]S6-,-+3=[R M]$Y<"?3AC)'-5KRDY#U;RTO$Q*5 '?\JGC] W?/GC>63B/IS;GF2:,<M=&C8 MKP)1(U%+XA8JJ,398LHA^>KZPI]IW1=3RT*/9=4"%FPU51_PK;+ZQ-RQB5J! MXY?5*MI77EZI]]WP)53P+7I)U7O0R:%<LQ-W7>5=B>;=^3=R#%E1#HOXUO'Y M.N)1IW?9N>J=/S/3E[&,"$?]RHG@\Y46(?V>MX*-^PRBU=<EVLN[ "ZM:9;' MZ'_I'&NI(DK:/8O%9 ES!M].DR9^#5TA07PF\:%T\P6NJ"OB%&'.L<<HG..M M<,G>]4FB5!.CH@SY%UT6@B/@DI]. T1>>W@8++M+9/ .?MY:R$;<H?L[^%[, M+!:ED5H&QTI.0RGEALZB\H2Y7DZ($@;Q.4[SD>1]HX6<Y,CF?>P<:Z@@1/P& MUT(B^$SB0VDOC=RV*2S)E +X[8=9#_W$XNQ8T6FR)&_^K"B+K.BTT3QQ26PQ M7'PN^:ESY"]I#9=5!<:_0_AH$+^NZMBDWK);79IJZ"3@/M%'3K%&H-/IQI"W M06?(<K@05N;U(J;_0^RN.;9<E-%M<TKQG6N;V/Q-9.&0Z\\=RQQC/EE.EDN8 M0>W5K</@Z1I1\<:(4,G;H*M>!;$L<1@!Q*'BCA]Y7_$[B/.)8RYD.F*Z5)K@ M3//2$X^"2?XAQQM!!>9R'QDG7%[F_9$Z[M8G)$#RPNKK&Q%JGJ1^4$6J^H_> M8;X/9P;%)N'%K0*"8([H_B7LLL4VDTU,[(F\K(P-&7/%G![HG4/27+U\L#Q1 M[QPZQW1'#,QF&' #P3*]6\W1&&?.%#73=]4<WQ&DMXZ]$TL%("YT2.AW B1! MH<96S=H\D#-E5J.M9FTH[(-G3 W"\&29''(C(!<AK!?2' FC !8A;"A<#S;% MR")_85-<3#RQ[Q']$VH&2>?8<"GAY(A80=J&:AKJ7WU73/A3V;;G:SY</I+! M;%J:JUZ7S1!7OF555L=,IH8"?'3/CXC815TYE[:AFB9"V]#\$,P@.F.8Z\97 MES"YOJ](#DI5T9BIMKCLBN2@5!4-=0LAN!!!WCB?J5Z*8KY53JD@WR8F?JS5 M)*#$9\S$"57O.GZ9(#ET+Q4ZY$A XX]V<8.49V^F.<"#(:;\R\L-1;"R(>XF M?Z0LQ]),M>?( I_.TS*7HIE*C0AT/QAH]N!X]\A&*^_&^2F()6\AV"_P,[^Q MP$%])4MQE![BO1]5>L?].EY@F-\1L_=VN-DB@V>HI*"I7PGQ>V*F*YQK*']< M35I\F-OCRK$T0$4YJ^L[1*0D,#U\%*.@O%)&@/$8!JPH<?UJ35PN?X@1!OWP M,/\@5E]$EPE$CCAD::[Z%0V#(<;!HWM!)8S-0H$R$XD?9E/J&!B;QSGBE!H: M&DQ)R:,9[[&+9A4V<Z;(AF< U6W$UF[H-G\5I*D\%17WCN;P;S5#8L9@9G!! MUJ'-,8P[0?R?7E35%;^M&C.\@8X# XIWW1VF&U^+U)**N9G_] 6L?I#%6T4X M6CS^N&Y!01!#G+M<P4RKPYB*K*$M?OJ6X:$]P\=<L0!=^4$<1O"M5^_I>FRW M(P?%$MSXPV:Z]D'*>\?F:VL_1?L-3JB0*&RF*GW\R(?0 I4_?-G'GH? Z+DB M.RQ^24@W#) W,1)5X&OF+#.TY:0NIGN&Q8]#0Y;1QSML.5M!.'@667,POQ2F M;J:RX?41L0Q"(_NO*47UKIB%A[#H8LXMHA0F]<^.6-SP?F$[;=PKPE3K(#@B MAG 8?46Q++E'7,0K>_&;YL?\-Y>FZGP$W">+/W9@*EFZMBDD>-C>41CT8L-A M/DDSNXG,[::(F M'=_G:H?)W%_P8.K7L^U%D8N,\7;SB9JH3\24Q8(G-'9'+ MR$;OB043#;25YX%%N)JIO%R"N(%)U@P?E='%TJVW(G:S/Y(<E-&?$#5!?R^= M]]Z/8\=IFX72_K&[>10_F1U:[_@;&E,.7JG1STOM.KZ0DD<=DWN4W[2)FC=M M5;JQTLH%^[7@-U["]1L6\S0V]1VF,*7[Y5-*#%S8R'^#(%6C""E7C9XL.R(D MB*8I=\20E;'2>;I#EVBIX7Z=I>)AT10466)H%G"UHXL)WZ3F>HWE[1TNG*D+ MR1!BT3W8\*)/$<*ZEU;"2]_2%[&_?QK#44U7%14N#K*\$"H\P]JI@V@YEK+S M]HN.=K>.[;T0QT&<'>0Q4PL9DD:L;:\($TL.<O<_<J8M4"VDUS'[?<DJZ^V2 M88E#<B5DQBEVJ,C[G2@L]S_BNT"5N1NZ Q36)WX,+M+CBQ#6&]:,,??M?4>= MC?_* ].77%RS9[J&''/]KJJOX,\=QN),RT3<3=$G%!O<9SLLS@7 ?[/:F[G2 M&^Q[Z98E7@.*>+MO$Q51(S?,DD(G!NIL_=)(OQ,MU<HU_F17E?G&Q-C EZ?, M6$$-38B=LT*N9/"LH*P[>D[NL#O+@^")MX&"5Q#*\333B3U)Y5F9)PJD-(!K MFQUIE66J.\1*RIG2L3+BC$J\]88>187./(ER2@7-=/,R?157Z>#-53T$V,/6 ML1=K?(O8VL*,1=ZAVA''9=8^M- =C1[C$_;+5UOS?FT\E@J)'&S/YM/4NB$0 MW2X.[Q,?-Y7#>A2@K;A0\C(G; J(V"NC3Z]FA;Q=_.,KID.;._IJ1>4]+]YR M<B0PBJS7E>.KU0\/=I>(8!CXF'R9A>R(A5>8>8HP$;*!'E+\X&1=!<;O2]-> M956K..^+ZAIRL"FB$SKG8EZ4<^+T$+:DS0QYM#4OPP8R>@+)"3U%@VAIO5N^ MR95[$9AX+RGXYHV-]"5Y:CU/%):UCYE!R=9K*JE*M+C>_8IDE"C>(C%=+\@) M22UWPPX@9(>8Q9@;N<K3AQ',Q+;YA6 KT##^L%87\X^?1;?$$D_K7HWP<RV9 M3DZ6D7@@HZS6T32VSW27NGRI(JHY>DXNIA^CR]2R9F9[*1LCGQ#$%Y$5"G\: M3@TX3ZJA5C<,GYX-;WC-L(')[CCH%J"K=92*K#'D;GD6HJRW8X5L[7<>M0^6 MYJHSLS-WIKGS)?>_U'P,"(N37C 0Q5T_K:!16W[AZU%L 0\(*5[BO+SH7=]C M[^1E[.J5+++*[WF:CGC'ZS0-](VX,\P4=W9[F1 (EY _CZA6Z5-#4):0/Y^L M9@W$>]P.31,Z5E*KG(<1G*>-W0G1BQ#7JLV<;$STG'CI(]%O<\EJU2#U$CAO ME>VXUIM0J!17K?KYGI,-3B9%K7+/9$SJ5>\MGV5K4("V5EWNQ<MWBR=XL/?^ M^EE00A,E9:UZ_,>U]N)RW4SQLPAJ[N'!F)F4.*VPWOZ:>6PS=Z8HQU;OG(&W MR*L\9\+(IJFW)],^X5"=D^RY\9*_4\[W7>_*[)__!U!+ P04 " #U@Q!3 M%?]#0RL- !<F@ %0 '1E;G@M,C R,3 V,S!?8V%L+GAM;-U=WW/:N!9^ MOS/[/^BR+^W,)4!(NVVFV1T"3LHLP5E,LMNGCF.+H*FQ6<DDX?[U5S*0"&Q+ MLK$MW^U#DX"._)WS'1W].)+UY;>7A0>>("8H\"\:G9-V T#?"5SD/UXT5J1I M$P>A!B"A[;NV%_CPHK&&I/';KS_]Z\N_F\V_+B<C, B<U0+Z(>AC:(?0!<\H MG /VU8U-0HB;S6WI^\USSL'I2?>D_>GU\TN;4*G CV3HEYW7;P:T/A#,@,-J MCD3;GUJ=CZW3]NE;(2N8A<\VAL#&SAR%T E7V/: "PEZ] $%#C8*G8,!6D+? MQ3;X_018])/Y:QW]8+G&Z'$>@G?.>\"J!\/FV)B"RQ5!/B0$6(&W8A#(?\#0 M=TY S_/ A$D0,($$XB?HGFRJ\Y#_XYS]]T#U M3 /CE_(>BB,0_#Y7FK]?S\ M?/+</0GP(]6CW6G]=3.RG#E<V$WD,T,[L+&38K4DR74^?_[<BK[=%8V5?'G MWNX9W=8.#BU.T#F)'C<*G,BH"F(@M03[J[DKUF0?-3NGS6[GY(6X#6H- #;V MP($')W &V,^[R?#UF2'T[9=P#K%]X@2+%ONZU0^H1U*DD> <P]E%@Q9[:3): MVA^[;5;WSWN%PO62>B9!BZ5'56SE?J[O0I_Z(OV%!!YRF3=?VAZCQ)I#&!(Y M*-4:JD)\2QN&3Z5"Y-C>\? 3JRM1%RND_[/@0LQ9/U@L,9S3,N@)C@)"[GQ[ MY=(&[^;2*UO5%>EHA8'S8QYX+@V5QM\K%*Z+4U*A[JJ8M,G\R@N>BV0PM<IB M=!I XF"T9/'2G.TZ!1EJH5 QN*S58F'C-667=G9H1INE'_8<)UCY(>W@;JFI M' 2E0+/54@SR*QOA>]M;01FX6,%BGL_'-=;^Z>#&ET=XL50QR$9&SS)D0/8* M%?/<<1!"&N'7]H,G)26I;#$H;HS)M3&1/7^_5%%Q:[% 8110>CZ+-,SYZ7!8 MH0$IB!;4WF-!7-JV4R6*BD /!/Z]HJH;3RHM**U\E?&PV+A83GQ4>_:4-<"" M]-BOJ^ HKP8TI7B9$5\-F(IL0=$?TIF4&JB$H@7%8(@?(58#D52VK%BGZ.T2 MN2K;YP"&-O(*:J 'E6G08VQC;(=TDE2H0K%:"XX]BB2DE2\'32<KG$X5T5#1 M5$K"%>"4&E%-N@*DRBTG6RT%]CF*U">5+1Z%E-C$PL7C4*9-*%3\_"PK/!79 M(L<.BLZ46+@$',IV$DN5/L_,"C='566-S51'.C+!DO%) XM<LF2$I[D1GE:$ ML)L;8;<BA&>Y$9Y5A%!])*U<0SGK.=E'_FKRZ6@=VW-67I2;'-&_]\K#%_I$ M]VUUGT%63R:&*&3%VYM_'=!\2UYSO[*4L4$C:;@&0W\6X$4$I52,RFE#3H%3 MBODU!4)_[YOC@3&VC '[S3)'PT%O2O^X[(UZX[X!K*^&,;4V.=F=%E[@["'W M6$HX.,B];H%'>=^931ZBY.^*-!]M>\DR\>T6]$*R^X0Y0[O9[FQSP#]O/_[> M(X3JT5]AED#</<"S'Z 7/?;[MMQ!L98NN+<8+FWD&B]+1HP4=DKQ??B<S_2P M P),F_1%XS5HV]C9\Y1XLGU;HD78Y)I5TT24_9W\# <+D2VWE@M4@/-6ID]M M@&?(]CI<-#H:.;FQ\0\:3.@(UH+."J.0CG*DS B%5/CI:N5'0>>:L<0RL6PL M2G^P[NK)]J+1:=BG'<":CD[W4GEQOA3%59@[T\I<)CO4C,.-?K(HK1&@R7K0 M#8IQX#NR()!27,6)/I3L1"G>(U2P9MYRBX,EQ.'ZUF.+O+[+W'W)!B5C*.PR M15(JU'S40XV*NC5CR*2 ;;8T$*U21=L6S=D=@9&>@F8C%E/AZ!=-S4=%8162 MDK7ZI$>KY&ZG7JXV0O8#\M3&9DEE]?5YCH-7T,V"7R"BXD6?2_.B="4./4JF M=,V\:YM"W*UDJS"46%Z%GDZ[%OP(]*T9.7R.0<I,8F$E6CKZ:1%H6C-..)54 M!LHIQ6LR<-FA6RN-^>6B2NY6WOJ,D!OA@$9@B)KY7](^47$P4*2EO&69++2D M;X.M#0.<.DKM7M'^Y2VN) ^L+J8H=RC^DYY<_U,.OW?]"AT\IN^NUCH9"F2 M2BR5-^U752V=NIIREH6EW+R4-]7/R8MLYWLR/5]:ATJ.Z-_Z4G_)1^ZX/& W M3QX0O-NK]WW5V<V,I^\X=<_4U+6F],>-,::JFE?TJYO;B?&5EAO>&V!D6M0 MKT]YKRTI^CJJV^;?!#UT0E%MX80=>&:'K6EC', GZ 71\N<66+H*$C&]R=)4 M*@Z"BI+N=0O_T*-U/EY#G^KH4>0]=X%\1,+-C@PI<:KR>M.IJ@QFLT;-J!S# M<.C3T!K%2<&$:K^8WCP=':,'.VXVJ*0>)Y/3F_Y-)"$I@2?5O&;>9>Z#%?M8 M8F&]*54E8M)UK!D;0S^$&))PSW.$.=5T";WY5!5>9-K6C)R]0>L&,P5KSJ;V MBV!SBTBH5ONJKFWDBYN_6$IO;EB!'(5]5H<VJ&.^.+NFR6VQWA/BK*\QX::+ M'_),%ZVIV?_]JSD:&!,+&'_<#:??]N:+.B?+Z2\ZX;3^F&N2W+.^@JN1^6<] M)L?449FRMSAX0M2$E^L[:I:A_]I_]QPZ7)>L:V>I0V,_S]YOQDZ/;7Y2?-O! MXW9I6VD)/ULM>B?;V:F-#1:RFZQF XBX"@?)?C8SC6W/R,*_6GUZ)^TE>$(6 M,];>)[;[\P=P!JE?[_;I4YVX#:)9?$*M/NW3ZZ)](HL9"_.)^-DH]LGWWB+ M(?JOO7DM&$6V0*N%Z2>-0!.8955DJD'[C#PGEYD5K6>+)F3%<CG;<2OUN#_9 M03@:GJX";$'\A!Q(3-SW;+00->1LU6B?[1_9?O,8K>QFNP-%T=Q#PO389*YH M(&%UK".H9O2R/\(A3FG"N6O3.[$^KCD?:<*J&(Y +0)_YWPT[FRZC>@#ZH)1 M?]%SZ.23H,W14"''.>K3NZA0#,NYS5BS$,Z6@0A;+*$QQS=>F $HXCF;69NS M 7P0K,<JB.K=*'YTJ%8V3LU(W1]91)LJ7<EI&(&(YNWD1[,HM4;-V(L/\'?9 M Y:61\P*ODLFT('H2;SS-'M-FO>HES Y4K-=S5Q@ )<8.FAC>3K%YSPXG6VA MD.;=X$<3JV"1FG%(=9VA4)QFXLMHWAA^-$-Q?6M&2(J&0_]I,UP_8LD]L0Y] MGF>OHWS*-(C&GQBF'NH5>&:&.C1OJ<_.ZZ'G9K97@F<W"YVM6;9'IQ@95LU$ M IJ/!^3G1Z98+<-,S)L464QSQB,XK7P5[(@VEY'AG,VMU)[D"OFV[QS7DR36 MH7,,XT#HDBO*_]O*QPUTT6HQA7@1G1 3#F]4Q#4?P,C.9GSDHVZEND6K).QX M$W1EAVE49)6XK7RQ[TAN$^U38V*W:\W&"\0.$A[$$$LID5GY>EX^,M-L4C,: MDU^T=0LQ"MS#Q8YT6K/5HK1]IKP%OSPJQ[<!9O64W-L?3\M;#BO/$J*!6GY+ ME+=^5)XE1 L<M=DW*KYKC=L:^0M[U2LBCA>0%8;L#\/J3X:WTZ$Y9KL@+^^L MX=BPK!(W>6:\;HT#_^D0O'5W<].;?(LVK0ZOQ\.K8;\WGH)>OV_>C:?#\36X M-4?#_M H4Y_X#6T<Y,^'D*]ZPPFX[XWNC!(A2>YI>\/7:1_BVSLH&YT<-<=L MBVR):/<O<^/ =0[!;4N6AB3QA18<H--#0&-S:EC@MO>M=SDJ$]C!A6\<I.XA MI%W1$C=IRV][XP">'0*D/G4SG&[V7??&T9YLUE2-<<GM5' @GH/[(19CXKOA M2PV.*??#<1 _QL/@I46148L"X[[DQIKS4C@.?JP+4H_BX-VNXC)/(>2Z+XY3 M\(AN"KS;5%NF>FFWS'$:"'JM*A J73?W!O=4N1.K GS2M70<UN0^K0I@B5?5 M<<ABG=NF)ZD"FO3..@YFK,-+/*Y4 >9<E]9QBL0ZQBQA8EMO;12,7W#!:1KO M4[-K"EZ?4$EL%/ 6ZW[YX%@!+^DWXW$@8YUL DC0J3Z("^P:ZS;3H_BKE?^Y M+_VN@S+76+8Y12BG]Y2=THO*%=]MOF>(FBT TY"\6C##0I?? T5_]V#"9J@< M6SV*>X+>TW8Y/*)HXPH3U=4N&2K>#<H%Z-BL0!J@60_S3WRC>85J&(NE%ZPA MG,#("[.HHR"J^8HFZ?O7@ZP*U3)$I[R^6$J@3$[S!4X9V5.S0MVHBT[(9@\E M,CG--SAEI4[)"O5)AV6\1?JMC^MF6$JJ=&*:>.\TASMM6:F"^6CR7=0<MMC" MTCZV<J>AXINI.92Q=:4#E)70K'11-0<ZMH:TEY"J&'SR==8<VM@ZT&Z%L0(O ME5QMS:&,K>\<H*S&F'GNMN:4B*W_"+-N%>LFOP6;TR2>34E:[ZUB/51^-38' M.S99$L$N-P0JW)C]!OPLU@,*@9]J =Y- A[K H7 NUJ GR4!C_6/0N!G6H"+ M@LV96DJFVA"C>@\WIT9"0N8@KYZNQ'9\R_Y[H ..7_\'4$L#!!0 ( /6# M$%,0BD;1=QT /#< 0 5 =&5N>"TR,#(Q,#8S,%]D968N>&UL[5U9<^,X MDG[?B/T/7,]+=<3Z=ITQ-1.R+'=IQI8\DEP]_=1!DY#,+8IT$Z1LSZ]?@"0D M'KAXB82+]>"R)228F5\B"202R+_^_65M:QO@0<MUOAZ<'IT<:, Q7--R5E\/ M GBH0\.R#C3HZXZIVZX#OAZ\ GCP][_]]W_]]7\.#_]].;O1KEPC6 /'UX8> MT'U@:L^6_ZCAKVYUZ /O\#!N_3UZSA?M[.C\Z.33]O-+'2(JUPEIT)>GVV^N M4'^:N]0,W'-(>O+I^/3#\=G)V:[1W%WZS[H'--TS'BT?&'[@Z;9F FBM' TQ MKD4"?=&NK"?@F)ZN_?-(FZ-/'K=]#-VG5\]:/?K:.^,7#7>OC0\GHX5V&4#+ M 1!J<]<., OP?[6Q8QQI ]O69I@":C, @;<!YE'4G6TY/[[@'P](+@TIV(%? M7J#U]>#1]Y^^'!\_/S\?/9\?N=X*R7%R>OSOVYNY\0C6^J'E8$4;X(!0X5YH M=*>?/W\^#K\E37,M7QX\FSSC_)BPL^T9?6OZ6X)DX_?'T9>H*;2^P)"S&]<( M]2_Q!(W9 O]U2)H=XH\.3\\.ST^/7J!Y@!2G:9'J/-<&,[#4\/_WL_'VF3YP M]!?_$7CZD>&NC_'7QT,7&2_B-"1\],#RZP%J]G*($3SY<'Z"^_Y+JI'_^H2, M&%KK)QMIX[CT<QT3.,ALT2_0M2T3&_ZE;F/TYH\ ^%#,E&P/^^+X#HTA!U'Y MEJ';U=FG=M>@+',?_<1^"$Z70W?]Y(%'U,;:@!L7PGM'#TSD&\Q2<A7K>D\R MSGW7^/'HVB;RJJ,_ \M_K4](B;[WA:0.'Z]M][E.!)E=UB/3%8"&9SUA?SE= MDO>'B&LN43U\S8/U6O=>$;KHO6@MT;!T_(%AN('CHW?A'5*580$AH\5ZJ8?S M:]WRONMV $3,Y1K6\_RD7\/C'\V#'+&'YU/5P]G-:# ?B1A)-:KGN1/7!\C# MO^H/MA 46MMZN+@=S7X=S43/3[>JRV^MUY8?.I2!@ST--GXT<Y880!*D-8WW MG!,7CFTF15T>Z &"/P,D^F@C,X)8[??I#^OUB\WX1[EG+_ K$F.=%\U>WDY M1AG-F_3X<HS)T-;D_0%:2<DQ16E:DP\&W@IX<DS0VC;EZR2M74"WS_%Y!7S= MLFL:H)G.6I!CHGN>[J-%4JT"Y7JMV?=(@L!JWPPWIT79.=V'-Y14E13Q'O@4 M*E&.>@^<2H^<8KW4^,Z1A)[6MGXNA,!2&]?/AS1L7*+ZUV=%V9.AK7/N(&E, MU,8-\"&M)SY5X^O,HNR6Z*JIN9GL3$=$V#!_0L<BIFR8P[/2')[MB</STAR> M[XG#B](<7NR)0_F9M'0/S<1SBL_\Y>C9W.J>01BF-4T^GK$O2;8[\8;D^Y"K M1]2%9P0/X-"TUGB?QW4.M/A!28UL>[$<_Q@U/8[;'%,[:)KK[:,.37>M6P59 MSE,WSF_XG,,U6#_@S=E"S*9)F^94M^UB_(4$37/EN/Z@*&.$9H^V")9Z8/NE MC9&0)SE&'UJ.A7?*;M"?*:[!"W(RYFY##W<GGS_@6SYN?A+].]4.=ZDMAUK8 M4KO35T ;.TO76X<)$5'> N',=HT4.S9.FW"]O!8A$1\"XVCE;HY-8.&DEA/\ M"_:1)X<GIW%JQ%_01W^$3Q\\0-_3#9_T9^L/P Z?\@=J$XL2:^J8HJK&="B= MR9!0\!G2Z797%NMW.KD:3>:C*_S;?'HSOAHLT!^7@YO!9#C2YM]&H\6\24,H ME\^0D.B\C$3:NU2_OY0T*&)/2QT^A&,J@(<K77^*C K8/B2?9*TK_OB/+>=( MEV",?H44,XL;T]H>M\[X(KG!R&$Z;I=F>&=+ R_-.O)*I-/804F^ 2*:I>>N MA<J+G^=R&78]-*_[>H"\[ FB"%WN%P,MXY"MC^RP(7+;8(5_V7UON\BFT=S+ M"W(BMX'1T-8AR2\9O%@R-I8G:1(YZMQ-A&3*\E@HYN78 MHB,DFNKN*I'PL2 M6MLFL<A/2D5 L,PK@PE-D!B,<W7!^.,TQWMC>)!Y66. A,+$F%Q(^+OV7!OP M+ '=ZA+X'DXTPS)<!LO39C.C4?4*(3II1,#/K8=9IT;3P[BWDY;??%D(R*< M2?36>-DT[6-38/K %B.&IDUDTC8S?T2S8#@(_$?7L_ZSF[?GT1'1*8202!0R M@-I\([GKM>N$_*%URM0+93/#K>8[X(4L<UY1,L0*X24E#YE'= ,T^7'%)5(3 M).:(NN@2.&,(@T+ $ *502$RQ("\[Q(@T\ /S[M9SJH *BDJE:%)"1+C\Z$S M$X7B;R%9>H4PDQ4I1N]C9]"3\W@\&F51HOJ]3QU#1LKU"0D5QXCF #]W9F.E MX%G$Q/[$A=S^Q'R!_KL=319S;7J-OKJ]FXV^H7;C[R/M9CJ?:^^V3_EES_LQ M18\H)H1_7T;X^6(Z_.>WZ<W5:#;71O^Z'R]^3TG?>C@]9][]7DV_5U,71M&H MVN452^[7T,G4W+.AR]*%?9L,9Z+= D;S;NW>\ PN@Q!#GBYLXM2!3!>W<JJB MH\R.3K&MG*[NX7#-D#L+KF?_)I_MB3])1EL@4[6X):VA(EIEL4\4VF9 ?V": MH<IT^TZWS+$SU)\L7[=%5BX@4P08.6$(3&V&\ >&$:P#&R]ZIGAEE%KIC1VT M3 )"R.2[4 P^><$(E&T&_&<XJ=T!YDCW',M9L;U>3,!JKQ9(+"D((FU&_.6B MD,K&':F1QFXE811)OE!+]Q3V*VWCBZ=1 \=$\[?K (?7?L,G9]#<?(XXF !_ MNIPNT<0.C;^A"]&GH6&(YUO%>U0!H<I"5MK9KQ/'P1K?C5 GCJ3'-XTC$;)2 M$@ ;QR<T 0G/A$R=:7B/&_L-$XO IE (![80E?;VQ>,E>LRUZ\V!M[$, &=X MAP$O8B7=G+ #A5"0EJG2AGX%4&1]EK"#MP1*QB.5VZ<O ,K0=3; \ZT'&] V M/@N@(^Q)99B$PE7:O:\#K\*C2=C3F\0K,[X^UXG7Z 5XA@7!=)F??O!&DP2= M*EA(B$)6G^4V9(JKGCLP).C>@.HS1G]::_C^WO& ;N-D6IQN,G5N=>\'\/%6 MZAP8@8=TQ31\.5)5 )"3AF#09L0?+82BH"AFE!UXR313 0<ZYT3GM:[3$R^< MJP"O*._0NM*-9]5DY)%!R5KR%>U$!0S*R$40JG4%SF BS(BM"!"K#\7Q88E% MX*EUX;[SE[\BN4J^.'BDJH A)PW!H*EU>A0U2TR5MY/I 83 'QA_!A8,]5<L M:%RD1U40JR0D ;*IM;T\1\6BQD5Z?-- 9J?3VT5_MS+!V35-$DG0'TIE@ _F MW[3KF^EO>\K\YE="24CS$5_09$&<-AMX /\QF@]GX[O%>#K!C%_>S\>3T;S! M2X,*UD))\/XIR_O\_O9V,/L]S#H?_SH97X^'@\E"&PR'T_O)8CSY5;M#^ S' MHP;%R5=/27#\.<OQ]6 \T[X/;NY'S7$D**&R8^_T),M>ZIJE\!C#=()-NCEF MTV56$KR=9GF+6S;%"+7@2H*?LRP_D^EB--?N!K\/+F\:Y"M3B"7!T7F6(]*T MN>,EXB(L"?XNLOPA>[H=+R(?.9B$_A,/TM&DV1'**="2X/9]SKGDS[$TZ109 M15L2''[(N[_+.6(,Z5,;?6]VF)8LU)+@/O?BD7?>VCO2<8-OT%(E7!+R57@Y M:>^B;AN4CE7W)2$ YUVU!P:EZK_LN#V3?G7M@7=:F9@$J_0WV1[XHE:.23"6 M>Z5%+Y ]<":L()/@,O>:HQXP;)[E4A5D$G+D7H=%'$3<;W]ZLC\]^09/3\97 MI\5AU:D7EHCFGYSDD"AU:I(C1Q=.3%+9D[QED4[4B=.30H.30:E+YR?KQJE# M9REKQ$J=TY1H,CS1UX#O ].ME')[:=83D+2N<M&@R;;KA#^CV0M#XQFO]5X] MG7?(-Q76>](#?6C& S&VOV)_Z+MW@6<\H@5K8F.'>Z98AK#]S2R)%V!R5TM& M*.*5:LT%FUMK4W^YL0R\,S58>2!$G L GZ1]U=-'<2J7@BL!T7/-9[THZ:W9 MFZH$9^D+]- ^"@4'0"'I"$*U9H?AQZ9R,!>%75.Q+I3#J)AX!*0VCVT/'-\R M+3O =<AVF3FC%\,.D!C72!\XMAOXT=FG)3GG3"Y?9&9;D$/L]73?OB%(!WEJ MDCA[GGF?:1@5*U4G(JCY+;KB$51M^X1][+9PPL&YW;SD=DL?[NW#O6\WW'MM M.;IC6+H]=B!B!;/(#W0P"92*>3"EZ$*@=X$F&!!- W%F1W3B$CGGZ9+",UP@ M7B#]*]%"OMZG="+T(C#FC W4JX N1)[5,YP.Q8_:,QYE0N%#UWMRT8P-S:4> M_-T46'0AE("L_25 $^,F5Z6 JX,NE)H:;- \%[\S\4%_/7F< RU=/!^?^,#7 MD'"6A+(=M(^X_*)/5J8.7%.%5G)H,FF.G0V 86IH=*IP!@Q@;?A3< E2E4 3 M2].!TE1LT_K5"Z_"3YZSXLS(B_:C$I %16OBAJO,D_ 97>9Q,D9;%33.8;^) M^Z;8R(Z@;ZWQ\:#<:8Z,LHMUH0H&Q:3*7E&USV!B-K)V2@NMY5+-*:$U[;0/ MKO7!M;<87",CY/)U^^LW"PTBSWA\O0$;8 MB;9+T:H7>)(7J0B1NR^ MT+'_ M"M=Y>:Y%$9."W70CEE;(=ED8RPG<A=A9&U!W*?JU-[B5B79M!1@[3X$/0R6< MBF)=7*+VYZ"EK)R%-DW$+@2R: R>E0'N[.T#=Y8%KLV("(W!\S+ G;]]X,ZS MP+5:[0/?.;*3:K?@&SQ W],-7M!83-H^B/(!*[$T'0@4X\M6\*T!Z#]\XG.C MVRFCW''-V=.1[T(A^ I(U>D <IE@L5) \<3(!H'W&1.C'YWGI)[EKBI@GYW? M)J+M^> _+[R7NZA R#X.]K4C "^?\;S '0;[S%X,KS-@F\\YZSZ#YFTER1G- M-,YS-QJD66O4#I+,<6'/76B087(?&"=O.Y+A.7=Y0>KVH_WR'EUKP3'07)XP MN=>B>0M-\<;5:"[_-\-D4I6MQ_MSK\9^HZ+?J*@ZDPP,K-KH*M?=&:3MI"HJ M'@$\G/;"W;$HW)%26Q>%I>O"'D8!IA?8)XHBW&7[Z\2N1DE#+V\'*15T89^C M&^;0H9V/-DU"F;V0B/-+42PVTZS]@$(U:\^^\-/2=6&K(SHZ#,,#AXD*3_&) M8F">LK&2(&T?/_G(G5B:2H%7B8O,\97;'J]<8KZE"@IF,M^!""@#]>@N].*V MOZ53 1=)49I(B;U#TVK$FKZ*RC<E;J$?HH4R\I'?77R>.#Q2STJ5+=B'"HB4 M$*M2:FV=8XA9+# RI/LGU]E9FFA@%>Q,!6RKR-=FDB[GGG"9R%@N?9=[;W@? M,.L#9C]'P.SGO!2P9!7,_E+ "I<"MAH[_+DO!3S?ZZ6 _6UTK-OH2E: K6<( MW+C.R@?>.GG;5S2ABHH0L@>%F+)]A*3?W6)AF@BOY Q#]W'@[O4*<<T8$WP2 M%30NEJ)2Y(6AZHGKS,(K[O"DX/[IVD,>[TY_C2=?-$US*511-%>(9HX3Z_@) MEKEP!X'_Z'J)&DBYT\2TIJIHELY]$V>):4^:.BP'P6RMLF)# ;)QAMK= G;Z MN,HN/AX>WG)X:]D ^JX#"G@*B4Y40:*H7.2RZ5:N?LR5^>%D;>4+:-'J_#2? MPL5DFIIQF$M&Y7'='SKO0U-]:*H/3?6AJ3XTU8>F!*&IL,"X@S<VK0W 7)V= MG'[@AZ:X).U/\"1"4UP)NA":"O<<+_6PJOKZ"9F='ND0K0]6H3%<ONZ:Q)/0 MP;/NF9, "S%=1IN6R;-4X=J"\UYO[(GM6X3\7*$Q)3010JO,[< T0R1T6]Y< MPO&SAP>K8#7[TD4'TK%*BSE]P@UA* D<.U%(.;R-K@%?Q'N8"@;5I/QMGIUE M+O;/*(O]B]R!3>YB_ZQ?[/>+_7ZQWR_V^\5^O]CO%_O]8O_G6>S'T[U$*<%H M4='<S)KRJ/9M8&_S:HKT';CRJ5^:*61"O*69RNO[Q-#X#> 3,, <;- :< 5& M+WCK'(([SS)X2XU],? 3&9NT3CIP5DDH*RPTLAHRPCJ9>$N&6*=>VCQ3Q0Q4 MG=,"5;DKNKB!JO,^4-4'JOI 51^HZ@-5?:"J#U3U@:J?)U"UO69Y &&PCJ:$ M,PO^N/8 &"-K\@#T9_2#/U670O*/;M]&FE\8RFM#Y< 63<K1RQ,PT)KCNVNC M;FPTL]^CP;$>_K.:'$L?70F$/8CE?"@BYP)X:\Z=14T^4S43:T@-E<[[==B= M75D;RP2.V8(S2S]:-3MK5AO9@&HG8E@7M!A6[BYW;@SKHH]A]3&L/H;5Q[#Z M&%8?P^IC6-PRZ.OPM7WZ^?/G\(V,^>)&L'@$[<^NQ/$K'O]*1Z_Z-"NUTZSJ M/CX5LWGM>DM@^6C63/:U6:'I!AZD@CDT)7M7HD1]NE1'#*U/ERJ>D;,;6&WG M3!7FY"V99.W*Z63V%.\BZHM<H3YN!*J_?KJ/1+WE2-16E*&M0Q@7?N"'I3@D M2L6H.')T(6"5Y$H40*&U[43@2FA>V:H(%$&Z$,FJ!D:'(EK5 =E#B*L/LI</ MLBL8\.V(KRH?9&^U#.//'63O=*W#&;#1,$;K+,]_7: U&-3#&H)\A\0E4LH_ M<25)X-<U?$0C24#6"6<F87IR:&5<W?NWAE>''&'-F"7=Y(<NN\EXCOD;#K4X M_M0+2]KQG22'1"D7R9&C"P..RI[D^H=.U GG*#0X&90RCO'#6\*I0TZQ1JR2 M#O%CEQUB&)''!5KX3C#33"G'E^$]@4K[6A<6JL\V[(13HQH-2^L9Y_5)1;UW MR$F5T'W2&7WNLC.*:M4/TD5JF9EEQ ?PB-K?4&6'<[-[!#PYB-.J-TVH/XO* M.(OZL=8J97V^9#Y?\F.KYY7"H799QL\PB-I'I:"?8<A!T*FUU-G8V>":4A[D M&GVN5?LZE0H")0T_)P/19ZWES6Z1%(^+9^3!7J.?\0J$KU\A5?OZEEA;)K4M ME(AH_T.=VO]'8+]BOR*E=%;C]G7-F HG]<MBGJCU8[U.P@R,<"8:.J0X24S@ M,7@D[:M8_*+D2T#T_*E./<=@+EQ2%'>ZQ$4 72?D0)09B;LHU$/[*,AE<Q<2 MJ@,W2%!=Y;96"S!PX5WTFA_JM@W,R]>1;CRFVQ8,UA7K6@74ZY.VB<K&0]=! MC_:0 ,CF-D@6Y$PB3W'O>&!E07RCB8DG<0&>:A,7O;7?A/$RAG&M3U !\-J% M;J+2<I*-Q,-RC QP.6Z4@7)<M(U4<E9FI/P3N0[SS4 ,&FQ]D)B93I[<[!E MY&NB3'22%\* S 1(@DY%.!BB9.L_UZ'Y"? )M->(\>ER"3S+6<'!$G%R!="D MV$=_;GWS8(5^7 , !XXYQ2<SKBP/
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end </TEXT> </DOCUMENT> </SEC-DOCUMENT>